<SEC-DOCUMENT>0001206774-15-001134.txt : 20150403
<SEC-HEADER>0001206774-15-001134.hdr.sgml : 20150403
<ACCEPTANCE-DATETIME>20150403163043
ACCESSION NUMBER:		0001206774-15-001134
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		7
CONFORMED PERIOD OF REPORT:	20150518
FILED AS OF DATE:		20150403
DATE AS OF CHANGE:		20150403
EFFECTIVENESS DATE:		20150403

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GERON CORP
		CENTRAL INDEX KEY:			0000886744
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				752287752
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-20859
		FILM NUMBER:		15751581

	BUSINESS ADDRESS:	
		STREET 1:		149 COMMONWEALTH DRIVE
		STREET 2:		SUITE 2070
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025
		BUSINESS PHONE:		6504737700

	MAIL ADDRESS:	
		STREET 1:		149 COMMONWEALTH DRIVE
		STREET 2:		SUITE 2070
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GERON CORPORATION
		DATE OF NAME CHANGE:	19960521
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>geron_def14a.htm
<DESCRIPTION>DEFINITIVE PROXY SATEMENT
<TEXT>

<HTML>
<HEAD>
   <TITLE></TITLE>
</HEAD>

<BODY bgcolor=#ffffff>
<BR>
<P align=left><FONT face="Times New Roman" size=2><A HREF="#toc"><B>Table of Contents</B></A></FONT></P>
<P align=center><B><FONT face="Times New Roman" size=2>UNITED STATES<BR>SECURITIES AND EXCHANGE COMMISSION<BR>Washington, D.C. 20549</FONT></B></P>
<P align=center><B><FONT face="Times New Roman" size=2>SCHEDULE 14A
INFORMATION<BR></FONT></B><FONT face="Times New Roman" size=2>Proxy Statement
Pursuant to Section 14(a) of the<BR>Securities Exchange Act of 1934</FONT></P>
<DIV align=justify><FONT face="Times New Roman" size=2>Filed by the
Registrant&nbsp; </FONT>&#9746;<FONT face="Times New Roman" size=2><BR><BR></FONT><FONT face="Times New Roman" size=2>Filed by a Party other than the Registrant&nbsp;</FONT>&#9744;<FONT face="Times New Roman" size=2><BR></FONT><FONT face="Times New Roman" size=2><BR>Check the
appropriate box:</FONT></DIV>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="1%">&#9744;</TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD>
    <TD noWrap align=left width="98%"><FONT face="Times New Roman" size=2>Preliminary Proxy
      Statement</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%">&#9744;</TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="98%"><B><FONT face="Times New Roman" size=2>Confidential, for
      Use of the Commission Only (as permitted by Rule
  14a-6(e)(2))</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%">&#9746;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="98%"><FONT face="Times New Roman" size=2>Definitive Proxy
      Statement</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%">&#9744;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="98%"><FONT face="Times New Roman" size=2>Definitive Additional
      Materials</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%">&#9744;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="98%"><FONT face="Times New Roman" size=2>Soliciting Material
      Pursuant to &#167;240.14a-12</FONT></TD></TR></TABLE><BR>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=center width="100%"><B><FONT face="Times New Roman" size=2>GERON
      CORPORATION</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD style="TEXT-ALIGN: center" width="100%"><FONT face="Times New Roman" size=2>(Name of Registrant as Specified In Its Charter)</FONT></TD></TR>
  <TR>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" width="100%">&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD style="TEXT-ALIGN: center" noWrap width="100%"><FONT face="Times New Roman" size=2>(Name of Person(s) Filing Proxy Statement if
      Other Than the Registrant)</FONT></TD></TR></TABLE><BR>
<DIV align=justify><FONT face="Times New Roman" size=2>Payment of Filing Fee
(Check the appropriate box)</FONT></DIV><BR>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="1%">&#9746;</TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD>
    <TD noWrap align=left width="98%" colSpan=3><FONT face="Times New Roman" size=2>No fee required.</FONT></TD></TR>
    <TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD>
    <TD NOWRAP COLSPAN="3" STYLE="text-align: left">&nbsp;</TD></TR>
<TR vAlign=bottom>
    <TD noWrap align=left width="1%">&#9744;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="98%" colSpan=3><FONT face="Times New Roman" size=2>Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and
      0-11.</FONT></TD></TR>
  <TR>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="96%">&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>(1)</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD>
    <TD noWrap align=left width="96%"><FONT face="Times New Roman" size=2>Title of each class of securities to which transaction
      applies:</FONT></TD></TR>
  <TR>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="96%">&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>(2)</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2></FONT></TD>
    <TD noWrap align=left width="96%"><FONT face="Times New Roman" size=2>Aggregate number of securities to which transaction
    applies:</FONT></TD></TR>
  <TR>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="96%">&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>(3)</FONT></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="96%"><FONT face="Times New Roman" size=2>Per
      unit price or other underlying value of transaction computed pursuant to
      Exchange Act Rule 0-11</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="96%"><FONT face="Times New Roman" size=2>(Set
      forth the amount on which the filing fee is calculated and state how it
      was determined):</FONT></TD></TR>
  <TR>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="96%">&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>(4)</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2></FONT></TD>
    <TD noWrap align=left width="96%"><FONT face="Times New Roman" size=2>Proposed maximum aggregate value of transaction:</FONT></TD></TR>
  <TR>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="96%">&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>(5)</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2></FONT></TD>
    <TD noWrap align=left width="96%"><FONT face="Times New Roman" size=2>Total fee paid:</FONT></TD></TR>
  <TR>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="96%">&nbsp; </TD></TR>
  <TR>
    <TD style="VERTICAL-ALIGN: top; TEXT-ALIGN: left" noWrap width="1%">&nbsp;</TD>
    <TD style="VERTICAL-ALIGN: top; TEXT-ALIGN: left" noWrap width="1%">&nbsp;</TD>
    <TD style="VERTICAL-ALIGN: top; TEXT-ALIGN: left" noWrap width="98%" colSpan=3>&nbsp;</TD></TR>
  <TR>
    <TD style="VERTICAL-ALIGN: top; TEXT-ALIGN: left" noWrap width="1%">&#9744;</TD>
    <TD style="VERTICAL-ALIGN: top; TEXT-ALIGN: left" noWrap width="1%"></TD>
    <TD style="VERTICAL-ALIGN: top; TEXT-ALIGN: left" noWrap width="98%" colSpan=3><FONT face="Times New Roman" size=2>Fee paid previously with
      preliminary materials. </FONT></TD></TR>
  <TR>
    <TD style="VERTICAL-ALIGN: top; TEXT-ALIGN: left" noWrap width="1%">&nbsp;</TD>
    <TD style="VERTICAL-ALIGN: top; TEXT-ALIGN: left" noWrap width="1%">&nbsp;</TD>
    <TD style="VERTICAL-ALIGN: top; TEXT-ALIGN: left" noWrap width="98%" colSpan=3>&nbsp;</TD></TR>
  <TR>
    <TD style="VERTICAL-ALIGN: top; LINE-HEIGHT: 11pt; TEXT-ALIGN: left" noWrap width="1%">&#9744;</TD>
    <TD style="VERTICAL-ALIGN: top; TEXT-ALIGN: left" noWrap width="1%"></TD>
    <TD style="VERTICAL-ALIGN: top; LINE-HEIGHT: normal; TEXT-ALIGN: left" width="98%" colSpan=3><FONT face="Times New Roman" size=2>Check box if any
      part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and
      identify the filing for which the offsetting fee was paid previously.
      Identify the previous filing by registration statement number, or the Form
      or Schedule and the date of its filing.</FONT></TD></TR>
  <TR>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="96%">&nbsp;&nbsp; </TD></TR>
  <TR>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>(1)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="96%"><FONT face="Times New Roman" size=2>Amount Previously Paid:</FONT></TD></TR>
  <TR>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="96%">&nbsp;&nbsp; </TD></TR>
  <TR>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>(2)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="96%"><FONT face="Times New Roman" size=2>Form, Schedule or Registration Statement No.:</FONT></TD></TR>
  <TR>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="96%">&nbsp; </TD></TR>
  <TR>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>(3)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="96%"><FONT face="Times New Roman" size=2>Filing Party:</FONT></TD></TR>
  <TR>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="96%">&nbsp; </TD></TR>
  <TR>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>(4)</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="96%"><FONT face="Times New Roman" size=2>Date
      Filed:</FONT></TD></TR>
  <TR>
    <TD style="TEXT-ALIGN: left" noWrap width="1%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: left" noWrap width="1%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: left" noWrap width="1%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: left" noWrap width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left" noWrap width="96%">&nbsp;</TD></TR></TABLE><BR>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=left><FONT face="Times New Roman" size=2><A HREF="#toc"><B>Table of Contents</B></A></FONT></P>
<P align=center><IMG src="geron_def14a1x1x1.jpg" border=0><BR><B><FONT face="Times New Roman" size=4>GERON CORPORATION<BR></FONT></B><B><FONT face="Times New Roman" size=2>149 Commonwealth Drive, Suite 2070<BR>Menlo Park,
CA 94025</FONT></B></P>
<P align=justify><FONT face="Times New Roman" size=2>April 3, 2015</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2>Dear Geron Stockholder:
</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>You are cordially invited
to attend the 2015 Annual Meeting of Stockholders of Geron Corporation, which
will be held on May 18, 2015 at 3:00 p.m. Pacific Daylight Time at the Westin
San Francisco Airport, One Old Bayshore Highway, Millbrae, California 94030. In
addition, we will be hosting the meeting via conference call which can be
accessed via telephone by dialing 877-303-9139 (U.S.); 760-536-5195
(international). The passcode is 10445504. A live audio-only webcast will also
be available at http://edge.media-server.com/m/p/bu3nq8gw/lan/en. </FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>As permitted by the rules
of the Securities and Exchange Commission, we are also pleased to furnish our
proxy materials to stockholders primarily over the Internet. We believe this
process will expedite stockholders&#146; receipt of materials, lower the costs of our
annual meeting and reduce the environmental impact of printing and mailing hard
copies. Stockholders who continue to receive hard copies of proxy materials may
help us reduce costs by opting to receive future proxy materials by e-mail.
</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>On or about April 6, 2015,
we will distribute to our stockholders a notice containing instructions on how
to access our 2015 Proxy Statement and our 2014 Annual Report on Form 10-K, and
how to vote online. This notice also will include instructions on how you can
receive a paper copy of the proxy materials, including the notice of the Annual
Meeting, 2015 Proxy Statement, 2014 Annual Report on Form 10-K and proxy card.
If you received your proxy materials by mail, the notice of Annual Meeting, 2015
Proxy Statement, 2014 Annual Report on Form 10-K and proxy card from our Board
of Directors were enclosed. If you received your proxy materials via e-mail, the
e-mail contained voting instructions and links to the 2015 Proxy Statement and
2014 Annual Report on Form 10-K.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>At this year&#146;s Annual
Meeting, the agenda includes the following items: </FONT></P>
<TABLE style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse; TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=justify><FONT face="Times New Roman" size=2>election of
      Directors;<BR>&nbsp;</FONT></P></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=justify><FONT face="Times New Roman" size=2>advisory vote to
      approve named executive officer compensation;
  and<BR>&nbsp;</FONT></P></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=justify><FONT face="Times New Roman" size=2>ratification of Ernst
      &amp; Young LLP as our independent registered public accounting firm.
      </FONT></P></TD></TR></TABLE>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2><u>Your vote is important to
us</u>. Whether or not you plan to attend the meeting, please vote electronically
via the Internet or by telephone, or, if you requested paper copies of the proxy
materials, please complete, sign, date and return the accompanying proxy card in
the enclosed postage-paid envelope. </FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Thank you for your ongoing
support of, and continued interest in, Geron Corporation. </FONT></P>
<DIV align=right>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="50%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="100%"><FONT face="Times New Roman" size=2>Sincerely,</FONT></TD></TR>
  <TR>
    <TD noWrap align=left width="100%"><IMG src="geron_def14a1x1x2.jpg" border=0></TD></TR>
  <TR>
    <TD noWrap align=left width="100%">
      <P align=justify><FONT face="Times New Roman" size=2>John A. Scarlett,
      M.D.<BR></FONT><FONT face="Times New Roman" size=2>President and Chief
      Executive Officer</FONT></P></TD></TR></TABLE></DIV><BR>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=left><FONT face="Times New Roman" size=2><A HREF="#toc"><B>Table of Contents</B></A></FONT></P>
<P align=center><IMG src="geron_def14a1x1x1.jpg" border=0><BR><B><FONT face="Times New Roman" size=4>GERON CORPORATION<BR></FONT></B><B><FONT face="Times New Roman" size=2>149 Commonwealth Drive, Suite 2070<BR>Menlo Park,
CA 94025</FONT></B><br><STRONG><FONT size=2 face="Times New Roman">_________________</FONT></STRONG></P>
<P align=center><B><FONT face="Times New Roman">NOTICE OF ANNUAL MEETING OF
STOCKHOLDERS<BR></FONT></B><B><FONT face="Times New Roman" size=2>To Be Held on
May 18, 2015</FONT></B></P>
<P align=justify><FONT face="Times New Roman" size=2>To the Stockholders of
Geron Corporation:</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>NOTICE IS HEREBY GIVEN that
the Annual Meeting of Stockholders of GERON CORPORATION, a Delaware corporation
(the &#147;Company&#148;), will be held on May 18, 2015, at 3:00 p.m. Pacific Daylight
Time at the Westin San Francisco Airport, One Old Bayshore Highway, Millbrae,
California 94030. Stockholders may also access the meeting via telephone by
dialing 877-303-9139 (U.S.); 760-536-5195 (international). The passcode is
10445504. A live audio-only webcast will also be available at
http://edge.media-server.com/m/p/bu3nq8gw/lan/en. The meeting will be held for
the following purposes:</FONT></P>
<TABLE style="TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 border=0>

  <TR>
    <TD vAlign=top noWrap></TD>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>1.</FONT></TD>
    <TD vAlign=top noWrap></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>To elect the two
      nominees for director named in the accompanying proxy statement, or the
      Proxy Statement, to hold office as Class I members of the Board of
      Directors until the 2018 annual meeting of
    stockholders;<BR>&nbsp;</FONT></TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT size=2 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>2.</FONT></TD>
    <TD vAlign=top noWrap><FONT size=2 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>To approve, on an
      advisory basis, the compensation of the Company&#146;s named executive
      officers, as disclosed in the Proxy Statement;<BR>&nbsp;</FONT></TD></TR>
  <TR>
    <TD vAlign=top noWrap></TD>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>3.</FONT></TD>
    <TD vAlign=top noWrap></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>To ratify the
      selection by the Audit Committee of the Board of Directors of Ernst &amp;
      Young LLP as the Company&#146;s independent registered public accounting firm
      for the fiscal year ending December 31, 2015; and<BR>&nbsp;</FONT></TD></TR>
  <TR>
    <TD vAlign=top noWrap></TD>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>4.</FONT></TD>
    <TD vAlign=top noWrap></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>To transact such
      other business as may properly come before the Annual Meeting or any
      postponement or adjournment thereof.</FONT></TD></TR></TABLE>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The foregoing items of
business are more fully described in the Proxy Statement accompanying this
Notice.</FONT></P>

<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Board of Directors has fixed the close of business on March 23,
2015, as the record date for the determination of stockholders entitled to
notice of and to vote at the Annual Meeting and at any adjournment or
postponement thereof. Each stockholder is entitled to one vote for each share of
common stock held at that time.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><B><FONT face="Times New Roman" size=2><u>Your Vote Is Important
To Us.</u></FONT></B><FONT face="Times New Roman" size=2> Whether or not you plan to
attend the meeting, please vote electronically via the Internet or by telephone,
or, if you requested paper copies of the proxy materials, please complete, sign,
date and return the accompanying proxy card in the enclosed postage-paid
envelope. Please note, however, that if your shares are held of record by a
broker, bank or other nominee and you wish to vote at the meeting, you must
obtain from the record holder a proxy issued in your name.</FONT></P>
<DIV align=right>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="50%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="100%"><FONT face="Times New Roman" size=2>By Order of the Board of
      Directors,</FONT></TD></TR>
  <TR>
    <TD noWrap align=left width="100%"><IMG src="geron_def14a1x2x1.jpg" border=0></TD></TR>
  <TR>
    <TD noWrap align=left width="100%">
      <P align=left><FONT face="Times New Roman" size=2>Stephen N.
      Rosenfield<BR></FONT><I><FONT face="Times New Roman" size=2>Executive Vice
      President, General Counsel<BR>and Corporate
  Secretary</FONT></I></P></TD></TR></TABLE></DIV><BR>
<P align=justify><FONT face="Times New Roman" size=2>Menlo Park,
California<BR>April 3, 2015</FONT></P>
<P align=center><B><FONT face="Times New Roman" size=2>Important Notice
Regarding the Availability of Proxy Materials for the Annual
Meeting:<BR></FONT></B><FONT face="Times New Roman" size=2>Letter to
Stockholders, Notice and 2015 Proxy Statement, and 2014 Annual Report on Form
10-K are available at<BR>www.proxyvote.com.</FONT></P>
<P align=center><B><FONT face="Times New Roman" size=2>YOUR VOTE IS VERY
IMPORTANT, REGARDLESS OF THE NUMBER OF SHARES YOU OWN.<BR>WHETHER OR NOT YOU
EXPECT TO ATTEND THE MEETING, WE URGE YOU TO SUBMIT<BR></FONT></B><B><FONT face="Times New Roman" size=2>YOUR PROXY PROMPTLY IN ORDER TO ASSURE THAT A
QUORUM IS PRESENT. </FONT></B></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=left><FONT face="Times New Roman" size=2><A HREF="#toc"><B>Table of Contents</B></A></FONT></P>
<P align=center><B><FONT face="Times New Roman" size=2><A NAME="toc"></A>Table of
Contents</FONT></B></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><B><FONT face="Times New Roman" size=1>Description</FONT></B></TD>
    <TD noWrap align=left width="92%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="6%" colSpan=3><B><FONT face="Times New Roman" size=1>Page</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="93%" bgColor=#c0c0c0 colSpan=2><FONT face="Times New Roman" size=2><A HREF="#QandA">Questions and Answers about These Proxy Materials and Voting</A><BR>&nbsp;</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD vAlign=top noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD vAlign=top noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2><A HREF="#QandA">1</A></FONT></TD>
    <TD vAlign=top noWrap align=right width="2%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="93%" colSpan=2><FONT face="Times New Roman" size=2><A HREF="#Proposal1">Proposal 1: Election of Directors</A><BR>&nbsp;</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD vAlign=top noWrap align=right width="2%" ></TD>
    <TD vAlign=top noWrap align=right width="2%"><FONT face="Times New Roman" size=2><A HREF="#Proposal1">8</A></FONT></TD>
    <TD vAlign=top noWrap align=right width="2%" ></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="93%" bgColor=#c0c0c0 colSpan=2><FONT face="Times New Roman" size=2><A HREF="#CorpGov">Corporate Governance Matters</A><BR>&nbsp;</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD vAlign=top noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD vAlign=top noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2><A HREF="#CorpGov">13</A></FONT></TD>
    <TD vAlign=top noWrap align=right width="2%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="93%" colSpan=2><FONT face="Times New Roman" size=2><A HREF="#Compensation">Compensation of Directors</A><BR>&nbsp;</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD vAlign=top noWrap align=right width="2%" ></TD>
    <TD vAlign=top noWrap align=right width="2%"><FONT face="Times New Roman" size=2><A HREF="#Compensation">17</A></FONT></TD>
    <TD vAlign=top noWrap align=right width="2%" ></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="93%" bgColor=#c0c0c0 colSpan=2><FONT face="Times New Roman" size=2><A HREF="#Proposal2">Proposal 2: Advisory Vote to Approve Named Executive Officer Compensation</A><BR>&nbsp;</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD vAlign=top noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD vAlign=top noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2><A HREF="#Proposal2">20</A></FONT></TD>
    <TD vAlign=top noWrap align=right width="2%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="93%" colSpan=2><FONT face="Times New Roman" size=2><A HREF="#CompensationDiscuss">Compensation Discussion and Analysis</A><BR>&nbsp;</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD vAlign=top noWrap align=right width="2%" ></TD>
    <TD vAlign=top noWrap align=right width="2%"><FONT face="Times New Roman" size=2><A HREF="#CompensationDiscuss">21</A></FONT></TD>
    <TD vAlign=top noWrap align=right width="2%" ></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="93%" bgColor=#c0c0c0 colSpan=2><FONT face="Times New Roman" size=2><A HREF="#CompensationComm">Compensation Committee Report</A><BR>&nbsp;</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD vAlign=top noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD vAlign=top noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2><A HREF="#CompensationComm">40</A></FONT></TD>
    <TD vAlign=top noWrap align=right width="2%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="93%" colSpan=2><FONT face="Times New Roman" size=2><A HREF="#ExecutiveCom">Executive Compensation Tables</A><BR>&nbsp;</FONT></TD>
    <TD noWrap align=right width="1%">&nbsp;</TD>
    <TD vAlign=top noWrap align=right width="2%" ></TD>
    <TD vAlign=top noWrap align=right width="2%"><FONT face="Times New Roman" size=2><A HREF="#ExecutiveCom">40</A></FONT></TD>
    <TD vAlign=top noWrap align=right width="2%" ></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="93%" bgColor=#c0c0c0 colSpan=2><FONT face="Times New Roman" size=2><A HREF="#EquityCom">Equity Compensation Plans</A><BR>&nbsp;</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD vAlign=top noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD vAlign=top noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2><A HREF="#EquityCom">47</A></FONT></TD>
    <TD vAlign=top noWrap align=right width="2%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="93%" colSpan=2><FONT face="Times New Roman" size=2><A HREF="#Proposal3">Proposal 3: Ratification of Selection of Independent Registered Public Accounting Firm</A><BR>&nbsp;</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD vAlign=top noWrap align=right width="2%" ></TD>
    <TD vAlign=top noWrap align=right width="2%"><FONT face="Times New Roman" size=2><A HREF="#Proposal3">48</A></FONT></TD>
    <TD vAlign=top noWrap align=right width="2%" ></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="93%" bgColor=#c0c0c0 colSpan=2><FONT face="Times New Roman" size=2><A HREF="#Principal">Principal Accountant Fees and Services</A><BR>&nbsp;</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD vAlign=top noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD vAlign=top noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2><A HREF="#Principal">48</A></FONT></TD>
    <TD vAlign=top noWrap align=right width="2%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="93%" colSpan=2><FONT face="Times New Roman" size=2><A HREF="#Audit">Audit Committee Report</A><BR>&nbsp;</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD vAlign=top noWrap align=right width="2%" ></TD>
    <TD vAlign=top noWrap align=right width="2%"><FONT face="Times New Roman" size=2><A HREF="#Audit">50</A></FONT></TD>
    <TD vAlign=top noWrap align=right width="2%" ></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="93%" bgColor=#c0c0c0 colSpan=2><FONT face="Times New Roman" size=2><A HREF="#Security">Security Ownership of Certain Beneficial Owners and Management</A><BR>&nbsp;</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD vAlign=top noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD vAlign=top noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2><A HREF="#Security">51</A></FONT></TD>
    <TD vAlign=top noWrap align=right width="2%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="93%" colSpan=2><FONT face="Times New Roman" size=2><A HREF="#CertainTransac">Certain Transactions</A><BR>&nbsp;</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD vAlign=top noWrap align=right width="2%" ></TD>
    <TD vAlign=top noWrap align=right width="2%"><FONT face="Times New Roman" size=2><A HREF="#CertainTransac">53</A></FONT></TD>
    <TD vAlign=top noWrap align=right width="2%" ></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="93%" bgColor=#c0c0c0 colSpan=2><FONT face="Times New Roman" size=2><A HREF="#Other">Other Matters</A></FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD vAlign=top noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD vAlign=top noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2><A HREF="#Other">54</A></FONT></TD>
    <TD vAlign=top noWrap align=right width="2%" bgColor=#c0c0c0></TD></TR></TABLE><BR>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=left><FONT face="Times New Roman" size=2><A HREF="#toc"><B>Table of Contents</B></A></FONT></P>
<P align=center><B><FONT face="Times New Roman" size=2>GERON CORPORATION<BR>149
Commonwealth Drive, Suite 2070<BR>Menlo Park, CA
94025<BR>___________________</FONT></B></P>
<P align=center><B><FONT face="Times New Roman">PROXY
STATEMENT<BR></FONT></B><B><FONT face="Times New Roman">FOR THE ANNUAL MEETING
OF STOCKHOLDERS<BR>TO BE HELD ON MAY 18, 2015<BR><FONT size=2 face="Times New Roman">___________________</FONT></FONT></B></P>
<P align=center><B><FONT face="Times New Roman" size=2><A NAME="QandA"></A>QUESTIONS AND ANSWERS
ABOUT THESE PROXY MATERIALS AND VOTING </FONT></B></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Why am I receiving these
materials? </FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>We have sent you a Notice
of Availability of Proxy Materials (the &#147;Notice&#148;) or our proxy materials, as
applicable, because the Board of Directors (the &#147;Board&#148;) of Geron Corporation, a
Delaware corporation (&#147;Geron&#148;, the &#147;Company&#148;, &#147;we&#148; or &#147;us&#148;), is soliciting your
proxy to vote at our 2015 Annual Meeting of Stockholders (the &#147;Annual Meeting&#148;),
to be held on May 18, 2015, at 3:00 p.m. Pacific Daylight Time at the Westin San
Francisco Airport, One Old Bayshore Highway, Millbrae, California 94030 or at
any adjournment or postponement thereof. You may vote by proxy over the Internet
or by phone, or by mail if you requested printed copies of the proxy materials.
</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>We intend to distribute the
Notice and the proxy materials on or about April 6, 2015 to all stockholders of
record entitled to vote at the Annual Meeting. </FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>What is the purpose of
the Annual Meeting? </FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>At our Annual Meeting,
stockholders will act upon the matters described in this Proxy Statement. In
addition, following the meeting, management will report on current events at
Geron and respond to questions from stockholders.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>How can I attend the
Annual Meeting? </FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>All stockholders are
cordially invited to attend the Annual Meeting in person at the Westin San
Francisco Airport, One Old Bayshore Highway, Millbrae, California 94030. For
directions to attend the Annual Meeting, please contact our Investor Relations
department at (650) 473-7765 or by email at investor@geron.com. Stockholders may
also access the meeting via telephone by dialing 877-303-9139 (U.S.);
760-536-5195 (international). The passcode is 10445504. A live audio-only
webcast will also be available at
http://edge.media-server.com/m/p/bu3nq8gw/lan/en via the Internet. The Annual
Meeting will start at 3:00 p.m., Pacific Daylight Time, on May 18,
2015.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>How can I participate in
the Annual Meeting if I cannot attend in person? </FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>If you cannot attend the
meeting in person, stockholders may participate via telephone by dialing
877-303-9139 (U.S.); 760-536-5195 (international). The passcode is 10445504. We
recommend that stockholders dial in at least 10 minutes early to minimize any
delay in joining the meeting. Participants via telephone will also have an
opportunity to ask questions during the meeting.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Annual Meeting will
also be available via the Internet in a live audio-only webcast available at
http://edge.media-server.com/m/p/bu3nq8gw/lan/en. The audio webcast of the
Annual Meeting will be available for replay approximately one hour following the
live meeting through June 18, 2015. Since the webcast is audio-only,
participants will be unable to ask questions in this forum. </FONT></P>
<P align=center><FONT face="Times New Roman" size=2>1</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=left><FONT face="Times New Roman" size=2><A HREF="#toc"><B>Table of Contents</B></A></FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Why did I receive a
Notice in the mail regarding the Internet availability of proxy materials
instead of a full set of proxy materials? </FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>We are pleased to continue
to apply the rules from the United States Securities and Exchange Commission
(the &#147;SEC&#148;) that allow companies to furnish their proxy materials over the
Internet. If you received the Notice by mail, you will not receive a printed
copy of the proxy materials unless you request one. Instead, the Notice will
instruct you as to how you may access and review the proxy materials and cast
your vote via the Internet. If you received a Notice by mail and would like to
receive a printed copy of our proxy materials, please follow the instructions
included in the Notice. A stockholder&#146;s election to receive proxy materials by
mail or electronically by email will remain in effect until the stockholder
terminates such election.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Why did I receive a full
set of proxy materials instead of a Notice regarding the Internet availability
of proxy materials? </FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>We are providing paper
copies of the proxy materials to stockholders who previously requested to
receive them. If you would like to reduce the environmental impact and the costs
incurred by us in mailing proxy materials, you may elect to receive all future
proxy materials electronically via email or the Internet. To sign up for
electronic delivery, please follow the instructions provided with your proxy
materials and on your proxy card or voting instruction card, to vote using the
Internet and, when prompted, indicate that you agree to receive or access future
stockholder communications electronically. Alternatively, you can go to
www.proxyvote.com and enroll for online delivery of proxy materials. </FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>How can I access the
proxy materials over the Internet? </FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>You may view and also
download our proxy materials, including the 2014 Annual Report on Form 10-K, at
www.proxyvote.com. </FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>How do I order proxy
materials if I have not received them? </FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>This Proxy Statement and
Geron&#146;s 2014 Annual Report on Form 10-K are available at www.proxyvote.com.
Internet distribution of proxy materials is designed to expedite receipt by
stockholders, lower the cost of the Annual Meeting and conserve natural
resources. However, if you have not received a copy of our proxy materials and
would like to receive one for the Annual Meeting or for future stockholder
meetings, you may request printed copies as follows: </FONT></P>
<TABLE style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse; TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=justify><FONT face="Times New Roman" size=2>by telephone: call
      1-800-579-1639 free of charge and follow the
      instructions;<BR>&nbsp;</FONT></P></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=justify><FONT face="Times New Roman" size=2>by Internet: go to
      www.proxyvote.com and follow the instructions;
  or<BR>&nbsp;</FONT></P></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=justify><FONT face="Times New Roman" size=2>by e-mail: send an
      e-mail message to sendmaterial@proxyvote.com. Please send a blank e-mail
      and put the 12-Digit Control Number located in your Notice in the subject
      line. </FONT></P></TD></TR></TABLE>
<P align=justify><B><FONT face="Times New Roman" size=2>Who can vote at the
Annual Meeting? </FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Only holders of record at
the close of business on March 23, 2015 (the &#147;Record Date&#148;) will be entitled to
notice of and to vote at the Annual Meeting or any adjournment or postponement
thereof. At the close of business on the Record Date, we had 157,845,799 shares
of common stock, par value $0.001 per share (&#147;Common Stock&#148;), outstanding. Each
holder of record of Common Stock on the Record Date will be entitled to one vote
for each share held on all matters to be voted upon at the Annual Meeting. The
stock transfer books will not be closed between the Record Date and the Annual
Meeting date. A list of stockholders entitled to vote at the Annual Meeting will
be available for examination at our principal executive offices at the address
listed above for a period of ten days prior to the Annual Meeting and during the
Annual Meeting. </FONT></P>
<P align=center><FONT face="Times New Roman" size=2>2</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=left><FONT face="Times New Roman" size=2><A HREF="#toc"><B>Table of Contents</B></A></FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>What am I voting on at
the Annual Meeting?</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>You are being asked to vote
on three proposals, as follows:</FONT></P>
<DIV align=right>
<TABLE style="BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD vAlign=top noWrap align=left width="1%"><FONT face="Times New Roman" size=2>Proposal 1</FONT></TD>
    <TD vAlign=top noWrap align=left width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD vAlign=top align=left width="96%">
      <P align=justify><FONT face="Times New Roman" size=2>To elect the two
      nominees for director named in this Proxy Statement to hold office as
      Class I members of our Board of Directors until the 2018 annual meeting of
      stockholders;<BR>&nbsp;</FONT></P></TD></TR>
  <TR>
    <TD noWrap align=left width="1%"></TD>
    <TD vAlign=top noWrap align=left width="1%"><P align=justify><FONT face="Times New Roman" size=2>Proposal 2 </FONT></P></TD>
    <TD vAlign=top noWrap align=left width="1%"></TD>
    <TD vAlign=top align=left width="96%">
      <P align=justify><FONT face="Times New Roman" size=2>To approve, on an
      advisory basis, the compensation of our named executive officers, as
      disclosed in this Proxy Statement; and<BR>&nbsp;</FONT></P></TD></TR>
  <TR>
    <TD noWrap align=left width="1%"></TD>
    <TD vAlign=top noWrap align=left width="1%"><P align=justify><FONT face="Times New Roman" size=2>Proposal 3 </FONT></P></TD>
    <TD vAlign=top noWrap align=left width="1%"></TD>
    <TD vAlign=top align=left width="96%">
      <P align=justify><FONT face="Times New Roman" size=2>To ratify the
      selection by the Audit Committee of the Board of Directors of Ernst &amp;
      Young LLP as our independent registered public accounting firm for the
      fiscal year ending December 31,
2015.</FONT></P></TD></TR></TABLE></DIV><BR>
<P align=justify><B><FONT face="Times New Roman" size=2>What are the choices in
voting? </FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>For Proposal 1, you may
either vote &#147;For&#148; all nominees to the Board of Directors or you may &#147;Withhold&#148;
your vote for any nominee you specify. For Proposals 2 and 3, you may vote &#147;For&#148;
the proposal or &#147;Against&#148; the proposal or &#147;Abstain&#148; from voting on the
proposal.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>What is the
recommendation of the Board on each of the matters scheduled to be voted on at
the Annual Meeting? </FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Board of Directors
recommends that you vote:</FONT></P>
<TABLE style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse; TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=justify><FONT face="Times New Roman" size=2>FOR the nominees to
      the Board of Directors (Proposal 1); <BR>&nbsp;</FONT></P></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=justify><FONT face="Times New Roman" size=2>FOR the approval, on
      an advisory basis, of the compensation of our named executive officers as
      disclosed in this Proxy Statement (Proposal 2); and
    <BR>&nbsp;</FONT></P></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=justify><FONT face="Times New Roman" size=2>FOR the ratification
      of the selection of Ernst &amp; Young LLP as our independent registered
      public accounting firm for the fiscal year ending December 31, 2015
      (Proposal 3). </FONT></P></TD></TR></TABLE>
<P align=justify><B><FONT face="Times New Roman" size=2>Could other matters be
decided at the Annual Meeting? </FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Our Bylaws require that we
receive advance notice of any proposal to be brought before the Annual Meeting
by our stockholders, and we have not received notice of any such proposals. If
any other matter were to be properly submitted for a vote at the Annual Meeting,
the proxy holders appointed by the Board will have the discretion to vote on
those matters for you as they see fit. This includes, among other things,
considering any motion to adjourn the Annual Meeting to another time and/or
place, including for the purpose of soliciting additional proxies for or against
a given proposal.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>What is the difference
between holding shares as a stockholder of record or as a beneficial owner?
</FONT></B></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2>Stockholder of
Record: Shares Registered in Your Name</FONT></I></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>You are a stockholder of
record if at the close of business on March 23, 2015, your shares were
registered directly in your name with our transfer agent, Computershare Trust
Company, N.A. As a stockholder of record, you may vote during the Annual Meeting
or vote by proxy.</FONT></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2>Beneficial Owner:
Shares Registered in the Name of a Broker or Bank </FONT></I></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>You are a beneficial owner,
if at the close of business on March 23, 2015, your shares were held in an
account at a brokerage firm, bank, dealer, or other similar organization and not
in your name. The organization holding your account is considered to be the
stockholder of record for purposes of voting at the Annual Meeting. Being a
beneficial owner means that, like most stockholders, your shares are held in
&#147;street name&#148; and these proxy materials are being forwarded to you by that
organization. As a beneficial owner, you have the right to direct your broker or
other agent on how to vote the shares in your account by following the voting
instructions your broker or other nominee provides. If you do not provide your
broker or nominee with instructions on how to vote your shares, your broker or
nominee will be able to vote your shares with respect to some of the proposals,
but not all. Refer to the section below &#147;What are broker non-votes?&#148; for more
information.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>3</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=left><FONT face="Times New Roman" size=2><A HREF="#toc"><B>Table of Contents</B></A></FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>How do I vote my shares
and what are the voting deadlines? </FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Please refer to the proxy
card for instructions on, and access information for, voting by telephone, over
the Internet or by mail.</FONT></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2>Stockholder of
Record: Shares Registered In Your Name</FONT></I></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>If you are a stockholder of
record, there are several ways for you to vote your shares.</FONT></P>
<TABLE style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse; TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=justify><B><FONT face="Times New Roman" size=2><u>Via the
      Internet</u></FONT></B><FONT face="Times New Roman" size=2>. You may vote at
      www.proxyvote.com, 24 hours a day, seven days a week. You will need the
      12-Digit Control Number included on your Notice or your proxy card (if you
      received a printed copy of the proxy materials). Votes submitted through
      the Internet must be received by 11:59 p.m., Eastern Time, on May 17,
      2015. <BR>&nbsp;</FONT></P></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=justify><B><FONT face="Times New Roman" size=2><u>By
      Telephone</u></FONT></B><FONT face="Times New Roman" size=2>. You may vote
      using a touch-tone telephone by calling 1-800-690-6903, 24 hours a day,
      seven days a week. You will need the 12-Digit Control Number included on
      your Notice or your proxy card (if you received a printed copy of the
      proxy materials). Votes submitted by telephone must be received by 11:59
      p.m., Eastern Time, on May 17, 2015.<BR>&nbsp;</FONT></P></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=justify><B><FONT face="Times New Roman" size=2><u>By
      Mail</u></FONT></B><FONT face="Times New Roman" size=2>. If you received
      printed proxy materials, you may submit your vote by completing, signing,
      and dating each proxy card received and returning it in the postage-paid
      envelope. Sign your name exactly as it appears on the proxy card. Proxy
      cards submitted by mail must be received no later than May 17, 2015 to be
      voted at the Annual Meeting.<BR>&nbsp;</FONT></P></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=justify><B><FONT face="Times New Roman" size=2><u>During the Annual
      Meeting</u></FONT></B><FONT face="Times New Roman" size=2>. Stockholders may
      also submit their vote if they attend the meeting in person.
  </FONT></P></TD></TR></TABLE>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Internet and telephone
voting procedures described above, which comply with Delaware law, are designed
to authenticate stockholders&#146; identities, to allow stockholders to vote their
shares, and to confirm that their instructions have been properly recorded.
However, please be aware that you must bear any costs associated with your
Internet access, such as usage charges from Internet access providers and
telephone companies.</FONT></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2>Beneficial Owner:
Shares Registered in the Name of a Broker or Bank</FONT></I></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>If you are a beneficial
owner of your shares, you should have received a Notice or voting instructions
from the broker or other nominee holding your shares. You should follow the
instructions in the Notice or voting instructions provided by your broker or
nominee in order to instruct your broker or other nominee on how to vote your
shares. The availability of telephone and Internet voting will depend on the
voting process of the broker or nominee. Please contact your bank, broker or
other agent if you have questions about their instructions on how to vote your
shares. To vote during the 2015 Annual Meeting, you must obtain a valid proxy
from your broker, bank, or other agent, and attend the meeting in person to
submit your vote.</FONT></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2>Geron Plan
Participants </FONT></I></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>As trustee of the Geron
401(k) Plan, Prudential Bank and Trust FSB will receive a proxy that
incorporates all the shares owned by the Geron 401(k) Plan and will vote such
proxy as directed by the Geron 401(k) sponsor.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Shares purchased through
the 1996 Employee Stock Purchase Plan and the 2014 Employee Stock Purchase Plan
will follow standard brokerage industry practices. Shares held in the name of
the broker will be voted on behalf of the holder on certain routine matters. To
the extent the brokerage firm votes shares on the behalf of the holder, the
shares will be counted for the purpose of determining a quorum.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Can I vote my shares by
filling out and returning the Notice? </FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>No. The Notice will,
however, provide instructions on how to vote by Internet, by telephone, or by
requesting and returning a paper proxy card or voting instruction
card.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>4</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=left><FONT face="Times New Roman" size=2><A HREF="#toc"><B>Table of Contents</B></A></FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>How many votes are
needed to approve a proposal? </FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>A quorum of stockholders is
necessary to hold a valid meeting. In order to constitute a quorum and to
transact business at the Annual Meeting, a majority of the outstanding shares of
Common Stock on the Record Date must be represented at the Annual Meeting.
Shares represented by proxies that reflect abstentions or &#147;broker non-votes&#148;
will be counted as shares that are present and entitled to vote for purposes of
determining the presence of a quorum.</FONT></P>
<TABLE style="PADDING-RIGHT: 4pt; PADDING-LEFT: 4pt; PADDING-BOTTOM: 2pt; PADDING-TOP: 2pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD style="BORDER-TOP: #000000 1pt solid; BORDER-LEFT: #000000 1pt solid" noWrap align=center width="3%"><B><FONT face="Times New Roman" size=1>Proposal<BR></FONT><FONT style="BORDER-BOTTOM: black 1pt solid" face="Times New Roman" size=1>Number</FONT></B></TD>
    <TD style="BORDER-TOP: #000000 1pt solid" noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-TOP: #000000 1pt solid" noWrap align=left width="47%"><B><FONT style="BORDER-BOTTOM: black 1pt solid" face="Times New Roman" size=1>Proposal</FONT></B></TD>
    <TD style="BORDER-TOP: #000000 1pt solid" noWrap align=left width="1%">&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; BORDER-TOP: #000000 1pt solid" noWrap align=left width="47%"><B><FONT style="BORDER-BOTTOM: black 1pt solid" face="Times New Roman" size=1>Vote
      Required</FONT></B></TD></TR>
  <TR STYLE="background-color: Silver">
    <TD style="BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid" vAlign=top noWrap align=center width="3%"><P align=center><FONT face="Times New Roman" size=2>1</FONT></P></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top noWrap align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="47%">
      <P align=justify><FONT face="Times New Roman" size=2>To elect the two
      nominees for director named in this Proxy Statement to hold office as
      Class I members of our Board of Directors until the 2018 annual meeting of
      stockholders.</FONT></P></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top noWrap align=left width="1%"></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="47%">
      <P align=justify><FONT face="Times New Roman" size=2>The two nominees
      receiving the most &#147;FOR&#148; votes properly cast in person or by proxy will be
      elected. Only votes &#147;FOR&#148; or &#147;WITHHOLD&#148; will affect the outcome of the
      vote.</FONT></P></TD></TR>
  <TR>
    <TD style="BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid" vAlign=top noWrap align=center width="3%"><P align=center><FONT face="Times New Roman" size=2>2</FONT></P></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top noWrap align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="47%">
      <P align=justify><FONT face="Times New Roman" size=2>To approve, on an
      advisory basis, the compensation of our named executive officers, as
      disclosed in this Proxy Statement.</FONT></P></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top noWrap align=left width="1%"></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="47%">
      <P align=justify><FONT face="Times New Roman" size=2>The affirmative vote
      of the holders of a majority of the shares present or represented, in
      person or by proxy at this meeting. Abstentions will have the same effect
      as a vote against this proposal, and broker non-votes will have no effect
      on the outcome of this proposal. However, this proposal is advisory and
      non-binding upon us.</FONT></P></TD></TR>
  <TR STYLE="background-color: Silver">
    <TD style="BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid" vAlign=top noWrap align=center width="3%"><P align=center><FONT face="Times New Roman" size=2>3</FONT></P></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top noWrap align=center width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="47%">
      <P align=justify><FONT face="Times New Roman" size=2>To ratify the
      selection by the Audit Committee of the Board of Directors of Ernst &amp;
      Young LLP as our independent registered public accounting firm for the
      fiscal year ending December 31, 2015.</FONT></P></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top noWrap align=left width="1%"></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="47%">
      <P align=justify><FONT face="Times New Roman" size=2>The affirmative vote
      of the holders of a majority of the shares present or represented, in
      person or by proxy, at this meeting. Abstentions will have the same effect
      as a vote against this proposal, and broker non-votes will have no effect
      on the outcome of this proposal.</FONT></P></TD></TR></TABLE>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Although the election of
directors at the Annual Meeting is uncontested and directors are elected by a
plurality of votes cast, and we therefore expect that each of the named nominees
for director will be elected at the Annual Meeting, under our Corporate
Governance Guidelines, any nominee for director is required to submit an offer
of resignation for consideration by the Nominating and Corporate Governance
Committee if such nominee for director (in an uncontested election) receives a
greater number of &#147;WITHHOLD&#148; votes from his or her election than votes &#147;FOR&#148;
such election. In such case, the Nominating and Corporate Governance Committee
will then consider all of the relevant facts and circumstances and recommend to
the Board the action to be taken with respect to such offer of resignation. For
more information on this policy see the section entitled &#147;Corporate Governance
Matters &#150; Corporate Governance Guidelines&#148;. </FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>What are &#147;broker
non-votes&#148;? </FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Broker non-votes occur when
a beneficial owner of shares held in &#147;street name&#148; does not give instructions to
the broker or nominee holding the shares on how to vote on matters deemed
&#147;non-routine.&#148; Generally, if shares are held in street name, the beneficial
owner of the shares is entitled to give voting instructions to the broker or
nominee holding the shares. If the beneficial owner does not provide voting
instructions, the broker or nominee can still vote the shares with respect to
matters that are considered to be &#147;routine,&#148; but not with respect to
&#147;non-routine&#148; matters. In the event that a broker, bank, custodian, nominee or
other record holder of Geron Common Stock indicates on a proxy that it does not
have discretionary authority to vote certain shares on a particular proposal,
then those shares will be treated as broker non-votes with respect to that
proposal. Accordingly, if you own shares through a nominee, such as a broker or
bank, please be sure to instruct your nominee on how to vote to ensure that your
vote is counted on each of the proposals. </FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Which ballot measures
are considered &#147;routine&#148; or &#147;non-routine?&#148; </FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The ratification of the
selection of Ernst &amp; Young LLP as our independent registered public
accounting firm for the fiscal year ending December 31, 2015 (Proposal 3) is
considered routine under applicable rules. A broker or other nominee may
generally vote on routine matters, and therefore no broker non-votes are
expected to occur in </FONT></P>
<P align=center><FONT face="Times New Roman" size=2>5</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=left><FONT face="Times New Roman" size=2><A HREF="#toc"><B>Table of Contents</B></A></FONT></P>
<P align=justify><FONT face="Times New Roman" size=2>connection with Proposal 3.
The election of directors (Proposal 1) and the advisory vote on the compensation
of our named executive officers (Proposal 2) are considered non-routine matters
under applicable rules. A broker or other nominee cannot vote without
instructions on non-routine matters, and therefore we expect broker non-votes on
Proposals 1 and 2.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>What does it mean if I
receive more than one proxy card? </FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>If you receive more than
one proxy card, your shares are registered in more than one name or are
registered in different accounts. Please complete, sign, date and return each
proxy card to ensure that all of your shares are voted. </FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>How will your proxy be
voted? </FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Votes will be counted by
the Inspector of Election appointed for the Annual Meeting, who will separately
count &#147;For&#148; and (with respect to proposals other than the election of directors)
&#147;Against&#148; votes, abstentions and broker non-votes. In addition, with respect to
the election of directors, the Inspector of Election will count the number of
&#147;Withhold&#148; votes received for the nominees. If your shares are held by your
broker as your nominee (that is, in &#147;street name&#148;), you will need to obtain a
proxy form from the institution that holds your shares and follow the
instructions included on that form regarding how to instruct your broker to vote
your shares. If you do not give instructions to your broker, your broker can
vote your shares with respect to &#147;routine&#148; items, but not with respect to
&#147;non-routine&#148; items. See &#147;What are &#147;broker non-votes?&#148; and &#147;Which ballot
measures are considered &#147;routine&#148; or &#147;non-routine&#148;?&#148; above for more information
regarding &#147;routine&#148; and &#147;non-routine&#148; matters.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Can I revoke or change
my vote after I submit my proxy? </FONT></B></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2>Stockholder of
Record: Shares Registered In Your Name </FONT></I></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>If you are a stockholder of
record, you may revoke or change your vote at any time before the final vote at
the Annual Meeting by: </FONT></P>
<TABLE style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse; TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=justify><FONT face="Times New Roman" size=2>signing and returning
      a new proxy card with a later date;<BR>&nbsp;</FONT></P></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=justify><FONT face="Times New Roman" size=2>submitting a
      later-dated vote by telephone or via the Internet &#151; only your latest
      Internet or telephone proxy received by 11:59 p.m., Eastern Time, on May
      17, 2015 will be counted;<BR>&nbsp;</FONT></P></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=justify><FONT face="Times New Roman" size=2>attending the Annual
      Meeting in person and voting again; or<BR>&nbsp;</FONT></P></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=justify><FONT face="Times New Roman" size=2>delivering a written
      revocation to our Corporate Secretary at Geron&#146;s offices, 149 Commonwealth
      Drive, Suite 2070, Menlo Park, California 94025, before the Annual
      Meeting. </FONT></P></TD></TR></TABLE>
<P align=justify><B><I><FONT face="Times New Roman" size=2>Beneficial Owner:
Shares Registered in the Name of a Broker or Bank </FONT></I></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>If you are a beneficial
owner of your shares, you must contact the broker or other nominee holding your
shares and follow their instructions for revoking or changing your
vote.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Is my vote confidential?
</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Yes. Proxy cards, ballots
and voting tabulations that identify stockholders by name are kept confidential.
There are exceptions for contested proxy solicitations or when necessary to meet
legal requirements. In addition, all comments written on a proxy card or
elsewhere will be forwarded to management, but your identity will be kept
confidential unless you ask that your name be disclosed. </FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>How can I obtain a copy
of Geron&#146;s Annual Report on Form 10-K?</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>We will mail to you without
charge, upon written request, a copy of our Annual Report on Form 10-K filed
with the SEC for the fiscal year ended December 31, 2014, as well as a copy of
any exhibit specifically requested. Requests should be sent to: Corporate
Secretary, Geron Corporation, 149 Commonwealth Drive, Suite 2070, Menlo
</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>6</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=left><FONT face="Times New Roman" size=2><A HREF="#toc"><B>Table of Contents</B></A></FONT></P>
<P align=justify><FONT face="Times New Roman" size=2>Park, California 94025. A
copy of our Annual Report on Form 10-K has also been filed with the SEC and may
be accessed from the SEC&#146;s homepage (www.sec.gov). You may also view and
download our 2014 Annual Report on Form 10-K on our website at www.geron.com as
well as www.proxyvote.com.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>How can I find out the
results of the voting at the Annual Meeting? </FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Preliminary voting results
will be announced at the Annual Meeting. Final voting results will be published
by Geron in a Current Report on Form 8-K, filed with the SEC, that we expect to
file within four business days after the Annual Meeting. If final voting results
are not available to us in time to file a Current Report on Form 8-K within four
business days after the Annual Meeting, we intend to file a Current Report on
Form 8-K to publish preliminary results and, within four business days after the
final results are known to us, file an additional Current Report on Form 8-K to
publish the final results.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Who is paying for this
proxy solicitation? </FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>We will pay the entire cost
of solicitation of proxies, including preparation, assembly, printing and
mailing of this Proxy Statement, the proxy card and any additional information
furnished to stockholders. Copies of solicitation materials will be furnished to
banks, brokerage houses, fiduciaries and custodians holding in their names
shares of Common Stock beneficially owned by others to forward to such
beneficial owners. In addition, we may reimburse persons representing beneficial
owners of Common Stock for their costs of forwarding solicitation materials to
such beneficial owners. The original solicitation of proxies by mail may be
supplemented by solicitation by mail, telephone or other electronic means, or in
person, by our directors, officers, or other regular employees, or at our
request, by Alliance Advisors, LLC. No additional compensation will be paid to
directors, officers or other regular employees for such services, but Alliance
Advisors will be paid its customary fee, estimated to be $6,000, to render
solicitation services. </FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>When are stockholder
proposals due for next year&#146;s Annual Meeting? </FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>To be considered for
inclusion in next year&#146;s proxy materials, your proposal must be submitted in
writing by December 8, 2015, to our Corporate Secretary at Geron Corporation,
149 Commonwealth Drive, Suite 2070, Menlo Park, California, 94025, and must
comply with all applicable requirements of Rule 14a-8 promulgated under the
Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;). However, if
our 2015 Annual Meeting of Stockholders is not held between April 18, 2016 and
June 17, 2016, then the deadline will be a reasonable time prior to the time we
begin to print and send our proxy materials.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>If you wish to bring a
proposal before the stockholders or nominate a director at the 2016 Annual
Meeting of Stockholders, but you are not requesting that your proposal or
nomination be included in next year&#146;s proxy materials, you must notify our
Corporate Secretary, in writing, not earlier than the close of business on
January 19, 2016 and not later than the close of business on February 18, 2016.
However, if our 2016 Annual Meeting of Stockholders is not held between April
18, 2016 and July 17, 2016, then the deadline will be the 90<SUP>th</SUP> day
prior to the 2016 Annual Meeting or, if later, the 10<SUP>th</SUP> day following
the day on which public disclosure of the date of the 2016 Annual Meeting of
Stockholders was first made. We also advise you to review Geron&#146;s Bylaws, which
contain additional requirements about advance notice of stockholder proposals
and director nominations. The chairman of the 2016 Annual Meeting of
Stockholders may determine, if the facts warrant, that a matter has not been
properly brought before the meeting and, therefore, may not be considered at the
meeting. Stockholders interested in submitting a proposal are advised to contact
knowledgeable counsel with regard to the detailed requirements of the applicable
securities laws. The submission of a stockholder proposal does not guarantee
that it will be included in our proxy statement. For additional discussion,
refer to the section entitled &#147;Stockholder Nominations and Proposals for 2016
Annual Meeting&#148; on page 54.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>What is householding and
how does it affect me? </FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Some brokers and other
nominee record holders may be participating in the practice of &#147;householding&#148;
proxy statements. This means that only one copy of this Proxy Statement and 2014
Annual Report on Form 10-K or the Notice may have been sent to multiple
stockholders in a stockholder&#146;s household. Once you have received notice from
your broker that they will be &#147;householding&#148; communications to your address,
&#147;householding&#148; will continue </FONT></P>
<P align=center><FONT face="Times New Roman" size=2>7</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=left><FONT face="Times New Roman" size=2><A HREF="#toc"><B>Table of Contents</B></A></FONT></P>
<P align=justify><FONT face="Times New Roman" size=2>until you are notified
otherwise or until you revoke your consent. If, at any time, you no longer wish
to participate in &#147;householding&#148; and would prefer to receive separate copies of
the proxy statement, annual report or the notice of internet availability,
please notify your broker or our Investor Relations department. We will promptly
deliver copies of the Proxy Statement and our 2014 Annual Report on Form 10-K or
the Notice to any stockholder who contacts our Investor Relations department at
(650) 473-7765 or by mail addressed to Investor Relations, Geron Corporation,
149 Commonwealth Drive, Suite 2070, Menlo Park, California 94025, requesting
such copies. If a stockholder is receiving multiple copies of the proxy
statement and annual report at the stockholder&#146;s household and would like to
receive a single copy of the proxy statement and annual report for a
stockholder&#146;s household in the future, stockholders should contact their broker,
other nominee record holder, or our Investor Relations department to request
mailing of a single copy of the proxy statement and annual report. </FONT></P>
<P align=center><B><FONT face="Times New Roman" size=2>MATTERS TO BE CONSIDERED
AT THE 2015 ANNUAL MEETING</FONT></B></P>
<P align=center><B><FONT face="Times New Roman" size=2><A NAME="Proposal1"></A>PROPOSAL 1</FONT></B></P>
<P align=center><B><FONT face="Times New Roman" size=2>ELECTION OF DIRECTORS
</FONT></B></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Board Structure
</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Our Board currently
consists of eight members, seven of whom are &#147;independent,&#148; as that term is
defined by NASDAQ Rule 5605(a)(2). On March 3, 2015, Thomas Hofstaetter, Ph.D.,
notified the Board of his decision to retire from our Board at the end of his
term on the date of the Annual Meeting. Upon his departure, the size of our
Board will be reduced to, and our Board will be comprised of, seven members, six
of whom are &#147;independent,&#148; as that term is defined by NASDAQ Rule
5605(a)(2).</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Our Bylaws provide for the
classification of the Board into three classes, as nearly equal in number as
possible, with staggered terms of office. Our Bylaws also provide that upon
expiration of the term of office for a class of directors, nominees for such
class will be elected for a term of three years or until their successors are
duly elected and qualified.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The term of office of the
Class I directors will expire at the Annual Meeting in May 2015. Effective as of
the date of the Annual Meeting, Thomas Hofstaetter, Ph.D., currently a Class I
director, will retire from the Board. The remaining two Class I nominees, John
A. Scarlett, M.D., and Robert J. Spiegel, M.D., FACP, are currently serving as
our directors. Proxies may only be voted for the two Class I directors nominated
for election at the Annual Meeting. The Class II directors, Hoyoung Huh, M.D.,
Ph.D., and Daniel M. Bradbury, have one year remaining on their terms of office.
The Class III directors, Karin Eastham, V. Bryan Lawlis, Ph.D., and Susan M.
Molineaux, Ph.D., have two years remaining on their terms of office.</FONT></P>
<P align=center><B><FONT face="Times New Roman" size=2>NOMINEES FOR ELECTION TO
THE BOARD OF DIRECTORS<BR>For a Three Year Term Expiring at the<BR>2018 Annual
Meeting </FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Board has selected two
nominees for Class I directors, both of whom are currently directors of Geron
and were previously elected by the stockholders. </FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Set forth below is a brief
biography of each nominee for Class I director, including their ages, the
periods during which they have served as a director of Geron, and information
furnished by them as to principal occupations and public company directorships
held by them. The biographies below also include a discussion of the specific
experience, qualifications, attributes or skills of each nominee that led the
Nominating and Corporate Governance Committee</FONT><B><FONT face="Times New Roman" size=2> </FONT></B><FONT face="Times New Roman" size=2>and the Board to conclude, as of the date of this Proxy Statement, that
each nominee for Class I director should continue to serve as a director. Each
person nominated for election has agreed to serve if elected, and the Board has
no reason to believe that any nominee will be unable to serve.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>8</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=left><FONT face="Times New Roman" size=2><A HREF="#toc"><B>Table of Contents</B></A></FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Class I Director
Nominees (Term Expiring at the 2018 Annual Meeting) </FONT></B></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="2%"><B><FONT face="Times New Roman" size=1>Name</FONT></B></TD>
    <TD noWrap align=left width="28%">&nbsp;</TD>
    <TD noWrap style="text-align: center" width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="3%"><B><FONT face="Times New Roman" size=1>Age</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="17%"><B><FONT face="Times New Roman" size=1>Principal Occupation/Position with
      the Company</FONT></B></TD>
    <TD noWrap align=left width="47%">&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="30%" bgColor=#c0c0c0 colSpan=2><FONT face="Times New Roman" size=2>John A. Scarlett, M.D.</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap style="text-align: center" width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>64</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="64%" bgColor=#c0c0c0 colSpan=2><FONT face="Times New Roman" size=2>President and Chief Executive
  Officer</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="30%" colSpan=2><FONT face="Times New Roman" size=2>Robert J. Spiegel, M.D., FACP</FONT></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="3%"><FONT face="Times New Roman" size=2>65</FONT></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap align=left width="64%" colSpan=2><FONT face="Times New Roman" size=2>Chief Medical Officer, PTC Therapeutics,
      Inc.</FONT></TD></TR></TABLE><BR>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><I><FONT face="Times New Roman" size=2>John A. Scarlett, M.D.,
</FONT></I><FONT face="Times New Roman" size=2>has served as our Chief Executive
Officer and a director since September 2011 and President since January 2012.
Prior to joining Geron, Dr. Scarlett served as President, Chief Executive
Officer and a member of the board of directors of Proteolix, Inc., a
privately-held oncology-oriented biopharmaceutical company, from February 2009
until its acquisition by Onyx Pharmaceuticals, Inc., an oncology-oriented
biopharmaceutical company, in November 2009. From February 2002 until its
acquisition by Ipsen, S.A. in October 2008, Dr. Scarlett served as the Chief
Executive Officer and a member of the board of directors of Tercica, Inc., an
endocrinology-oriented biopharmaceutical company, and also as its President from
February 2002 through February 2007. From March 1993 to May 2001, Dr. Scarlett
served as President and Chief Executive Officer of Sensus Drug Development
Corporation. In 1995, he co-founded Covance Biotechnology Services, Inc., a
contract biopharmaceutical manufacturing operation, and served as a member of
its board of directors from inception to 2000. From 1991 to 1993, Dr. Scarlett
headed the North American Clinical Development Center and served as Senior Vice
President of Medical and Scientific Affairs at Novo Nordisk Pharmaceuticals,
Inc., a wholly-owned subsidiary of Novo Nordisk A/S. Dr. Scarlett holds a B.A.
in chemistry from Earlham College and an M.D. from the University of Chicago,
Pritzker School of Medicine. </FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>As the only management
representative on the Board, Dr. Scarlett brings management&#146;s perspective to
board discussions about Geron&#146;s business and strategic direction. In addition,
the Board believes Dr. Scarlett&#146;s medical background and extensive drug
development experience, which provides substantial understanding of potential
clinical product opportunities, qualifies Dr. Scarlett to be nominated as a
director. </FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><I><FONT face="Times New Roman" size=2>Robert J. Spiegel, M.D.,
FACP,</FONT></I><FONT face="Times New Roman" size=2> has served as a director of
Geron since May 2010. Dr. Spiegel currently serves as Chief Medical Officer of
PTC Therapeutics, Inc., a biopharmaceutical company focused on the development
and commercialization of treatments for rare and neglected disorders. He is also
a director of Edge Therapeutics, Inc., a biopharmaceutical company focused on
products for acute, fatal or debilitating conditions; Sucampo Pharmaceuticals,
Inc., a global biopharmaceutical company focused on the development and
commercialization of medicines to treat gastrointestinal, ophthalmic, and
oncology-based inflammatory disorders; and Avior Computing Corporation, a
governance risk and compliance process technology company. He also is an
Associate Fellow at the University of Pennsylvania Center for Bioethics and an
Associate Professor at the Weill Cornell Medical School. He served as a director
for the Cancer Institute of New Jersey from 1999 to 2009 and as a director of
Cancer Care New Jersey from 1995 to 2011. After 26 years with the
Schering-Plough Corporation (now Merck &amp; Co.), a global healthcare company,
Dr. Spiegel retired in 2009 as Chief Medical Officer and Senior Vice President
of the Schering-Plough Research Institute, the pharmaceutical research arm of
the Schering-Plough Corporation. He initially joined Schering-Plough as Director
of clinical research for oncology and rose to hold various positions including
Vice President of clinical research and Senior Vice President of worldwide
clinical research. As Senior Vice President of worldwide clinical research, Dr.
Spiegel managed Phase 1 to Phase 3 clinical development in all therapy areas,
including allergy, respiratory, cardiovascular, immunology, dermatology,
oncology and infectious diseases. As Chief Medical Officer, Dr. Spiegel was
involved with over 30 New Drug Applications, participated in multiple due
diligence reviews and in-licensing decisions, re-engineered pharmacovigilence
and risk management areas and built a quality system for all research
operations. Following a residency in internal medicine, Dr. Spiegel completed a
fellowship in medical oncology at the National Cancer Institute, and from 1981
to 1999 he held academic positions at the National Cancer Institute and New York
University Cancer Center. Dr. Spiegel holds a B.A. from Yale University and an
M.D. from the University of Pennsylvania.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Board believes Dr.
Spiegel&#146;s extensive medical experience developing oncology products, his deep
understanding of pharmaceutical research and development and broad expertise in
gaining regulatory approval for drug candidates, enhances the Board&#146;s ability to
critically assess the progress and potential of imetelstat, and qualifies Dr.
Spiegel to be nominated as a director.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>9</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<!-- PART B -->

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=justify><FONT face="Times New Roman" size=2><A HREF="#toc"><B>Table of Contents</B></A></font></p>



<P align=justify><B><FONT face="Times New Roman" size=2>Vote Required and Board
Recommendation</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Directors are elected by a
plurality of the votes of the holders of shares present in person or represented
by proxy at the meeting. The two nominees receiving the highest number of &#147;FOR&#148;
votes properly cast in person or by proxy at the meeting will be elected as a
Class I director of Geron. The election of directors is a non-routine matter on
which a broker or other nominee is not empowered to vote. Accordingly, if the
beneficial owner does not give a broker specific instructions, the beneficially
owned shares may not be voted on this proposal and will not be counted in
determining the number of shares necessary for election. Broker non-votes will
not have any effect on the outcome of this proposal. In tabulating the voting
results for the election of directors, only &#147;FOR&#148; and &#147;WITHHOLD&#148; votes are
counted. In the event that any nominee should be unavailable for election as a
result of an unexpected occurrence, such shares will be voted for the election
of such substitute nominee as our Nominating and Corporate Governance Committee
and Board may propose. </FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Although the election of
directors at the Annual Meeting is uncontested and directors are elected by a
plurality of votes cast, and we therefore expect that each of the named nominees
for director will be elected at the Annual Meeting, under our Corporate
Governance Guidelines, any nominee for director is required to submit an offer
of resignation for consideration by the Nominating and Corporate Governance
Committee if such nominee for director (in an uncontested election) receives a
greater number of &#147;WITHHOLD&#148; votes from his or her election than votes &#147;FOR&#148;
such election. In such case, the Nominating and Corporate Governance Committee
will then consider all of the relevant facts and circumstances and recommend to
the Board the action to be taken with respect to such offer of resignation. For
more information on this policy see the section entitled &#147;Corporate Governance
Matters &#150; Corporate Governance Guidelines&#148;. </FONT></P>
<P align=center><B><FONT face="Times New Roman" size=2>The Board of Directors
Unanimously Recommends That Stockholders<BR>Vote <U>FOR</U> the Election of Each
Nominee to the Board of Directors</FONT></B></P>
<P align=center><B><FONT face="Times New Roman" size=2>MEMBERS OF THE BOARD OF
DIRECTORS CONTINUING IN OFFICE</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Set forth below is a brief
biography of each continuing director composing the remainder of the Board with
terms expiring as shown, including their ages, the periods during which they
have served as a director of Geron, and information furnished by them as to
principal occupations and public company directorships held by them. The
biographies below also include a discussion of the specific experience,
qualifications, attributes or skills of each continuing director that led the
Nominating and Corporate Governance Committee and the Board to conclude, as of
the date of this Proxy Statement, that the applicable director should continue
to serve as a director.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Class II Directors (Term
Expiring at the 2016 Annual Meeting)</FONT></B></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="60%" border=0>

  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><B><FONT face="Times New Roman" size=1>Name</FONT></B></TD>
    <TD noWrap align=left width="94%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="2%"><B><FONT face="Times New Roman" size=1>Age</FONT></B></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><B><FONT face="Times New Roman" size=1>Principal Occupation</FONT></B></TD>
    <TD noWrap align=left width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="95%" bgColor=#c0c0c0 colSpan=2><FONT face="Times New Roman" size=2>Hoyoung Huh, M.D., Ph.D.</FONT></TD>
    <TD noWrap style="text-align: center" width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>45</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0 colSpan=2><FONT face="Times New Roman" size=2>Independent Director</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="95%" colSpan=2><FONT face="Times New Roman" size=2>Daniel M. Bradbury</FONT></TD>
    <TD noWrap style="text-align: center" width="2%"><FONT face="Times New Roman" size=2>53</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%" colSpan=2><FONT face="Times New Roman" size=2>Independent
Director</FONT></TD></TR></TABLE><BR>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><I><FONT face="Times New Roman" size=2>Hoyoung Huh, M.D.,
Ph.D., </FONT></I><FONT face="Times New Roman" size=2>has been the Chairman of
the Board since September 2011, served as our interim Executive Chairman from
February 2011 to September 2011, and has served as a director of Geron since May
2010. He is Chairman of the board of directors of CytomX Therapeutics, Inc., an
emerging medical technology company. Dr. Huh also is a director of AntriaBio,
Inc., a biopharmaceutical company focused on developing novel therapeutic
products for the diabetes market. Additionally, Dr. Huh serves on the boards of directors of
several privately-held companies. Dr. Huh served as a director of ADDEX
Pharmaceuticals, a pharmaceutical discovery and development company, from May
2011 to May 2014. From February 2008 to December 2011, Dr. Huh
was Chairman of the board of directors of BiPar Sciences, Inc., a wholly-owned
subsidiary of Sanofi-Aventis, a global pharmaceutical company developing
treatments in cardiology, oncology, central nervous system disorders, metabolic
diseases, ophthalmology and vaccines, since the April 2009 merger of BiPar and
Sanofi-Aventis, and served as BiPar&#146;s President and Chief Executive Officer from
February 2008 to December 2009. Dr. Huh served on the board of directors of
Facet Biotech (a wholly-owned subsidiary of Abbott, a global, broad-based health
care company devoted to the discovery, development, manufacture and marketing of
pharmaceuticals and medical products, including nutritionals, devices and
diagnostics) from September 2009 to April 2010. From February 2008 to May 2009,
he was a member of the board of directors at Nektar Therapeutics, a
clinical-stage </FONT></P>
<P align=center><FONT face="Times New Roman" size=2>10</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=justify><FONT face="Times New Roman" size=2><A HREF="#toc"><B>Table of Contents</B></A></font></p>
<P align=justify><FONT face="Times New Roman" size=2>biopharmaceutical company developing small
molecule drugs, peptides and other biologic drug candidates as treatments for
oncology, pain, anti-infectives, anti-virals and immunology. From March 2005 to
February 2008, Dr. Huh held positions as Nektar&#146;s Chief Operating Officer and
Senior Vice President of Business Development and Marketing where he was
responsible for the company&#146;s worldwide business development, marketing and
manufacturing and led Nektar&#146;s PEGylation business. Prior to Nektar, Dr. Huh was
a partner at McKinsey &amp; Company, a global management consulting firm, where
he was in the biotechnology and biopharmaceutical sectors. Prior to McKinsey, he
held positions as a physician and researcher at Cornell University Medical
College and Sloan-Kettering Cancer Center. Dr. Huh holds an A.B. in biochemistry
from Dartmouth College and an M.D. and Ph.D. in genetics and cell biology from
Cornell University Medical College and Sloan-Kettering Institute.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Board believes Dr.
Huh&#146;s management and operational experience as President and Chief Executive
Officer of BiPar Sciences and Chief Operating Officer of Nektar Therapeutics,
his significant expertise with implementing strategic and line management
initiatives from McKinsey and his knowledge of biotechnology and pharmaceutical
collaborations, qualifies Dr. Huh to serve as a director and serve as Chairman
of the Board.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><I><FONT face="Times New Roman" size=2>Daniel M.
Bradbury</FONT></I><FONT face="Times New Roman" size=2> has served as a director
of Geron since September 2012. He also serves as a member of the boards of
directors of Illumina, Inc., a manufacturer of life-science tools and integrated
systems for the analysis of genetic variation and biological function; Corcept
Therapeutics, a company focused on the discovery and development of drugs that
regulate the effects of cortisol; BioCon Ltd., a company focused on reducing
therapy costs of chronic diseases like diabetes, cancer and autoimmune diseases;
and BioMed Realty, a real estate investment trust focused on providing real
estate to the life science industry, as well as being a member of the board of
trustees of the Keck Graduate Institute. He also serves on the University of
California San Diego, Rady School of Management&#146;s Advisory Council, Investor
Growth Capital Advisory Board and the BioMed Ventures Advisory Committee. Mr.
Bradbury served as Chief Executive Officer of Amylin Pharmaceuticals, Inc., a
biopharmaceutical company focused on diabetes and metabolic disorders, from
March 2007 until its acquisition by Bristol-Myers Squibb Company in August 2012.
Mr. Bradbury served as Amylin&#146;s President from June 2006 until March 2007, as
Chief Operating Officer from June 2003 until June 2006, as Executive Vice
President from June 2000 until June 2003 and in other positions in corporate
development and marketing from 1994 until 2000. In addition, Mr. Bradbury served
as a member of the board of directors of Amylin from June 2006 until August
2012. Prior to joining Amylin, he spent ten years at SmithKline Beecham
Pharmaceuticals, a pharmaceutical company, holding a number of sales and
marketing positions. He received a Bachelor of Pharmacy from Nottingham
University and a Diploma in Management Studies from Harrow and Ealing Colleges
of Higher Education in the United Kingdom.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Board believes that Mr.
Bradbury&#146;s extensive experience in the biopharmaceutical industry, together with
his experience in the research, development and commercialization of
pharmaceutical drug products, qualifies Mr. Bradbury to serve as a
director.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Class III Directors
(Term Expiring at the 2017 Annual Meeting)</FONT></B></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><B><FONT face="Times New Roman" size=1>Name</FONT></B></TD>
    <TD noWrap align=left width="94%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="1%"><B><FONT face="Times New Roman" size=1>Age</FONT></B></TD>
    <TD noWrap align=left width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><B><FONT face="Times New Roman" size=1>Principal
      Occupation</FONT></B></TD>
    <TD noWrap align=left width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="95%" bgColor=#c0c0c0 colSpan=2><FONT face="Times New Roman" size=2>Karin Eastham</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>65</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0 colSpan=2><FONT face="Times New Roman" size=2>Independent Director</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="95%" colSpan=2><FONT face="Times New Roman" size=2>V.
      Bryan Lawlis, Ph.D.</FONT></TD>
    <TD noWrap style="text-align: center" width="1%"><FONT face="Times New Roman" size=2>63</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="2%" colSpan=2><FONT face="Times New Roman" size=2>President and Chief Executive Officer, Itero
      Biopharmaceuticals LLC</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="95%" bgColor=#c0c0c0 colSpan=2><FONT face="Times New Roman" size=2>Susan M. Molineaux,
Ph.D.</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>61</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0 colSpan=2><FONT face="Times New Roman" size=2>President and Chief Executive
      Officer, Calithera Biosciences, Inc.</FONT></TD></TR></TABLE><BR>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><I><FONT face="Times New Roman" size=2>Karin
Eastham</FONT></I><FONT face="Times New Roman" size=2> has served as a director
of Geron since March 2009. Ms. Eastham also serves as a director for MorphoSys
AG, a Frankfurt Stock Exchange-listed biotechnology company; Illumina, Inc., a
manufacturer of life science tools and reagents; and Veracyte, Inc., a molecular
diagnostics company. Ms. Eastham also served as a director of Trius
Therapeutics, Inc., a biopharmaceutical company, from 2009 until its sale in
2013; Amylin Pharmaceuticals, Inc., a biopharmaceutical company, from 2005 until
its sale in 2012; Genoptix, Inc., a provider of specialized laboratory services,
from 2008 until its sale in 2011; Tercica, Inc., a biopharmaceutical company,
from 2003 until its sale in 2008; and SGX Pharmaceuticals, Inc., a
biopharmaceutical company, from 2005 until its sale in 2008. From May 2004 to
September 2008, she served as Executive Vice President and Chief Operating
Officer, and as a member of the Board of Trustees, of Burnham Institute for
Medical Research, a non-profit corporation engaged in basic biomedical research.
From 1999 to 2004, Ms. Eastham served as Senior Vice President, Finance, Chief
Financial Officer and Secretary of Diversa Corporation, a biotechnology company.
</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>11</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=justify><FONT face="Times New Roman" size=2><A HREF="#toc"><B>Table of Contents</B></A></font></p>
<P align=justify><FONT face="Times New Roman" size=2>She previously held similar
positions with CombiChem, Inc., a computational chemistry company, and Cytel
Corporation, a biopharmaceutical company. Ms. Eastham also held several
positions, including Vice President, Finance, at Boehringer Mannheim
Corporation, a biopharmaceutical company, from 1976 to 1988. Ms. Eastham holds a
B.S. and an M.B.A. from Indiana University and is a Certified Public
Accountant.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Board believes Ms.
Eastham&#146;s understanding of biotechnology companies combined with her business
leadership and financial experience, her contributions to the Board&#146;s
understanding of corporate governance and strategy for life sciences companies
through her experience as a director in the biopharmaceutical industry and her
extensive senior management experience in the biopharmaceutical industry,
particularly in key corporate finance and accounting positions, qualifies Ms.
Eastham to serve as a director.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><I><FONT face="Times New Roman" size=2>V. Bryan Lawlis,
Ph.D.,</FONT></I><FONT face="Times New Roman" size=2> has served as a director
of Geron since March 2012. He currently serves as a director for BioMarin
Pharmaceuticals, Inc., a biopharmaceutical company specializing in rare genetic
diseases, Coherus Biosciences, a biosimilar-oriented biologics platform company,
and several privately-held biotechnology companies. From August 2013 to
September 2014, Dr. Lawlis served as a director for KaloBios Pharmaceuticals,
Inc., a biopharmaceutical company specializing in customized antibodies for the
treatment of human disease. Dr. Lawlis is the President and Chief Executive
Officer of Itero Biopharmaceuticals LLC, a privately-held, early stage
biopharmaceutical company that he co-founded in 2006. Dr. Lawlis served as
President and Chief Executive Officer of Aradigm Corporation, a specialty drug
company focused on drug delivery technologies, from August 2004, and served on
its board of directors from February 2005; continuing in both capacities until
August 2006. Dr. Lawlis served as Aradigm Corporation&#146;s President and Chief
Operating Officer from June 2003 to August 2004 and its Chief Operating Officer
from November 2001 to June 2003. Previously, Dr. Lawlis co-founded Covance
Biotechnology Services, a contract biopharmaceutical manufacturing operation,
served as its President and Chief Executive Officer from 1996 to 1999, and
served as Chairman from 1999 to 2001, when it was sold to Diosynth RTP, Inc., a
division of Akzo Nobel, NV. From 1981 to 1996, Dr. Lawlis was employed at
Genencor, Inc. and Genentech, Inc. His last position at Genentech was Vice
President of Process Sciences. Dr. Lawlis holds a B.A. in microbiology from the
University of Texas at Austin and a Ph.D. in biochemistry from Washington State
University.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Board believes Dr.
Lawlis&#146; extensive experience in manufacturing biotechnology and other
pharmaceutical products, research and development of drug products and managing
and conducting clinical trials and drug regulatory processes, qualifies Dr.
Lawlis to serve as a director.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><I><FONT face="Times New Roman" size=2>Susan M. Molineaux,
Ph.D., </FONT></I><FONT face="Times New Roman" size=2>has served as a director
of Geron since September 2012. She has been Chief Executive Officer and
President of Calithera Biosciences, Inc., a biotechnology company developing
oncology therapeutics, since co-founding the company in June 2010. Prior to
Calithera, Dr. Molineaux co-founded Proteolix, Inc., a privately-held
oncology-oriented biopharmaceutical company, where she served as Chief
Scientific Officer from December 2003 until December 2005 and from February 2009
until November 2009, and as President and Chief Executive Officer from January
2006 until February 2009. Dr. Molineaux was responsible for leading the
development of Proteolix&#146;s second-generation proteasome inhibitor, carfilzomib
(now marketed as Kyprolis), for the treatment of multiple myeloma, from
discovery through completion of clinical trials for accelerated approval, until
the company&#146;s acquisition by Onyx Pharmaceuticals, Inc., a global
oncology-oriented biopharmaceutical company, in November 2009. From 2000 to
2003, Dr. Molineaux served as Vice President of Biology at Rigel
Pharmaceuticals, Inc., a biopharmaceutical company focused on inflammatory and
autoimmune diseases. She served as Vice President of Biology at Praelux, Inc.
from 1999 to 2000, and from 1994 through 1999, as Vice President of Drug
Development at Praecis Pharmaceuticals, Inc., an oncology-focused
biopharmaceutical company. From 1989 until 1994, she was a scientist in the
Immunology group at Merck &amp; Co., a pharmaceutical company. Dr. Molineaux
holds a B.S. in biology from Smith College and a Ph.D. in molecular biology from
Johns Hopkins University, and completed a postdoctoral fellowship at Columbia
University. She currently serves as the Chairman of Bay Bio, Northern
California&#146;s Life Science Association, and as a member of the board of directors
of We Teach Science, a San Francisco Bay Area mentoring program for students in
math and science.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Board believes Dr.
Molineaux&#146;s extensive experience in pharmaceutical and oncology drug
development, and her expertise in managing and conducting clinical trials,
qualifies Dr. Molineaux to serve as a director.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>12</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=justify><FONT face="Times New Roman" size=2><A HREF="#toc"><B>Table of Contents</B></A></font></p>
<P align=center><B><FONT face="Times New Roman" size=2><A NAME="CorpGov"></A>CORPORATE GOVERNANCE
MATTERS</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>We have an ongoing
commitment to excellence in corporate governance and business practices. In
furtherance of this commitment, we regularly monitor developments in the area of
corporate governance and review our processes, policies and procedures in light
of such developments. We comply with the rules and regulations promulgated by
the SEC and NASDAQ, and implement additional corporate governance practices that
we believe are in the best interest of Geron and our stockholders.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Corporate Governance
Guidelines</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Our Board has adopted
Corporate Governance Guidelines that set forth key principles to guide the Board
in their exercise of responsibilities and serve the interests of Geron and our
stockholders. In February 2014, the Board amended the Corporate Governance
Guidelines to include provisions whereby any nominee for director would submit
an offer of resignation for consideration by the Nominating and Corporate
Governance Committee of the Board, if such nominee for director in an
uncontested election receives a greater number of votes &#147;withheld&#148; from his or
her election than votes &#147;for&#148; such election. The Nominating and Corporate
Governance Committee would then consider all of the relevant facts and
circumstances and recommend to the Board the action to be taken with respect to
such offer of resignation. Promptly following the Board&#146;s decision, we would
disclose that decision and an explanation of such decision in a filing with the
SEC or a press release. The current form of the Corporate Governance Guidelines
can be found on the Corporate Governance page under the Investor Relations
section of our website at www.geron.com. In addition, these guidelines are
available in print to any stockholder who requests a copy. Please direct all
requests to our Corporate Secretary, Geron Corporation, 149 Commonwealth Drive,
Suite 2070, Menlo Park, California 94025. In accordance with these guidelines, a
member of our Board may serve as a director of another company only to the
extent such position does not conflict or interfere with such person&#146;s service
as a director of Geron.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Board
Independence</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>In accordance with NASDAQ
listing standards and Geron&#146;s Corporate Governance Guidelines, our Board has
affirmatively determined that all nominees for election at the Annual Meeting
and all current and continuing directors, other than Dr. Scarlett, are
independent under NASDAQ listing standards. The Board consults with our counsel
to ensure that the Board&#146;s determinations are consistent with relevant
securities and other laws and regulations regarding the definition of
&#147;independent,&#148; including those set forth in pertinent listing standards of NASDAQ, as in effect from time-to-time.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>One class of the Board is
elected annually, and each class of directors stands for election every three
years. Our Board is comprised of eight directors, one of whom is an executive
officer and seven of whom were affirmatively determined by the Board to be
independent, meeting the objective requirements set forth by the SEC and NASDAQ,
and having no relationship, direct or indirect, to Geron other than as
stockholders or through their service on the Board. Commencing on May 18, 2015,
the date of the Annual Meeting, our Board will be comprised of seven directors:
one non-independent member, Dr. Scarlett, our Chief Executive Officer, and six
members who have been affirmatively determined by the Board to be independent,
meeting the objective requirements set forth by the SEC and NASDAQ, and having
no relationship direct or indirect, to Geron other than as stockholders or
through their service on the Board.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Board Leadership
Structure</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Board has an
independent Chair, Dr. Huh, who has authority, among other things, to call and
preside over Board meetings, including meetings of the independent directors, to
set meeting agendas and to determine materials to be distributed to the Board.
Accordingly, the Board Chair has substantial ability to shape the work of the
Board. We believe that separation of the positions of Board Chair and Chief
Executive Officer reinforces the independence of the Board in its oversight of
the business and affairs of Geron. As a result, we believe that having an
independent Board Chair enhances the effectiveness of the Board as a whole. In
addition, we believe that having an independent Board Chair creates an
environment that is more conducive to objective evaluation and oversight of
management&#146;s performance, increasing management accountability and improving the
ability of the Board to monitor whether management&#146;s actions are in the best
interests of Geron and our stockholders.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>13</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=justify><FONT face="Times New Roman" size=2><A HREF="#toc"><B>Table of Contents</B></A></font></p>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Board regularly meets
in executive sessions without the presence of the non-independent director or
management.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Board&#146;s Role in Risk
Oversight</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Geron is subject to a
variety of risks, which generally include any undesired event, circumstance or
outcome that could affect Geron&#146;s ability to achieve its objectives or adversely
impact Geron&#146;s business, operations or financial condition. Some risks may be
readily perceived and even quantified, while others are unexpected or
unforeseeable. Risks can be external, such as those arising from the
macroeconomic or industry environment, government policies or regulations,
competitors&#146; activities or natural disasters. Alternatively, risks can arise as
a result of our business or financial activities.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Board and Geron&#146;s
management team work together to manage Geron&#146;s risks. It is management&#146;s
responsibility to manage risk and bring to the Board&#146;s attention the material
risks to the Company. The Board has an active role in overseeing management of
the Company&#146;s risks. The Board regularly reviews information regarding our
credit, liquidity and operations, as well as the risks associated with each. In
addition, our Corporate Governance Guidelines specify that each of our Board
committees oversees the risks within its areas of responsibilities. While each
committee is responsible for evaluating certain risks and overseeing the
management of such risks within its respective oversight area, the entire Board
is regularly informed through committee reports about such risks.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Compensation Committee
of the Board is responsible for overseeing the management of risks relating to
Geron&#146;s employment policies and executive compensation plans and arrangements.
In connection with the structuring of the compensation elements for executive
officers, the Compensation Committee, together with the Board, considers whether
such programs, individually or in the aggregate, encourage executive officers to
take unnecessary risks.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Audit Committee of the
Board oversees management of financial risks. In addition to fulfilling its
responsibilities for the oversight of our financial reporting processes and
annual audit of Geron&#146;s financial statements, the Audit Committee also reviews
with the independent auditors and the Company&#146;s management the adequacy and
effectiveness of our policies and procedures to assess, monitor and manage
business risk and Geron&#146;s ethical compliance program. The Audit Committee takes
the appropriate actions to set the best practices and highest standards for
quality financial reporting, sound business risk practices and ethical
behavior.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Nominating and
Corporate Governance Committee of the Board manages Geron&#146;s corporate governance
practices, including certain risks that those practices are intended to address.
In addition, the Nominating and Corporate Governance Committee reviews risks
associated with the independence of the Board, potential conflicts of interest
and risks relating to management and Board succession planning.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Board Committees and
Meetings</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>It is Geron&#146;s policy to
encourage directors to attend annual meetings of stockholders. All of our
current directors attended our 2014 Annual Meeting. During the fiscal year ended
December 31, 2014, the Board held nine meetings. The Board has an Audit
Committee, a Compensation Committee, and a Nominating and Corporate Governance
Committee. During the fiscal year ended December 31, 2014, each of the directors
attended at least 75% of the aggregate number of meetings of the Board and the
committees on which the director served, held during the portion of the last
fiscal year for which he or she was a director or committee member.</FONT></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2>Audit
Committee</FONT></I></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Audit Committee, which
is comprised of Ms. Eastham, Mr. Bradbury and Dr. Lawlis, met seven times in
2014. All of the members of the Audit Committee are, &#147;independent&#148; as required
by NASDAQ Rule 5605(c)(2)(A). The Board has determined that all of the members
of the Audit Committee are financially literate and that two members of the
Audit Committee, Ms. Eastham and Mr. Bradbury, have accounting and financial
management expertise that qualifies each as an &#147;Audit Committee Financial
Expert,&#148; as such term is defined in Item 407(d)(5) of Regulation S-K promulgated
by the SEC. The Audit Committee&#146;s responsibilities include: (i) sole authority
to select, oversee and replace Geron&#146;s independent registered public accounting
firm and pre-approve any fees paid to such firm, (ii) consulting with the
independent auditors with regard to the plan and scope of the annual </FONT></P>
<P align=center><FONT face="Times New Roman" size=2>14</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>


<P align=justify><FONT face="Times New Roman" size=2><A HREF="#toc"><B>Table of Contents</B></A></font></p>
<P align=justify><FONT face="Times New Roman" size=2>audit of financial
statements, (iii) reviewing, in consultation with the independent auditors,
their report of the audit or proposed report of the audit, and the accompanying
management letter, if any, and (iv) consulting with the independent auditors and
management with regard to the adequacy of Geron&#146;s internal controls. The Audit
Committee operates under a written charter that satisfies the applicable
standards of the SEC and NASDAQ. A copy of the Audit Committee charter is
available on our website at www.geron.com. See more information about the Audit
Committee in the Audit Committee report on page 50.</FONT></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2>Compensation
Committee</FONT></I></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Compensation Committee,
which is comprised of Drs. Hofstaetter, Lawlis and Spiegel, met seven times in
2014. Dr. Hofstaetter will retire from the Board and the Compensation Committee,
and the Board has appointed Ms. Eastham to the Compensation Committee, in each
case effective as of the date of our Annual Meeting, and thereafter our
Compensation Committee will be comprised of Drs. Lawlis and Spiegel and Ms.
Eastham. All of the current members of the Compensation Committee in 2014 are,
and Ms. Eastham, who will join the Compensation Committee on the date of the
Annual Meeting, is &#147;independent,&#148; as required by NASDAQ Rules 5605(a)(2) and
5605(d)(2). In determining whether Drs. Hofstaetter, Lawlis and Spiegel and Ms.
Eastham are independent within the meaning of NASDAQ Rules pertaining to
membership of the Compensation Committee, our Board determined, based on its
consideration of factors specifically relevant to determining whether any such
director has a relationship to us that is material to that director&#146;s ability to
be independent from management in connection with the duties of a compensation
committee member, that no member of the Compensation Committee has a
relationship that would impair that member&#146;s ability to make independent
judgments about our executive compensation.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Compensation
Committee&#146;s responsibilities include making recommendations concerning
compensation of executive officers, administering Geron&#146;s incentive compensation
and benefit plans, and performing such other functions regarding compensation as
the Board may delegate. In addition, the Compensation Committee has authority to
administer the 2011 Incentive Award Plan (the &#147;2011 Plan&#148;) and the 2014 Employee
Stock Purchase Plan. The Compensation Committee operates under a written charter
that satisfies the applicable standards of NASDAQ. A copy of the Compensation
Committee charter is available on our website at www.geron.com.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Under its charter, the
Compensation Committee has the sole authority, as it deems appropriate, to
retain and/or replace, at Geron&#146;s expense, as needed, any independent counsel,
compensation and benefits consultants and other outside experts or advisors as
the Compensation Committee believes to be necessary or appropriate. In this
regard, the Compensation Committee has engaged Radford, an Aon Hewitt Company
(&#147;Radford&#148;), since December 2011 as a compensation consultant in evaluating
certain executive compensation. For information regarding the Compensation
Committee&#146;s processes and procedures for the consideration and determination of
executive compensation, including the role of Radford and our Chief Executive
Officer in the determination of executive compensation, see the section entitled
&#147;Compensation Discussion and Analysis &#150; Role of the Compensation Committee&#148; on
page 27. With respect to director compensation matters, our Board determines and
sets non-employee director compensation. Our compensation arrangements for our
non-employee directors, including Radford&#146;s role with respect to such
arrangements for 2014, are described under the section entitled &#147;Compensation of
Directors.&#148; The charter of the Compensation Committee allows it to delegate
responsibilities to a subcommittee of the Compensation Committee, but only to
the extent consistent with our certificate of incorporation, Bylaws, NASDAQ
rules and Section 162(m) of the Internal Revenue Code of 1986, as amended (the
&#147;Code&#148;).</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><U>Compensation Committee
Interlocks and Insider Participation</U></FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Drs. Hofstaetter, Lawlis
and Spiegel served on the Compensation Committee for the entire fiscal year
ended December 31, 2014. Not one of Drs. Hofstaetter, Lawlis or Spiegel is a
former or current officer or employee of Geron. Effective on the date of the
Annual Meeting, Dr. Hofstaetter will retire from Compensation Committee, and Ms.
Eastham will join the Compensation Committee. Ms. Eastham is not a former or
current officer or employee of Geron. None of our executive officers serves as a
member of a compensation committee of any entity that has one or more executive
officers serving as a member of our Board or Compensation Committee.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>15</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=justify><FONT face="Times New Roman" size=2><A HREF="#toc"><B>Table of Contents</B></A></font></p>
<P align=justify><B><I><FONT face="Times New Roman" size=2>Nominating and
Corporate Governance Committee</FONT></I></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Nominating and
Corporate Governance Committee&#146;s responsibilities include developing, reviewing
and recommending to the Board corporate governance guidelines and principles
applicable to Geron, making recommendations to the Board for candidates to be
nominated for election or re-election as a director by the stockholders or by
the Board and the corporate governance functions described in the Nominating and
Corporate Governance Committee&#146;s charter. The members of the Nominating and
Corporate Governance Committee are Ms. Eastham and Drs. Molineaux and Huh. The
members of the Nominating and Corporate Governance Committee are &#147;independent&#148;
as defined in NASDAQ Rule 5605(a)(2). The Nominating and Corporate Governance
Committee met on two occasions during 2014. The Nominating and Corporate
Governance Committee will consider nominees for director nominated by
stockholders upon submission in writing to our Corporate Secretary of the names
of such nominees in accordance with our Bylaws. Members of the Nominating and
Corporate Governance Committee also obtain recommendations for potential
directors from their and other Board members&#146; contacts in our industry, and may
from time to time engage a search firm to assist in identifying potential
directors. The Nominating and Corporate Governance Committee will investigate,
evaluate and interview, as appropriate, a director candidate with regard to his
or her individual characteristics as well as how those characteristics fit with
the needs of the Board as a whole. The Nominating and Corporate Governance
Committee operates under a written charter that satisfies the applicable
standards of NASDAQ. A copy of the Nominating and Corporate Governance Committee
charter is available on our website at www.geron.com. Specific qualifications
and the process for identifying and recommending director candidates are
provided in more detail under the section entitled &#147;Stockholder Nominations and
Proposals for 2016 Annual Meeting&#148; on page 54.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Code of
Conduct</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>In 2003, we adopted a Code
of Conduct, which is available in its entirety on the Corporate Governance page
in the Investor Relations section of our website at www.geron.com and to any
stockholder otherwise requesting a copy. All our employees, officers, and
directors, including the Chief Executive Officer and Chief Financial Officer,
are required to adhere to the Code of Conduct in discharging their work-related
responsibilities. Employees are required to report any conduct that they believe
in good faith to be an actual or apparent violation of the Code of Conduct.
Amendments to the Code of Conduct, and any waivers from the Code of Conduct
granted to directors or executive officers, will be made available through our
website as they are adopted. Accordingly, we intend to satisfy the disclosure
requirement under Item 5.05 of Form 8-K regarding an amendment to, or waiver
from, a provision of the Code of Conduct by posting such information on our
website at the website address and location specified above.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>In keeping with the
Sarbanes-Oxley Act of 2002, the Audit Committee has established procedures for
the receipt and handling of complaints received by us regarding accounting,
internal accounting controls or auditing matters. Contact information for the
Chairperson of the Audit Committee has been distributed to all employees to
allow for the confidential, anonymous submission by our employees of concerns
regarding accounting or auditing matters.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Communications with the
Board</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Stockholders wishing to
communicate with the Board, or with a specific Board member, may do so by
writing to the Board, or to the particular Board member, and delivering the
communication in person or mailing it to: Board of Directors, c/o Stephen N.
Rosenfield, Corporate Secretary, Geron Corporation, 149 Commonwealth Drive,
Suite 2070, Menlo Park, CA 94025. All mail addressed in this manner will be
delivered to the Chair or Chairs of the Committees with responsibilities
touching most closely on the matters addressed in the communication. From
time-to-time, the Board may change the process by means of which stockholders
may communicate with the Board or its members. Please refer to our website for
any changes to this process.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>16</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=justify><FONT face="Times New Roman" size=2><A HREF="#toc"><B>Table of Contents</B></A></font></p>
<P align=center><B><FONT face="Times New Roman" size=2><A NAME="Compensation"></A>COMPENSATION OF
DIRECTORS</FONT></B></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Cash
Compensation</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>In March 2014, the
Compensation Committee recommended and the Board adopted a Non-Employee
Director Compensation Policy (the &#147;Director Compensation Policy&#148;) that outlines
cash and equity compensation automatically payable to non-employee members of
the Board, unless such non-employee director declines receipt of such cash or
equity compensation by written notice to us. Based on their evaluation, Radford
did not recommend any changes to the compensation arrangements for our
non-employee directors in 2014. The following table describes the annual cash
compensation applicable to each role performed by non-employee directors in
2014:</FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="92%" colSpan=2></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"><B><FONT face="Times New Roman" size=1>Base</FONT></B></TD>
    <TD style="text-align: center" width="1%"></TD>
    <TD style="text-align: center" width="5%" colSpan=4><B><FONT face="Times New Roman" size=1>Additional</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><B><FONT face="Times New Roman" size=1>Role</FONT></B></TD>
    <TD noWrap align=left width="91%">&nbsp;</TD>
    <TD noWrap style="text-align: center" width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="1%"><B><FONT face="Times New Roman" size=1>Retainer</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=4><B><FONT face="Times New Roman" size=1>Retainer</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="92%" bgColor=#c0c0c0 colSpan=2><FONT face="Times New Roman" size=2>Board member</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>$42,500</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>N/A</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="92%" colSpan=2><FONT face="Times New Roman" size=2>Chairman of the Board</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>N/A</FONT></TD>
    <TD noWrap align=left width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD noWrap align=left width="1%">&nbsp;&nbsp; </TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>30,000</FONT></TD>
    <TD noWrap align=right width="1%">&nbsp;&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="92%" bgColor=#c0c0c0 colSpan=2><FONT face="Times New Roman" size=2>Audit Committee Chair<SUP>(1)</SUP></FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>N/A</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>25,000</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="92%" colSpan=2><FONT face="Times New Roman" size=2>Compensation Committee
      Chair<SUP>(1)</SUP></FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>N/A</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>15,000</FONT></TD>
    <TD noWrap align=right width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="92%" bgColor=#c0c0c0 colSpan=2><FONT face="Times New Roman" size=2>Nominating and Corporate Governance Committee
      Chair<SUP>(1)</SUP></FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>N/A</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>10,000</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="92%" colSpan=2><FONT face="Times New Roman" size=2>Audit Committee member</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>N/A</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>12,500</FONT></TD>
    <TD noWrap align=right width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="92%" bgColor=#c0c0c0 colSpan=2><FONT face="Times New Roman" size=2>Compensation Committee member</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>N/A</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>7,500</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="92%" colSpan=2><FONT face="Times New Roman" size=2>Nominating and Corporate Governance Committee
      member</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>N/A</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>5,000</FONT></TD>
    <TD noWrap align=right width="1%"></TD></TR></TABLE><div>____________________</div><BR>
<P align=justify><FONT face="Times New Roman" size=2>(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Committee Chair does not also
receive additional Committee member compensation.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>In 2014, the annual
non-employee director cash compensation was paid quarterly in arrears in cash,
or, at each director&#146;s election, in fully vested shares of our Common Stock
issued under the 2011 Plan based on the closing price of our Common Stock on the
NASDAQ Global Select Market on the date retainers would have otherwise been
paid.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Additionally, under the
Director Compensation Policy, non-employee directors are eligible to receive
equity grants, as more fully described below under the sub-section entitled
&#147;Equity Compensation.&#148; Non-employee directors also receive reimbursement for
out-of-pocket expenses incurred in connection with attendance at meetings of the
Board.</FONT></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2>Director Compensation
Table</FONT></I></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The following table
provides compensation information for the fiscal year ended December 31, 2014
(&#147;fiscal 2014&#148;), for each non-employee member of the Board who served in such
capacity during fiscal 2014. Dr. Scarlett does not receive any compensation for
his Board service.</FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="90%" colSpan=2></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="3%" colSpan=3><B><FONT face="Times New Roman" size=1>Fees</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%" colSpan=2></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="3%" colSpan=3><B><FONT face="Times New Roman" size=1>Earned</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%" colSpan=2></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="3%" colSpan=3><B><FONT face="Times New Roman" size=1>or Paid in</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="2%" colSpan=2><B><FONT face="Times New Roman" size=1>Option</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%" colSpan=2></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="3%" colSpan=3><B><FONT face="Times New Roman" size=1>Cash</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="2%" colSpan=2><B><FONT face="Times New Roman" size=1>Awards</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="2%" colSpan=2><B><FONT face="Times New Roman" size=1>Total</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><B><FONT face="Times New Roman" size=1>Director</FONT></B></TD>
    <TD noWrap align=left width="89%">&nbsp;</TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="3%" colSpan=3><B><FONT face="Times New Roman" size=1>($)</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="2%" colSpan=2><B><FONT face="Times New Roman" size=1>($)<SUP>(1)</SUP></FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"><B><FONT face="Times New Roman" size=1><SUP></SUP></FONT></B></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="2%" colSpan=2><B><FONT face="Times New Roman" size=1>($)</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%" bgColor=#c0c0c0 colSpan=2><FONT face="Times New Roman" size=2>Bradbury, Daniel</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>54,999</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2><SUP>(2)</SUP></FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>48,951</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>103,950</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%" colSpan=2><FONT face="Times New Roman" size=2>Eastham, Karin</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>72,499</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2><SUP>(3)</SUP></FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>48,951</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>121,450</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%" bgColor=#c0c0c0 colSpan=2><FONT face="Times New Roman" size=2>Hofstaetter, Thomas<SUP>(4)</SUP></FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>50,000</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>48,951</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>98,951</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%" colSpan=2><FONT face="Times New Roman" size=2>Huh,
      Hoyoung</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>77,499</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2><SUP>(5)</SUP></FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>48,951</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>126,450</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%" bgColor=#c0c0c0 colSpan=2><FONT face="Times New Roman" size=2>Lawlis, V. Bryan</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>62,500</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>48,951</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>111,451</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%" colSpan=2><FONT face="Times New Roman" size=2>Molineaux, Susan</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>52,499</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2><SUP>(6)</SUP></FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>48,951</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>101,450</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="90%" bgColor=#c0c0c0 colSpan=2><FONT face="Times New Roman" size=2>Spiegel, Robert</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>57,501</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2><SUP>(7)</SUP></FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>48,951</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>106,452</FONT></TD></TR></TABLE><div>____________________</div><BR>
<TABLE cellSpacing=0 cellPadding=0 border=0>

  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD>
    <TD WIDTH="100%" STYLE="text-align: justify"><FONT face="Times New Roman" size=2>Amounts represent the
      aggregate grant date fair value of stock option awards granted during the
      fiscal year ended December 31, 2014 as calculated in accordance with FASB
      ASC Topic 718. For additional information, refer to Note 9 of the
      consolidated financial statements in our Annual Report on Form 10-K
      for</FONT></TD></TR></TABLE>
<P align=center><FONT face="Times New Roman" size=2>17</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>


<P align=justify><FONT face="Times New Roman" size=2><A HREF="#toc"><B>Table of Contents</B></A></font></p>
<TABLE cellSpacing=0 cellPadding=0 border=0>

  <TR>
    <TD></TD>
    <TD WIDTH="100%" STYLE="text-align: justify"><FONT face="Times New Roman" size=2>the year ended
      December 31, 2014 regarding assumptions underlying the valuation of stock
      option awards and the calculation method. Please see the section entitled
      &#147;Outstanding Equity Awards at Fiscal Year-End for Non-Employee Directors&#148;
      for information regarding the aggregate number of stock option awards and
      restricted stock awards held by the non-employee members of the Board at
      December 31, 2014.</FONT></TD></TR>
  <TR>
    <TD vAlign=top noWrap>&nbsp;</TD>
    <TD WIDTH="100%" STYLE="text-align: justify"></TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD>
    <TD WIDTH="100%" STYLE="text-align: justify"><FONT face="Times New Roman" size=2>Includes $27,499 in
      fees paid in stock in lieu of cash through the issuance of an aggregate
      10,862 shares of Geron Common Stock under the 2011 Plan.</FONT></TD></TR>
  <TR>
    <TD colSpan=2>&nbsp;</TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(3)</FONT></TD>
    <TD WIDTH="100%" STYLE="text-align: justify"><FONT face="Times New Roman" size=2>Includes $36,249 in
      fees paid in stock in lieu of cash through the issuance of an aggregate
      11,223 shares of Geron Common Stock under the 2011 Plan.</FONT></TD></TR>
  <TR>
    <TD colSpan=2>&nbsp;</TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(4)</FONT></TD>
    <TD WIDTH="100%" STYLE="text-align: justify"><FONT face="Times New Roman" size=2>Dr. Hofstaetter is
      retiring from our Board effective as of the date of the Annual
      Meeting.</FONT></TD></TR>
  <TR>
    <TD colSpan=2>&nbsp;</TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(5)</FONT></TD>
    <TD WIDTH="100%" STYLE="text-align: justify"><FONT face="Times New Roman" size=2>Includes $19,374 in
      fees paid in stock in lieu of cash through the issuance of an aggregate
      9,270 shares of Geron Common Stock under the 2011 Plan.</FONT></TD></TR>
  <TR>
    <TD colSpan=2>&nbsp;</TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(6)</FONT></TD>
    <TD WIDTH="100%" STYLE="text-align: justify"><FONT face="Times New Roman" size=2>Includes $39,374 in
      fees paid in stock in lieu of cash through the issuance of an aggregate
      14,407 shares of Geron Common Stock under the 2011 Plan.</FONT></TD></TR>
  <TR>
    <TD colSpan=2>&nbsp;</TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(7)</FONT></TD>
    <TD WIDTH="100%" STYLE="text-align: justify"><FONT face="Times New Roman" size=2>Includes $35,938 in
      fees paid in stock in lieu of cash through the issuance of an aggregate
      13,568 shares of Geron Common Stock under the 2011
  Plan.</FONT></TD></TR></TABLE>
<P align=justify><B><FONT face="Times New Roman" size=2>Equity
Compensation</FONT></B></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2>Terms of
Awards</FONT></I></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Pursuant to the Director
Compensation Policy, each of our non-employee directors is eligible for stock
option grants on an annual basis or, for each person who first becomes a
non-employee director, an initial stock option grant. Non-employee director
stock options under the Director Compensation Policy are granted pursuant to the
2011 Plan.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><I><FONT face="Times New Roman" size=2>Initial
Grants.</FONT></I><FONT face="Times New Roman" size=2> Each person who becomes a
non-employee director, whether by election by Geron&#146;s stockholders or by
appointment by the Board to fill a vacancy, will automatically be granted an
option to purchase 70,000 shares of Common Stock on the date such person first
becomes a non-employee director (the &#147;Initial Grant&#148;). The Initial Grant will
vest annually over three years upon each anniversary date of appointment to the
Board.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><I><FONT face="Times New Roman" size=2>Annual
Grants.</FONT></I><FONT face="Times New Roman" size=2> On the date of each
annual meeting of our stockholders, each non-employee director (other than any
director receiving an Initial Grant on the date of such annual meeting) who is
then serving as a non-employee director and who will continue as a non-employee
director following the date of such annual meeting will automatically be granted
an option to purchase 35,000 shares of Common Stock (the &#147;Annual Grant&#148;). The
Annual Grant will vest in full on the earlier of: (i) the date of the next
annual meeting of our stockholders or (ii) the first anniversary of the date of
grant, subject to the non-employee director&#146;s continuous service.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><I><FONT face="Times New Roman" size=2>Exercise Price and Term
of Options.</FONT></I><FONT face="Times New Roman" size=2> The exercise price of
all options granted under the 2011 Plan is equal to the fair market value of a
share of our Common Stock on the NASDAQ Global Select Market on the date of
grant of the option. Options granted under the 2011 Plan have a term of ten
years from the date of grant, unless terminated earlier.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><I><FONT face="Times New Roman" size=2>Exercise Period
Post-Termination.</FONT></I><FONT face="Times New Roman" size=2> The options
issued pursuant to the 2011 Plan remain exercisable until the earlier of the
original expiration date of the option or 36 months following the optionee&#146;s
termination of service as our director, unless such termination is a result of
death or permanent and total disability, in which case the options (both those
already exercisable and those that would have become exercisable had the
director remained on the Board for an additional 36 months) remain exercisable
for up to a 36 month period.</FONT></P>

<P align=center><FONT face="Times New Roman" size=2>18</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>

<P align=justify><FONT face="Times New Roman" size=2><A HREF="#toc"><B>Table of Contents</B></A></font></p>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The 2011 Plan allows for
grants of discretionary restricted stock awards. In prior years, directors have
also received grants of performance-based restricted stock awards under our 2006
Directors&#146; Stock Option Plan (the &#147;2006 Directors&#146; Plan&#148;), which plan terminated
in March 2014. No restricted stock awards were granted under the 2011 Plan in
2014.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>In February 2015, the
Director Compensation Policy was amended to establish a procedure for
non-employee directors to elect payments of annual director compensation in cash
or equity. To receive payment of annual director compensation in equity in lieu
of cash, a non-employee director must elect such payment method in January each
calendar year during an open trading window, and such election will be applied
to each quarter&#146;s payment during the calendar year of such election.</FONT></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2>Effect of Certain
Corporate Events</FONT></I></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><I><FONT face="Times New Roman" size=2>2011
Plan</FONT></I><FONT face="Times New Roman" size=2>. As set forth in each option
agreement under the 2011 Plan, the vesting for each Initial Grant and Annual
Grant will accelerate in full in the event of a Change in Control of Geron (as
defined in the 2011 Plan and described below under &#147;Compensation Discussion and
Analysis &#150; Severance and Change in Control Benefits &#150; Equity Plans&#148;).</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><I><FONT face="Times New Roman" size=2>2006 Directors&#146;
Plan</FONT></I><FONT face="Times New Roman" size=2>. Prior to March 2014, equity
awards were granted under the 2006 Directors&#146; Plan. Under the 2006 Directors&#146;
Plan, in the event of the dissolution or liquidation of the Company, a sale of
all or substantially all of the assets of the Company, the merger or
consolidation of the Company with or into another corporation in which the
Company is not the surviving corporation or any other capital reorganization in
which more than 50% of the shares of the Company entitled to vote are exchanged,
each non-employee director shall have a reasonable time within which to exercise
the option, including any part of the option that would not otherwise be
exercisable, prior to the effectiveness of such dissolution, liquidation, sale,
merger or reorganization, at the end of which time the option shall terminate.
In addition, except as otherwise provided in an award agreement, unvested shares
subject to awards of restricted stock and restricted stock units will become
fully vested immediately prior to the date of such dissolution, liquidation,
sale, merger, consolidation or reorganization.</FONT></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2>2014 Option
Grants</FONT></I></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The following table sets
forth the following information with respect to non-employee directors (seven
persons) for the fiscal year ended December 31, 2014: (i) stock options granted
under the 2011 Plan; and (ii) the grant date fair value of stock options
granted.</FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" colSpan=2></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="3%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="3%"><B><FONT face="Times New Roman" size=1>Option Awards</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="3%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" colSpan=2></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="3%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="3%"><B><FONT face="Times New Roman" size=1>Granted</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="3%"><B><FONT face="Times New Roman" size=1>Grant Date Fair Value of</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" colSpan=2></TD>
    <TD noWrap style="text-align: center" width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap style="text-align: center" width="3%"><B><FONT face="Times New Roman" size=1>Grant</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap style="text-align: center" width="3%"><B><FONT face="Times New Roman" size=1>During 2014</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap style="text-align: center" width="3%"><B><FONT face="Times New Roman" size=1>Option Awards Granted</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><B><FONT face="Times New Roman" size=1>Director</FONT></B></TD>
    <TD noWrap align=left width="86%">&nbsp;</TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="3%"><B><FONT face="Times New Roman" size=1>Date</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="3%"><B><FONT face="Times New Roman" size=1>(#)</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="3%"><B><FONT face="Times New Roman" size=1>During 2014 ($)</FONT></B><B><FONT face="Times New Roman" size=1><SUP>(1)</SUP></FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#c0c0c0 colSpan=2><FONT face="Times New Roman" size=2>Bradbury, Daniel</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>5/20/14</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2><SUP>(2)</SUP></FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap style="text-align: center" width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>35,000</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap style="text-align: center" width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>$48,951</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" colSpan=2><FONT face="Times New Roman" size=2>Eastham, Karin</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>5/20/14</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2><SUP>(2)</SUP></FONT></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="3%"><FONT face="Times New Roman" size=2>35,000</FONT></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="3%"><FONT face="Times New Roman" size=2>$48,951</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#c0c0c0 colSpan=2><FONT face="Times New Roman" size=2>Hofstaetter, Thomas<SUP>(3)</SUP></FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>5/20/14</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2><SUP>(2)</SUP></FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap style="text-align: center" width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>35,000</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap style="text-align: center" width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>$48,951</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" colSpan=2><FONT face="Times New Roman" size=2>Huh,
      Hoyoung</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>5/20/14</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2><SUP>(2)</SUP></FONT></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="3%"><FONT face="Times New Roman" size=2>35,000</FONT></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="3%"><FONT face="Times New Roman" size=2>$48,951</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#c0c0c0 colSpan=2><FONT face="Times New Roman" size=2>Lawlis, V. Bryan</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>5/20/14</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2><SUP>(2)</SUP></FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap style="text-align: center" width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>35,000</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap style="text-align: center" width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>$48,951</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" colSpan=2><FONT face="Times New Roman" size=2>Molineaux, Susan</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>5/20/14</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2><SUP>(2)</SUP></FONT></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="3%"><FONT face="Times New Roman" size=2>35,000</FONT></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="3%"><FONT face="Times New Roman" size=2>$48,951</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#c0c0c0 colSpan=2><FONT face="Times New Roman" size=2>Spiegel, Robert</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>5/20/14</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2><SUP>(2)</SUP></FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap style="text-align: center" width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>35,000</FONT></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap style="text-align: center" width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>$48,951</FONT></TD></TR></TABLE><div>____________________</div><BR>
<TABLE cellSpacing=0 cellPadding=0 border=0>

  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD>
    <TD WIDTH="100%" STYLE="text-align: justify"><FONT face="Times New Roman" size=2>Amounts represent the
      grant date fair value of each stock option granted in 2014 calculated in
      accordance with FASB ASC Topic 718. For additional information, refer to
      Note 9 of the consolidated financial statements in our Annual Report on
      Form 10-K for the year ended December 31, 2014 regarding assumptions
      underlying the valuation of stock option awards and the calculation
      method.</FONT></TD></TR>
  <TR>
    <TD vAlign=top noWrap>&nbsp;</TD>
    <TD WIDTH="100%" STYLE="text-align: justify"></TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(2)</FONT></TD>
    <TD WIDTH="100%" STYLE="text-align: justify"><FONT face="Times New Roman" size=2>Stock option vests on
      the earlier of: (i) the date of the Annual Meeting or (ii) the first
      anniversary of the date of grant of such option, subject to the non-employee director&#146;s continuous service.</FONT></TD></TR>
  <TR>
    <TD colSpan=2>&nbsp;</TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(3)</FONT></TD>
    <TD WIDTH="100%" STYLE="text-align: justify"><FONT face="Times New Roman" size=2>Dr. Hofstaetter is
      retiring from our Board effective as of the date of the Annual
      Meeting.</FONT></TD></TR></TABLE>
<P align=center><FONT face="Times New Roman" size=2>19</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=justify><FONT face="Times New Roman" size=2><A HREF="#toc"><B>Table of Contents</B></A></font></p>
<P align=justify><B><I><FONT face="Times New Roman" size=2>Outstanding Equity
Awards at Fiscal Year-End for Non-Employee Directors</FONT></I></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The following table sets
forth stock options and restricted stock awards having time-based vesting,
outstanding for each non-employee director as of December 31, 2014.</FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="84%" colSpan=2></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="9%" colSpan=5><B><FONT face="Times New Roman" size=1>Option Awards
      Outstanding</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="3%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="84%" colSpan=2></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="9%" colSpan=5><B><FONT face="Times New Roman" size=1>as of December
      31, 2014</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="5%" colSpan=3><B><FONT face="Times New Roman" size=1>Unvested Restricted
      Stock Awards</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><B><FONT face="Times New Roman" size=1>Director</FONT></B></TD>
    <TD noWrap align=left width="83%">&nbsp;</TD>
    <TD noWrap style="text-align: center" width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=3><B><FONT face="Times New Roman" size=1>Exercisable
      (#)</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="3%"><B><FONT face="Times New Roman" size=1>Unexercisable
      (#)</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=3><B><FONT face="Times New Roman" size=1>Outstanding as
      of December 31, 2014 (#)</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="84%" bgColor=#c0c0c0 colSpan=2><FONT face="Times New Roman" size=2>Bradbury, Daniel</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp; </TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>81,667</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp; </TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap style="text-align: center" width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>58,333</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT size=2 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      </FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT size=2 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      </FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="84%" colSpan=2><FONT face="Times New Roman" size=2>Eastham, Karin</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>180,500</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="3%"><FONT face="Times New Roman" size=2>35,000</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>2,250</FONT></TD>
    <TD noWrap align=right width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="84%" bgColor=#c0c0c0 colSpan=2><FONT face="Times New Roman" size=2>Hofstaetter,
      Thomas<SUP>(1)</SUP></FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>146,375</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap style="text-align: center" width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>35,000</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>1,500</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="84%" colSpan=2><FONT face="Times New Roman" size=2>Huh,
      Hoyoung</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>253,385</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="3%"><FONT face="Times New Roman" size=2>44,115</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>16,562</FONT></TD>
    <TD noWrap align=right width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="84%" bgColor=#c0c0c0 colSpan=2><FONT face="Times New Roman" size=2>Lawlis, V. Bryan</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>116,667</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap style="text-align: center" width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>58,333</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="84%" colSpan=2><FONT face="Times New Roman" size=2>Molineaux, Susan</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>81,667</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="3%"><FONT face="Times New Roman" size=2>58,333</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=right width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="84%" bgColor=#c0c0c0 colSpan=2><FONT face="Times New Roman" size=2>Spiegel, Robert</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>140,000</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap style="text-align: center" width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>35,000</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>1,250</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD></TR></TABLE><div>____________________</div><BR>
<P align=justify><FONT face="Times New Roman" size=2>(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dr. Hofstaetter is retiring from
our Board effective as of the date of the Annual Meeting.</FONT></P>
<P align=center><B><FONT face="Times New Roman" size=2><A NAME="Proposal2"></A>PROPOSAL 2</FONT></B></P>
<P align=center><B><FONT face="Times New Roman" size=2>ADVISORY VOTE TO APPROVE
NAMED EXECUTIVE OFFICER COMPENSATION</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>As required by Section 951
of the Dodd-Frank Wall Street Reform and Consumer Protection Act and Section 14A
of the Exchange Act, the Board is requesting stockholders to vote, on a
non-binding advisory basis, to approve the compensation paid to Geron&#146;s Named
Executive Officers as disclosed in this Proxy Statement in the sections
entitled, &#147;Compensation Discussion and Analysis&#148; and &#147;Executive Compensation
Tables.&#148; This proposal, commonly known as a &#147;say-on-pay&#148; proposal, gives
stockholders the opportunity to express their views on the compensation of
Geron&#146;s Named Executive Officers. </FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Compensation Committee
continually reviews the compensation program for our executive officers,
including the Named Executive Officers, to determine whether the compensation
program achieves our desired goals of aligning our executive compensation
structure with the Company&#146;s stockholders&#146; interests and current market
practices. As part of its ongoing review, the Compensation Committee considered
the &#147;say-on-pay&#148; advisory vote from our 2014 Annual Meeting of Stockholders
(where approximately 81.6% of the stockholders voting on the advisory proposal
supported the proposal). We believe the outcome of the 2014 &#147;say-on-pay&#148;
advisory vote reflects our stockholders&#146; support of our executive compensation
approach, specifically the changes we implemented in the previous year, as
discussed below. Accordingly, no significant design changes were made to the
executive compensation program due to the 2014 &#147;say-on-pay&#148; advisory vote. We
value the opinions of our stockholders and will continue to monitor the outcome
of future &#147;say-on-pay&#148; proposals, as well as feedback received throughout the
year from our stockholders, when making compensation decisions for our executive
officers.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Based on feedback from
stockholders in 2013 and early 2014 and a low approval rate for the &#147;say-on-pay&#148;
proposal at the 2013 Annual Meeting of Stockholders, the Compensation Committee
conducted a comprehensive stockholder outreach program in 2013 to gain a full
understanding regarding the concerns of stockholders, and in response, made
several changes to the Company&#146;s executive compensation program. Some of the key
changes made to the executive compensation program included: i) implementing a
&#147;double-trigger&#148; requirement in order for cash severance to be paid under our
Amended Severance Plan; ii) implementing anti-hedging and anti-pledging clauses
in our Insider Trading Policy; and iii) amending all executive officer
employment agreements to include clawback provisions requiring relinquishment of
bonuses in the event an executive officer has engaged in any misconduct or in
any act or omission that would constitute cause for termination of employment.
In addition, the Compensation Committee continues to ensure that its
compensation disclosures describe the relationship between pay and performance
by providing strategic context for the corporate goal achievements. </FONT></P>
<P align=center><FONT face="Times New Roman" size=2>20</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=justify><FONT face="Times New Roman" size=2><A HREF="#toc"><B>Table of Contents</B></A></font></p>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>As discussed in detail in
the section entitled &#147;Compensation Discussion and Analysis&#148; of this Proxy
Statement, Geron&#146;s executive compensation strategy and structure is designed to
i) reward successful execution of business strategy; ii) attract and retain
qualified management; and iii) align management and stockholder interests. The
Compensation Committee strives to act in the long-term best interests of Geron
and our stockholders. As described in the section entitled &#147;Compensation
Discussion and Analysis&#148;, we structured our 2014 executive compensation program
to emphasize pay for performance and to be competitive with the companies with
whom we compete for executive talent. The Compensation Committee believes that
Geron&#146;s executive compensation program is strongly aligned with the long-term
interests of our stockholders. Please read the &#147;Compensation Discussion and
Analysis&#148; section of the Proxy Statement for additional details about our
executive compensation program, including information about the 2014
compensation of our Named Executive Officers.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Advisory Vote and Board
Recommendation</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>We request stockholder
approval of the 2014 compensation of our Named Executive Officers as disclosed
in this Proxy Statement pursuant to the SEC&#146;s compensation disclosure rules
which disclosure includes the section entitled &#147;Compensation Discussion and
Analysis,&#148; and the compensation tables and accompanying narrative disclosures
within the section entitled &#147;Executive Compensation Tables&#148; of this Proxy
Statement. This vote is not intended to address any specific element of
compensation, but rather the overall compensation of our Named Executive
Officers and the compensation philosophy, policies and practices described in
this Proxy Statement. </FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Accordingly, the Board
recommends that stockholders vote in favor of the following resolution:
</FONT></P>
<P style="padding-left: 15pt" align=justify><B><FONT face="Times New Roman" size=2>&#147;RESOLVED, that the
stockholders approve, on a non-binding advisory basis, the compensation paid to
Geron&#146;s Named Executive Officers, as disclosed in the Compensation Discussion
and Analysis section, the tabular disclosure regarding such compensation and the
accompanying narrative disclosure set forth in the Proxy Statement relating to
the Company&#146;s 2015 Annual Meeting of Stockholders.&#148; </FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Approval of the above
resolution requires the affirmative vote of the shares present in person or
represented by proxy at this meeting. Abstentions will have the same effect as a
vote against this proposal, and broker non-votes will have no effect on the
outcome of this proposal. </FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Stockholders are not being
asked to approve or disapprove the Board&#146;s recommendation. As this is an
advisory vote, the outcome of the vote is non-binding on us with respect to
future executive officer compensation decisions, including those related to our
Named Executive Officers, or otherwise. However, the Board and the Compensation
Committee will review the results of the vote and take them into account when
considering future executive officer compensation policies and decisions.
</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Board has approved
holding a &#147;say-on-pay&#148; advisory vote every year. Unless the Board modifies its
policy on the frequency of future &#147;say-on-pay&#148; advisory votes, the next
&#147;say-on-pay&#148; advisory vote will be held at the 2016 Annual Meeting of
Stockholders. </FONT></P>
<P align=center><B><FONT face="Times New Roman" size=2>The Board of Directors
Unanimously Recommends That<BR>Stockholders Vote <U>FOR</U> Proposal
2</FONT></B></P>
<P align=center><B><FONT face="Times New Roman" size=2><A NAME="CompensationDiscuss"></A>COMPENSATION DISCUSSION
AND ANALYSIS</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>This Compensation
Discussion and Analysis section presents and discusses executive compensation
policies and practices and the compensation decisions relating to the &#147;Named
Executive Officers&#148; (as defined below) for the 2014 fiscal year, and includes
the following:</FONT></P>
<TABLE style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse; TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=justify><FONT face="Times New Roman" size=2>an executive summary
      of the compensation program for the Named Executive Officers;
      <BR>&nbsp;</FONT></P></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=justify><FONT face="Times New Roman" size=2>an overview of the
      executive compensation program; <BR>&nbsp;</FONT></P></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=justify><FONT face="Times New Roman" size=2>the role of the
      Compensation Committee; <BR>&nbsp;</FONT></P></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=justify><FONT face="Times New Roman" size=2>a detailed discussion
      and analysis of the Compensation Committee&#146;s specific decisions about the
      2014 compensation for the Named Executive Officers;
  </FONT></P></TD></TR></TABLE>
<P align=center><FONT face="Times New Roman" size=2>21</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<!-- PART C -->
<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=left><FONT face="Times New Roman" size=2><A HREF="#toc"><B>Table of Contents</B></A></FONT></P>
<TABLE style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse; TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">a description of the employment agreements for
      the Named Executive Officers; and<BR>&nbsp;</TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">a summary of the potential severance benefits
      for the Named Executive Officers in the event of a change in
  control.</TD></TR></TABLE>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>In addition to the
historical information contained herein, this Compensation Discussion and
Analysis also contains forward-looking statements based on current plans,
considerations, expectations and determinations regarding future compensation
decisions. The actual compensation program that we adopt in the future may
differ materially from the current program summarized in this discussion. </font></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The
following executive officers are collectively referred to herein as the Named
Executive Officers: </FONT></P>
<TABLE style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse; TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">Dr. John A. Scarlett, President and Chief
      Executive Officer;<BR>&nbsp;</TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">Ms. Olivia K. Bloom, Executive Vice President,
      Finance, Chief Financial Officer and Treasurer;<BR>&nbsp;</TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">Ms. Melissa A. Kelly Behrs, Executive Vice
      President, Business Development and Portfolio &amp; Alliance
      Management;<BR>&nbsp;</TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">Dr. Andrew J. Grethlein,
      Executive Vice President, Development and Technical Operations;
    and<BR>&nbsp;</TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">Mr. Stephen N. Rosenfield,
      Executive Vice President, General Counsel and Corporate
  Secretary.</TD></TR></TABLE>
<P align=justify><B><FONT face="Times New Roman" size=2>Executive
Summary</FONT></B></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2>Effect of Prior Year
Stockholder Advisory Vote on Executive Compensation </FONT></I></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>At our 2014 Annual Meeting
of Stockholders held in May 2014, we sought an advisory vote from our
stockholders regarding the compensation of our named executive officers
(commonly referred to as a &#147;say-on-pay&#148; proposal). The 2014 &#147;say-on-pay&#148;
proposal was approved, with approximately 81.6% of votes cast supporting the
proposal. The Compensation Committee considers the results of the advisory vote
as it completes its annual review of each pay element and the compensation
packages provided to our Named Executive Officers and other executive officers.
The Compensation Committee considered the outcome of the 2014 &#147;say-on&#150;pay&#148; vote
and did not make further changes to Geron&#146;s executive compensation program for
2014 as a result of the vote.</FONT></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2>Business Highlights
that Impacted 2014 Compensation Decisions </FONT></I></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>In 2014, executive
compensation decisions were highly influenced by retention challenges stemming
from the significant uncertainty relating to our future in light of our
dependence on one product candidate, imetelstat, the need to motivate executive
officers and employees to pursue new development opportunities for imetelstat
despite the continued challenges in clinical development, especially the full
clinical hold placed by the United States Food and Drug Administration (the
&#147;FDA&#148;) on our investigational new drug application (&#147;IND&#148;) for imetelstat in the
first quarter of 2014 and the competitive local market environment for qualified
biotechnology employees. Accordingly, our 2014 goals were designed to focus our
resources and efforts on raising and maintaining adequate capital to support the
then-planned Phase 2 clinical trial of imetelstat and achieving regulatory
clearance to re-start clinical development of imetelstat in the United States
(&#147;U.S.&#148;) for the treatment of hematologic myeloid malignancies. As a result, our
2014 activities centered on raising funds through an equity financing, managing
our operating spend to conserve our cash resources, and conducting extensive
follow-up activities to collect, analyze and collate key nonclinical and
clinical data, which were submitted to the FDA and led to the release of the
full clinical hold on our IND for imetelstat. </FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Key 2014 company
achievements included: i) raising approximately $96.8 million in net proceeds in
February 2014 from an underwritten public offering of Common Stock; ii) transfer
to Geron of the IND supporting the investigator-sponsored trial in myelofibrosis
being conducted at Mayo Clinic (the &#147;MF Pilot Study&#148;) as well as sponsorship of
MF Pilot Study; iii) removal of the full clinical hold by the FDA on the
Company&#146;s IND for imetelstat in late October 2014; and iv) executing an
exclusive global collaboration and license agreement with Janssen Biotech, Inc.
(&#147;Janssen&#148;) to develop and commercialize imetelstat in hematologic myeloid
malignancies and other human therapeutic uses. For details regarding our
achievement of corporate goals in 2014, see the section entitled &#147;Compensation
Discussion and Analysis &#150; 2014 Corporate Goal Achievement Factor&#148; on page 31.
</FONT></P>
<P STYLE="text-align: center"><FONT face="Times New Roman" size=2>22</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=left><FONT face="Times New Roman" size=2><A HREF="#toc"><B>Table of Contents</B></A></FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Compensation Committee
and the Board evaluated our efforts and results of these key achievements in
2014 and determined that we exceeded our 2014 corporate goals. The Compensation
Committee and the Board also determined that our Named Executive Officers,
including our Chief Executive Officer, made crucial efforts towards achievement
of these corporate goals, as well as leading individual, team, departmental and
functional performance and achievements, despite challenges during the
year.</FONT></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2>Emphasis on Pay for
Performance </FONT></I></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>We structure a significant
portion of our executive officers&#146; total compensation to be variable, at risk
and tied directly to our measurable performance. For 2014, 89.3% of our Chief
Executive Officer&#146;s total compensation was linked to performance, as reported in
the &#147;Summary Compensation Table&#148;. &#147;Total compensation&#148; referred to in this
Compensation Discussion and Analysis consists of annual base salary, annual
incentive bonus and the value of equity awards.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Our annual incentive bonus
for our Chief Executive Officer is entirely dependent upon our achievement of
annual corporate goals established for the year by the Board. Our annual
incentive bonus for our other Named Executive Officers is dependent upon
achievement of our annual corporate goals as well as each executive officer&#146;s
achievement against their individual goals and demonstration of our corporate
values. None of our Named Executive Officers are entitled to guaranteed or
minimum bonuses under our annual incentive bonus plan.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Our long-term incentive
awards for 2014 consist of stock options, which only provide value if the market
price of our stock increases and if the executive officer continues in our
employment. Therefore, these awards strongly align our executive officers&#146;
interests with those of our stockholders by providing a continuing financial
incentive to maximize long-term value, keeping the executive officers&#146; total
compensation opportunity competitive and encouraging our executive officers to
remain in the long-term employ of our Company. </FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Compensation Committee
believes that this structure, which puts a considerable proportion of the
executive officers&#146; total compensation &#147;at risk,&#148; contingent on the appreciation
of our Common Stock, achievement of specific corporate goals, and continued
employment, strongly aligns the interests of our executive officers with those
of our stockholders, ties their compensation to the most concrete measure of
performance against critical corporate goals and promotes retention. </FONT></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2>Market Positioning
</FONT></I></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Compensation Committee
actively reviews and assesses our executive compensation program in light of the
highly competitive employment environment in the San Francisco Bay Area, the
challenge of recruiting, motivating and retaining executive officers in an
industry with much longer business cycles than other commercial industries, and
evolving compensation governance and best practices. </FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Compensation Committee
utilizes Radford, an independent compensation consultant, to assess our
executive compensation program against market data. The Compensation Committee
generally referenced total compensation in the 50<SUP>th </SUP></FONT><FONT face="Times New Roman" size=2>to 60<SUP>th </SUP></FONT><FONT face="Times New Roman" size=2>percentile paid to executive officers in
comparable positions and responsibilities in our peer group companies based on
the market data provided by Radford, along with other factors, in setting our
Named Executive Officers&#146; 2014 total compensation (base salary, annual incentive
bonus and equity awards value). The Compensation Committee believes referencing
this percentile is appropriate because competition for executive management is
intense in our industry and in our geographic area and continued leadership from
our executive officers is deemed critical to our success. </FONT></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2>Commitment to
Compensation Governance </FONT></I></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>We are committed to having
strong governance standards with respect to our compensation program, procedures
and practices, which include:</FONT></P>

<TABLE style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse; TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%"><EM>Independent Compensation Consultant Advice.
      </EM><FONT face="Times New Roman" size=2>The Compensation Committee
      engages, on an annual basis, an experienced, independent compensation
      consultant who reports directly to the Compensation Committee to advise on
      executive and equity compensation
matters.</FONT>&nbsp;</TD></TR></TABLE>
<P align=center><FONT face="Times New Roman" size=2>23</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=left><FONT face="Times New Roman" size=2><A HREF="#toc"><B>Table of Contents</B></A></FONT></P>
<TABLE style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse; TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%"><EM>Responsible Internal Pay Equity. </EM><FONT face="Times New Roman" size=2>For 2014, our Chief Executive Officer&#146;s
      total cash compensation was less than two times the average total cash
      compensation of our other Named Executive Officers, which reflects
      internal fairness and an important benchmark to avoid excessive
      compensation of the Chief Executive Officer.</FONT><BR>&nbsp;</TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%"><EM>Limited Personal Benefits. </EM><FONT face="Times New Roman" size=2>Our executive officers are eligible for the
      same benefits as non-executive, salaried employees, and do not receive any
      personal benefits other than reimbursements for housing costs and travel
      expenses for Dr. Scarlett, our President and Chief Executive Officer, for
      the commute from his principal residence in Texas to our headquarters in
      Menlo Park, California.</FONT><BR>&nbsp;</TD></TR>
    <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top"><I>No Tax Gross-Ups on Compensation</I>. None of our executive officers receive tax related gross-ups on
any element of compensation.<BR>
&nbsp;</TD></TR>
<TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%"><EM>No Single-Trigger Change in Control Cash Benefits.
      </EM><FONT face="Times New Roman" size=2>Executive officer employment
      agreements and our Amended Severance Plan (as defined under the
      sub-section entitled &#147;Severance and Change in Control Benefits&#148;) permit
      payment of cash benefits in connection with a Change in Control (as
      defined under the sub-section entitled &#147;Severance and Change in Control
      Benefits&#148;) only if an executive officer&#146;s position is terminated or the
      executive officer resigns due to a material adverse change in his or her
      employment terms.</FONT><BR>&nbsp;</TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%"><EM>Clawback Terms. </EM><FONT face="Times New Roman" size=2>Executive officer employment agreements require that an executive
      officer forfeit his/her entire annual incentive bonus if we determine that
      such executive officer has engaged in any misconduct intended to affect
      the payment of his or her annual incentive bonus, or has otherwise engaged
      in any act or omission that would constitute cause for termination of
      his/her employment, as defined by his or her employment
      agreement.</FONT><BR>&nbsp;</TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%"><EM>No Retirement Benefits. </EM><FONT face="Times New Roman">We do not offer any pension plans or health
      benefits during retirement.<BR>&nbsp;</FONT></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%"><EM>No Hedging or Pledging. </EM><FONT face="Times New Roman">Our Insider Trading Policy prohibits employees from
      engaging in speculative trading activities, including hedging or pledging
      company securities as collateral. Accordingly, our employees, including
      our executive officers, may not hedge the economic risk of, or pledge
      ownership of, our Common Stock.</FONT></TD></TR></TABLE>
<P align=justify><B><FONT face="Times New Roman" size=2>Overview of the
Executive Compensation Program </FONT></B></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2>Philosophy and
Objectives </FONT></I></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The overall objective of
our compensation program is to support business objectives by attracting,
retaining and engaging the highest caliber of employees, including executive
officers, while maintaining a fiscally responsible position in a highly
competitive employment environment. Consistent with this overall objective, the
goals of the executive compensation program are to:</FONT></P>

<TABLE style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse; TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">pay appropriate cash and equity compensation to
      executive officers for retention purposes during periods of significant
      uncertainty (e.g., in the first quarter of 2014, the FDA placed the IND
      for the Company&#146;s sole product candidate, imetelstat, on full clinical
      hold);<BR>&nbsp;</TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">attract and retain executive officers that can
      capably lead by incentivizing them with competitive cash and non-cash
      compensation opportunities;<BR>&nbsp;</TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">enable a high performing culture by employing
      and retaining successful and experienced executive
  officers;<BR>&nbsp;</TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">encourage and inspire executive
      officers to achieve key corporate strategic and financial objectives by
      linking incentive award opportunities to the achievement of individual and
      corporate goals; and<BR>&nbsp;</TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">align the interests of executive
      officers with stockholders by motivating executive officers to focus on
      achievements that will result in an increase in value for our stockholders
      and reward executive officers for excellence in
performance.</TD></TR></TABLE>
<P align=center><FONT face="Times New Roman" size=2>24</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=left><FONT face="Times New Roman" size=2><A HREF="#toc"><B>Table of Contents</B></A></FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Compensation Committee
reviews and approves the compensation of our executive officers (except for the
Chief Executive Officer, whose compensation is approved by the Board upon
recommendation from the Compensation Committee), including salaries, annual
incentive bonuses, equity awards and any other benefits. As discussed in further
detail below, the 2014 compensation program for the Named Executive Officers was
intended to strike an appropriate balance among base salary, annual incentive
bonuses and equity awards. The Compensation Committee strives to act in the best
interests of Geron and our stockholders, as well as to ensure that the elements
of compensation do not, individually or in the aggregate, encourage excessive
risk taking. </FONT></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2>Components
</FONT></I></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The components of the
executive compensation program consist primarily of base salary, annual
incentive bonuses, equity awards and broad-based benefits. To provide
competitive total compensation to executive officers, we utilize a mix of cash
(base salaries and annual incentive bonuses) and long-term incentives (equity
awards) that are competitive with the market. The Compensation Committee has
structured our executive compensation program to ensure that executive officers
are compensated in a manner consistent with stockholder interests, competitive
pay practices and applicable requirements of regulatory bodies. </FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Compensation Committee
does not have any formal policies for allocating compensation among the various
components of compensation. Instead, the Compensation Committee uses its
judgment to establish for each Named Executive Officer a mix of current,
short-term and long-term incentive compensation, and cash and equity
compensation that it believes appropriate to achieve the compensation and
corporate objectives described above. However, because we believe it is
important to our success to aggressively pursue long-term goals, to avoid
excessive risk taking, to preserve our cash resources, and to further our
pay-for-performance philosophy, a significant portion of our Named Executive
Officers&#146; total compensation is comprised of performance-based bonus
opportunities and long-term equity awards, which align the Named Executive
Officers&#146; incentives with the interests of our stockholders.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><U>Base Salary</U></FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Base salaries serve to
provide fixed cash compensation to our executive officers for performing daily
responsibilities, and also provide stability and security. We establish base
salaries for our executive officers when they join our Company or upon
promotion. In addition, base salaries for executive officers are reviewed and
determined by the Compensation Committee (or the Board with respect to our Chief
Executive Officer, upon recommendation from the Compensation Committee) on an
annual basis, in consultation with our independent compensation consultant,
Radford, based on each executive officer&#146;s position and specific
responsibilities, individual performance, level of experience, achievement of
corporate and strategic goals, and a review of competitive salary, total
compensation market data, and cost of living increases in the San Francisco Bay
Area. Any increase in base salary beyond a cost of living increase is based on
an evaluation of the individual&#146;s performance, changes in responsibilities or
position and the individual&#146;s criticality to our future plans. Increases in base
salary, including cost of living increases, typically take effect on January
1<SUP>st</SUP> of each calendar year.</FONT></P>
<P ALIGN="JUSTIFY" ><FONT face="Times New Roman" size=2><U>Annual Incentive Bonuses</U></FONT></P><P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Under our annual
incentive bonus plan, every employee, including executive officers, has an
established annual incentive bonus target, which is equal to a percentage of the
employee&#146;s base salary. This percentage increases with increasing level of
responsibility and title. Each employee&#146;s actual earned annual incentive bonus,
if any, is calculated based on: (1) corporate goal achievement (the &#147;corporate
goal achievement factor&#148;), (2) individual performance achievements (the
&#147;individual performance factor&#148;) and (3) support of corporate values (the
&#147;corporate values performance factor&#148;). </FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>For more senior employees
and executive officers, the corporate goal achievement factor is weighted more
heavily and thus has greater influence on the annual incentive bonus, as
performance from these individuals has a larger impact on corporate goal
achievement. This practice is designed to create a direct link between executive
compensation and operational and financial goals to provide motivation for
executive officers to implement strategic initiatives intended to meet or exceed
pre-established corporate goals.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>25</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=left><FONT face="Times New Roman" size=2><A HREF="#toc"><B>Table of Contents</B></A></FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>At the beginning of each
year, the Chief Executive Officer develops, with input from our executive
management, the annual corporate goals, which generally relate to our
operational and financial performance, together with recommended weightings for
each goal, and presents the annual corporate goals and recommended weightings to
the Compensation Committee and the Board. The weighting for each corporate goal
depends on its importance and business value for Geron and our stockholders. The
Board approves or adjusts the corporate goals and weightings. </FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>As part of the annual
year-end performance review process, the Compensation Committee, taking into
consideration recommendations from the Chief Executive Officer, evaluates our
overall achievement of the corporate goals during the preceding year and other
significant company accomplishments, while taking into consideration the degree
of difficulty in achieving the corporate goals and any particular events or
circumstances that impacted performance. The corporate goal achievement factor
generally ranges from 0 to 1.0 and is approved by the Board upon recommendation
from the Compensation Committee based upon the Board&#146;s assessment of the
Company&#146;s achievement of that year&#146;s annual corporate goals. The Board has the
discretion to approve a corporate goal achievement factor above 1.0 in
extraordinary circumstances where it determines such an increase is
warranted.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Chief Executive
Officer&#146;s annual incentive bonus is based entirely on the corporate goal
achievement factor. The annual incentive bonus for each of our Named Executive
Officers, other than the Chief Executive Officer, is based on the corporate goal
achievement factor, the individual performance factor and the corporate values
performance factor. The Chief Executive Officer presents to the Compensation
Committee written assessments of the performance and achievements, including
support of our corporate values, for each of the executive officers (other than
himself) for the prior year and recommends the individual performance factor and
the corporate values performance factor for each executive officer (other than
himself). The Compensation Committee reviews and approves or adjusts the
individual performance factor and the corporate values performance factor for
each of the executive officers (other than the Chief Executive Officer). The
corporate values performance factor ranges from 0 to 1.0, based on the extent to
which an executive officer, including the Named Executive Officers, other than
the Chief Executive Officer, supported corporate value adherence. The individual
performance factor ranges from 0 to 1.3, and this is the primary factor that
increases an annual incentive bonus above the annual target incentive bonus
percentage for any executive officer, including the Named Executive Officers,
other than the Chief Executive Officer. The Compensation Committee has the
discretion to approve an individual performance factor above 1.3 upon evaluation
of appropriate criteria. There are no minimum or guaranteed bonus payments for
employees, including the Named Executive Officers.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><U>Equity Awards</U></FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Equity awards are designed
to encourage high performance by and long-term tenure for executive officers,
thereby strongly aligning executive officers&#146; interests with the interests of
our stockholders. We granted equity awards in the form of stock options in 2014.
Stock option grants under our 2011 Plan encourage employee ownership in Geron,
link pay with performance and align the interests of stockholders and employees.
Primarily through sustained growth by and positive price per share performance
in our stock, employees, including the Named Executive Officers, may realize
gains from equity-based awards. The Compensation Committee (and the Board, with
respect to our Chief Executive Officer) determines the size of any stock option
grant according to each executive officer&#146;s position. To do so, the Compensation
Committee references the 50<SUP>th </SUP></FONT><FONT face="Times New Roman" size=2>to 60<SUP>th </SUP></FONT><FONT face="Times New Roman" size=2>percentile
of the total compensation (base salary, annual incentive bonus and equity awards
value) paid to comparable executive officers based on the market data provided
by Radford. The Compensation Committee also takes into account each Named
Executive Officer&#146;s recent performance history, his or her potential for future
responsibility, and criticality of his or her work. Other factors may include
equity awards previously granted, the amount of actual versus theoretical equity
value per year that has been derived to date by the individual, the current
actual value of unvested equity grants for each individual, the percentage of
stock option grants with exercise prices greater than Geron&#146;s current stock
price and the number of stock option grants that have expired unexercised as a
result of market conditions. The Compensation Committee has the discretion to
give relative weight to each of these factors as it sets the size of the stock
option grant to appropriately create an opportunity for reward based on
increasing stockholder value. There is no set formula for the granting of stock
options or other equity awards to employees, including </FONT></P>
<P align=center><FONT face="Times New Roman" size=2>26</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=left><FONT face="Times New Roman" size=2><A HREF="#toc"><B>Table of Contents</B></A></FONT></P>
<P align=justify><FONT face="Times New Roman" size=2>the Named Executive
Officers. For non-executive employees, the Chief Executive Officer and other
executive officers determine the size of any stock option grant or other equity
award according to each position and/or the individual&#146;s past performance and
criticality of the individual&#146;s work. </FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Compensation Committee
grants equity awards to newly hired and existing executive officers, except the
Chief Executive Officer, with respect to whom the Board determines equity awards
based on the recommendation of the Compensation Committee. Our general policy is
to grant stock options and other equity awards on fixed dates determined in
advance, although there are occasions when grants are made on other dates. All
required approvals are obtained in advance of or on the actual grant date. Other
than stock option grants to new hires, stock option grants to executive officers
are generally approved once a year (typically near the beginning of the year)
unless an executive officer is promoted, in which case a grant will normally be
made at the time of such promotion, or, in rare circumstances, for recognition
of outstanding performance. With respect to annual stock option grants to our
continuing executive officers, these grants are typically approved early in each
fiscal year and prior to the full release of our annual financial and operating
results for that year. Since our full annual financial and operating results are
typically not disclosed prior to approval of annual stock option grants for our
executive officers, in 2015, we adopted an equity incentive grant policy that
provides that if at the time the Compensation Committee (or the Board, in the
case of the Chief Executive Officer) approves annual equity awards to our
executive officers (and other employees) our trading window is closed, then the
annual equity awards that are approved for executive officers (and other
employees) will be granted on the second trading day following the filing date
with SEC of our next quarterly or annual report that occurs after the date on
which such grants are approved by the Board or the Compensation Committee, as
applicable. Accordingly, our equity incentive grant policy provides the market
with an opportunity to absorb the financial and other information included in
our annual and periodic reports before annual equity awards are effective. As a
result, the timing of annual equity awards to our continuing executive officers
is not coordinated in a manner that intentionally benefits our executive
officers; rather, the policy is designed with the objective to generally allow
the market price of our common stock to reflect our then-current results and
prospects at the time the equity grant becomes effective and the exercise price
is set. </FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The exercise price of all
stock option grants is equal to the closing price of Geron Common Stock as
reported by the NASDAQ Global Select Market on the date of grant, so employees
and executive officers who receive stock option grants do not realize any
compensation from such options unless the stock price increases above the
exercise price. In this manner, the interests of our stockholders, and employees
and executive officers during their employment, are aligned for the long-term
success of Geron.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Geron&#146;s standard vesting
schedule for the first stock option grant awarded to newly hired employees,
including executive officers, provides that 12.5% of the shares granted will
vest six months after the date of the grant, and the remaining shares will vest
in equal monthly installments over the following 42 months so that vesting is
complete four years from the date of grant, provided the employee continues to
provide services to the Company during that time. Additional option grants made
after an employee, including an executive officer, has provided services to the
Company for more than six months generally vest monthly from the date of grant
over four years.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><U>Broad-Based Benefits and
Other Compensation</U></FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Benefit programs include a variety of health
insurance plans, 401(k) plan with Company matching contributions  at Board-approved levels, employee stock purchase plan and
flexible spending 125  cafeteria plan covering health and dependent care services. These benefits are offered to all
employees, including executive officers. We do not offer pension  or other retirement benefits to employees. Currently, Dr.
Scarlett also receives  housing and travel expense reimbursements for the commute from his principal  residence in Texas to
our headquarters in Menlo Park, California.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Role of the Compensation
Committee</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Compensation Committee
acts on behalf of the Board with respect to overseeing our compensation program
and policies and in determining compensation for executive officers, including
the Named Executive Officers, other than our Chief Executive Officer.
Compensation Committee members are independent of management and meet the NASDAQ
listing standards for independence. Typically, the Compensation Committee
</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>27</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=left><FONT face="Times New Roman" size=2><A HREF="#toc"><B>Table of Contents</B></A></FONT></P>
<P align=justify><FONT face="Times New Roman" size=2>meets at least once
quarterly and with greater frequency if necessary. The agenda for each meeting
is usually developed by the Chair of the Compensation Committee, in consultation
with the Chief Executive Officer, Executive Director of Human Resources, General
Counsel and Radford. The Compensation Committee also meets in executive session
without the presence of any employees. The Compensation Committee exercises
independent judgment in allocating between cash and equity compensation. In
setting the annual level of cash and equity compensation for executive officers,
the Compensation Committee typically considers various factors, which include:
corporate performance, our achievement toward meeting annual corporate goals,
each executive officer&#146;s individual performance, the criticality of each
executive officer&#146;s skill set, and market data for our industry. Each of these
factors is balanced against Geron&#146;s ability to award cash and equity incentives.
The Compensation Committee has the authority to retain special counsel and other
experts, including compensation consultants, to support their responsibilities
in determining executive officer compensation and related benefits. Since
December 2011, the Compensation Committee has retained Radford as its
independent compensation consultant due to its extensive analytical and
consulting work in the biotech/pharmaceutical industry. In this capacity,
Radford has provided documentary support, including industry data from
third-party salary survey sources, and recommendations related to cash and
equity compensation for executive officers and members of the Board.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>In February 2014, the
Compensation Committee reviewed information from Radford about potential
conflicts of interest and analyzed whether the work of Radford as a compensation
consultant has raised any conflict of interest, taking into consideration the
following factors: i) the provision of other services to Geron by Radford or any
other AON Hewitt Company; ii) the amount of fees Geron paid to Radford or any
other AON Hewitt Company as a percentage of the firm&#146;s total revenue; iii)
Radford&#146;s policies and procedures that are designed to prevent conflicts of
interest; iv) any business or personal relationship of Radford, any other AON
Hewitt Company or the individual compensation advisors employed by Radford with
an executive officer of the Company; v) any business or personal relationship of
the individual compensation advisors with any member of the Compensation
Committee; and vi) any Geron Common Stock owned by the individual compensation
advisors employed by Radford. Based on these factors, the Compensation Committee
determined that there were no conflicts of interest with respect to Radford
providing services to the Compensation Committee. In 2014, the Company paid
$45,000 to Radford for their services as a compensation consultant to the
Compensation Committee regarding executive and Board compensation.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Compensation Committee
reviews, and thereafter recommends to the Board, both the establishment and
achievement of annual corporate goals for the annual incentive bonus plan. With
respect to achievement of annual corporate goals, the Board considers the
recommendations of the Compensation Committee and may accept or modify such
recommendations before approval. To aid the Compensation Committee in its
responsibilities, the Chief Executive Officer, with assistance from the General
Counsel and Executive Director of Human Resources, provides the Compensation
Committee with recommendations relating to the achievement of our annual
corporate goals, individual performance of executive officers and cash and
equity compensation recommendations for each executive officer. The Compensation
Committee does not consult with any other executive officer with regard to its
decisions concerning compensation for executive officers. In making such
decisions, the Compensation Committee gives considerable weight to the Chief
Executive Officer&#146;s performance evaluations of the executive officers, since he
has direct knowledge of the criticality of their work, performance and
contributions. The Chief Executive Officer does not participate in the
Compensation Committee&#146;s or Board&#146;s deliberations or decisions with regard to
his own compensation, which must be approved by the Board.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>28</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=left><FONT face="Times New Roman" size=2><A HREF="#toc"><B>Table of Contents</B></A></FONT></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2>Peer
Group</FONT></I></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>In January 2014, the
Compensation Committee determined that defining a definitive group of peer
companies was desirable to provide benchmarks to reference in connection with
making 2014 executive officer and director compensation decisions. Accordingly,
the Compensation Committee engaged Radford to determine an appropriate
comparable peer group for such purposes. Based on Radford&#146;s recommendations, in
January 2014 the Compensation Committee approved a peer group consisting of 17
publicly traded, U.S.-based biotechnology/pharmaceutical companies. These peer
group companies were selected because a majority of them did not have
commercialized products or services, had market capitalizations between
approximately $250 million and $1.3 billion, headcount of fewer than 200
employees and annual research and development expenditures ranging from
approximately $30 million to $80 million. These parameters represented approximately
one-half to two times to those comparable parameters of Geron at the time the
peer group was approved in January 2014. The compensation practices of the 2014
peer group companies is herein referred to as the &#147;market data.&#148; The companies
comprising the 2014 peer group were: </FONT></P>
<DIV align=center>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="90%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="32%"><FONT face="Times New Roman" size=2>Achillion Pharmaceuticals, Inc.</FONT></TD>
    <TD noWrap align=left width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD noWrap align=left width="33%"><FONT face="Times New Roman" size=2>Insmed Incorporated</FONT></TD>
    <TD noWrap align=left width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD noWrap align=left width="32%"><FONT face="Times New Roman" size=2>Sunesis Pharmaceuticals, Inc.</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="32%"><FONT face="Times New Roman" size=2>Anacor Pharmaceuticals, Inc.</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="33%"><FONT face="Times New Roman" size=2>Neurocrine Biosciences, Inc.</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="32%"><FONT face="Times New Roman" size=2>XenoPort, Inc.</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="32%"><FONT face="Times New Roman" size=2>Array BioPharma Inc.</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="33%"><FONT face="Times New Roman" size=2>Novavax, Inc.</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="32%"><FONT face="Times New Roman" size=2>XOMA
      Corporation</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="32%"><FONT face="Times New Roman" size=2>Cytokinetics Incorporated</FONT></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="33%"><FONT face="Times New Roman" size=2>PTC
      Therapeutics, Inc.</FONT></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="32%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="32%"><FONT face="Times New Roman" size=2>Dyax
      Corp.</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="33%"><FONT face="Times New Roman" size=2>Raptor Pharmaceuticals Corp.</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="32%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="32%"><FONT face="Times New Roman" size=2>Dynavax Technologies Corporation</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="33%"><FONT face="Times New Roman" size=2>Rigel Pharmaceuticals, Inc.</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="32%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="32%"><FONT face="Times New Roman" size=2>Infinity Pharmaceuticals, Inc.</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="33%"><FONT face="Times New Roman" size=2>Sangamo Biosciences, Inc.</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="32%"></TD></TR></TABLE></DIV><BR>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Compensation
Committee&#146;s general compensation decision making strategy for 2014, in
consultation with Radford, was to generally reference the 50<SUP>th</SUP> to
60<SUP>th</SUP> percentile of the market data in combination with multiple other
factors, such as the executive officers&#146; respective levels of experience and
responsibility, prior performance, specific skills or competencies, internal pay
equity, the desired pay mix (including the other compensation elements provided
to the executive officers), and our budget, in determining the total target compensation (consisting of base salary, annual incentive bonus and value of
equity awards) for all Named Executive Officers for 2014. The Compensation
Committee believes this strategy was necessary and appropriate in 2014 in order
to retain top executive talent in the competitive environment in which we
operate.</FONT></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2>Compensation Risk
Assessment</FONT></I></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Compensation Committee
annually evaluates Geron&#146;s compensation elements of base salary, annual
incentive bonuses, equity awards, severance and change in control benefits,
other benefits and Geron&#146;s compensation philosophy generally as it relates to
all employees. The Compensation Committee reviews the following elements of
Geron&#146;s compensation practices that comprise our compensation program to
mitigate the risks associated with our compensation practices:</FONT></P>

<TABLE style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse; TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">performance assessment based upon a mix of
      individual and corporate performance and achievement;<BR>&nbsp;</TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">annual incentive bonuses determined by
      performance with no minimum payments;<BR>&nbsp;</TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">utilization of a combination of cash and equity
      awards to encourage short-term and long-term incentives;<BR>&nbsp;</TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">absence of employment agreements
      or contracts that contain multi-year guarantees of salary increases,
      non-performance-based bonuses or equity compensation; and<BR>&nbsp;</TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">emphasis on equity amongst our
      employees and in comparison with external benchmarks.</TD></TR></TABLE>
<P STYLE="text-align: justify; text-indent: 15pt"><FONT face="Times New Roman" size=2>
      The Compensation
      Committee has reviewed our compensation policies and practices as they
      relate to all employees and has determined that such policies and
      practices do not present any risks that are reasonably likely to have a
      material adverse effect on Geron.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>29</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=left><FONT face="Times New Roman" size=2><A HREF="#toc"><B>Table of Contents</B></A></FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>2014 Compensation
Decisions </FONT></B></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2>Base
Salaries</FONT></I></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>In the first quarter of
2014, the Compensation Committee performed their annual analysis of base
salaries for all of our executive officers. The Compensation Committee reviewed
the market data provided by Radford and noted that the market data showed that
each of our Named Executive Officers&#146; base salaries at the end of 2013 was
between the 25<SUP>th</SUP> to 75<SUP>th</SUP> percentile of the market data.
Given the desire to have competitive positioning of base salaries and in
discretionary consideration of the performance of each of the Named Executive
Officers during 2013, the Compensation Committee and, with respect to Dr.
Scarlett, the Board, approved average salary increases of 3.2% as a cost of
living adjustment for each of the Named Executive Officers, except for Ms.
Bloom, who received a 10.6% increase to her base salary to ensure that her total
cash compensation in 2014 as Chief Financial Officer was commensurate with the
market data. </FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The following 2014 base
salaries for the Named Executive Officers were effective as of January 1,
2014.</FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="76%" colSpan=2></TD>
    <TD noWrap align=right width="2%"></TD>
    <TD noWrap style="text-align: center" width="7%" colSpan=2><B><FONT face="Times New Roman" size=1>2013</FONT></B></TD>
    <TD noWrap style="text-align: center" width="2%"></TD>
    <TD noWrap style="text-align: center" width="5%"><B><FONT face="Times New Roman" size=1>Salary</FONT></B></TD>
    <TD noWrap style="text-align: center" width="2%"></TD>
    <TD noWrap style="text-align: center" width="7%" colSpan=2><B><FONT face="Times New Roman" size=1>2014</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="3%"><B><FONT face="Times New Roman" size=1>Named Executive
      Officer</FONT></B></TD>
    <TD noWrap align=left width="73%">&nbsp;</TD>
    <TD noWrap style="text-align: center" width="2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="7%" colSpan=2><B><FONT face="Times New Roman" size=1>Base
    Salary</FONT></B></TD>
    <TD noWrap style="text-align: center" width="2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%"><B><FONT face="Times New Roman" size=1>Increase
      (%)</FONT></B></TD>
    <TD noWrap style="text-align: center" width="2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="7%" colSpan=2><B><FONT face="Times New Roman" size=1>Base
    Salary</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="76%" bgColor=#c0c0c0 colSpan=2><FONT face="Times New Roman" size=2>John A. Scarlett, M.D.</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="5%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>$569,250</FONT></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap style="text-align: center" width="5%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>3.0%</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="5%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>$586,500</FONT></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="76%" colSpan=2><FONT face="Times New Roman" size=2>Olivia K. Bloom</FONT></TD>
    <TD noWrap align=right width="2%"></TD>
    <TD noWrap align=right width="5%"><FONT face="Times New Roman" size=2>$330,000</FONT></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=right width="2%"></TD>
    <TD noWrap style="text-align: center" width="5%"><FONT face="Times New Roman" size=2>10.6%</FONT></TD>
    <TD noWrap align=right width="2%"></TD>
    <TD noWrap align=right width="5%"><FONT face="Times New Roman" size=2>$365,000</FONT></TD>
    <TD noWrap align=left width="2%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="76%" bgColor=#c0c0c0 colSpan=2><FONT face="Times New Roman" size=2>Melissa A. Kelly Behrs</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="5%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>$341,550</FONT></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap style="text-align: center" width="5%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>3.1%</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="5%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>$352,000</FONT></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="76%" colSpan=2><FONT face="Times New Roman" size=2>Andrew J. Grethlein, Ph.D.</FONT></TD>
    <TD noWrap align=right width="2%"></TD>
    <TD noWrap align=right width="5%"><FONT face="Times New Roman" size=2>$367,425</FONT></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=right width="2%"></TD>
    <TD noWrap style="text-align: center" width="5%"><FONT face="Times New Roman" size=2>3.2%</FONT></TD>
    <TD noWrap align=right width="2%"></TD>
    <TD noWrap align=right width="5%"><FONT face="Times New Roman" size=2>$379,000</FONT></TD>
    <TD noWrap align=left width="2%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="76%" bgColor=#c0c0c0 colSpan=2><FONT face="Times New Roman" size=2>Stephen N. Rosenfield,
    J.D.</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="5%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>$377,775</FONT></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2><SUP>(1)</SUP></FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap style="text-align: center" width="5%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>3.2%</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="5%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>$390,000</FONT></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2><SUP>(1)</SUP></FONT></TD></TR></TABLE><div>____________________</div>&nbsp;<BR>
<TABLE style="TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 border=0>

  <TR>
    <TD vAlign=top noWrap STYLE="padding-right: 15pt"><FONT face="Times New Roman" size=2>(1)</FONT></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>We employ Mr.
      Rosenfield at 80% full-time equivalent. Thus, the actual base salary paid
      to Mr. Rosenfield is 80% of the amounts presented in the
  table.</FONT></TD></TR></TABLE>
<P align=justify><B><I><FONT face="Times New Roman" size=2>2014 Annual Incentive
Bonuses</FONT></I></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Named Executive
Officers&#146; 2014 annual incentive bonus targets, as a percentage of base salary
depending on the executive officer&#146;s position, remained at the same historical
levels that we have applied since 2010. These annual incentive bonus targets
continue to generally reference the 50<SUP>th</SUP> to 60<SUP>th</SUP>
percentile of market data for total compensation (consisting of base salary,
annual incentive bonus and value of equity awards) for executive officers in
comparable positions and responsibilities in our peer group companies. The
annual incentive bonus target percentage for the executive vice president
position is 45% and for the Chief Executive Officer position is 60%. For 2014,
Dr. Scarlett&#146;s annual incentive bonus payout was 100% dependent upon achievement
of our corporate goals. For 2014, other than Dr. Scarlett, each Named Executive
Officer&#146;s annual incentive bonus payout was 50% dependent upon achievement of
our corporate goals, 30% dependent on individual performance, and 20% dependent
upon individual support and manifestation of our corporate values. The table
below summarizes the annual incentive bonus targets as a percentage of annual
salary for each of our Named Executive Officers for 2014. </FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" colSpan=2></TD>
    <TD noWrap style="text-align: center" width="6%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD noWrap style="text-align: center" width="4%"><B><FONT face="Times New Roman" size=1>Annual Incentive Bonus</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="2%"><B><FONT face="Times New Roman" size=1>Named Executive
      Officer</FONT></B></TD>
    <TD noWrap align=left width="87%">&nbsp;</TD>
    <TD noWrap style="text-align: center" width="6%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%"><B><FONT face="Times New Roman" size=1>Target as a % of
      Salary</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" bgColor=#c0c0c0 colSpan=2><FONT face="Times New Roman" size=2>John A. Scarlett, M.D.</FONT></TD>
    <TD noWrap style="text-align: center" width="6%" bgColor=#c0c0c0></TD>
    <TD noWrap style="text-align: center" width="4%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>60%</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" colSpan=2><FONT face="Times New Roman" size=2>Olivia K. Bloom</FONT></TD>
    <TD noWrap style="text-align: center" width="6%"></TD>
    <TD noWrap style="text-align: center" width="4%"><FONT face="Times New Roman" size=2>45%</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" bgColor=#c0c0c0 colSpan=2><FONT face="Times New Roman" size=2>Melissa A. Kelly Behrs</FONT></TD>
    <TD noWrap style="text-align: center" width="6%" bgColor=#c0c0c0></TD>
    <TD noWrap style="text-align: center" width="4%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>45%</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" colSpan=2><FONT face="Times New Roman" size=2>Andrew J. Grethlein, Ph.D.</FONT></TD>
    <TD noWrap style="text-align: center" width="6%"></TD>
    <TD noWrap style="text-align: center" width="4%"><FONT face="Times New Roman" size=2>45%</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" bgColor=#c0c0c0 colSpan=2><FONT face="Times New Roman" size=2>Stephen N. Rosenfield,
    J.D.</FONT></TD>
    <TD noWrap style="text-align: center" width="6%" bgColor=#c0c0c0></TD>
    <TD noWrap style="text-align: center" width="4%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>45%</FONT></TD></TR></TABLE><BR>
<P align=center><FONT face="Times New Roman" size=2>30</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=left><FONT face="Times New Roman" size=2><A HREF="#toc"><B>Table of Contents</B></A></FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><U>2014 Corporate Goal
Achievement Factor</U></FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The table below summarizes
the corporate goals approved by the Board for 2014, including assigned
weightings, and the Compensation Committee&#146;s and Board&#146;s assessment of our level
of achievement of those goals in 2014. The corporate goals in 2014 were designed
to focus our resources and efforts on raising and maintaining adequate capital
to support the then-planned Phase 2 clinical trial of imetelstat and achieving
regulatory clearance to re-start clinical development of imetelstat in the U.S.
for the treatment of hematologic myeloid malignancies. As a result, many of our
2014 activities centered on raising funds through an equity financing, managing
our operating spend to conserve our cash resources, and conducting extensive
clinical follow-up activities, including establishing relationships with
industry experts to analyze and collate key nonclinical and clinical data, which
were submitted to the FDA and led to the release of the full clinical hold on
our IND for imetelstat. Based on the achievements noted below, the Board deemed
these corporate goals to be fully achieved for 2014.</FONT></P>
<TABLE style="PADDING-RIGHT: 2pt; PADDING-LEFT: 2pt; PADDING-BOTTOM: 2pt; PADDING-TOP: 2pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR style="LINE-HEIGHT: 14pt" vAlign=bottom>
    <TD style="BORDER-TOP: #000000 1pt solid; BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="41%"><B><FONT face="Times New Roman" size=1>2014 Corporate Goals</FONT></B></TD>
    <TD style="BORDER-TOP: #000000 1pt solid; BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="3%"><B><FONT face="Times New Roman" size=1>Weighting<BR>(A)</FONT></B></TD>
    <TD style="BORDER-TOP: #000000 1pt solid; BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="42%"><B><FONT face="Times New Roman" size=1>Highlights of<BR>Company
    Performance</FONT></B></TD>
    <TD style="BORDER-TOP: #000000 1pt solid; BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="10%"><B><FONT face="Times New Roman" size=1>Percent<BR>Achievement<BR>(B)</FONT></B></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; BORDER-TOP: #000000 1pt solid; BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="3%"><B><FONT face="Times New Roman" size=1>Total<BR>(A x B)</FONT></B></TD></TR>
  <TR>
    <TD style="BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="41%">
      <DIV STYLE="padding-left: 16pt; font-size: 10pt; text-indent: -16pt; text-align: left"><FONT size=2 face="Times New Roman"><FONT style="PADDING-RIGHT: 8pt; FONT-SIZE: 9.5pt">1)</FONT><FONT face="Times New Roman">Prepare proposed plan to re-start clinical
      development in the U.S., European Union or both and present to the Board
      no later than September 2014.</FONT></FONT></DIV>
      <DIV style="PADDING-LEFT: 15pt; FONT-SIZE: 10pt; TEXT-INDENT: -14.5pt; TEXT-ALIGN: justify">
      <DIV style="PADDING-LEFT: 15pt; FONT-SIZE: 10pt; TEXT-INDENT: -14.5pt; TEXT-ALIGN: justify"><FONT face="Times New Roman" size=2></FONT></DIV><FONT size=2 face="Times New Roman"></FONT></DIV></TD>
    <TD style="BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=center width="3%">
      <P align=center><FONT face="Times New Roman" size=2>20%</FONT></P></TD>
    <TD style="BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="42%">
      <DIV STYLE="padding-left: 15pt; font-size: 10pt; text-indent: -14.5pt; text-align: left"><FONT style="PADDING-RIGHT: 8pt; FONT-SIZE: 9.5pt">&#9679;</FONT><FONT face="Times New Roman" size=2>Developed a comprehensive plan that provided
      clinical follow-up information from patients in the previously ongoing
      Geron-sponsored Phase 2 trials, data from nonclinical toxicology studies,
      and engaged industry experts to analyze and collate data that would be
      provided to the FDA to seek release of the full clinical
    hold.</FONT></DIV></TD>
    <TD style="BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=center width="10%"><FONT size=2 face="Times New Roman">100%</FONT></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=center width="3%"><FONT size=2 face="Times New Roman">20%</FONT></TD></TR>
  <TR>
    <TD style="BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="41%">
      <DIV STYLE="padding-left: 16pt; font-size: 10pt; text-indent: -16pt; text-align: left"><FONT size=2 face="Times New Roman"><FONT style="PADDING-RIGHT: 8pt; FONT-SIZE: 9.5pt">2)</FONT><FONT face="Times New Roman">Make &#147;Go/No-Go&#148; recommendation by September 2014 to
      pursue Clinical Trial Authorization submission(s) in the European
      Union.</FONT></FONT></DIV></TD>
    <TD style="BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=center width="3%"><FONT size=2 face="Times New Roman">10%</FONT></TD>
    <TD style="BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=center width="42%">
      <DIV STYLE="padding-left: 15pt; font-size: 10pt; text-indent: -14.5pt; text-align: left"><FONT style="PADDING-RIGHT: 8pt; FONT-SIZE: 9.5pt">&#9679;</FONT><FONT face="Times New Roman" size=2>Presented to the Board the clinical and
      regulatory implications of pursuing independent clinical trial
      authorization in the European Union.</FONT></DIV>
      <DIV STYLE="padding-left: 15pt; font-size: 10pt; text-indent: -14.5pt; text-align: left"><FONT style="PADDING-RIGHT: 8pt; FONT-SIZE: 9.5pt">&#9679;</FONT><FONT face="Times New Roman" size=2>Concluded that moving forward with such a
      submission pending FDA action while on clinical hold was not
      advantageous.</FONT><FONT face="Times New Roman" size=2>&nbsp;</FONT></DIV></TD>
    <TD style="BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=center width="10%"><FONT size=2 face="Times New Roman">100%</FONT></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=center width="3%"><FONT size=2 face="Times New Roman">10%</FONT></TD></TR>
  <TR>
    <TD style="BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="41%">
      <DIV STYLE="padding-left: 16pt; font-size: 10pt; text-indent: -16pt; text-align: left"><FONT size=2 face="Times New Roman"><FONT style="PADDING-RIGHT: 8pt; FONT-SIZE: 9.5pt">3)</FONT><FONT face="Times New Roman">Submit package to FDA to address clinical hold
      issues by mid-November 2014.</FONT></FONT></DIV></TD>
    <TD style="BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=center width="3%">
      <P align=center><FONT face="Times New Roman" size=2>15%</FONT></P></TD>
    <TD style="BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="42%">
      <DIV STYLE="padding-left: 15pt; font-size: 10pt; text-indent: -14.5pt; text-align: left"><FONT style="PADDING-RIGHT: 8pt; FONT-SIZE: 9.5pt">&#9679;</FONT><FONT face="Times New Roman" size=2>Submitted a complete response to the FDA in
      early October 2014 that included the required clinical follow-up and
      nonclinical data.</FONT></DIV></TD>
    <TD style="BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=center width="10%"><FONT size=2 face="Times New Roman">100%</FONT></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=center width="3%"><FONT size=2 face="Times New Roman">15%</FONT></TD></TR>
  <TR>
    <TD style="BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="41%">
      <DIV STYLE="padding-left: 16pt; font-size: 10pt; text-indent: -16pt; text-align: left"><FONT size=2 face="Times New Roman"><FONT style="PADDING-RIGHT: 8pt; FONT-SIZE: 9.5pt">4)</FONT><FONT face="Times New Roman">Achieve regulatory clearance to re-start clinical
      development in the U.S. (e.g., partial lift of the full clinical hold on
      Geron&#146;s IND for imetelstat) by end of 2014.</FONT></FONT></DIV></TD>
    <TD style="BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=center width="3%"><FONT size=2 face="Times New Roman">20%</FONT></TD>
    <TD style="BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="42%">
      <DIV STYLE="padding-left: 15pt; font-size: 10pt; text-indent: -14.5pt; text-align: left"><FONT style="PADDING-RIGHT: 8pt; FONT-SIZE: 9.5pt">&#9679;</FONT><FONT face="Times New Roman" size=2>The FDA removed the full clinical hold on
      our IND for imetelstat on October 31, 2014, and deemed acceptable, our
      proposed clinical development plan for imetelstat that is focused on
      high-risk myeloid malignancies.</FONT></DIV></TD>
    <TD style="BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=center width="10%">
      <P align=center><FONT face="Times New Roman" size=2>100%</FONT></P></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=center width="3%">
      <P align=center><FONT face="Times New Roman" size=2>20%</FONT></P></TD></TR></TABLE><BR>


<P align=center><FONT face="Times New Roman" size=2>31</FONT></P>

<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=left><FONT face="Times New Roman" size=2><A HREF="#toc"><B>Table of Contents</B></A></FONT></P>
<TABLE style="PADDING-RIGHT: 2pt; PADDING-LEFT: 2pt; PADDING-BOTTOM: 2pt; PADDING-TOP: 2pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR style="LINE-HEIGHT: 14pt" vAlign=bottom>
    <TD style="BORDER-TOP: #000000 1pt solid; BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="41%"><B><FONT face="Times New Roman" size=1>2014 Corporate Goals</FONT></B></TD>
    <TD style="BORDER-TOP: #000000 1pt solid; BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="3%"><B><FONT face="Times New Roman" size=1>Weighting<BR>(A)</FONT></B></TD>
    <TD style="BORDER-TOP: #000000 1pt solid; BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="42%"><B><FONT face="Times New Roman" size=1>Highlights of<BR>Company
    Performance</FONT></B></TD>
    <TD style="BORDER-TOP: #000000 1pt solid; BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="10%"><B><FONT face="Times New Roman" size=1>Percent<BR>Achievement<BR>(B)</FONT></B></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; BORDER-TOP: #000000 1pt solid; BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="3%"><B><FONT face="Times New Roman" size=1>Total<BR>(A x B)</FONT></B></TD></TR>
  <TR>
    <TD style="BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="41%">
      <DIV STYLE="padding-left: 16pt; font-size: 10pt; text-indent: -16pt; text-align: left"><FONT size=2 face="Times New Roman"><FONT style="PADDING-RIGHT: 8pt; FONT-SIZE: 9.5pt">5)</FONT><FONT face="Times New Roman">Raise at least $50 million through an equity
      financing, usage of the at-the-market equity facility and/or partnering by
      end of the second quarter of 2014.</FONT></FONT></DIV>
      <DIV style="PADDING-LEFT: 15pt; FONT-SIZE: 10pt; TEXT-INDENT: -14.5pt; TEXT-ALIGN: justify">
      <DIV style="PADDING-LEFT: 15pt; FONT-SIZE: 10pt; TEXT-INDENT: -14.5pt; TEXT-ALIGN: justify"><FONT face="Times New Roman" size=2></FONT></DIV><FONT size=2 face="Times New Roman"></FONT></DIV></TD>
    <TD style="BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=center width="3%">
      <P align=center><FONT face="Times New Roman" size=2>25%</FONT></P></TD>
    <TD style="BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="42%">
      <DIV STYLE="padding-left: 15pt; font-size: 10pt; text-indent: -14.5pt; text-align: left"><FONT style="PADDING-RIGHT: 8pt; FONT-SIZE: 9.5pt">&#9679;</FONT><FONT face="Times New Roman" size=2>Raised $96.8 million in net proceeds through
      an underwritten public offering of Geron Common Stock in the first quarter
      of 2014.</FONT></DIV></TD>
    <TD style="BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=center width="10%"><FONT size=2 face="Times New Roman">100%</FONT></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=center width="3%"><FONT size=2 face="Times New Roman">25%</FONT></TD></TR>
  <TR>
    <TD style="BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="41%">
      <DIV STYLE="padding-left: 16pt; font-size: 10pt; text-indent: -16pt; text-align: left"><FONT size=2 face="Times New Roman"><FONT style="PADDING-RIGHT: 8pt; FONT-SIZE: 9.5pt">6)</FONT><FONT face="Times New Roman">Conduct at least two meetings with 40 institutional
      investors by the end of the fourth quarter of 2014.</FONT></FONT></DIV></TD>
    <TD style="BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=center width="3%"><FONT size=2 face="Times New Roman">5%</FONT></TD>
    <TD style="BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=center width="42%">
      <DIV STYLE="padding-left: 15pt; font-size: 10pt; text-indent: -14.5pt; text-align: left"><FONT style="PADDING-RIGHT: 8pt; FONT-SIZE: 9.5pt">&#9679;</FONT><FONT face="Times New Roman" size=2>Conducted more than 100 meetings with over
      70 institutional investors.</FONT></DIV>
</TD>
    <TD style="BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=center width="10%"><FONT size=2 face="Times New Roman">100%</FONT></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=center width="3%"><FONT size=2 face="Times New Roman">5%</FONT></TD></TR>
  <TR>
    <TD style="BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="41%">
      <DIV STYLE="padding-left: 16pt; font-size: 10pt; text-indent: -16pt; text-align: left"><FONT size=2 face="Times New Roman"><FONT style="PADDING-RIGHT: 8pt; FONT-SIZE: 9.5pt">7)</FONT><FONT face="Times New Roman">Manage expenditures to Board-approved
      budget.</FONT></FONT></DIV></TD>
    <TD style="BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=center width="3%">
      <P align=center><FONT face="Times New Roman" size=2>5%</FONT></P></TD>
    <TD style="BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="42%">
      <DIV STYLE="padding-left: 15pt; font-size: 10pt; text-indent: -14.5pt; text-align: left"><FONT style="PADDING-RIGHT: 8pt; FONT-SIZE: 9.5pt">&#9679;</FONT><FONT face="Times New Roman" size=2>Controlled expenses to be in line with
      established budget to maintain sufficient cash resources to advance
      development of imetelstat.</FONT></DIV></TD>
    <TD style="BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=center width="10%"><FONT size=2 face="Times New Roman">100%</FONT></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=center width="3%"><FONT size=2 face="Times New Roman">5%</FONT></TD></TR>
  <TR>
    <TD style="BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=left width="41%"><STRONG><FONT size=2 face="Times New Roman">Total</FONT></STRONG></TD>
    <TD style="BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=center width="3%">
      <P align=center><FONT face="Times New Roman" size=2>100%</FONT></P></TD>
    <TD style="BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=center width="42%"></TD>
    <TD style="BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=center width="10%"></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid" vAlign=top align=center width="3%">
      <P align=justify><FONT face="Times New Roman" size=2>100%</FONT></P></TD></TR></TABLE>
<P></P>
<P ALIGN="LEFT" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Board determined the
Company had additional accomplishments in 2014 beyond the pre-established
corporate goals stated above. These additional achievements included:</FONT></P>
<TABLE style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse; TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">negotiating and executing a global strategic
      collaboration and license agreement with Janssen for imetelstat which
      included cash consideration comprised of a $35 million upfront payment, up
      to a potential total of $900 million for the achievement of development,
      regulatory and commercial milestones, and tiered royalties on worldwide
      net sales;<BR>&nbsp;</TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">negotiating and completing successful transfer
      to Geron of the IND supporting the MF Pilot Study as well as sponsorship
      of MF Pilot Study, enabling access to study data critical to completion of
      Janssen&#146;s due diligence process and closure of the Janssen transaction;
      <BR>&nbsp;</TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">raised capital in excess of $50 million
      corporate goal through combination of successful public offering of Common
      Stock and receipt of $35 million in upfront payment under the Janssen
      collaboration; and<BR>&nbsp;</TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">retained key managers and leaders
      during the uncertain period of the full clinical hold imposed by the FDA
      on our IND for imetelstat.</TD></TR></TABLE>
<P ALIGN="LEFT" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>As a result of these
additional extraordinary accomplishments, the Board approved a discretionary
increase to the 2014 corporate goal achievement factor of 0.2, raising the
overall 2014 corporate goal achievement factor to 1.2.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><U>Individual Performance
and Corporate Values Performance Factors</U></FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>For all employees in 2014,
including the Named Executive Officers other than the Chief Executive Officer,
actual individual performance factors ranged from 1.0 to 1.3. Each Named
Executive Officer&#146;s 2014 individual performance factor was based on overall
performance and achievement, which reflected: his or her support of the 2014
corporate goals; and individual, team, departmental and functional performance
and achievements, including performance and achievements beyond the original
pre-established corporate, individual, team, departmental and functional goals.
</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Our corporate values are
authenticity, accountability, excellence, integrity and respect. The
Compensation Committee determined that the actual individual corporate values
performance factor was 1.0 for each of the Named Executive Officers, whose
actions during 2014 demonstrated their full support and manifestation of our
corporate values.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>32</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=left><FONT face="Times New Roman" size=2><A HREF="#toc"><B>Table of Contents</B></A></FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The following are the
annual incentive bonus targets and weighting percentages used to calculate the
2014 annual incentive bonus for each of the Named Executive Officers as well as
the 2014 actual bonus percentage awarded.</FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="2%" colSpan=2></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: center" noWrap width="12%"><B><FONT face="Times New Roman" size=1>(A)</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%">&nbsp;</TD>
    <TD noWrap align=center width="8%" colSpan=3><B><FONT face="Times New Roman" size=1>(B)</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: center" noWrap width="12%"><B><FONT face="Times New Roman" size=1>(C)</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: center" noWrap width="12%"><B><FONT face="Times New Roman" size=1>(D)</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: center" noWrap width="11%"><B><FONT face="Times New Roman" size=1>(E)</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: center" noWrap width="11%"><B><FONT face="Times New Roman" size=1>(F)</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: center" noWrap width="10%"><B><FONT face="Times New Roman" size=1>(G)</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: center" noWrap width="10%"><B><FONT face="Times New Roman" size=1>(H)</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: center" noWrap width="8%"><B><FONT face="Times New Roman" size=1>= (A*B*(C+D))</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="2%" colSpan=2></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="12%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD noWrap align=center width="3%" ></TD>
    <TD style="TEXT-ALIGN: center" noWrap align=center width="2%"></TD>
    <TD noWrap align=center width="3%" ></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="12%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="12%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="11%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="11%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="10%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="10%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="8%"><B><FONT face="Times New Roman" size=1>+ (A*E*F)</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="2%" colSpan=2></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: center" noWrap width="12%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD noWrap align=center width="3%" ></TD>
    <TD style="TEXT-ALIGN: center" noWrap align=center width="2%"></TD>
    <TD noWrap align=center width="3%" ></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="12%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="12%"><B><FONT face="Times New Roman" size=1>2014</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="11%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="11%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="10%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="10%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="8%"><B><FONT face="Times New Roman" size=1>+ (A*G*H)</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="2%" colSpan=2></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="12%"><B><FONT face="Times New Roman" size=1>Annual</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD noWrap align=center width="3%" ></TD>
    <TD style="TEXT-ALIGN: center" noWrap align=center width="2%"></TD>
    <TD noWrap align=center width="3%" ></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="12%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="12%"><B><FONT face="Times New Roman" size=1>Discretionary</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="11%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="11%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="10%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="10%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="8%"><B><FONT face="Times New Roman" size=1>Annual</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="2%" colSpan=2></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="12%"><B><FONT face="Times New Roman" size=1>Incentive</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD noWrap align=center width="3%" ></TD>
    <TD style="TEXT-ALIGN: center" noWrap align=center width="2%"></TD>
    <TD noWrap align=center width="3%" ></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="12%"><B><FONT face="Times New Roman" size=1>2014</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="12%"><B><FONT face="Times New Roman" size=1>Additional</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="11%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="11%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="10%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="10%"><B><FONT face="Times New Roman" size=1>2014</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="8%"><B><FONT face="Times New Roman" size=1>Incentive</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="2%" colSpan=2></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="12%"><B><FONT face="Times New Roman" size=1>Bonus</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD noWrap align=center width="8%" colSpan=3><B><FONT face="Times New Roman" size=1>Corporate</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="12%"><B><FONT face="Times New Roman" size=1>Corporate</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="12%"><B><FONT face="Times New Roman" size=1>Corporate</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="11%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="11%"><B><FONT face="Times New Roman" size=1>2014</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="10%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="10%"><B><FONT face="Times New Roman" size=1>Corporate</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="8%"><B><FONT face="Times New Roman" size=1>Bonus</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="2%" colSpan=2></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="12%"><B><FONT face="Times New Roman" size=1>Target</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD noWrap align=center width="8%" colSpan=3><B><FONT face="Times New Roman" size=1>Goal</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="12%"><B><FONT face="Times New Roman" size=1>Goal</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="12%"><B><FONT face="Times New Roman" size=1>Goal</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="11%"><B><FONT face="Times New Roman" size=1>Individual</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="11%"><B><FONT face="Times New Roman" size=1>Individual</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="10%"><B><FONT face="Times New Roman" size=1>Corporate</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="10%"><B><FONT face="Times New Roman" size=1>Values</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="8%"><B><FONT face="Times New Roman" size=1>Awarded</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="2%" colSpan=2></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="12%"><B><FONT face="Times New Roman" size=1>as a</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD noWrap align=center width="8%" colSpan=3><B><FONT face="Times New Roman" size=1>Achievement</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="12%"><STRONG><FONT face="Times New Roman" size=1>Achievement</FONT></STRONG></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="12%"><STRONG><FONT face="Times New Roman" size=1>Achievement</FONT></STRONG></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="11%"><STRONG><FONT face="Times New Roman" size=1>Performance</FONT></STRONG></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: center" noWrap width="11%"><STRONG><FONT face="Times New Roman" size=1>Performance</FONT></STRONG></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="10%"><B><FONT face="Times New Roman" size=1>Values</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="10%"><B><FONT face="Times New Roman" size=1>Performance</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="8%"><B><FONT face="Times New Roman" size=1>as a % of</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><B><FONT face="Times New Roman" size=1>Named Executive
      Officer</FONT></B></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="12%"><B><FONT face="Times New Roman" size=1>% of
    Salary</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="8%" colSpan=3><B><FONT face="Times New Roman" size=1>Weighting</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="12%"><B><FONT face="Times New Roman" size=1>Factor</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="12%"><B><FONT face="Times New Roman" size=1>Factor</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="11%"><B><FONT face="Times New Roman" size=1>Weighting</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="11%"><B><FONT face="Times New Roman" size=1>Factor</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="10%"><B><FONT face="Times New Roman" size=1>Weighting</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="10%"><B><FONT face="Times New Roman" size=1>Factor</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="8%"><B><FONT face="Times New Roman" size=1>Salary</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0 colSpan=2><FONT face="Times New Roman" size=2>John A. Scarlett, M.D.</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="12%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>60%</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap width="3%" bgColor=#c0c0c0></TD>
    <TD NOWRAP WIDTH="2%" BGCOLOR="#c0c0c0" STYLE="text-align: right; vertical-align: middle"><FONT face="Times New Roman" size=2>100%</FONT></TD>
    <TD noWrap width="3%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="12%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>1.0</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="12%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>0.2</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="11%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>N/A</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="11%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>N/A</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD style="TEXT-ALIGN: center" noWrap width="10%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>N/A</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="10%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>N/A</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="8%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>72.0%</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="2%" colSpan=2><FONT face="Times New Roman" size=2>Olivia K. Bloom</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="12%"><FONT face="Times New Roman" size=2>45%</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD noWrap width="3%" >&nbsp;</TD>
    <TD style="TEXT-ALIGN: center" noWrap align=right width="2%">
      <P align=right><FONT face="Times New Roman" size=2>50%</FONT></P></TD>
    <TD noWrap width="3%" ></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="12%"><FONT face="Times New Roman" size=2>1.0</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="12%"><FONT face="Times New Roman" size=2>0.2</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="11%"><FONT face="Times New Roman" size=2>30%</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="11%"><FONT face="Times New Roman" size=2>1.2</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="10%"><FONT face="Times New Roman" size=2>20%</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="10%"><FONT face="Times New Roman" size=2>1.0</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="8%"><FONT face="Times New Roman" size=2>52.2%</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0 colSpan=2><FONT face="Times New Roman" size=2>Melissa A. Kelly Behrs</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="12%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>45%</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap width="3%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap align=right width="2%" bgColor=#c0c0c0>
      <P align=right><FONT face="Times New Roman" size=2>50%</FONT></P></TD>
    <TD noWrap width="3%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="12%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>1.0</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="12%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>0.2</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="11%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>30%</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="11%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>1.3</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="10%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>20%</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD style="TEXT-ALIGN: center" noWrap width="10%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>1.0</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="8%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>53.6%</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="2%" colSpan=2><FONT face="Times New Roman" size=2>Andrew J. Grethlein, Ph.D.</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="12%"><FONT face="Times New Roman" size=2>45%</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD noWrap width="3%" >&nbsp;</TD>
    <TD style="TEXT-ALIGN: center" noWrap align=right width="2%">
      <P align=right><FONT face="Times New Roman" size=2>50%</FONT></P></TD>
    <TD noWrap width="3%" ></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="12%"><FONT face="Times New Roman" size=2>1.0</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="12%"><FONT face="Times New Roman" size=2>0.2</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="11%"><FONT face="Times New Roman" size=2>30%</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="11%"><FONT face="Times New Roman" size=2>1.2</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="10%"><FONT face="Times New Roman" size=2>20%</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="10%"><FONT face="Times New Roman" size=2>1.0</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="8%"><FONT face="Times New Roman" size=2>52.2%</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0 colSpan=2><FONT face="Times New Roman" size=2>Stephen N. Rosenfield, J.D.</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="12%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>45%</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap width="3%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap align=right width="2%" bgColor=#c0c0c0>
      <P align=right><FONT face="Times New Roman" size=2>50%</FONT></P></TD>
    <TD noWrap width="3%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="12%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>1.0</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="12%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>0.2</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="11%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>30%</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="11%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>1.2</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="10%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>20%</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="10%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>1.0</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="8%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>52.2%</FONT></TD></TR></TABLE><BR>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>For 2014, the Compensation
Committee considered Dr. Scarlett&#146;s recommendations for each Named Executive Officer&#146;s
individual performance and corporate values performance factors, and determined
for each Named Executive Officer their individual and corporate values performance
factors, as discussed in detail below.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Ms. Bloom was awarded an
individual performance factor of 1.2 and a corporate values performance factor of
1.0 based primarily on the following achievements and contributions she made
during 2014:</FONT></P>

<TABLE style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse; TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">executed financing initiatives to support our strategic
      plans, which resulted in raising approximately $96.8 million in net
      proceeds from an underwritten public offering of Common Stock in the first
      quarter of 2014;<BR>&nbsp;</TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">provided analytical financial contributions that resulted
      in an executed global strategic collaboration and license agreement with
      Janssen in the second half of 2014;&nbsp;<BR>&nbsp;</TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">completed the distribution of the Asterias Series A
      common stock to Geron stockholders, which required resolution of timing
      and securities registration filings with Asterias, the SEC and
    NASDAQ;<BR>&nbsp;</TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">developed and directed a successful investor relations
      strategy that effectively maintained investor interest and support during
      the FDA full clinical hold of the imetelstat program; and<BR>&nbsp;</TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">monitored and controlled operating expenses to stay
      within budgeted spending levels, including analysis of budget changes in
      light of the full clinical hold.</TD></TR></TABLE>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Ms. Behrs was awarded an
individual performance factor of 1.3 and a corporate values performance factor
of 1.0 based primarily on the following achievements and contributions she made
during 2014:</FONT></P>

<TABLE style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse; TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">performed key role in leading teams to complete
      Janssen technical and business due diligence requirements across all
      aspects of the imetelstat program, including data, documents, and
      responses related to clinical, regulatory, pharmacokinetics, translational
      research, nonclinical, quality control and compliance, intellectual
      property, and contractual aspects of the imetelstat
  program;<BR>&nbsp;</TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">negotiated and executed a global strategic
      collaboration and license agreement with Janssen;<BR>&nbsp;</TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">negotiated and completed successful transfer to
      Geron of the IND for the MF Pilot Study and sponsorship of MF Pilot Study,
      enabling access to study data critical to the completion of the Janssen
      due diligence process;<BR>&nbsp;</TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">provided senior level Program
      Management leadership and hands-on support for the imetelstat teams to
      ensure successful completion of 2014 corporate goals for the imetelstat
      program; and</TD></TR></TABLE><BR>

<P align=center><FONT face="Times New Roman" size=2>33</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<!-- PART D -->
<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=left><FONT face="Times New Roman" size=2><A HREF="#toc"><B>Table of Contents</B></A></FONT></P>
<TABLE style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse; TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">led the preparation of the initial action plan
      to collect clinical and nonclinical information requested by the FDA to
      address clinical hold issues, including leading the Nonclinical Toxicology
      Working Group in the successful preparation of an assessment of liver
      findings in our imetelstat chronic toxicology nonclinical
  findings.</TD></TR></TABLE>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Dr. Grethlein was awarded
an individual performance factor of 1.2 and a corporate values performance
factor of 1.0 based primarily on the following achievements and contributions he
made during 2014:</FONT></P>
<P align=justify>
<TABLE style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse; TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">led a full strategic assessment of pursuing a
      clinical trial authorization submission in the European Union, including
      making extensive presentations to the Board to enable the Board to reach a
      &#147;No-Go&#148; decision in a timely and strategically sound manner;<BR>&nbsp;
  </TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">oversaw the Development, Quality and Product
      Development &amp; Manufacturing functions to fully achieve their internal
      goals, focusing attention on the critical details and technical execution
      in providing a comprehensive response to the FDA regarding the full
      clinical hold for imetelstat ahead of schedule;<BR>&nbsp; </TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">planned and directed activities of key
      functions that enabled achievement of regulatory clearance to re-start
      clinical development of imetelstat in the United States; and<BR>&nbsp;
  </TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">provided extensive technical analysis and input
      that resulted in an executed global strategic collaboration and license
      agreement with Janssen in the second half of 2014.</TD></TR></TABLE></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Mr. Rosenfield was awarded
an individual performance factor of 1.2 and a corporate values performance
factor of 1.0 based primarily on the following achievements and contributions he
made during 2014: </FONT></P>
<TABLE style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse; TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">rendered expert legal advice and guidance to
      management, the Board and Board committees and, in particular, regarding
      the implications of the complex business strategies contemplated
      throughout the year;<BR>&nbsp;&nbsp; </TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">provided risk management and detailed strategic
      and tactical legal and business counsel, as particularly evidenced by
      careful and timely review of key SEC documents, including preparation and
      review of all risk factors called out in such documents, and other
      documents, including press releases, Form 8-Ks and analyst, partnering and
      investor presentations;<BR>&nbsp;&nbsp; </TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">provided expert leadership and counsel
      regarding corporate law, securities law, contracts, employment matters,
      and intellectual property matters;<BR>&nbsp;&nbsp; </TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">supervised the Human Resources function and
      oversaw structuring of additional compensation elements that had higher
      retention value and which led to greater employee satisfaction (which was
      of particular importance during the FDA full clinical hold of our IND for
      imetelstat); and<BR>&nbsp; </TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">supervised the Legal function and assured
      continuation of all key activities within the department at a high level,
      including very significant contributions of those employees to the
      execution of the Janssen collaboration and license agreement in the second
      half of 2014.</TD></TR></TABLE>
<P align=justify><FONT face="Times New Roman" size=2><U>2014 Annual Incentive
Bonus for Chief Executive Officer</U></FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Dr. Scarlett&#146;s 2014 annual
incentive bonus was structured to be 100% dependent on corporate goal
achievement. Accordingly, with the Board approved corporate goal achievement
factor of 100% plus the 20% additional discretionary corporate factor, the
Compensation Committee recommended and the Board determined that Dr. Scarlett
should receive 120% of his 2014 target annual incentive bonus.</FONT></P>
<P align=justify><B><I><FONT face="times new roman" size=2>2014 Equity
Awards</FONT></I></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Compensation Committee
granted stock options to all employees on February 10, 2014, except for the
Chief Executive Officer whose stock options were granted by the Board on
February 11, 2014. To determine the appropriate size of the February 2014 option
grants to each of the Named Executive Officers, the Compensation Committee first
pre-approved an option grant benchmarking guideline provided by Radford that was
based on employee level. This guideline recommended a target number of options
that could be awarded to an employee, including the Named Executive Officers,
based on an individual&#146;s position. For the Named Executive Officers,</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>34</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=left><FONT face="Times New Roman" size=2><A HREF="#toc"><B>Table of Contents</B></A></FONT></P>
<P align=justify><FONT face="Times New Roman" size=2>equity awards were targeted
to reference the 50<SUP>th</SUP> to 60<SUP>th</SUP> percentile of the market
data provided by Radford for equity awards based on employee level. The
Compensation Committee determined that the equity awards granted to the Named
Executive Officers in 2014 should continue to consist of stock options rather
than restricted stock awards that vest over time because stock options deliver
future value only if the value of our stock increases above the exercise price.
The Compensation Committee believed that this structure was the best approach
for 2014 for incentivizing our executive officers to increase stockholder
value.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Each of our Named Executive
Officers received the following stock option grants in February 2014:</FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="7%"><B><FONT face="times new roman" size=1>Named Executive Officer</FONT></B></TD>
    <TD noWrap align=left width="86%">&nbsp;</TD>
    <TD noWrap align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=3><B><FONT face="times new roman" size=1>2014 Stock<BR>Option
      Grant<BR>(# of shares)</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="93%" bgColor=#c0c0c0 colSpan=2><FONT face="Times New Roman" size=2>John A. Scarlett, M.D.</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT size=2 face="Times New Roman">&nbsp;&nbsp;&nbsp; </FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>1,340,000</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT size=2 face="Times New Roman">&nbsp; &nbsp; </FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="93%" colSpan=2><FONT face="Times New Roman" size=2>Olivia K. Bloom</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>400,000</FONT></TD>
    <TD noWrap align=right width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="93%" bgColor=#c0c0c0 colSpan=2><FONT face="Times New Roman" size=2>Melissa A. Kelly Behrs</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>400,000</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="93%" colSpan=2><FONT face="Times New Roman" size=2>Andrew J. Grethlein, Ph.D.</FONT></TD>
    <TD noWrap align=right width="1%">&nbsp;</TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>400,000</FONT></TD>
    <TD noWrap align=right width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="93%" bgColor=#c0c0c0 colSpan=2><FONT face="Times New Roman" size=2>Stephen N. Rosenfield, J.D.</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>400,000</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD></TR></TABLE><BR>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The exercise price for the
February 2014 stock option grants was equal to the closing price of Geron Common
Stock as reported by the NASDAQ Global Select Market on the date of grant and
the vesting schedule is monthly over four years from the date of grant, provided
the employee continues to provide services to Geron. See the section entitled
&#147;Grants of Plan-Based Awards for 2014&#148; on page 42 for additional information
regarding stock option awards to Named Executive Officers in 2014.</FONT></P>
<P align=justify><B><FONT face="times new roman" size=2>Other Compensation</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Geron offers a
comprehensive array of benefit programs to its employees, including Named
Executive Officers. These include:</FONT></P>
<P align=justify>
<TABLE style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse; TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">comprehensive medical, dental, vision coverage
      and life insurance;<BR>&nbsp; </TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">a &#147;cafeteria&#148; plan administered pursuant to
      Section 125 of the Code. The cafeteria plan includes Geron&#146;s medical and
      dental insurance, medical reimbursement, and dependent care reimbursement
      plans;<BR>&nbsp; </TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">a 401(k) plan, which is a retirement savings
      defined contribution plan established in accordance with Section 401(a) of
      the Code. For 2014, we provided a fully vested employer matching
      contribution in cash equal to 50% of each employee&#146;s annual contributions;
      and<BR>&nbsp; </TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">an Employee Stock Purchase Plan, which is
      implemented and administered pursuant to Section 423 of the
  Code.</TD></TR></TABLE></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Executive officers pay for
30% of their health premium cost, which is deducted from their gross salary.
Other employees pay either 16% or 25% of their health premium cost.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>We do not offer any pension
plans or health benefits during retirement.</FONT></P>
<P align=justify><B><FONT face="times new roman" size=2>Perquisites</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>In accordance with the
terms of his employment agreement, Dr. Scarlett receives reimbursement for
housing expenses (not to exceed $2,000 per month) and travel costs (not to
exceed $20,000 per year) in connection with the commute from his personal
residence in Texas to our headquarters in Menlo Park, California. These
commuting expense benefits were negotiated with Dr. Scarlett at the time of his
initial employment and were deemed a reasonable expense and necessary inducement
to his commencement of employment with us. Dr. Scarlett does not receive
separate compensation for serving as a member of our Board.</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>35</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=left><FONT face="Times New Roman" size=2><A HREF="#toc"><B>Table of Contents</B></A></FONT></P>
<P align=justify><B><FONT face="times new roman" size=2>Employment Agreements</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>We have entered into a
written employment agreement with each of the Named Executive Officers setting
forth the terms of their employment. The agreements also provide for certain
severance benefits upon a covered termination of the Named Executive Officer&#146;s
employment, and for accelerated vesting of options in connection with a change
in control transaction, which terms are further described below under the
section entitled &#147;Severance and Change in Control Benefits.&#148; Each of our Named
Executive Officers is employed &#147;at will&#148;.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>We entered into an
employment agreement with Dr. Scarlett dated September 29, 2011, in connection
with commencement of his employment with us. Dr. Scarlett&#146;s employment agreement
originally provided him with an annual base salary of $550,000, subject to
increase, and an annual bonus targeted at 60% of his annual base salary. On
February 11, 2014, we amended Dr. Scarlett&#146;s employment agreement to provide for
an annual base salary of $586,500, subject to increase, and to include a
clawback provision that provides that Dr. Scarlett&#146;s annual bonus is subject to
forfeiture or repayment to the Company should the Company determine, in its
reasonable discretion, that Dr. Scarlett has engaged in any misconduct intended
to affect the payment of his annual discretionary bonus, or has otherwise
engaged in any act or omission that would constitute cause for termination of
employment (the &#147;clawback provision&#148;).</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>We entered into an
employment agreement with Ms. Bloom dated December 7, 2012, in connection with
her appointment as our Senior Vice President, Finance, Chief Financial Officer
and Treasurer, to provide an annual base salary of $330,000 and an annual
discretionary bonus targeted at 40% of her annual base salary. On September 24,
2013, we amended Ms. Bloom&#146;s employment agreement to provide that Ms. Bloom&#146;s
annual discretionary bonus is subject to forfeiture or repayment to the Company
pursuant to the same clawback provision described above for Dr. Scarlett, but
with respect to Ms. Bloom. On February 11, 2014, in connection with her
promotion to Executive Vice President, we amended Ms. Bloom&#146;s employment
agreement to provide for an annual base salary of $365,000, subject to increase,
and an annual discretionary bonus targeted at 45% of her annual base
salary.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>We entered into an
employment agreement with Ms. Behrs effective January 31, 2013, to provide an
annual base salary of $341,550, subject to increase, and an annual discretionary
bonus targeted at 40% of her annual base salary. On September 24, 2013, we
amended Ms. Behrs&#146; employment agreement to provide that Ms. Behrs&#146; annual
discretionary bonus is subject to forfeiture or repayment to the Company
pursuant to the same clawback provision described above for Dr. Scarlett, but
with respect to Ms. Behrs. On February 11, 2014, in connection with her
promotion to Executive Vice President, we amended Ms. Behrs&#146; employment
agreement to provide for an annual base salary of $352,000, subject to increase,
and an annual discretionary bonus targeted at 45% of her annual base
salary.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>We entered into an
employment agreement with Dr. Grethlein effective September 17, 2012, in
connection with commencement of his employment with us, to provide an annual
base salary of $355,000 and an annual discretionary bonus targeted at 45% of his
annual base salary. On February 11, 2014, we amended Dr. Grethlein&#146;s employment
agreement to provide for an annual base salary of $379,000, subject to increase,
and to provide that Dr. Grethlein&#146;s annual discretionary bonus is subject to
forfeiture or repayment to the Company pursuant to the same clawback provision
described above for Dr. Scarlett, but with respect to Dr. Grethlein.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>We entered into an
employment agreement with Mr. Rosenfield effective February 16, 2012, in
connection with commencement of his employment with us, to provide an annual
base salary of $292,000, pro-rated to reflect Mr. Rosenfield&#146;s 80% of a full-time work schedule, and an annual discretionary bonus targeted at 45% of his
annual base salary. On September 24, 2013, we amended Mr. Rosenfield&#146;s
employment agreement to provide that Mr. Rosenfield&#146;s annual discretionary bonus
is subject to forfeiture or repayment to the Company pursuant to the same
clawback provision described above for Dr. Scarlett, but with respect to Mr.
Rosenfield.</FONT></P>
<P align=justify><B><FONT face="times new roman" size=2>Severance and Change in Control
Benefits</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Our Named Executive
Officers are entitled to certain severance and change in control benefits under
the terms of our Amended Severance Plan, their employment agreements and our
equity plans. These severance and change in control provisions are intended to
allow employees, including Named Executive Officers, to focus their</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>36</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=left><FONT face="Times New Roman" size=2><A HREF="#toc"><B>Table of Contents</B></A></FONT></P>
<P align=justify><FONT face="Times New Roman" size=2>attention on the business
operations of Geron in the face of the potentially disruptive impact of a
proposed change in control transaction, to assess takeover bids objectively
without regard to the potential impact on their own job security and to allow
for a smooth transition in the event of a change in control of Geron.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Compensation Committee
believes that the severance benefits we offer remain essential to fulfill the
objective to recruit, retain and develop key management talent in the
competitive market. These arrangements enable us to recruit and retain
high-quality new management talent because they provide reasonable protection to
the executive officer in the event that he or she is not retained under limited
circumstances. We do not provide for any excise tax gross-ups in the Amended
Severance Plan or in any individual agreement with a Named Executive
Officer.</FONT></P>
<P align=justify><B><I><FONT face="times new roman" size=2>Amended Severance
Plan</FONT></I></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>In September 2002, the
Board approved a Severance Plan that originally became effective on January 21,
2003 and was subsequently amended and restated, most recently in May 2013
(collectively referred to herein as the &#147;Amended Severance Plan&#148;). The May 2013
amendment included modifications that require a &#147;double trigger&#148; for cash
severance benefits to be paid to employees, including Named Executive Officers
in the event of a Change in Control, as defined below, so that benefits are paid
only upon a Change in Control and a termination of employment, such termination
being either by the Company or because the employee resigns due to a material
change in their employment terms. Prior to the May 2013 amendment, the Amended
Severance Plan had provided a &#147;single trigger&#148; for payment of cash severance
benefits upon a Change in Control. The &#147;single trigger&#148; was removed from the
Amended Severance Plan in response to stockholders feedback and because the
Board believes that a &#147;double trigger&#148; provides reasonable protection of their
interests in connection with any potential change in control.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Amended Severance Plan
applies to all employees, including the Named Executive Officers, who are not
subject to a performance improvement plan. Severance benefits provided under the
employment agreements with the Named Executive Officers are generally reduced by
the same type of severance payments the Named Executive Officer is entitled to
receive under the Amended Severance Plan in order to prevent duplication of
benefits.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Amended Severance Plan
provides for severance benefits to the Named Executive Officers only if there is
a Change in Control triggering event. Under the Amended Severance Plan, upon a
Change in Control triggering event, each of our Named Executive Officers is
entitled to a payment equal to 15 months (18 months, with respect to Dr.
Scarlett) of his or her base salary then in effect as of such Change in Control
triggering event and payment of COBRA premiums for up to 15 months (18 months,
with respect to Dr. Scarlett).</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>A Change in Control
triggering event is defined by the Amended Severance Plan as a termination
without Cause in connection with a Change in Control (which has the same
definition as under the 2011 Plan described below) or within 12 months following
a Change in Control. Additionally, if an individual is terminated by the Company
in connection with a Change in Control but immediately accepts employment with
the Company&#146;s successor or acquirer, they will not be deemed to have had a
Change in Control triggering event unless: i) such individual is subsequently
terminated without Cause by the successor or acquirer within the 12 months
following the Change in Control; ii) such individual resigns employment with the
Company because in connection with a Change in Control he or she is offered
terms of employment (new or continuing) by the Company or the Company&#146;s
successor or acquirer within 30 days after the Change in Control that results in
a material change in the terms of employment; or iii) after accepting (or
continuing) employment with the Company or the Company&#146;s successor or acquirer
after a Change in Control, such individual resigns employment within 12 months
following the Change in Control due to a material change in terms of employment
as defined below. </FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>For purposes of the Amended
Severance Plan a &#147;material change in terms of employment&#148; shall occur if one of
the following events occurs without the employee&#146;s consent: i) base salary is
materially reduced from that in effect immediately prior to the Change in
Control; ii) if as of the Change in Control they are employed at the director
level or above, they are subject to a material reduction in their duties
(including responsibilities and/or authority); iii) their principal work
location is to be moved to a location that is either more than 45 miles from
their principal work location immediately prior to the Change in Control or more
than 30 miles farther from their principal weekday residence than was their
principal work location immediately prior to the Change in Control; or iv) the
Company or the Company&#146;s successor or acquirer materially breaches the terms of
any employment or similar </FONT></P>
<P align=center><FONT face="Times New Roman" size=2>37</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=left><FONT face="Times New Roman" size=2><A HREF="#toc"><B>Table of Contents</B></A></FONT></P>
<P align=justify><FONT face="Times New Roman" size=2>service agreement with the
employee. Additionally, in order for the resignation to be deemed due to a
material change in terms of their employment, the employee must provide written
notice to the Company&#146;s General Counsel within 30 days after the first
occurrence of the event giving rise to a material change in their terms of
employment setting forth the basis for their resignation, allow the Company at
least 30 days from receipt of such written notice to cure such event, and if
such event is not reasonably cured within such period, the employee resignation
from all positions they then hold with the Company is effective not later than
90 days after the expiration of the cure period.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>For purposes of the Amended
Severance Plan, &#147;Cause&#148; generally means an employee&#146;s continued failure to
satisfactorily perform duties, willful act or omission constituting dishonesty,
fraud or other malfeasance against the Company, conviction of a felony,
debarment by the FDA from working in or providing services to any pharmaceutical
or biotechnology company or other ineligibility under any law or regulation to
perform the employee&#146;s duties to the Company, or breach of any material Company
policies.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Payment of any benefits
under the Amended Severance Plan is conditioned on the timely provision of an
effective release of claims against Geron.</FONT></P>
<P align=justify><B><I><FONT face="times new roman" size=2>Employment
Agreements</FONT></I></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Under Dr. Scarlett&#146;s
employment agreement, in the event of a Covered Termination (as defined below)
and subject to his provision of a release of claims against Geron, Dr. Scarlett
will be entitled to: i) any unpaid annual incentive bonus to which he would have
become entitled for any fiscal year that ends on or before the termination date
had he remained employed through the payment date, payable in a single lump-sum
payment; ii) a lump-sum severance payment equal to 24 months of his base salary
then in effect as of such termination; iii) continued healthcare coverage as
permitted under COBRA for a period of one year following a Covered Termination
at the same cost as in effect immediately prior to such termination; and iv) the
vested portion of any stock options or other exercisable equity interest in
Geron will remain outstanding until the earlier of the second anniversary of the
date of termination and the original expiration date of such award. In addition,
Dr. Scarlett&#146;s employment agreement provides that the initial option granted to
him will vest in full upon a change in control if he is providing services
through the date of such change in control. In addition, other stock options
granted to Dr. Scarlett will vest in full upon a Change in Control (as defined
in the relevant equity plan under which the options were granted) if Dr.
Scarlett is providing services through the date of such Change in Control. As
described above, Dr. Scarlett is also eligible to participate in Geron&#146;s Amended
Severance Plan, provided that any severance benefits payable under Dr.
Scarlett&#146;s employment agreement, other than annual discretionary bonuses and
extended exercisability of any stock options or equity awards, shall be reduced
by the amount of severance or other cash payable to Dr. Scarlett under the
Amended Severance Plan.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Under the employment
agreements for each of the other Named Executive Officers, in the event of a
Covered Termination and subject to a release of claims against Geron, each Named
Executive Officer will be entitled to a lump-sum severance payment equal to 12
months of base salary then in effect as of such termination, a pro-rated portion
of any target annual incentive bonus, continued COBRA coverage for a period of
one year following a Covered Termination, and the vested portion of any stock
options or other exercisable equity interest in Geron in either case shall
remain outstanding until the earlier of the second anniversary of the date of
termination and the original expiration date of such award. In addition, stock
options granted to each of the Named Executive Officers will vest in full upon a
Change in Control (as defined in the relevant equity plan under which the
options were granted) if the Named Executive Officer is providing services
through the date of such Change in Control. As described above, each of the
Named Executive Officers is also eligible to participate in Geron&#146;s Amended
Severance Plan, provided that any severance benefits payable under the Named
Executive Officer&#146;s employment agreements, other than annual discretionary
bonuses and extended exercisability of any stock options or equity awards, shall
be reduced by the amount of severance or other cash payable to the Named
Executive Officers under the Amended Severance Plan.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>For the purposes of the
Named Executive Officers&#146; employment agreements, a &#147;Covered Termination&#148;
generally means an Involuntary Termination Without Cause that occurs at any
time, provided that such termination constitutes a &#147;separation from service&#148;
within the meaning of Section 409A of the Code, and &#147;Involuntary Termination
Without Cause&#148; generally means an executive officer&#146;s dismissal or discharge
other than: i) for cause </FONT></P>
<P align=center><FONT face="Times New Roman" size=2>38</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=left><FONT face="Times New Roman" size=2><A HREF="#toc"><B>Table of Contents</B></A></FONT></P>
<P align=justify><FONT face="Times New Roman" size=2>or ii) following an
involuntary or voluntary filing of bankruptcy, an assignment for the benefit of
creditors, a liquidation of our assets in a formal proceeding or otherwise or
any other event of insolvency by Geron, in any case, without an offer of
comparable employment by Geron or a successor, acquirer, or affiliate of
Geron.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>For purposes of the Named
Executive Officers&#146; employment agreements, &#147;Cause&#148; generally means the executive
officer&#146;s: i) willful act or omission constituting dishonesty, fraud or other
malfeasance against the Company; ii) conviction of a felony; iii) debarment by
the FDA from working in or providing services to any pharmaceutical or
biotechnology company or other ineligibility under any law or regulation to
perform the employee&#146;s duties to the Company; or iv) breach of any material
Company policies.</FONT></P>
<P align=justify><B><I><FONT face="times new roman" size=2>Equity Plans</FONT></I></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>As set forth in each
individual stock option or restricted stock award agreement under the 2011 Plan,
in the event of a Change in Control of Geron (defined below), the vesting of
each outstanding option and award held by all employees and outside directors
will accelerate so that each option shall become fully exercisable for all of
the outstanding shares subject to such option immediately prior to the
consummation of such transaction and each other type of award shall be fully
vested with all forfeiture restrictions on any or all of such awards to lapse.
For purposes of the 2011 Plan, a &#147;Change in Control&#148; generally means and
includes each of the following: a) as a result of any merger or consolidation,
the voting securities of Geron outstanding immediately prior thereto represent
(either by remaining outstanding or by being converted into voting securities of
the surviving or acquiring entity) less than 49% of the combined voting power of
the voting securities of Geron or such surviving or acquiring entity outstanding
immediately after such merger or consolidation; b) during any period of 24
consecutive calendar months, the individuals who at the beginning of such period
constitute the board of directors, and any new directors whose election by such
board of directors or nomination for election by stockholders was approved by a
vote of at least two-thirds of the members of such board of directors who were
either directors on such board of directors at the beginning of the period or
whose election or nomination for election as directors was previously so
approved, for any reason cease to constitute at least a majority of the members
thereof; c) any individual, entity or group becomes the beneficial owner of more
than 20% of the then outstanding shares of Geron Common Stock; d) any sale of
all or substantially all of the assets of Geron; or e) the complete liquidation
or dissolution of Geron.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>In the event of a merger,
acquisition or similar change in control, the 1996 Directors&#146; Stock Option Plan,
the 2002 Equity Incentive Plan and the 2006 Directors&#146; Plan provide through each
respective plan or the individual stock option or restricted stock award
agreements or both, that each outstanding option and award held by all employees
or outside directors will accelerate so that each option will be fully
exercisable for all of the shares subject to such option immediately prior to
the effective date of the transaction and each other type of award shall be
fully vested. In addition, upon the occurrence of such transaction, the 2002
Equity Incentive Plan and the 2006 Directors&#146; Plan provide that all of the
outstanding repurchase rights of Geron with respect to shares of Common Stock
acquired upon exercise of options granted, as well as shares of restricted stock
under the 2002 Equity Incentive Plan and the 2006 Directors&#146; Plan, will
terminate.</FONT></P>
<P align=justify><B><FONT face="times new roman" size=2>Tax and Accounting Implications for
Executive Compensation</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Compensation Committee
is responsible for addressing the issues raised by Section 162(m) of the Code,
which makes certain &#147;non-performance-based&#148; compensation to certain executive
officers of Geron in excess of $1,000,000 non-deductible to us. To qualify as
&#147;performance-based&#148; under Section 162(m), compensation payments must be
determined pursuant to a plan, by a committee of at least two &#147;outside&#148;
directors (as defined in the regulations promulgated under the Code) and must be
based on achieving objective performance goals. In addition, the material terms
of the plan must be disclosed to and approved by stockholders and the outside
directors or the Compensation Committee, as applicable, must certify that the
performance goals were achieved before payments can be awarded.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Compensation Committee
will continue to examine the effects of Section 162(m), to monitor the level of
compensation paid to executive officers and take appropriate action in response
to the provisions of Section 162(m), to the extent practicable while maintaining
competitive compensation practices. To maintain flexibility in compensating
executive officers in a manner designed to promote varying corporate goals, the
Compensation Committee reserves the right to recommend and award compensation
that is not deductible under Section 162(m).</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>39</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=left><FONT face="Times New Roman" size=2><A HREF="#toc"><B>Table of Contents</B></A></FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>In addition to considering
the tax consequences, the Compensation Committee considers the accounting
consequences of its decisions, including the impact of expenses being recognized
in connection with equity-based awards, in determining the size and form of
different equity-based awards.</FONT></P>
<P align=center><B><FONT face="Times New Roman" size=2><A NAME="CompensationComm"></A>COMPENSATION COMMITTEE
REPORT</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Our Compensation Committee
has reviewed and discussed the Compensation Discussion and Analysis required by
Item 402(b) of Regulation S-K and contained within this Proxy Statement with
management and, based on such review and discussions, our Compensation Committee
recommended to our Board that the Compensation Discussion and Analysis be
included in this Proxy Statement and incorporated into our Annual Report on Form
10-K for the year ended December 31, 2014.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Submitted on March 16, 2015
by the members of the Compensation Committee of the Board of
Directors:</FONT></P>
<DIV align=center>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="75%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="49%"><FONT face="Times New Roman" size=2>Robert J. Spiegel, M.D., FACP</FONT></TD>
    <TD noWrap align=left width="50%"><FONT face="Times New Roman" size=2>Compensation Committee Chair</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="49%"><FONT face="Times New Roman" size=2>Thomas Hofstaetter, Ph.D.</FONT></TD>
    <TD noWrap align=left width="50%"><FONT face="Times New Roman" size=2>Compensation Committee Member</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="49%"><FONT face="Times New Roman" size=2>V.
      Bryan Lawlis, Ph.D.</FONT></TD>
    <TD noWrap align=left width="50%"><FONT face="Times New Roman" size=2>Compensation Committee
  Member</FONT></TD></TR></TABLE></DIV><BR>
<P align=justify><I><FONT face="Times New Roman" size=2>This Section is not
&#147;soliciting material,&#148; is not deemed &#147; filed&#148; with the SEC and is not to be
incorporated by reference in any filing of the Company under the Securities
Exchange Act of 1934, as amended, or the Securities Act of 1933, as amended,
other than in Geron&#146;s Annual Report on Form 10-K where it shall be deemed to be
furnished, whether made before or after the date hereof and irrespective of any
general incorporation language in any such filing.</FONT></I></P>
<P align=center><B><FONT face="Times New Roman" size=2><A NAME="ExecutiveCom"></A>EXECUTIVE COMPENSATION
TABLES</FONT></B></P>
<P align=justify><B><FONT face="Times New Roman" size=2>2014 Summary
Compensation Table</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The following table
includes information concerning compensation for the years ended December 31,
2014, 2013 and 2012 to our Principal Executive Officer, Principal Financial
Officer and our three other most highly compensated executive officers of the
Company as of December 31, 2014 (our &#147;Named Executive Officers&#148;).</FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="8%"><B><FONT face="Times New Roman" size=1>Name and Principal
      Position</FONT></B></TD>
    <TD noWrap align=left width="52%">&nbsp;</TD>
    <TD noWrap align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%"><B><FONT face="Times New Roman" size=1>Year</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=2><B><FONT face="Times New Roman" size=1>Salary<BR>($)</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%">&nbsp;</TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=3><B><FONT face="Times New Roman" size=1>Bonus<BR>($)</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=2><B><FONT face="Times New Roman" size=1></FONT></B><B><FONT face="Times New Roman" size=1>Option<BR>Awards<BR>($)<SUP>(1)</SUP></FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"><B><FONT face="Times New Roman" size=1><SUP></SUP></FONT></B></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="6%" colSpan=4><B><FONT face="Times New Roman" size=1></FONT></B><B><FONT face="Times New Roman" size=1>Non-Equity<BR>Incentive
      Plan<BR>Compensation<BR>($)<SUP>(2)</SUP></FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="6%" colSpan=4><B><FONT face="Times New Roman" size=1><SUP></SUP></FONT></B><B><FONT face="Times New Roman" size=1></FONT></B><B><FONT face="Times New Roman" size=1>All<BR>Other<BR>Compensation<BR>($)<SUP>(3)</SUP></FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"><B><FONT face="Times New Roman" size=1><SUP></SUP></FONT></B></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=2><B><FONT face="Times New Roman" size=1>Total<BR>
($)</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="60%" bgColor=#c0c0c0 colSpan=2><FONT face="Times New Roman" size=1>John A. Scarlett, M.D.</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT size=1 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD>
    <TD noWrap style="text-align: center" width="4%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>2014</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT size=1 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>586,500</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT size=1 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>70,380</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1><SUP>(4)</SUP></FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT size=1 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>5,001,416</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT size=1 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT size=1 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>351,900</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT size=1 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT size=1 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT size=1 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>60,807</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT size=1 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT size=1 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>6,071,003</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="60%" bgColor=#c0c0c0 colSpan=2><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; President
      and Chief Executive Officer</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap style="text-align: center" width="4%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>2013</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>569,250</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>&#151;</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>1,308,242</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>341,550</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>59,299</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>2,278,341</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="60%" bgColor=#c0c0c0 colSpan=2></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap style="text-align: center" width="4%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>2012</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>550,000</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>39,600</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1><SUP>(5)</SUP></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>410,111</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>290,400</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>54,842</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>1,344,953</FONT></TD></TR>
  <TR>
    <TD width="100%" bgColor=#c0c0c0 colSpan=28>&nbsp;&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="60%" colSpan=2><FONT face="Times New Roman" size=1>Olivia K. Bloom<SUP>(6)</SUP></FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap style="text-align: center" width="4%"><FONT face="Times New Roman" size=1>2014</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=1>365,000</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=1>16,425</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=1><SUP>(4)</SUP></FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=1>1,468,600</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=1>174,105</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=1>12,126</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=1>2,036,256</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="60%" colSpan=2><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Executive
      Vice President, Finance,</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap style="text-align: center" width="4%"><FONT face="Times New Roman" size=1>2013</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=1>330,000</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=1>&#151;</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=1>462,899</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=1>135,960</FONT></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=1>28,297</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=1>957,156</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="60%" colSpan=2><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chief
      Financial Officer and Treasurer</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap style="text-align: center" width="4%"><FONT face="Times New Roman" size=1>2012</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=1>259,038</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=1>&#151;</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=1>174,602</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=1>114,654</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=1>30,524</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=1>578,818</FONT></TD></TR>
  <TR>
    <TD width="100%" colSpan=28>&nbsp;&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="60%" bgColor=#c0c0c0 colSpan=2><FONT face="Times New Roman" size=1>Melissa A. Kelly Behrs</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap style="text-align: center" width="4%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>2014</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>352,000</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>15,840</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1><SUP>(4)</SUP></FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>1,468,600</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>172,656</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>33,467</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>2,042,563</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="60%" bgColor=#c0c0c0 colSpan=2><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Executive
      Vice President, Bus. Dev. and</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap style="text-align: center" width="4%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>2013</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>341,550</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>&#151;</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>417,480</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>148,916</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>38,310</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>946,256</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="60%" bgColor=#c0c0c0 colSpan=2><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Portfolio
      &amp; Alliance Management</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap style="text-align: center" width="4%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>2012</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>330,000</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>&#151;</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>243,630</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>132,000</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>36,255</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>741,885</FONT></TD></TR>
  <TR>
    <TD width="100%" bgColor=#c0c0c0 colSpan=28>&nbsp;&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="60%" colSpan=2><FONT face="Times New Roman" size=1>Andrew J. Grethlein,
    Ph.D.<SUP>(7)</SUP></FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap style="text-align: center" width="4%"><FONT face="Times New Roman" size=1>2014</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=1>379,000</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=1>17,055</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=1><SUP>(4)</SUP></FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=1>1,468,600</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=1>180,783</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=1>34,379</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=1>2,079,817</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="60%" colSpan=2><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Executive
      Vice President, Development</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap style="text-align: center" width="4%"><FONT face="Times New Roman" size=1>2013</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=1>367,425</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=1>&#151;</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=1>294,630</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=1>170,301</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=1>34,219</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=1>866,575</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="60%" colSpan=2><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and
      Technical Operations</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap style="text-align: center" width="4%"><FONT face="Times New Roman" size=1>2012</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=1>103,542</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=1>&#151;</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=1>649,140</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=1>44,577</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=1>4,347</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=1>801,606</FONT></TD></TR>
  <TR>
    <TD width="100%" colSpan=28>&nbsp;&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="60%" bgColor=#c0c0c0 colSpan=2><FONT face="Times New Roman" size=1>Stephen N. Rosenfield,
    J.D.<SUP>(8)</SUP></FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap style="text-align: center" width="4%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>2014</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>312,000</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1><SUP>(9)</SUP></FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>14,040</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1><SUP>(4)</SUP></FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>1,468,600</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>148,824</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>13,347</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>1,956,811</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="60%" bgColor=#c0c0c0 colSpan=2><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Executive
      Vice President, General</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap style="text-align: center" width="4%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>2013</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>302,220</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1><SUP>(9)</SUP></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>&#151;</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>415,916</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>146,199</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>19,039</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>883,374</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="60%" bgColor=#c0c0c0 colSpan=2><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Counsel
      and Corporate Secretary</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap style="text-align: center" width="4%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>2012</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>255,500</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1><SUP>(9)</SUP></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>&#151;</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>685,510</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>133,371</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>112,900</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>1,187,281</FONT></TD></TR></TABLE><BR>
<P align=center><FONT face="Times New Roman" size=2>40</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><br>
<P align=left><FONT face="Times New Roman" size=2><A HREF="#toc"><B>Table of Contents</B></A></FONT></P>
<div>____________________</div><BR>
<TABLE cellSpacing=0 cellPadding=0 border=0>

  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(1)</FONT></TD>
    <TD vAlign=top align=left width="100%">
      <P align=justify><FONT face="Times New Roman" size=2>Amounts represent the
      aggregate grant date fair value of stock option awards granted during the
      applicable fiscal year as calculated in accordance with FASB ASC Topic
      718. For additional information, refer to Note 9 of the consolidated
      financial statements in our Annual Report on Form 10-K for the year ended
      December 31, 2014 regarding assumptions underlying the valuation of stock
      option awards and the calculation method. For 2013, amounts shown under
      the &#147;Option Awards&#148; column for Ms. Bloom, Mr. Rosenfield and Ms. Behrs
      also include the aggregate incremental fair value associated with the
      modification of stock options modified in 2013. Refer to the supplemental
      table under &#147;Outstanding Equity Awards at Fiscal Year-End&#148; on page 43 for
      information as to each Named Executive Officers&#146; unvested stock award
      holdings and vested and unvested stock option holdings, and &#147;Grants of
      Plan-Based Awards for 2014&#148; on page 42 for the number of stock options
      granted during 2014.</FONT></P></TD></TR>
  <TR>
    <TD vAlign=top colSpan=2>&nbsp;&nbsp; </TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(2)</FONT></TD>
    <TD vAlign=top align=left width="100%">
      <P align=justify><FONT face="Times New Roman" size=2>Amounts disclosed
      under &#147;Non-Equity Incentive Plan Compensation&#148; column represent the annual
      incentive bonuses earned pursuant to our annual incentive bonus plan. For
      further discussion see the section entitled &#147;Compensation Discussion and
      Analysis &#150; 2014 Annual Incentive Bonuses&#148; on page 30.</FONT></P></TD></TR>
  <TR>
    <TD vAlign=top noWrap>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD vAlign=top align=left width="100%"></TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(3)</FONT></TD>
    <TD vAlign=top align=left width="100%">
      <P align=justify><FONT face="Times New Roman" size=2>Amounts shown
      include: i) reimbursements for housing and travel expenses; ii) the
      portion of life and health insurance premiums paid by the Company; and
      iii) the matching contributions made to the Geron 401(k) Plan on behalf of
      the Named Executive Officers. These amounts for the year ended December
      31, 2014 were as follows:</FONT></P></TD></TR></TABLE><BR>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD noWrap align=left width="83%" colSpan=2></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap style="text-align: center" width="4%" colSpan=4><B><FONT face="times new roman" size=1>Housing</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="83%" colSpan=2></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap style="text-align: center" width="4%" colSpan=4><B><FONT face="times new roman" size=1>and Travel</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="4%" colSpan=4><B><FONT face="times new roman" size=1>Insurance</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="2%" colSpan=2><B><FONT face="times new roman" size=1>401(k)</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"><B><FONT face="times new roman" size=1></FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="83%" colSpan=2></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="text-align: center" width="4%" colSpan=4><B><FONT face="times new roman" size=1>Reimbursements</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="4%" colSpan=4><B><FONT face="times new roman" size=1>Premiums</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="2%" colSpan=2><B><FONT face="times new roman" size=1>Match</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="2%" colSpan=2><B><FONT face="times new roman" size=1>Total</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="5%"><B><FONT face="times new roman" size=1>Named Executive Officer</FONT></B></TD>
    <TD noWrap align=left width="78%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=4><B><FONT face="times new roman" size=1>($)</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=4><B><FONT face="times new roman" size=1>($)</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="2%" colSpan=2><B><FONT face="times new roman" size=1>($)<SUP>(a)</SUP></FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="2%" colSpan=2><B><FONT face="times new roman" size=1>($)</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="83%" bgColor=#c0c0c0 colSpan=2><FONT face="Times New Roman" size=2>John A. Scarlett, M.D.</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT size=2 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;
      </FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>44,000</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT size=2 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT size=2 face="Times New Roman">&nbsp;&nbsp;&nbsp; </FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>16,807</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT size=2 face="Times New Roman">&nbsp;&nbsp;&nbsp; </FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>60,807</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="83%" colSpan=2><FONT face="Times New Roman" size=2>Olivia K. Bloom</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%">&nbsp;</TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>3,376</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>8,750</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>12,126</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="83%" bgColor=#c0c0c0 colSpan=2><FONT face="Times New Roman" size=2>Melissa A. Kelly Behrs</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>22,808</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>10,659</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>33,467</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="83%" colSpan=2><FONT face="Times New Roman" size=2>Andrew J. Grethlein, Ph.D.</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>22,879</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>11,500</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>34,379</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="83%" bgColor=#c0c0c0 colSpan=2><FONT face="Times New Roman" size=2>Stephen N. Rosenfield, J.D.</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>1,847</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>11,500</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>13,347</FONT></TD></TR></TABLE>
<TABLE cellSpacing=0 cellPadding=0 border=0>

  <TR>
    <TD vAlign=top noWrap></TD>
    <TD vAlign=top width="100%" colSpan=2>____________________<BR>&nbsp;&nbsp; </TD></TR>
  <TR>
    <TD vAlign=top noWrap>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD>
    <TD WIDTH="100%" STYLE="text-align: justify"><FONT face="Times New Roman" size=2>Under Geron&#146;s 401(k)
      Plan, all participating employees may contribute up to the annual Internal
      Revenue Service contribution limit. In December 2014, the Board approved a
      fully vested matching contribution equal to 50% of each employee&#146;s annual
      contributions during 2014. The matching contribution was made in cash in
      February 2015.</FONT></TD></TR>
  <TR>
    <TD noWrap></TD>
    <TD width="100%" colSpan=2>&nbsp; </TD></TR></TABLE>
<TABLE cellSpacing=0 cellPadding=0 border=0>

  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(4)</FONT></TD>
    <TD WIDTH="100%" STYLE="text-align: justify"><FONT face="Times New Roman" size=2>Amount represents the
      discretionary portion of the annual incentive bonus. For further
      discussion, see the section entitled &#147;Compensation Discussion and Analysis
      &#150; 2014 Annual Incentive Bonuses&#148; on page 30.</FONT></TD></TR>
  <TR>
    <TD vAlign=top noWrap>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD width="100%">&nbsp; </TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(5)</FONT></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>Amount represents the
      discretionary portion of the incentive bonus awarded to Dr. Scarlett in
      2012.</FONT></TD></TR>
  <TR>
    <TD colSpan=2>&nbsp; </TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(6)</FONT></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>Ms. Bloom was
      appointed Senior Vice President, Finance, and Chief Financial Officer in
      December 2012.</FONT></TD></TR>
  <TR>
    <TD colSpan=2>&nbsp; </TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(7)</FONT></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>Dr. Grethlein joined
      the Company in September 2012.</FONT></TD></TR>
  <TR>
    <TD colSpan=2>&nbsp; </TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(8)</FONT></TD>
    <TD WIDTH="100%" STYLE="text-align: justify"><FONT face="Times New Roman" size=2>Mr. Rosenfield joined
      the Company in February 2012. Mr. Rosenfield served as a consultant to the
      Company from October 2011 to January 2012. The consulting fees paid to him
      in 2012 are included in the &#147;All Other Compensation&#148; column.</FONT></TD></TR>
  <TR>
    <TD colSpan=2>&nbsp; </TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(9)</FONT></TD>
    <TD WIDTH="100%" STYLE="text-align: justify"><FONT face="Times New Roman" size=2>The actual base
      salary amount reflects Mr. Rosenfield&#146;s employment at 80% full-time
      equivalent.</FONT></TD></TR></TABLE>
<P align=center><FONT face="Times New Roman" size=2>41</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=left><FONT face="Times New Roman" size=2><A HREF="#toc"><B>Table of Contents</B></A></FONT></P>
<P align=justify><B><FONT face="times new roman" size=2>Grants of Plan-Based Awards for
2014</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The following table sets
forth information regarding grants of plan-based awards with respect to each of
the Named Executive Officers for the fiscal year ended December 31,
2014:</FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="69%" colSpan=2></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="6%" colSpan=4></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="4%"><B><FONT face="times new roman" size=1>All</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="4%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="69%" colSpan=2></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="6%" colSpan=4><B><FONT face="times new roman" size=1>Estimated</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="4%"><B><FONT face="times new roman" size=1>Other</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="4%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="69%" colSpan=2></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="6%" colSpan=4><B><FONT face="times new roman" size=1>Possible</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="4%"><B><FONT face="times new roman" size=1>Option</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="4%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="69%" colSpan=2></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="6%" colSpan=4><B><FONT face="times new roman" size=1>Payouts Under</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="4%"><B><FONT face="times new roman" size=1>Awards:</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="7%" colSpan=4><B><FONT face="times new roman" size=1>Grant Date</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="69%" colSpan=2></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="6%" colSpan=4><B><FONT face="times new roman" size=1>Non-Equity</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="4%"><B><FONT face="times new roman" size=1>Number of</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="5%" colSpan=4><B><FONT face="times new roman" size=1>Exercise</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="7%" colSpan=4><B><FONT face="times new roman" size=1>Fair Value of</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="69%" colSpan=2></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="6%" colSpan=4><B><FONT face="times new roman" size=1>Incentive Plan</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="4%"><B><FONT face="times new roman" size=1>Securities</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="5%" colSpan=4><B><FONT face="times new roman" size=1>Price</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="7%" colSpan=4><B><FONT face="times new roman" size=1>Stock</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="69%" colSpan=2></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="6%" colSpan=4><B><FONT face="times new roman" size=1>Awards</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="4%"><B><FONT face="times new roman" size=1>Underlying</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="5%" colSpan=4>&nbsp;
      <STRONG><FONT face="times new roman" size=1>of Stock</FONT></STRONG></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="7%" colSpan=4><B><FONT face="times new roman" size=1>Option</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="69%" colSpan=2></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="4%" colSpan=2><B><FONT face="times new roman" size=1>Grant</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="6%" colSpan=4><B><FONT face="times new roman" size=1>Target</FONT></B><B><FONT face="times new roman" size=1><SUP>(1)</SUP></FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="4%"><B><FONT face="times new roman" size=1>Options</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="5%" colSpan=4><B><FONT face="times new roman" size=1>Options</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="7%" colSpan=4><B><FONT face="times new roman" size=1>Awards</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="2%"><B><FONT face="times new roman" size=1>Named Executive
      Officer</FONT></B></TD>
    <TD noWrap align=left width="67%" >&nbsp;</TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=2><B><FONT face="times new roman" size=1>Date</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="6%" colSpan=4><B><FONT face="times new roman" size=1>($)</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%"><B><FONT face="times new roman" size=1>(#)</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=4><B><FONT face="times new roman" size=1>($/Sh)</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="7%" colSpan=4><B><FONT face="times new roman" size=1></FONT></B><B><FONT face="times new roman" size=1>($)<SUP>(2)</SUP></FONT></B> <B><FONT face="times new roman" size=1><SUP></SUP></FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="69%" bgColor=#c0c0c0 colSpan=2><FONT face="Times New Roman" size=2>John A. Scarlett, M.D.</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>2/11/14</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2><SUP>(3)</SUP></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>1,340,000</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>5.09</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>&nbsp;&nbsp; </FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>5,001,416</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>&nbsp;&nbsp; </FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="69%" bgColor=#c0c0c0 colSpan=2>&nbsp; </TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>351,900</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="69%" colSpan=2><FONT face="Times New Roman" size=2>Olivia K. Bloom</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>2/10/14</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2><SUP>(4)</SUP></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=right width="1%">&nbsp;</TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face="Times New Roman" size=2>400,000</FONT></TD>
    <TD noWrap align=right width="1%">&nbsp;</TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>5.01</FONT></TD>
    <TD noWrap align=right width="1%">&nbsp;</TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="4%"><FONT face="Times New Roman" size=2>1,468,600</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="69%" colSpan=2>&nbsp; </TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%">&nbsp;</TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>164,250</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%">&nbsp;</TD>
    <TD noWrap align=right width="4%"><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="69%" bgColor=#c0c0c0 colSpan=2><FONT face="Times New Roman" size=2>Melissa A. Kelly Behrs</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>2/10/14</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2><SUP>(4)</SUP></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>400,000</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>5.01</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>1,468,600</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="69%" bgColor=#c0c0c0 colSpan=2>&nbsp; </TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>158,400</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="69%" colSpan=2><FONT face="Times New Roman" size=2>Andrew J. Grethlein, Ph.D.</FONT></TD>
    <TD noWrap align=right width="1%">&nbsp;</TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>2/10/14</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2><SUP>(4)</SUP></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face="Times New Roman" size=2>400,000</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>5.01</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="4%"><FONT face="Times New Roman" size=2>1,468,600</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="69%" colSpan=2>&nbsp; </TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>170,550</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="69%" bgColor=#c0c0c0 colSpan=2><FONT face="Times New Roman" size=2>Stephen N. Rosenfield, J.D.</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>2/10/14</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2><SUP>(4)</SUP></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>400,000</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>5.01</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>1,468,600</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="69%" bgColor=#c0c0c0 colSpan=2>&nbsp; </TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>140,400</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR></TABLE><div>____________________</div>
<BR>
<TABLE cellSpacing=0 cellPadding=0 border=0>

  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      </FONT></TD>
    <TD WIDTH="100%" STYLE="padding-left: 0pt; text-align: justify"><FONT face="Times New Roman" size=2>This column sets forth the target amount of
      each Named Executive Officer&#146;s annual incentive bonus award for the fiscal
      year ended December 31, 2014 under our annual incentive bonus plan.
      Accordingly, the amounts set forth in this column do not represent actual
      compensation earned by the Named Executive Officers for the fiscal year
      ended December 31, 2014. For the actual compensation paid to our Named
      Executive Officers for the fiscal year ended December 31, 2014, see the
      section entitled &#147;2014 Summary Compensation Table&#148; on page 40. For further
      discussion see the section entitled &#147;Compensation Discussion and Analysis
      &#150; 2014 Annual Incentive Bonuses&#148; on page 30.</FONT></TD></TR>
  <TR>
    <TD colSpan=2>&nbsp; </TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(2)</FONT></TD>
    <TD WIDTH="100%" STYLE="text-align: justify"><FONT face="Times New Roman" size=2>Amounts represent the grant date fair value
      of each stock option granted in 2014 calculated in accordance with FASB
      ASC Topic 718. For additional information, refer to Note 9 of the
      consolidated financial statements in our Annual Report on Form 10-K for
      the year ended December 31, 2014 regarding assumptions underlying the
      valuation of stock option awards and the calculation method.</FONT></TD></TR>
  <TR>
    <TD colSpan=2>&nbsp; </TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(3)</FONT></TD>
    <TD WIDTH="100%" STYLE="text-align: justify"><FONT face="Times New Roman" size=2>Stock option vests in a series of 48 equal
      consecutive monthly installments commencing February 11, 2014, provided
      the executive officer continues to provide services to the
    Company.</FONT></TD></TR>
  <TR>
    <TD colSpan=2>&nbsp; </TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(4)</FONT></TD>
    <TD WIDTH="100%" STYLE="text-align: justify"><FONT face="Times New Roman" size=2>Stock option vests in a series of 48 equal
      consecutive monthly installments commencing February 10, 2014, provided
      the executive officer continues to provide services to the
    Company.</FONT></TD></TR></TABLE>
<P align=justify><B><FONT face="times new roman" size=2>Narrative Disclosure to Summary
Compensation Table and Grants of Plan-Based Awards Table</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><I><FONT face="times new roman" size=2>Employment
Agreements.</FONT></I><FONT face="Times New Roman" size=2> Each of our Named
Executive Officers has entered into a written employment agreement with Geron.
Descriptions of our employment agreements with our Named Executive Officers are
included under the section entitled &#147;Compensation Discussion and Analysis &#150;
Employment Agreements&#148; on page 38. Our Named Executive Officers are entitled to
certain severance benefits payable in connection with a Covered Termination and
upon a change in control of Geron under their employment agreements as described
under the section entitled &#147;Compensation Discussion and Analysis &#150; Severance and
Change in Control Benefits&#148; on page 36.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><I><FONT face="times new roman" size=2>Severance Plan.</FONT></I><FONT face="Times New Roman" size=2> Our Amended Severance Plan provides for all of
our employees, including each of our Named Executive Officers, to receive a cash
severance payment and other benefits on a &#147;double-trigger&#148; basis. Description of
our Amended Severance Plan is included under the section entitled &#147;Compensation
Discussion and Analysis &#150; Severance and Change in Control Benefits&#148; on page
36.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><I><FONT face="times new roman" size=2>Annual Incentive
Bonuses.</FONT></I><FONT face="Times New Roman" size=2> We provide for annual
incentive bonuses to reward executive officers for performance in the prior
fiscal year. For more information regarding our annual incentive bonus plan, see
the section entitled &#147;Compensation Discussion and Analysis &#150; 2014 Annual
Incentive Bonuses&#148; on page 30. </FONT></P>
<P align=center><FONT face="Times New Roman" size=2>42</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=left><FONT face="Times New Roman" size=2><A HREF="#toc"><B>Table of Contents</B></A></FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><I><FONT face="times new roman" size=2>Equity Awards.</FONT></I><FONT face="Times New Roman" size=2> All stock options awarded to our Named Executive
Officers during 2014 were granted under our 2011 Plan. Descriptions of the terms
of the stock options granted to our Named Executive Officers are included under
the section entitled &#147;Compensation Discussion and Analysis &#150; Components &#150; 2014
Equity Awards&#148; on page 34. Events that can accelerate the vesting of our stock
options are described under the section entitled &#147;Compensation Discussion and
Analysis &#150; Severance and Change in Control Benefits&#148; on page 36.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Our 2011 Plan was approved
by our Board and our stockholders in 2011 and replaced our Amended and Restated
2002 Equity Incentive Plan. The 2011 Plan provides for the grant of stock
options, restricted stock, restricted stock units, performance awards and other
stock and cash awards. The exercise price of a stock option may not be less than
100% of the closing price of Geron Common Stock as reported by the NASDAQ Global
Select Market on the date of grant. Stock options generally have a term of ten
years, but may terminate sooner in connection with the holder&#146;s termination of
service with us. Stock options vest based on conditions determined by the
Compensation Committee or the Board, which typically include continued service,
but may also include performance goals and/or other conditions. All equity
awards granted under the 2011 Plan are subject to acceleration under certain
change in control circumstances described under the section entitled
&#147;Compensation Discussion and Analysis &#150; Severance and Change in Control
Benefits&#148; on page 36.</FONT></P>
<P align=justify><B><FONT face="times new roman" size=2>Outstanding Equity Awards at Fiscal
Year-End </FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The following table
includes information with respect all outstanding equity awards held by our
Named Executive Officers as of December 31, 2014.</FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="52%" colSpan=2></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="30%" colSpan=19><B><FONT face="times new roman" size=1>Option Awards</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="16%" colSpan=8><B><FONT face="times new roman" size=1>Stock Awards</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="52%" colSpan=2></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="4%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="3%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="4%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="2%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="3%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="3%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="5%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="5%" colSpan=3><B><FONT face="times new roman" size=1>Market</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="52%" colSpan=2></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="4%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="3%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="4%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="2%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="3%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="3%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="5%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="5%" colSpan=3><B><FONT face="times new roman" size=1>Value
      of</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="52%" colSpan=2></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="4%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="3%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="4%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="2%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="3%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="3%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="5%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="5%" colSpan=3><B><FONT face="times new roman" size=1>Shares
      or</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="52%" colSpan=2></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="4%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="3%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="4%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="2%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="3%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="3%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="5%"><B><FONT face="times new roman" size=1>Number of</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="5%" colSpan=3><B><FONT face="times new roman" size=1>Units
      of</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="52%" colSpan=2></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="4%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="3%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="4%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="2%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="3%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="3%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="5%"><B><FONT face="times new roman" size=1>Shares or</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="5%" colSpan=3><B><FONT face="times new roman" size=1>Stock</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="52%" colSpan=2></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="4%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="12%" colSpan=7><B><FONT face="times new roman" size=1>Number of Securities</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="2%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="3%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="3%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="5%"><B><FONT face="times new roman" size=1>Units of</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="5%" colSpan=3><B><FONT face="times new roman" size=1>That</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="52%" colSpan=2></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="4%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="12%" colSpan=7><B><FONT face="times new roman" size=1>Underlying</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="5%" colSpan=4><B><FONT face="times new roman" size=1>Option</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="3%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="3%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="5%"><B><FONT face="times new roman" size=1>Stock</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="5%" colSpan=3><B><FONT face="times new roman" size=1>Have</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="52%" colSpan=2></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="4%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="12%" colSpan=7><B><FONT face="times new roman" size=1>Unexercised
    Options</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="5%" colSpan=4><B><FONT face="times new roman" size=1>Exercise</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="5%" colSpan=3><B><FONT face="times new roman" size=1>Option</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="3%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="5%"><B><FONT face="times new roman" size=1>That Have</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="5%" colSpan=3><B><FONT face="times new roman" size=1>Not</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="52%" colSpan=2></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="5%" colSpan=2><B><FONT face="times new roman" size=1>Grant</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="5%" colSpan=3><STRONG><FONT face="times new roman" size=1>Exercisable</FONT></STRONG></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="6%" colSpan=3><STRONG><FONT face="times new roman" size=1>Unexercisable</FONT></STRONG></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="5%" colSpan=4><B><FONT face="times new roman" size=1>Price</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="5%" colSpan=3><B><FONT face="times new roman" size=1>Expiration</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="4%" colSpan=2><STRONG><FONT face="times new roman" size=1>Grant</FONT></STRONG></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="5%"><B><FONT face="times new roman" size=1>Not Vested</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="5%" colSpan=3><STRONG><FONT face="times new roman" size=1>Vested</FONT></STRONG></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="6%"><B><FONT face="times new roman" size=1>Named Executive Officer</FONT></B></TD>
    <TD noWrap align=left width="46%">&nbsp;</TD>
    <TD noWrap style="text-align: center" width="1%"><FONT size=1 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=2><B><FONT face="times new roman" size=1>Date</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"><FONT size=1 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=3><B><FONT face="times new roman" size=1>(#)</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"><FONT size=1 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="6%" colSpan=3><B><FONT face="times new roman" size=1>(#)</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"><FONT size=1 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=4><B><FONT face="times new roman" size=1>($/Sh)</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"><FONT size=1 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=3><B><FONT face="times new roman" size=1>Date</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"><FONT size=1 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=2><B><FONT face="times new roman" size=1>Date</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"><FONT size=1 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%"><B><FONT face="times new roman" size=1>(#)</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"><FONT size=1 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%" colSpan=3><B><FONT face="times new roman" size=1></FONT></B><B><FONT face="times new roman" size=1>($)<SUP>(1)</SUP></FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="52%" bgColor=#c0c0c0 colSpan=2><FONT face="Times New Roman" size=1>John A. Scarlett, M.D.</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>9/29/11</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1><SUP>(2)</SUP></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT size=1 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>812,500</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT size=1 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT size=1 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>187,500</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT size=1 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT size=1 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>2.16</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT size=1 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT size=1 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>9/29/21</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT size=1 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="5%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="52%" bgColor=#c0c0c0 colSpan=2></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>5/17/12</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1><SUP>(3)</SUP></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>326,146</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>178,854</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>1.41</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>5/17/22</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="5%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="52%" bgColor=#c0c0c0 colSpan=2></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>2/13/13</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1><SUP>(3)</SUP></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>614,167</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>725,833</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>1.50</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>2/13/23</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="5%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="52%" bgColor=#c0c0c0 colSpan=2></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>2/11/14</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1><SUP>(3)</SUP></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>279,167</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="4%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>1,060,833</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>5.09</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>2/11/24</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="5%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR>
    <TD width="100%" bgColor=#c0c0c0 colSpan=31>&nbsp;&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="52%" colSpan=2><FONT face="Times New Roman" size=1>Olivia K. Bloom</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face="Times New Roman" size=1>5/6/05</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=1>30,000</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face="Times New Roman" size=1>&#151;</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=1>6.40</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=1>5/6/15</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=1>5/20/11</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=1><SUP>(4)</SUP></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap style="text-align: center" width="5%"><FONT face="Times New Roman" size=1>6,250</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1></FONT></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=1>$20,313</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="52%" colSpan=2></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face="Times New Roman" size=1>5/24/06</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=1>33,750</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face="Times New Roman" size=1>&#151;</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=1>6.63</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=1>5/24/16</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="5%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="52%" colSpan=2></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face="Times New Roman" size=1>5/23/07</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=1>20,000</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face="Times New Roman" size=1>&#151;</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=1>9.32</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=1>5/23/17</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=left width="3%">&nbsp;</TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="5%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="52%" colSpan=2></TD>
    <TD noWrap align=right width="1%">&nbsp;</TD>
    <TD noWrap align=right width="4%"><FONT face="Times New Roman" size=1>5/28/08</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=1>20,000</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face="Times New Roman" size=1>&#151;</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=1>3.97</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%">&nbsp;</TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=1>5/28/18</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="5%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="52%" colSpan=2></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face="Times New Roman" size=1>5/28/08</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=1>10,829</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face="Times New Roman" size=1>&#151;</FONT></TD>
    <TD noWrap align=right width="1%">&nbsp;</TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=1>3.97</FONT></TD>
    <TD noWrap align=right width="1%">&nbsp;</TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%">&nbsp;</TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=1>5/28/18</FONT></TD>
    <TD noWrap align=right width="1%">&nbsp;</TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="5%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="52%" colSpan=2></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face="Times New Roman" size=1>5/29/09</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=1>20,000</FONT></TD>
    <TD noWrap align=right width="1%">&nbsp;</TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face="Times New Roman" size=1>&#151;</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%">&nbsp;</TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=1>6.52</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=1>5/29/19</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%">&nbsp;</TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="5%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="52%" colSpan=2></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face="Times New Roman" size=1>5/29/09</FONT></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=1>7,500</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%">&nbsp;</TD>
    <TD noWrap align=right width="4%"><FONT face="Times New Roman" size=1>&#151;</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%">&nbsp;</TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=1>6.52</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=1>5/29/19</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="5%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="52%" colSpan=2></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face="Times New Roman" size=1>5/29/09</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=1>20,000</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%">&nbsp;</TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face="Times New Roman" size=1>&#151;</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=1>6.52</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=1>5/29/19</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="5%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="52%" colSpan=2></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face="Times New Roman" size=1>5/19/10</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=1>20,000</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face="Times New Roman" size=1>&#151;</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=1>5.29</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=1>5/19/20</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="5%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="52%" colSpan=2></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face="Times New Roman" size=1>5/20/11</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=1><SUP>(3)</SUP></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=1>44,792</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face="Times New Roman" size=1>5,208</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=1>4.65</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=1>5/20/21</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="5%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="52%" colSpan=2></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face="Times New Roman" size=1>5/17/12</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=1><SUP>(3)</SUP></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=1>138,854</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face="Times New Roman" size=1>76,146</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=1>1.41</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=1>5/17/22</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="5%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="52%" colSpan=2></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face="Times New Roman" size=1>2/12/13</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=1><SUP>(3)</SUP></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=1>183,333</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face="Times New Roman" size=1>216,667</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=1>1.51</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=1>2/12/23</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="5%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="52%" colSpan=2></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face="Times New Roman" size=1>2/10/14</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=1><SUP>(3)</SUP></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=1>83,333</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="4%"><FONT face="Times New Roman" size=1>316,667</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=1>$</FONT></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=1>5.01</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=1>2/10/24</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="5%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD></TR></TABLE><BR>
<P align=center><FONT face="Times New Roman" size=2>43</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=left><FONT face="Times New Roman" size=2><A HREF="#toc"><B>Table of Contents</B></A></FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="65%" colSpan=2></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="28%" colSpan=14><B><FONT face="times new roman" size=1>Option
    Awards</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="12%" colSpan=6><B><FONT face="times new roman" size=1>Stock
  Awards</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="65%" colSpan=2></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"><B><FONT face="times new roman" size=1>Market</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="65%" colSpan=2></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"><B><FONT face="times new roman" size=1>Value of</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="65%" colSpan=2></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"><B><FONT face="times new roman" size=1>Shares or</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="65%" colSpan=2></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"><B><FONT face="times new roman" size=1>Number of</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"><B><FONT face="times new roman" size=1>Units of</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="65%" colSpan=2></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"><B><FONT face="times new roman" size=1>Shares or</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"><B><FONT face="times new roman" size=1>Stock</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="65%" colSpan=2></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="14%" colSpan=7><B><FONT face="times new roman" size=1>Number of Securities</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"><B><FONT face="times new roman" size=1>Units of</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"><B><FONT face="times new roman" size=1>That</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="65%" colSpan=2></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD noWrap align=center width="14%" colSpan=7><B><FONT face="times new roman" size=1>Underlying</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"><B><FONT face="times new roman" size=1>Option</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"><B><FONT face="times new roman" size=1>Stock</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"><B><FONT face="times new roman" size=1>Have</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="65%" colSpan=2></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap width="14%" colSpan=7><B><FONT face="times new roman" size=1>Unexercised
      </FONT></B><STRONG><FONT face="times new roman" size=1>Options</FONT></STRONG></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"><B><FONT face="times new roman" size=1>Exercise</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"><B><FONT face="times new roman" size=1>Option</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"><B><FONT face="times new roman" size=1>That Have</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"><B><FONT face="times new roman" size=1>Not</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="65%" colSpan=2></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="4%" colSpan=2><B><FONT face="times new roman" size=1>Grant</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="6%" colSpan=3><STRONG><FONT face="times new roman" size=1>Exercisable</FONT></STRONG></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="6%" colSpan=3><STRONG><FONT face="times new roman" size=1>Unexercisable</FONT></STRONG></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"><B><FONT face="times new roman" size=1>Price</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"><B><FONT face="times new roman" size=1>Expiration</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="4%" colSpan=2><STRONG><FONT face="times new roman" size=1>Grant</FONT></STRONG></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"><B><FONT face="times new roman" size=1>Not Vested</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"><STRONG><FONT face="times new roman" size=1>Vested</FONT></STRONG></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="3%"><B><FONT face="times new roman" size=1>Named Executive
      Officer</FONT></B></TD>
    <TD noWrap align=left width="62%" >&nbsp;</TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=2><B><FONT face="times new roman" size=1>Date</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="2%"><B><FONT face="times new roman" size=1>(#)</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="6%" colSpan=3><B><FONT face="times new roman" size=1>(#)</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="2%"><B><FONT face="times new roman" size=1>($/Sh)</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center" noWrap align=center width="2%"><B><FONT face="times new roman" size=1>Date</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="4%" colSpan=2><B><FONT face="times new roman" size=1>Date</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="2%"><B><FONT face="times new roman" size=1>(#)</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"><FONT face="times new roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="2%"><B><FONT face="times new roman" size=1>($)<SUP>(1)</SUP></FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="65%" bgColor=#c0c0c0 colSpan=2><FONT face="Times New Roman" size=1>Melissa A. Kelly Behrs</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>5/6/05</FONT></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>60,000</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>&#151;</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>$6.40</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>5/6/15</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>5/20/11</FONT></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1><SUP>(4)</SUP></FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>6,250</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1></FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>$20,313</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="65%" bgColor=#c0c0c0 colSpan=2></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>5/24/06</FONT></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>60,000</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>&#151;</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>$6.63</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>5/24/16</FONT></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="65%" bgColor=#c0c0c0 colSpan=2></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>5/23/07</FONT></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>50,000</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>&#151;</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>$9.32</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>5/23/17</FONT></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="65%" bgColor=#c0c0c0 colSpan=2>&nbsp;</TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>5/28/08</FONT></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>50,000</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>&#151;</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>$3.97</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>5/28/18</FONT></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="65%" bgColor=#c0c0c0 colSpan=2></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>5/28/08</FONT></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>14,167</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>&#151;</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>$3.97</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>5/28/18</FONT></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="65%" bgColor=#c0c0c0 colSpan=2></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>5/29/09</FONT></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>50,000</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>&#151;</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>$6.52</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>5/29/19</FONT></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="65%" bgColor=#c0c0c0 colSpan=2></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>5/29/09</FONT></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>20,000</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>&#151;</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>$6.52</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>5/29/19</FONT></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="65%" bgColor=#c0c0c0 colSpan=2></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>5/19/10</FONT></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>50,000</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>&#151;</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>$5.29</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>5/19/20</FONT></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="65%" bgColor=#c0c0c0 colSpan=2></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>5/19/10</FONT></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>10,000</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>&#151;</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>$5.29</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>5/19/20</FONT></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="65%" bgColor=#c0c0c0 colSpan=2></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>5/20/11</FONT></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1><SUP>(3)</SUP></FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>44,792</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>5,208</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>$4.65</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>5/20/21</FONT></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="65%" bgColor=#c0c0c0 colSpan=2></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>5/17/12</FONT></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1><SUP>(3)</SUP></FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>193,750</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>106,250</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>$1.41</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>5/17/22</FONT></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="65%" bgColor=#c0c0c0 colSpan=2></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>2/12/13</FONT></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1><SUP>(3)</SUP></FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>137,500</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>162,500</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>$1.51</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>2/12/23</FONT></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="65%" bgColor=#c0c0c0 colSpan=2></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>2/10/14</FONT></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1><SUP>(3)</SUP></FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>83,333</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>316,667</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>$5.01</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>2/10/24</FONT></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD></TR>
  <TR>
    <TD width="109%" bgColor=#c0c0c0 colSpan=24>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="65%" colSpan=2><FONT face="Times New Roman" size=1>Andrew J. Grethlein, Ph.D.</FONT></TD>
    <TD noWrap align=right width="2%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=1>9/19/12</FONT></TD>
    <TD noWrap align=left width="2%"><FONT face="Times New Roman" size=1><SUP>(5)</SUP></FONT></TD>
    <TD noWrap align=right width="2%"></TD>
    <TD noWrap align=right width="2%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=1>337,500</FONT></TD>
    <TD noWrap align=right width="2%"></TD>
    <TD noWrap align=right width="2%"></TD>
    <TD noWrap align=right width="2%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=1>262,500</FONT></TD>
    <TD noWrap align=right width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"><FONT face="Times New Roman" size=1>$1.70</FONT></TD>
    <TD noWrap align=right width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap align=right width="2%"><FONT face="Times New Roman" size=1>9/19/22</FONT></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="2%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="65%" colSpan=2></TD>
    <TD noWrap align=right width="2%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=1>2/12/13</FONT></TD>
    <TD noWrap align=left width="2%"><FONT face="Times New Roman" size=1><SUP>(3)</SUP></FONT></TD>
    <TD noWrap align=right width="2%"></TD>
    <TD noWrap align=right width="2%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=1>137,500</FONT></TD>
    <TD noWrap align=right width="2%"></TD>
    <TD noWrap align=right width="2%"></TD>
    <TD noWrap align=right width="2%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=1>162,500</FONT></TD>
    <TD noWrap align=right width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"><FONT face="Times New Roman" size=1>$1.51</FONT></TD>
    <TD noWrap align=right width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap align=right width="2%"><FONT face="Times New Roman" size=1>2/12/23</FONT></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="2%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="65%" colSpan=2></TD>
    <TD noWrap align=right width="2%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=1>2/10/14</FONT></TD>
    <TD noWrap align=left width="2%"><FONT face="Times New Roman" size=1><SUP>(3)</SUP></FONT></TD>
    <TD noWrap align=right width="2%"></TD>
    <TD noWrap align=right width="2%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=1>83,333</FONT></TD>
    <TD noWrap align=right width="2%"></TD>
    <TD noWrap align=right width="2%"></TD>
    <TD noWrap align=right width="2%"></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=1>316,667</FONT></TD>
    <TD noWrap align=right width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%"><FONT face="Times New Roman" size=1>$5.01</FONT></TD>
    <TD noWrap align=right width="2%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap align=right width="2%"><FONT face="Times New Roman" size=1>2/10/24</FONT></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="2%"></TD>
    <TD noWrap align=left width="2%"></TD></TR>
  <TR>
    <TD width="109%" colSpan=24>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="65%" bgColor=#c0c0c0 colSpan=2><FONT face="Times New Roman" size=1>Stephen N. Rosenfield, J.D.</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>11/1/11</FONT></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1><SUP>(6)</SUP></FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>36,000</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>&#151;</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>$2.22</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>11/1/21</FONT></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="65%" bgColor=#c0c0c0 colSpan=2></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>2/16/12</FONT></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1><SUP>(7)</SUP></FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>301,042</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>123,958</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>$2.14</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>2/16/22</FONT></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="65%" bgColor=#c0c0c0 colSpan=2></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>5/17/12</FONT></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1><SUP>(8)</SUP></FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>129,167</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>70,833</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>$1.41</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>5/17/22</FONT></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="65%" bgColor=#c0c0c0 colSpan=2></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>2/12/13</FONT></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1><SUP>(3)</SUP></FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>192,500</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>227,500</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>$1.51</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>2/12/23</FONT></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="65%" bgColor=#c0c0c0 colSpan=2></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>2/10/14</FONT></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1><SUP>(3)</SUP></FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>83,333</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>316,667</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>$5.01</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=1>2/10/24</FONT></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD></TR></TABLE><div>____________________</div><BR>
<TABLE cellSpacing=0 cellPadding=0 border=0>

  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD>
    <TD WIDTH="100%" STYLE="text-align: justify"><FONT face="Times New Roman" size=2>The market values of
      the unvested restricted stock awards are calculated by multiplying the
      number of such unvested restricted stock awards shown in the table by the
      closing share price of our Common Stock on December 31, 2014, which was
      $3.25.</FONT></TD></TR>
  <TR>
    <TD colSpan=2>&nbsp;</TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(2)</FONT></TD>
    <TD WIDTH="100%" STYLE="text-align: justify"><FONT face="Times New Roman" size=2>Stock option vests as
      follows: 125,000 shares on March 29, 2012, and the remaining 875,000
      shares in a series of 42 equal consecutive monthly installments commencing
      from March 29, 2012, provided the executive officer continues to provide
      services to the Company.</FONT></TD></TR>
  <TR>
    <TD colSpan=2>&nbsp;</TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(3)</FONT></TD>
    <TD WIDTH="100%" STYLE="text-align: justify"><FONT face="Times New Roman" size=2>Stock option vests in
      a series of 48 equal consecutive monthly installments commencing from the
      date of grant, provided the executive officer continues to provide
      services to the Company.</FONT></TD></TR>
  <TR>
    <TD colSpan=2>&nbsp;</TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(4)</FONT></TD>
    <TD WIDTH="100%" STYLE="text-align: justify"><FONT face="Times New Roman" size=2>Restricted stock
      award vests in a series of four equal consecutive annual installments
      commencing on the date of grant, provided the executive officer continues
      to provide services to the Company.</FONT></TD></TR>
  <TR>
    <TD colSpan=2>&nbsp;</TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(5)</FONT></TD>
    <TD WIDTH="100%" STYLE="text-align: justify"><FONT face="Times New Roman" size=2>Stock option vests as
      follows: 75,000 shares on March 17, 2013 and the remaining 525,000 shares
      in a series of 42 equal consecutive monthly installments commencing from
      March 17, 2013, provided the executive officer continues to provide
      services to the Company.</FONT></TD></TR>
  <TR>
    <TD colSpan=2>&nbsp;</TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(6)</FONT></TD>
    <TD WIDTH="100%" STYLE="text-align: justify"><FONT face="Times New Roman" size=2>Stock option was
      granted in connection with Mr. Rosenfield&#146;s consulting agreement prior to
      his employment with the Company.</FONT></TD></TR>
  <TR>
    <TD colSpan=2>&nbsp;</TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(7)</FONT></TD>
    <TD WIDTH="100%" STYLE="text-align: justify"><FONT face="Times New Roman" size=2>Stock option vests as
      follows: 53,125 shares on August 16, 2012 and the remaining 371,875 shares
      in a series of 42 equal consecutive monthly installments commencing from
      August 16, 2012, provided the executive officer continues to provide
      services to the Company.</FONT></TD></TR>
  <TR>
    <TD colSpan=2>&nbsp;</TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(8)</FONT></TD>
    <TD WIDTH="100%" STYLE="text-align: justify"><FONT face="Times New Roman" size=2>Stock option vests as
      follows: 12,500 shares on August 17, 2012 and the remaining 187,500 shares
      in a series of 45 equal consecutive monthly installments commencing from
      August 17, 2012, provided the executive officer continues to provide
      services to the Company.</FONT></TD></TR></TABLE>
<P align=center><FONT face="Times New Roman" size=2>44</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=left><FONT face="Times New Roman" size=2><A HREF="#toc"><B>Table of Contents</B></A></FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Option Exercises and
Restricted Stock Awards Vested in 2014</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The following table
includes certain information with respect to the vesting of restricted stock
awards held by the Named Executive Officers during the fiscal year ended
December 31, 2014. No options were exercised by the Named Executive Officers
during the fiscal year ended December 31, 2014. </FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" colSpan=2></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=center width="4%"  colSpan=3><B><FONT face="Times New Roman" size=1>Number of</FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="5%"  colSpan=4><B><FONT face="Times New Roman" size=1>Value</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" colSpan=2></TD>
    <TD noWrap align=left width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=center width="4%"  colSpan=3><B><FONT face="Times New Roman" size=1>Shares Acquired</FONT></B></TD>
    <TD noWrap align=center width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=center width="5%"  colSpan=4><B><FONT face="Times New Roman" size=1>Realized on</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" colSpan=2></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=center width="4%"  colSpan=3><B><FONT face="Times New Roman" size=1>On Vesting</FONT></B></TD>
    <TD noWrap align=center width="1%"></TD>
    <TD noWrap align=center width="5%"  colSpan=4><B><FONT face="Times New Roman" size=1>Vesting</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=bottom noWrap align=left width="8%"><B><FONT face="Times New Roman" size=1>Named Executive
      Officer</FONT></B></TD>
    <TD noWrap align=left width="81%" >&nbsp;</TD>
    <TD noWrap align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=bottom noWrap align=center width="4%"  colSpan=3><B><FONT face="Times New Roman" size=1>(#)<SUP>(1)</SUP></FONT></B></TD>
    <TD noWrap align=center width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=bottom noWrap align=center width="5%"  colSpan=4><B><FONT face="Times New Roman" size=1>($)<SUP>(2)</SUP></FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" bgColor=#c0c0c0 colSpan=2><FONT face="Times New Roman" size=2>John A. Scarlett, M.D.</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%"  bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=left width="1%"  bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%"  bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=right width="1%"  bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" colSpan=2><FONT face="Times New Roman" size=2>Olivia K. Bloom</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%" ></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>28,000</FONT></TD>
    <TD noWrap align=left width="1%" ></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%" ></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>58,783</FONT></TD>
    <TD noWrap align=right width="1%" ></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" bgColor=#c0c0c0 colSpan=2><FONT face="Times New Roman" size=2>Melissa A. Kelly Behrs</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%"  bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>44,375</FONT></TD>
    <TD noWrap align=left width="1%"  bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%"  bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>93,119</FONT></TD>
    <TD noWrap align=right width="1%"  bgColor=#c0c0c0>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" colSpan=2><FONT face="Times New Roman" size=2>Andrew J. Grethlein, Ph.D.</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%" ></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=left width="1%" ></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%" ></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="2%"><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=right width="1%" ></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" bgColor=#c0c0c0 colSpan=2><FONT face="Times New Roman" size=2>Stephen N. Rosenfield,
    J.D.</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%"  bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=left width="1%"  bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%"  bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=right width="1%"  bgColor=#c0c0c0></TD></TR></TABLE><div>____________________</div><BR>
<TABLE style="TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 border=0>

  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(1)</FONT></TD>
    <TD vAlign=top noWrap >&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>Represents the
      vesting of previously granted restricted stock
  awards.<BR>&nbsp;</FONT></TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(2)</FONT></TD>
    <TD vAlign=top noWrap ></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>The value realized is
      based upon the closing market price of our Common Stock on the vesting
      date multiplied by the number of shares of restricted stock
    vested.</FONT></TD></TR></TABLE>
<P align=justify><B><FONT face="Times New Roman" size=2>Pension
Benefits</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>None of the Named Executive
Officers participates in or has an account balance under any pension or
qualified or non-qualified defined benefit retirement plans sponsored by the
Company.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Non-Qualified Deferred
Compensation</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>None of the Named Executive
Officers participates in or has an account balance under non-qualified defined
contribution plans or other non-qualified deferred compensation plans maintained
by the Company.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Additional Benefits
</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Named Executive
Officers are eligible to participate in our benefit plans generally available to
all employees, as described in &#147;Compensation Discussion and Analysis &#150; Other
Compensation.&#148; </FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Potential Payments Upon
Termination or Change in Control </FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>See discussion of potential
payments upon termination or change in control in the section entitled,
&#147;Compensation Discussion and Analysis &#150; Severance and Change in Control
Benefits.&#148; </FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The table below summarizes potential maximum payments under the
Amended Severance Plan, or individual employment agreements, as applicable, for
the Named Executive Officers and our equity plans if a qualifying termination
and/or change in control event occurred on December 31, 2014.</FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="79%" colSpan=2></TD>
    <TD noWrap align=center width="3%"></TD>
    <TD noWrap align=center width="1%" ></TD>
    <TD noWrap align=center width="5%"  colSpan=4><B><FONT face="Times New Roman" size=1>Covered</FONT></B></TD>
    <TD noWrap align=center width="1%" ></TD>
    <TD noWrap align=center width="5%"  colSpan=4><B><FONT face="Times New Roman" size=1>Termination</FONT></B></TD>
    <TD noWrap align=center width="1%" ></TD>
    <TD noWrap align=center width="5%"  colSpan=4><B><FONT face="Times New Roman" size=1>Change in</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="79%" colSpan=2></TD>
    <TD noWrap align=center width="3%"></TD>
    <TD noWrap align=center width="1%" ></TD>
    <TD noWrap align=center width="5%"  colSpan=4><B><FONT face="Times New Roman" size=1>Termination</FONT></B></TD>
    <TD noWrap align=center width="1%" ></TD>
    <TD noWrap align=center width="5%"  colSpan=4><B><FONT face="Times New Roman" size=1>Without Cause or</FONT></B></TD>
    <TD noWrap align=center width="1%" ></TD>
    <TD noWrap align=center width="5%"  colSpan=4><B><FONT face="Times New Roman" size=1>Control</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="79%" colSpan=2></TD>
    <TD noWrap align=center width="3%"></TD>
    <TD noWrap align=center width="1%" ></TD>
    <TD noWrap align=center width="5%"  colSpan=4><B><FONT face="Times New Roman" size=1>(No Change in</FONT></B></TD>
    <TD noWrap align=center width="1%" ></TD>
    <TD noWrap align=center width="5%"  colSpan=4><B><FONT face="Times New Roman" size=1>for Good Reason</FONT></B></TD>
    <TD noWrap align=center width="1%" ></TD>
    <TD noWrap align=center width="5%"  colSpan=4><B><FONT face="Times New Roman" size=1>Without</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="5%"><B><FONT face="Times New Roman" size=1>Named Executive Officer</FONT></B></TD>
    <TD noWrap align=left width="74%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="3%"><B><FONT face="Times New Roman" size=1>Benefit</FONT></B></TD>
    <TD noWrap align=center width="1%" >&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%"  colSpan=4><B><FONT face="Times New Roman" size=1>Control)</FONT></B><B><FONT face="Times New Roman" size=1><SUP>(1)</SUP></FONT></B></TD>
    <TD noWrap align=center width="1%" >&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%"  colSpan=4><B><FONT face="Times New Roman" size=1>(Change in
      Control)<SUP>(2)(3)</SUP></FONT></B></TD>
    <TD noWrap align=center width="1%" >&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="5%"  colSpan=4><B><FONT face="Times New Roman" size=1>Termination<SUP>(3)</SUP></FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="79%" bgColor=#c0c0c0 colSpan=2><FONT face="Times New Roman" size=2>John A. Scarlett, M.D.</FONT></TD>
    <TD noWrap align=center width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>Severance</FONT></TD>
    <TD noWrap align=right width="1%"  bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%"  bgColor=#c0c0c0>&nbsp;&nbsp;</TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>1,595,280</FONT></TD>
    <TD noWrap align=right width="1%"  bgColor=#c0c0c0>&nbsp;&nbsp;</TD>
    <TD noWrap align=right width="1%"  bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%"  bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>1,595,280</FONT></TD>
    <TD noWrap align=left width="1%"  bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=left width="1%"  bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%"  bgColor=#c0c0c0>&nbsp;&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%"  bgColor=#c0c0c0>&nbsp;&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="79%" bgColor=#c0c0c0 colSpan=2></TD>
    <TD noWrap align=center width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>Continued</FONT></TD>
    <TD noWrap align=left width="1%"  bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%"  bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%"  bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%"  bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%"  bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%"  bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%"  bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%"  bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%"  bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="79%" bgColor=#c0c0c0 colSpan=2></TD>
    <TD noWrap align=center width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>Healthcare</FONT></TD>
    <TD noWrap align=left width="1%"  bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%"  bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%"  bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%"  bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%"  bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%"  bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%"  bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%"  bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%"  bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="79%" bgColor=#c0c0c0 colSpan=2></TD>
    <TD noWrap align=center width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>Benefits</FONT></TD>
    <TD noWrap align=left width="1%"  bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%"  bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>22,495</FONT></TD>
    <TD noWrap align=left width="1%"  bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%"  bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%"  bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>33,742</FONT></TD>
    <TD noWrap align=left width="1%"  bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%"  bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%"  bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%"  bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="79%" bgColor=#c0c0c0 colSpan=2></TD>
    <TD noWrap align=center width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>Option and</FONT></TD>
    <TD noWrap align=left width="1%"  bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%"  bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%"  bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%"  bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%"  bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%"  bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%"  bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%"  bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%"  bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="79%" bgColor=#c0c0c0 colSpan=2></TD>
    <TD noWrap align=center width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>Restricted</FONT></TD>
    <TD noWrap align=left width="1%"  bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%"  bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%"  bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%"  bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%"  bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%"  bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%"  bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%"  bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="2%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%"  bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="79%" bgColor=#c0c0c0 colSpan=2></TD>
    <TD noWrap align=center width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>Stock Vesting</FONT></TD>
    <TD noWrap align=left width="1%"  bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%"  bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=left width="1%"  bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%"  bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%"  bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>4,364,200</FONT></TD>
    <TD noWrap align=right width="1%"  bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%"  bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%"  bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="2%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>4,364,200</FONT></TD>
    <TD noWrap align=right width="1%"  bgColor=#c0c0c0>&nbsp;</TD></TR>
  <TR STYLE="background-color: Silver">
    <TD noWrap align=left width="79%" colSpan=2><FONT face="Times New Roman" size=2>Total</FONT></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=right width="1%" ></TD>
    <TD noWrap align=right width="1%" ></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="2%"><FONT face="Times New Roman" size=2>1,617,775</FONT></TD>
    <TD noWrap align=right width="1%" ></TD>
    <TD noWrap align=right width="1%" ></TD>
    <TD noWrap align=right width="1%" ></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="2%"><FONT face="Times New Roman" size=2>5,993,222</FONT></TD>
    <TD noWrap align=right width="1%" ></TD>
    <TD noWrap align=right width="1%" ></TD>
    <TD noWrap align=right width="1%" ></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="2%"><FONT face="Times New Roman" size=2>4,364,200</FONT></TD>
    <TD noWrap align=right width="1%" ></TD></TR></TABLE><BR>
<P STYLE="text-align: center"><FONT face="Times New Roman" size=2>45</FONT></P>
<HR align=center width="100%" noShade SIZE=2>
<!-- PART E -->
<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=left><FONT face="Times New Roman" size=2><A HREF="#toc"><B>Table of Contents</B></A></FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="73%" colSpan=2></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%"><STRONG><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></STRONG></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"><STRONG><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></STRONG></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="6%" colSpan=4><B><FONT face="Times New Roman" size=1>Covered</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%" bgColor=#ffffff><STRONG><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></STRONG></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="6%" colSpan=4><B><FONT face="Times New Roman" size=1>Termination</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"><STRONG><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></STRONG></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="6%" colSpan=4><B><FONT face="Times New Roman" size=1>Change in</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="73%" colSpan=2></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="6%" colSpan=4><B><FONT face="Times New Roman" size=1>Termination</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="6%" colSpan=4><B><FONT face="Times New Roman" size=1>Without Cause or</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="6%" colSpan=4><B><FONT face="Times New Roman" size=1>Control</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="73%" colSpan=2></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="6%" colSpan=4><B><FONT face="Times New Roman" size=1>(No Change in</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="6%" colSpan=4><B><FONT face="Times New Roman" size=1>for Good Reason</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="6%" colSpan=4><B><FONT face="Times New Roman" size=1>Without</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><B><FONT face="Times New Roman" size=1>Named Executive
      Officer</FONT></B></TD>
    <TD noWrap align=left width="72%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="3%"><B><FONT face="Times New Roman" size=1>Benefit</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="6%" colSpan=4><B><FONT face="Times New Roman" size=1>Control)<SUP>(1)</SUP></FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="6%" colSpan=4><B><FONT face="Times New Roman" size=1>(Change in
      Control)<SUP>(2)(3)</SUP></FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="6%" colSpan=4><B><FONT face="Times New Roman" size=1>Termination<SUP>(3)</SUP></FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="73%" bgColor=#c0c0c0 colSpan=2><FONT face="Times New Roman" size=2>Olivia K. Bloom</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>Severance</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>529,250</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>620,500</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="73%" bgColor=#c0c0c0 colSpan=2></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>Continued</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="73%" bgColor=#c0c0c0 colSpan=2></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>Healthcare</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="73%" bgColor=#c0c0c0 colSpan=2></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>Benefits</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>3,376</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>4,220</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="73%" bgColor=#c0c0c0 colSpan=2></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>Option and</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="73%" bgColor=#c0c0c0 colSpan=2></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>Restricted</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="73%" bgColor=#c0c0c0 colSpan=2></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>Stock Vesting</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>1,111,913</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>1,111,913</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="73%" bgColor=#c0c0c0 colSpan=2><FONT face="Times New Roman" size=2>Total</FONT></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>532,626</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>1,736,633</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>1,111,913</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR>
    <TD noWrap align=left width="73%" bgColor=#c0c0c0 colSpan=2>&nbsp;</TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="73%" bgColor=#ffffff colSpan=2><FONT face="Times New Roman" size=2>Melissa A. Kelly Behrs</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%" bgColor=#ffffff></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%" bgColor=#ffffff><FONT face="Times New Roman" size=2>Severance</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#ffffff><FONT face="Times New Roman" size=2>510,400</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#ffffff><FONT face="Times New Roman" size=2>598,400</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="3%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="73%" bgColor=#ffffff colSpan=2></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%" bgColor=#ffffff></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%" bgColor=#ffffff><FONT face="Times New Roman" size=2>Continued</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="3%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="3%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="3%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="73%" bgColor=#ffffff colSpan=2></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%" bgColor=#ffffff></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%" bgColor=#ffffff><FONT face="Times New Roman" size=2>Healthcare</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="3%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="3%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="3%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="73%" bgColor=#ffffff colSpan=2></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%" bgColor=#ffffff></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%" bgColor=#ffffff><FONT face="Times New Roman" size=2>Benefits</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="3%" bgColor=#ffffff><FONT face="Times New Roman" size=2>30,822</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="3%" bgColor=#ffffff><FONT face="Times New Roman" size=2>38,527</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="3%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="73%" bgColor=#ffffff colSpan=2></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%" bgColor=#ffffff></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%" bgColor=#ffffff><FONT face="Times New Roman" size=2>Option and</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="3%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="3%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="3%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="73%" bgColor=#ffffff colSpan=2></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%" bgColor=#ffffff></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%" bgColor=#ffffff><FONT face="Times New Roman" size=2>Restricted</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="3%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="3%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="3%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="73%" bgColor=#ffffff colSpan=2></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%" bgColor=#ffffff></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%" bgColor=#ffffff><FONT face="Times New Roman" size=2>Stock Vesting</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#ffffff><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#ffffff><FONT face="Times New Roman" size=2>1,094,313</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#ffffff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="3%" bgColor=#ffffff><FONT face="Times New Roman" size=2>1,094,313</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="73%" bgColor=#ffffff colSpan=2><FONT face="Times New Roman" size=2>Total</FONT></TD>
    <TD noWrap align=left width="3%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="3%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#ffffff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%" bgColor=#ffffff><FONT face="Times New Roman" size=2>541,222</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="1%" bgColor=#ffffff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%" bgColor=#ffffff><FONT face="Times New Roman" size=2>1,731,240</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#ffffff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="3%" bgColor=#ffffff><FONT face="Times New Roman" size=2>1,094,313</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD></TR>
  <TR>
    <TD noWrap align=left width="73%" bgColor=#ffffff colSpan=2>&nbsp;</TD>
    <TD noWrap align=left width="3%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="3%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="3%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="3%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="3%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="73%" bgColor=#c0c0c0 colSpan=2><FONT face="Times New Roman" size=2>Andrew J. Grethlein, Ph.D.</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>Severance</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>549,550</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>644,300</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="73%" bgColor=#c0c0c0 colSpan=2></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>Continued</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="73%" bgColor=#c0c0c0 colSpan=2></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>Healthcare</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="73%" bgColor=#c0c0c0 colSpan=2></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>Benefits</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>30,893</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>38,616</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="73%" bgColor=#c0c0c0 colSpan=2></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>Option and</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="73%" bgColor=#c0c0c0 colSpan=2></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>Restricted</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="73%" bgColor=#c0c0c0 colSpan=2></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%" bgColor=#c0c0c0></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>Stock Vesting</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>1,452,000</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>1,452,000</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="73%" bgColor=#c0c0c0 colSpan=2><FONT face="Times New Roman" size=2>Total</FONT></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>580,443</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>2,134,916</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>1,452,000</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR>
    <TD noWrap align=left width="73%" bgColor=#c0c0c0 colSpan=2>&nbsp;</TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="73%" colSpan=2><FONT face="Times New Roman" size=2>Stephen N. Rosenfield, J.D.</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%"><FONT face="Times New Roman" size=2>Severance</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>452,400</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>530,400</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="73%" colSpan=2></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%"><FONT face="Times New Roman" size=2>Continued</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="73%" colSpan=2></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%"><FONT face="Times New Roman" size=2>Healthcare</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="73%" colSpan=2></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%"><FONT face="Times New Roman" size=2>Benefits</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>1,847</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>2,309</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="73%" colSpan=2></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%"><FONT face="Times New Roman" size=2>Option and</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="73%" colSpan=2></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%"><FONT face="Times New Roman" size=2>Restricted</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="73%" colSpan=2></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%"><FONT face="Times New Roman" size=2>Stock Vesting</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face="Times New Roman" size=2>1,607,630</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="3%"><FONT face="Times New Roman" size=2>1,607,630</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="73%" bgColor=#ffffff colSpan=2><FONT face="Times New Roman" size=2>Total</FONT></TD>
    <TD noWrap align=left width="3%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="3%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#ffffff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%" bgColor=#ffffff><FONT face="Times New Roman" size=2>454,247</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="1%" bgColor=#ffffff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%" bgColor=#ffffff><FONT face="Times New Roman" size=2>2,140,339</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=right width="1%" bgColor=#ffffff></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="1%" bgColor=#ffffff><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=left width="3%" bgColor=#ffffff><FONT face="Times New Roman" size=2>1,607,630</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD></TR></TABLE><div>____________________</div><BR>
<TABLE style="TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 border=0>

  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>Amounts represent
      lump-sum severance payments, target annual incentive bonus or accrued
      annual incentive bonus and continued healthcare benefits that could be
      paid to the Named Executive Officer upon a Covered Termination, not in
      connection with a change in control transaction on December 31, 2014,
      under such Named Executive Officer&#146;s employment agreement as of December
      31, 2014, as applicable. Descriptions of the severance payments in the
      event of the Covered Termination provided for under such Named Executive
      Officer&#146;s employment agreement are included under the section entitled
      &#147;Compensation Discussion and Analysis &#150; Severance and Change in Control
      Benefits&#148; on page 36. Any payments made under the Named Executive
      Officer&#146;s employment agreement would be deducted from payments due under
      the Amended Severance Plan.</FONT></TD></TR></TABLE>
<P align=center><FONT face="Times New Roman" size=2>46</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=left><FONT face="Times New Roman" size=2><A HREF="#toc"><B>Table of Contents</B></A></FONT></P>
<TABLE style="TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 border=0>

  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>Amounts represent
      lump-sum severance payments, target annual incentive bonus or accrued
      annual incentive bonus, continued healthcare benefits and the intrinsic
      value of acceleration of stock option and restricted stock vesting, as
      applicable, that could be paid to the Named Executive Officer under such
      Named Executive Officer&#146;s employment agreement and/or our Amended
      Severance Plan in the event of the Covered Termination or Change in
      Control triggering event on December 31, 2014, as applicable. Any payments
      made under the Named Executive Officer&#146;s employment agreement would be
      deducted from payments due under the Amended Severance Plan.</FONT></TD></TR>
  <TR>
    <TD colSpan=2><FONT size=2 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(3)</FONT></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>Amounts represent the
      intrinsic value of options that would become fully vested and exercisable
      and restricted stock awards that would fully vest upon a change in control
      regardless of termination, based on a market value of $3.25 per share of
      Common Stock as of December 31, 2014. Drs. Scarlett and Grethlein and Mr.
      Rosenfield do not hold any restricted stock
awards.</FONT></TD></TR></TABLE>
<P align=center><B><FONT face="Times New Roman" size=2><A NAME="EquityCom"></A>EQUITY COMPENSATION
PLANS</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The following table
summarizes information with respect to equity awards under Geron&#146;s equity
compensation plans at December 31, 2014: </FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="80%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="6%" colSpan=4><B><FONT face="Times New Roman" size=1>Number of</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"><STRONG><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></STRONG></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="6%" colSpan=4><B><FONT face="Times New Roman" size=1>Weighted-</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"><STRONG><FONT face="Times New Roman" size=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></STRONG></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="6%" colSpan=4><B><FONT face="Times New Roman" size=1>Number of securities</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="80%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="6%" colSpan=4><B><FONT face="Times New Roman" size=1>securities to be</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="6%" colSpan=4><B><FONT face="Times New Roman" size=1>average</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="6%" colSpan=4><B><FONT face="Times New Roman" size=1>remaining available for</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="80%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="6%" colSpan=4><B><FONT face="Times New Roman" size=1>issued upon exercise</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="6%" colSpan=4><B><FONT face="Times New Roman" size=1>exercise price</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="6%" colSpan=4><B><FONT face="Times New Roman" size=1>future issuance under</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="80%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="6%" colSpan=4><B><FONT face="Times New Roman" size=1>of outstanding</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="6%" colSpan=4><B><FONT face="Times New Roman" size=1>of outstanding</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="6%" colSpan=4><B><FONT face="Times New Roman" size=1>equity compensation</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="80%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="6%" colSpan=4><B><FONT face="Times New Roman" size=1>options, warrants</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="6%" colSpan=4><B><FONT face="Times New Roman" size=1>options, warrants</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="6%" colSpan=4><B><FONT face="Times New Roman" size=1>plans (excluding securities</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="80%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="6%" colSpan=4><B><FONT face="Times New Roman" size=1>and
      rights</FONT></B><B><FONT face="Times New Roman" size=1><SUP>(1)</SUP></FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="6%" colSpan=4><B><FONT face="Times New Roman" size=1>and rights</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="6%" colSpan=4><B><FONT face="Times New Roman" size=1>reflected in column
      (a))<SUP>(1)</SUP></FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="80%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="6%" colSpan=4><B><FONT face="Times New Roman" size=1>(a)</FONT></B></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="6%" colSpan=4><B><FONT face="Times New Roman" size=1>(b)</FONT></B></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%"></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%"><B><FONT face="Times New Roman" size=1>(c)</FONT></B></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="80%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>Equity compensation plans approved
    by</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="80%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;security
holders</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>16,958,944</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2><SUP>(2)</SUP></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>3.16</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>14,360,508</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2><SUP>(3)</SUP></FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="80%"><FONT face="Times New Roman" size=2>Equity compensation plans not approved by</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="80%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;security
holders</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face="Times New Roman" size=2>470,000</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2><SUP>(4)</SUP></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%"><FONT face="Times New Roman" size=2>3.75</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=right width="3%"><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="80%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>17,428,944</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD style="TEXT-ALIGN: center" noWrap width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>3.18</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD style="BORDER-BOTTOM: #000000 2pt double" noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>14,360,508</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR></TABLE><div>____________________</div><BR>
<TABLE style="TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 border=0>

  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>The table does not
      include information regarding Geron&#146;s 401(k) Plan. The Geron 401(k) Plan
      permits us to make matching contributions on behalf of plan participants,
      which matching contributions can be made in Common Stock that vests
      ratably over four years for each year of service completed by the
      employee, commencing from the date of hire, until it is fully vested when
      the employee has completed four years of service. As of December 31, 2014,
      there were approximately 893,548 shares of Common Stock held in this
      plan.</FONT></TD></TR>
  <TR>
    <TD colSpan=2><FONT size=2 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(2)</FONT></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>Consists of 1,588,086
      shares to be issued upon exercise of outstanding options under the 2002
      Equity Incentive Plan, 14,139,233 shares under the 2011 Plan, 50,000
      shares under the 1996 Directors&#146; Stock Option Plan and 1,181,625 shares
      under the 2006 Directors&#146; Plan.</FONT></TD></TR>
  <TR>
    <TD colSpan=2><FONT size=2 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(3)</FONT></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>Consists of 975,625
      shares of Common Stock available for issuance under the 2014 Employee
      Stock Purchase Plan and 13,384,883 shares of Common Stock available for
      issuance under the 2011 Plan.</FONT></TD></TR>
  <TR>
    <TD colSpan=2><FONT size=2 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(4)</FONT></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>Represents
      outstanding warrants issued in conjunction with consulting services. For
      further details, see Note 9 of the consolidated financial statements in
      our Annual Report on Form 10-K for the year ended December 31,
    2014.</FONT></TD></TR></TABLE>
<P align=center><FONT face="Times New Roman" size=2>47</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=left><FONT face="Times New Roman" size=2><A HREF="#toc"><B>Table of Contents</B></A></FONT></P>
<P align=center><B><FONT face="Times New Roman" size=2><A NAME="Proposal3"></A>PROPOSAL 3</FONT></B></P>
<P align=center><B><FONT face="Times New Roman" size=2>RATIFICATION OF SELECTION
OF<BR></FONT></B><B><FONT face="Times New Roman" size=2>INDEPENDENT REGISTERED
PUBLIC ACCOUNTING FIRM</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Audit Committee of the
Board has selected Ernst &amp; Young LLP as our independent registered public
accounting firm for the fiscal year ending December 31, 2015, and has further
directed that management submit the selection of the independent registered
public accounting firm for ratification by our stockholders at the Annual
Meeting. Ernst &amp; Young LLP has served as our independent registered public
accounting firm since 1992. Representatives of Ernst &amp; Young LLP are
expected to be present at the Annual Meeting, will have an opportunity to make a
statement if they so desire, and will be available to respond to appropriate
questions from stockholders. </FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>We have been informed by
Ernst &amp; Young LLP that, to the best of their knowledge, neither the firm nor
any of its members or their associates has any direct financial interest or
material indirect financial interest in Geron or our affiliates. </FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Stockholder ratification of
the selection of Ernst &amp; Young LLP as our independent registered public
accounting firm is not required by our Bylaws or otherwise. However, the Board
is submitting the selection of Ernst &amp; Young LLP to our stockholders for
ratification as a matter of good corporate practice. If our stockholders fail to
ratify the selection, the Audit Committee and the Board will reconsider whether
or not to retain that firm. Even if the selection is ratified, the Audit
Committee and the Board in their discretion may direct the appointment of a
different independent registered public accounting firm at any time during the
year if they determine that such a change would be in the best interests of
Geron and our stockholders. </FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Vote Required and Board
Recommendation </FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Stockholder ratification of
Ernst &amp; Young LLP as our independent registered public accounting firm
requires the affirmative vote of the holders of a majority of the shares present
in person or represented by proxy at this meeting. Abstentions will have the
same effect as a vote against this proposal, and broker non-votes will have no
effect on the outcome of this proposal. </FONT></P>
<P align=center><B><FONT face="Times New Roman" size=2>The Board of Directors
Unanimously Recommends That<BR>Stockholders Vote <u>FOR</u> Proposal 3 </FONT></B></P>
<P align=center><B><FONT face="Times New Roman" size=2><A NAME="Principal"></A>PRINCIPAL ACCOUNTANT FEES
AND SERVICES </FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Audit Committee
maintains policies and procedures for the pre-approval of work performed by the
independent registered public accounting firm. Under the Audit Committee&#146;s
charter, all engagements of the independent registered public accounting firm
must be approved in advance by the Audit Committee. The Chairperson of the Audit
Committee must be notified at any time the fees for a specific project exceed
20% of the approved budget for authorization to continue the project. Management
recommendations will be considered in connection with such engagements, but
management will have no authority to approve engagements. For each quarterly
Audit Committee meeting, management prepares a schedule of all fees paid to
Ernst &amp; Young LLP during the previous quarter and estimated fees for
projects contemplated in the following quarter. </FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Upon recommendation by the
Audit Committee, the Board selected Ernst &amp; Young LLP to act in the same
capacity for the fiscal year ending December 31, 2015. We have been informed by
Ernst &amp; Young LLP, to the best of their knowledge, that neither the firm nor
any of its members or their associates has any financial interest, direct or
indirect in Geron or our affiliates. </FONT></P>
<P align=center><FONT face="Times New Roman" size=2>48</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=left><FONT face="Times New Roman" size=2><A HREF="#toc"><B>Table of Contents</B></A></FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Audit Fees and All Other
Fees </FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Audit Committee
approved 100% of all audit, tax and other services provided by Ernst &amp; Young
LLP in 2014 and 2013. The total fees paid to Ernst &amp; Young LLP for the last
two fiscal years are as follows:</FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="87%"></TD>
    <TD noWrap style="text-align: center" width="6%" colSpan=4><B><FONT face="Times New Roman" size=1>Fiscal Year
      Ended</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"><STRONG><FONT size=1 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></STRONG></TD>
    <TD noWrap style="text-align: center" width="6%" colSpan=4><B><FONT face="Times New Roman" size=1>Fiscal Year
      Ended</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="6%" colSpan=4><B><FONT face="Times New Roman" size=1>December 31,
      2014</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="6%" colSpan=4><B><FONT face="Times New Roman" size=1>December 31,
      2013</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>Audit Fees<SUP>(1)</SUP></FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>615,679</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>$</FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>541,321</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%"><FONT face="Times New Roman" size=2>Audit Related Fees</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=right width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>Tax
      Fees</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0>&nbsp;</TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>&#151;</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="87%"><FONT face="Times New Roman" size=2>All
      Other Fees<SUP>(2)</SUP></FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>1,995</FONT></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>1,305</FONT></TD>
    <TD noWrap align=right width="1%">&nbsp;</TD></TR></TABLE><div>____________________</div><BR>
<TABLE style="TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 border=0>

  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>Audit Fees include
      the integrated audit of annual financial statements and internal control
      over financial reporting, reviews of quarterly financial statements
      included in Quarterly Reports on Forms 10-Q, consultations on matters
      addressed during the audit or quarterly reviews, and services provided in
      connection with SEC filings, including consents and comment and comfort
      letters.</FONT></TD></TR>
  <TR>
    <TD colSpan=2><FONT size=2 face="Times New Roman">&nbsp;</FONT></TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(2)</FONT></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>Amounts represent
      fees for access to Ernst &amp; Young&#146;s technical research
  portal.</FONT></TD></TR></TABLE>
<P align=center><FONT face="Times New Roman" size=2>49</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=left><FONT face="Times New Roman" size=2><A HREF="#toc"><B>Table of Contents</B></A></FONT></P>
<P align=center><B><FONT face="Times New Roman" size=2><A NAME="Audit"></A>AUDIT COMMITTEE
REPORT</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Audit Committee of
Geron Corporation&#146;s Board of Directors is comprised of three independent
directors as required by the listing standards of NASDAQ. The Audit Committee
operates pursuant to a written charter adopted and amended by the Board in May
2014. A copy of the Audit Committee&#146;s amended and restated charter is available
on our website at www.geron.com.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The members of the Audit
Committee are Ms. Eastham (Chairperson), Dr. Lawlis and Mr. Bradbury. The Board
has determined that all members of the Audit Committee are financially literate
as required by NASDAQ. The Board has also determined that Ms. Eastham and Mr.
Bradbury are audit committee financial experts as defined by NASDAQ. </FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The function of the Audit
Committee is to assist the Board in fulfilling its oversight responsibilities
regarding: (i) the quality and integrity of our financial statements, (ii) our
compliance with legal and regulatory requirements, (iii) the qualifications and
independence of the independent registered public accounting firm serving as our
auditors and (iv) the performance of the independent registered public
accounting firm. </FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Management is responsible
for Geron&#146;s internal controls and financial reporting. The independent
registered public accounting firm is responsible for performing an independent
audit of Geron&#146;s consolidated financial statements in accordance with generally
accepted auditing standards and to issue a report thereon. The Audit Committee&#146;s
responsibility is to monitor and oversee these processes. </FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>In this context, the Audit
Committee hereby reports as follows: </FONT></P>
<TABLE style="TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 border=0>

  <TR>
    <TD vAlign=top noWrap><FONT size=2 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>The Audit Committee
      has reviewed and discussed the audited financial statements of the Company
      as of and for the fiscal year ended December 31, 2014 with management and
      the independent registered public accounting firm serving as the Company&#146;s
      independent auditors.</FONT></TD></TR>
  <TR>
    <TD></TD>
    <TD colSpan=2><FONT size=2 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR>
    <TD vAlign=top noWrap></TD>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>2)</FONT></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>The Audit Committee
      has discussed with the independent auditors the matters required to be
      discussed by Auditing Standard No. 16 (Communication with Audit
      Committees) as adopted by the Public Company Accounting Oversight Board,
      other professional standards, membership provisions of the SEC Practice
      Session, and other SEC rules, as currently in effect.</FONT></TD></TR>
  <TR>
    <TD></TD>
    <TD colSpan=2><FONT size=2 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR>
    <TD vAlign=top noWrap></TD>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>3)</FONT></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>The Audit Committee
      has received the written disclosures and the letter from the independent
      auditors required by applicable requirements of the Public Company
      Accounting Oversight Board regarding the independent auditor&#146;s
      communications with the Audit Committee concerning independence, and has
      discussed with the independent auditors the independent auditor&#146;s
      independence.</FONT></TD></TR>
  <TR>
    <TD></TD>
    <TD colSpan=2><FONT size=2 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR>
    <TD vAlign=top noWrap></TD>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>4)</FONT></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>The Audit Committee
      has considered whether the independent auditor&#146;s provision of non-audit
      services to the Company is compatible with maintaining the independent
      auditor&#146;s independence.</FONT></TD></TR></TABLE>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Based on the reports and
discussions described above, the Audit Committee recommended to the Board that
the audited financial statements be included in Geron&#146;s Annual Report on Form
10-K for the year ended December 31, 2014, for filing with the SEC. </FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Submitted on March 5, 2015
by the members of the Audit Committee of Geron&#146;s Board of Directors. </FONT></P>
<DIV align=right>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="50%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="100%"><FONT face="Times New Roman" size=2>Karin Eastham (Chairperson)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="100%"><FONT face="Times New Roman" size=2>Daniel M. Bradbury</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="100%"><FONT face="Times New Roman" size=2>V.
      Bryan Lawlis, Ph.D.</FONT></TD></TR></TABLE></DIV>
      <div>____________________</div>
<P align=justify><I><FONT face="Times New Roman" size=2>This Section is not
&#147;soliciting material,&#148; is not deemed &#147; filed&#148; with the SEC and is not to be
incorporated by reference in any filing of the Company under the Securities
Exchange Act of 1934, as amended, or the Securities Act of 1933, as amended,
whether made before or after the date hereof and irrespective of any general
incorporation language in any such filing. </FONT></I></P>
<P align=center><FONT face="Times New Roman" size=2>50</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=left><FONT face="Times New Roman" size=2><A HREF="#toc"><B>Table of Contents</B></A></FONT></P>
<P align=center><B><FONT face="Times New Roman" size=2><A NAME="Security"></A>SECURITY OWNERSHIP OF
CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The following table sets
forth the amount and percentage of the outstanding shares of Common Stock,
which, according to the information supplied to us, are beneficially owned by:
(i) each person, or group of affiliated persons, who is known by us to be a
beneficial owner of more than 5% of our outstanding Common Stock, (ii) each of
our directors and nominees for director, (iii) each of our Named Executive
Officers, as defined on page 22 and (iv) all current directors and executive
officers as a group. Unless otherwise indicated, the address for each of the
stockholders in the table below is c/o Geron Corporation, 149 Commonwealth
Drive, Suite 2070, Menlo Park, CA 94025. Except for information based on
Schedules 13G, as indicated in the footnotes, beneficial ownership is stated as
of February 11, 2015. </FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" colSpan=2></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="10%" colSpan=6><B><FONT face="Times New Roman" size=1>Beneficial
      Ownership</FONT></B><B><FONT face="Times New Roman" size=1><SUP>(1)</SUP></FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" colSpan=2></TD>
    <TD noWrap style="text-align: center" width="3%"><B><FONT face="Times New Roman" size=1>Number of</FONT></B></TD>
    <TD noWrap style="text-align: center" width="1%"><STRONG><FONT size=1 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></STRONG></TD>
    <TD noWrap style="text-align: center" width="6%" colSpan=4><B><FONT face="Times New Roman" size=1>Percent of</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="1%"><B><FONT face="Times New Roman" size=1>Beneficial Owner</FONT></B></TD>
    <TD noWrap align=left width="88%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="3%"><B><FONT face="Times New Roman" size=1>Shares</FONT></B></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="6%" colSpan=4><B><FONT face="Times New Roman" size=1>Total</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" bgColor=#c0c0c0 colSpan=2><B><FONT face="Times New Roman" size=2>Directors/Nominees and Named
      Executive Officers:</FONT></B></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" colSpan=2><FONT face="Times New Roman" size=2>Daniel M. Bradbury<SUP>(2)</SUP></FONT></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>235,305</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>*</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" bgColor=#c0c0c0 colSpan=2><FONT face="Times New Roman" size=2>Karin Eastham<SUP>(3)</SUP></FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>219,547</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>*</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" colSpan=2><FONT face="Times New Roman" size=2>Thomas Hofstaetter,
    Ph.D.<SUP>(4)</SUP></FONT></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>172,939</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>*</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" bgColor=#c0c0c0 colSpan=2><FONT face="Times New Roman" size=2>Hoyoung Huh, M.D.,
Ph.D.<SUP>(5)</SUP></FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>379,223</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>*</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" colSpan=2><FONT face="Times New Roman" size=2>V.
      Bryan Lawlis, Ph.D.<SUP>(6)</SUP></FONT></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>140,000</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>*</FONT></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" bgColor=#c0c0c0 colSpan=2><FONT face="Times New Roman" size=2>Susan M. Molineaux,
    Ph.D.<SUP>(7)</SUP></FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>102,761</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>*</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" colSpan=2><FONT face="Times New Roman" size=2>Robert J. Spiegel, M.D.,
      FACP<SUP>(8)</SUP></FONT></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>188,739</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%">&nbsp;</TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>*</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" bgColor=#c0c0c0 colSpan=2><FONT face="Times New Roman" size=2>Melissa A. Kelly Behrs<SUP>(9)</SUP></FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>1,023,495</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>*</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" colSpan=2><FONT face="Times New Roman" size=2>Olivia K. Bloom<SUP>(10)</SUP></FONT></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>825,506</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>*</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" bgColor=#c0c0c0 colSpan=2><FONT face="Times New Roman" size=2>Andrew J. Grethlein,
    Ph.D.<SUP>(11)</SUP></FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>650,183</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>*</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" colSpan=2><FONT face="Times New Roman" size=2>Stephen N. Rosenfield,
      J.D.<SUP>(12)</SUP></FONT></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>858,312</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>*</FONT></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" bgColor=#c0c0c0 colSpan=2><FONT face="Times New Roman" size=2>John A. Scarlett, M.D.<SUP>(13)</SUP></FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>2,446,460</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>1.53</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>%</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" colSpan=2><FONT face="Times New Roman" size=2>All
      directors and executive officers as a group (12
      persons)<SUP>(14)</SUP></FONT></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>7,242,470</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>4.42</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>%</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" bgColor=#c0c0c0 colSpan=2><B><FONT face="Times New Roman" size=2>5% Beneficial
    Holders:</FONT></B></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" colSpan=2><FONT face="Times New Roman" size=2>FMR
      LLC<SUP>(15)</SUP></FONT></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>23,540,143</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>14.94</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>%</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" colSpan=2><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;245
      Summer Street, Boston, MA 02210</FONT></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" bgColor=#c0c0c0 colSpan=2><FONT face="Times New Roman" size=2>BlackRock, Inc.<SUP>(16)</SUP></FONT></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>11,201,887</FONT></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=right width="3%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>7.11</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>%</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" bgColor=#c0c0c0 colSpan=2><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;55
      East 52<SUP>nd </SUP>Street, New York, NY 10022</FONT></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="3%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" colSpan=2><FONT face="Times New Roman" size=2>State Street
    Corporation<SUP>(17)</SUP></FONT></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>8,018,906</FONT></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="3%"><FONT face="Times New Roman" size=2>5.09</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>%</FONT></TD>
    <TD noWrap align=left width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="89%" colSpan=2><FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;One
      Lincoln Street, Boston, MA 02111</FONT></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="1%"></TD></TR></TABLE><div>____________________</div><BR>
<TABLE style="TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 border=0>

  <TR>
    <TD vAlign=top noWrap>
      <P align=justify><FONT face="Times New Roman" size=2>*</FONT></P></TD>
    <TD width="100%">
      <P align=justify><FONT face="Times New Roman" size=2>Represents beneficial
      ownership of less than 1% of Common Stock.</FONT></P></TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT size=2 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD width="100%"><FONT size=2 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>Beneficial ownership is determined in
      accordance with the rules of the SEC. In computing the number of shares
      beneficially owned by a person and the percentage of ownership of that
      person, shares of Common Stock exercisable pursuant to the exercise of
      options held by that person that are currently exercisable or exercisable
      within 60 days of February 11, 2015 are deemed outstanding. Such shares,
      however, are not deemed outstanding for the purpose of computing the
      percentage ownership of each other person. Applicable percentages are
      based on 157,527,199 shares outstanding on February 11, 2015, adjusted as
      required by rules promulgated by the SEC. The persons named in this table,
      to the best of our knowledge, have sole voting and investment power with
      respect to all shares of Common Stock shown as beneficially owned by them,
      subject to community property laws where applicable and except as
      indicated in the other footnotes to this table.</FONT></TD></TR>
  <TR>
    <TD colSpan=2><FONT size=2 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(2)</FONT></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>Consists of 142,776 shares held directly by
      Daniel M. Bradbury, 10,862 shares held by The Bradbury Family Trust and
      81,667 shares issuable upon the exercise of outstanding options held by
      Mr. Bradbury exercisable within 60 days of February 11, 2015.</FONT></TD></TR>
  <TR>
    <TD colSpan=2><FONT size=2 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(3)</FONT></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>Consists of 36,797 shares held directly by
      Karin Eastham, 2,250 shares held under unvested restricted stock awards
      and 180,500 shares issuable upon the exercise of outstanding options held
      by Ms. Eastham exercisable within 60 days of February 11,
  2015.</FONT></TD></TR></TABLE>
<P align=center><FONT face="Times New Roman" size=2>51</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=left><FONT face="Times New Roman" size=2><A HREF="#toc"><B>Table of Contents</B></A></FONT></P>
<TABLE style="TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 border=0>

  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(4)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>Consists of 25,064
      shares held directly by Thomas Hofstaetter, 1,500 shares held under
      unvested restricted stock awards and 146,375 shares issuable upon the
      exercise of outstanding options held by Dr. Hofstaetter exercisable within
      60 days of February 11, 2015. Dr. Hofstaetter is retiring from our Board
      effective as of the date of the Annual Meeting.</FONT></TD></TR>
  <TR>
    <TD colSpan=2><FONT size=2 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(5)</FONT></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>Consists of 111,932
      shares held directly by Hoyoung Huh, 7,187 shares held under unvested
      restricted stock awards and 260,104 shares issuable upon the exercise of
      outstanding options held by Dr. Huh exercisable within 60 days of February
      11, 2015.</FONT></TD></TR>
  <TR>
    <TD colSpan=2><FONT size=2 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(6)</FONT></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>Consists of 140,000
      shares issuable upon the exercise of outstanding options held by V. Bryan
      Lawlis exercisable within 60 days of February 11, 2015.</FONT></TD></TR>
  <TR>
    <TD colSpan=2><FONT size=2 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(7)</FONT></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>Consists of 21,094
      shares held by the Molineaux Family Trust and 81,667 shares issuable upon
      the exercise of outstanding options held by Dr. Molineaux exercisable
      within 60 days of February 11, 2015.</FONT></TD></TR>
  <TR>
    <TD colSpan=2><FONT size=2 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(8)</FONT></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>Consists of 47,489
      shares held directly by Robert J. Spiegel, 1,250 shares held under
      unvested restricted stock awards and 140,000 shares issuable upon exercise
      of outstanding options held by Dr. Spiegel exercisable within 60 days of
      February 11, 2015.</FONT></TD></TR>
  <TR>
    <TD colSpan=2><FONT size=2 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(9)</FONT></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>Consists of 119,744
      shares held directly by Melissa A. Kelly Behrs, 6,250 shares held under
      unvested restricted stock awards and 897,501 shares issuable upon exercise
      of outstanding options held by Ms. Behrs exercisable within 60 days of
      February 11, 2015.</FONT></TD></TR>
  <TR>
    <TD colSpan=2><FONT size=2 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(10)</FONT></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>Consists of 111,969
      shares held directly by Olivia K. Bloom, 6,250 shares held under unvested
      restricted stock awards and 707,287 shares issuable upon the exercise of
      outstanding options held by Ms. Bloom exercisable within 60 days of
      February 11, 2015.</FONT></TD></TR>
  <TR>
    <TD colSpan=2><FONT size=2 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(11)</FONT></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>Consists of 2,267
      shares held directly by Andrew J. Grethlein and 647,916 shares issuable
      upon the exercise of outstanding options held by Dr. Grethlein exercisable
      within 60 days of February 11, 2015.</FONT></TD></TR>
  <TR>
    <TD colSpan=2><FONT size=2 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(12)</FONT></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>Consists of 17,624
      shares held directly by Stephen N. Rosenfield and 840,688 shares issuable
      upon the exercise of outstanding options held by Mr. Rosenfield
      exercisable within 60 days of February 11, 2015.</FONT></TD></TR>
  <TR>
    <TD colSpan=2><FONT size=2 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(13)</FONT></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>Consists of 125,000
      shares held by the John A. Scarlett III 1999 Trust and 2,321,460 shares
      issuable upon exercise of outstanding options held by Dr. Scarlett
      exercisable within 60 days of February 11, 2015.</FONT></TD></TR>
  <TR>
    <TD colSpan=2><FONT size=2 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(14)</FONT></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>Consists of shares
      beneficially owned by our current directors and executive officers as
      described in footnotes (2) through (13).</FONT></TD></TR>
  <TR>
    <TD colSpan=2><FONT size=2 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(15)</FONT></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>The indicated
      ownership is based solely on a Schedule 13G/A filed with the SEC by FMR
      LLC on February 13, 2015, reporting beneficial ownership as of December
      31, 2014. The Schedule 13G/A filed by the reporting person provides
      information only as of December 31, 2014, and, consequently, the
      beneficial ownership of the above-mentioned reporting person may have
      changed between December 31, 2014 and February 11, 2015.</FONT></TD></TR>
  <TR>
    <TD colSpan=2><FONT size=2 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(16)</FONT></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>The indicated
      ownership is based solely on a Schedule 13G/A filed with the SEC by
      BlackRock, Inc. on January 26, 2015, reporting beneficial ownership as of
      December 31, 2014. The Schedule 13G/A filed by the reporting person
      provides information only as of December 31, 2014, and, consequently, the
      beneficial ownership of the above-mentioned reporting person may have
      changed between December 31, 2014 and February 11, 2015.</FONT></TD></TR>
  <TR>
    <TD colSpan=2><FONT size=2 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(17)</FONT></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>The indicated
      ownership is based solely on a Schedule 13G filed with the SEC by State
      Street Corporation on February 12, 2015, reporting beneficial ownership as
      of December 31, 2014. The Schedule 13G filed by the reporting person
      provides information only as of December 31, 2014, and, consequently, the
      beneficial ownership of the above-mentioned reporting person may have
      changed between December 31, 2014 and February 11,
  2015.</FONT></TD></TR></TABLE>
<P align=center><FONT face="Times New Roman" size=2>52</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=left><FONT face="Times New Roman" size=2><A HREF="#toc"><B>Table of Contents</B></A></FONT></P>
<P align=center><B><FONT face="Times New Roman" size=2><A NAME="CertainTransac"></A>CERTAIN
TRANSACTIONS</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>There has not been, nor is
there currently proposed, any transaction or series of similar transactions to
which the Company was or is to be a party in which the amount involved exceeds
$120,000 and in which any current director, executive officer, holder of more
than 5% of our Common Stock or any immediate family member of any of the
foregoing persons had or will have a direct or indirect material interest other
than with respect to compensation arrangements described under the sections
entitled &#147;Executive Compensation Tables&#148; and &#147;Compensation of Directors,&#148; the
indemnification agreements described below, and as described below under
&#147;Participation in Public Offering.&#148;</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Certain Transactions
With or Involving Related Persons</FONT></B></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2>Participation in
Public Offering</FONT></I></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>On February 4, 2014, we
completed an underwritten public offering of 25,875,000 shares of our Common
Stock at a price to the public of $4.00 per share. Net cash proceeds from the
public offering were approximately $96.8 million, after deducting the
underwriting discounts and commissions and offering expenses payable by us.
Based on information provided to us, FMR LLC, which beneficially owns more than
5% of our outstanding Common Stock, purchased 5,625,000 shares in the public
offering from the underwriters for a total purchase price of $22.5 million
(based on the price to the public of $4.00 per share). To our knowledge, no
other holder of 5% of our outstanding Common Stock participated in the offering.
None of our directors or executive officers participated in the offering, nor
did any of such persons have a direct or indirect material interest in the
offering. Since this offering was public, with the price to the public in the
offering determined by a book building process with the underwriters, the
offering was not specifically reviewed in advance as a related-party
transaction. However, the offering was approved by our Board and a Pricing
Committee of our Board, and consistent with our Audit Committee charter, the
Audit Committee subsequently reviewed the offering. </FONT></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2>Indemnity
Agreements</FONT></I></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>We have entered into
indemnity agreements with all of our officers and directors which provide, among
other things, that we will indemnify such executive officer or director, under
the circumstances and to the extent provided for therein, for expenses, damages,
judgments, fines, settlements he or she may be required to pay in actions or
proceedings which he or she is or may be made a party by reason for his or her
position as a director, officer or other agent of the Company, and otherwise to
the full extent permitted under Delaware law and our Bylaws.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Policies and Procedures
</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Our Audit Committee is
responsible for reviewing and approving all related party transactions, which
would include a transaction, arrangement or relationship (or any series of
similar transactions, arrangements or relationships) in which we and any
&#147;related person&#148; are participants involving an amount that exceeds $120,000, not
including transactions involving compensation for services provided to Geron as
an employee, director, consultant or similar capacity by a related person.
Related parties include any of our directors or executive officers, certain of
our stockholders and their immediate family members. This obligation is set
forth in writing in the Audit Committee charter. A copy of the Audit Committee
charter is available on the Corporate Governance page under the Investor
Relations section of our website at www.geron.com. </FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Where a transaction has
been identified as a related-person transaction, management would present
information regarding the proposed related-person transaction to the Audit
Committee (or, where Audit Committee approval would be inappropriate, to another
independent body of the Board) for consideration and approval or ratification.
The presentation would include a description of, among other things, the
material facts, the interests, direct and indirect, of the related persons, the
benefits to Geron of the transaction and whether any alternative transactions
were available. To identify related-person transactions in advance, the Audit
Committee relies on information supplied by Geron&#146;s executive officers and
directors. In considering related-person transactions, the Audit Committee takes
into account the relevant available facts and circumstances including, but not
limited to: (a) the risks, costs and benefits to Geron, (b) the impact on a
director&#146;s independence in the event the related </FONT></P>
<P align=center><FONT face="Times New Roman" size=2>53</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=left><FONT face="Times New Roman" size=2><A HREF="#toc"><B>Table of Contents</B></A></FONT></P>
<P align=justify><FONT face="Times New Roman" size=2>person is a director,
immediate family member of a director or an entity with which a director is
affiliated, (c) the terms of the transaction, (d) the availability of other
sources for comparable services or products and (e) the terms available to or
from, as the case may be, unrelated third parties or to or from employees
generally. In the event a director has an interest in the proposed transaction,
the director must recuse himself or herself from the deliberations and approval.
In determining whether to approve, ratify or reject a related-person
transaction, the Audit Committee considers, in light of known circumstances,
whether the transaction is in, or is not inconsistent with, the best interests
of Geron and our stockholders, as the Audit Committee determines in the good
faith exercise of its discretion.</FONT></P>
<P align=center><B><FONT face="Times New Roman" size=2><A NAME="Other"></A>OTHER
MATTERS</FONT></B></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Section 16(a) Beneficial
Ownership Reporting Compliance </FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Section 16(a) of the
Exchange Act requires our directors and executive officers, and persons who
beneficially own more than 10% of a registered class of our equity securities
(collectively, &#147;Reporting Persons&#148;), to file with the SEC initial reports of
ownership and reports of changes in ownership of Geron Common Stock and other
equity securities. Reporting Persons are required by SEC regulations to furnish
us with copies of all Section 16(a) forms they file.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>To our knowledge, based
solely upon a review of the copies of such reports furnished to us and written
representations from such directors, executive officers and stockholders that no
other reports were required, we believe that during fiscal year ended December
31, 2014, all Reporting Persons complied with the applicable Section 16(a)
reporting requirements.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Stockholder Nominations
and Proposals for 2016 Annual Meeting </FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>We expect to hold our 2016
Annual Meeting of Stockholders in May 2016. All proposals or director
nominations of stockholders intended to be presented at the 2016 Annual Meeting
of Stockholders must be directed to the attention of our Corporate Secretary, at
the address set forth on the first page of this Proxy Statement.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>To be considered for
inclusion in next year&#146;s proxy materials, your proposal must be submitted in
writing by December 8, 2015, to our Corporate Secretary at Geron Corporation,
149 Commonwealth Drive, Suite 2070, Menlo Park, California, 94025, and must
comply with all applicable requirements of Rule 14a-8 promulgated under the
Exchange Act. However, if our 2016 Annual Meeting of Stockholders is not held
between April 18, 2016 and June 17, 2016, then the deadline will be a reasonable
time prior to the time we begin to print and send our proxy
materials.</FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>If you wish to bring a
proposal before the stockholders or nominate a director at the 2016 Annual
Meeting of Stockholders, but you are not requesting that your proposal or
nomination be included in next year&#146;s proxy materials, you must notify our
Corporate Secretary, in writing, not earlier than the close of business on
January 19, 2016 and not later than the close of business on February 18, 2016.
However, if the 2016 Annual Meeting of Stockholders is not held between April
18, 2016 and July 17, 2016, the notice must be delivered no later than the
90<SUP>th</SUP> day prior to the 2016 Annual Meeting of Stockholders or, if
later, the 10<SUP>th</SUP> day following the day on which public disclosure of
the date of the 2016 Annual Meeting of Stockholders is made. In addition, our
Bylaws provide that the stockholder&#146;s notice must include certain information
for the person making the proposal or the nomination for director,
including:</FONT></P>
<TABLE style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse; TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=justify><FONT face="Times New Roman" size=2>name and
      address;<BR>&nbsp;</FONT></P></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=justify><FONT face="Times New Roman" size=2>the class and number
      of shares of the Company, owned of record or beneficially
      owned;<BR>&nbsp;</FONT></P></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=justify><FONT face="Times New Roman" size=2>any derivative, swap
      or other transaction which gives economic risk similar to ownership of
      shares of the Company;<BR>&nbsp;</FONT></P></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=justify><FONT face="Times New Roman" size=2>any proxy, agreement,
      arrangement, understanding or relationship that confers a right to vote
      any shares of the Company; </FONT></P></TD></TR></TABLE>
<P align=center><FONT face="Times New Roman" size=2>54</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=left><FONT face="Times New Roman" size=2><A HREF="#toc"><B>Table of Contents</B></A></FONT></P>
<TABLE style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse; TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=justify><FONT face="Times New Roman" size=2>any agreement,
      arrangement, understanding or relationship, engaged in to increase or
      decrease the level of risk related to, the voting power with respect to,
      and certain other arrangements or agreements with respect to, shares of
      the Company;<BR>&nbsp;</FONT></P></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=justify><FONT face="Times New Roman" size=2>any
      performance-related fees that the proposing/nominating person is entitled,
      based on any increase or decrease in the value of any shares of the
      Company; and<BR>&nbsp;</FONT></P></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=justify><FONT face="Times New Roman" size=2>any other
      information required by the SEC to be disclosed in a proxy statement or
      certain other filings. </FONT></P></TD></TR></TABLE>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The stockholder&#146;s notice
must also include information for each proposed director nominee, including:
</FONT></P>
<TABLE style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse; TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=justify><FONT face="Times New Roman" size=2>the same information
      as for the nominating person set forth above;<BR>&nbsp;</FONT></P></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=justify><FONT face="Times New Roman" size=2>all information
      required to be disclosed in a proxy statement in connection with election
      of directors; and<BR>&nbsp;</FONT></P></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 8pt; PADDING-LEFT: 15pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%">
      <P align=justify><FONT face="Times New Roman" size=2>financial or other
      relationships between the nominating person and the nominee during the
      past three years. </FONT></P></TD></TR></TABLE>
<P ALIGN="JUSTIFY"><FONT face="Times New Roman" size=2>Copies of our Bylaws may be
obtained from our Corporate Secretary.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>Director Nominees
Recommended by Stockholders</FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Nominating and
Corporate Governance Committee, to date, has not adopted a formal policy with
regard to the consideration of director candidates recommended by stockholders
and will consider director candidates recommended by stockholders on a
case-by-case basis, as appropriate. Stockholders who wish to recommend
individuals for consideration by the Nominating and Corporate Governance
Committee should send written notice to the Nominating and Corporate Governance
Committee Chairman, Geron Corporation, 149 Commonwealth Drive, Suite 2070, Menlo
Park, CA 94025, within the time periods set forth above. Such notification
should set forth all information relating to such nominee as is required to be
disclosed in solicitations of proxies for elections of directors pursuant to
Regulation 14A under the Exchange Act, including such person&#146;s written consent
to being named in a proxy statement as a nominee and to serving as a director if
elected, the name and address of such stockholder or beneficial owner on whose
behalf the nomination is being made, the class and number of shares of the
Company, owned beneficially and of record by such stockholder or beneficial
owner, and all information regarding the nominee that would be required to be
included in the Company&#146;s proxy statement by the rules of the SEC, including the
nominee&#146;s age, business experience for the past five years and any directorships
held by the nominee during the past five years. The Nominating and Corporate
Governance Committee does not intend to alter the manner in which it evaluates
candidates based on whether the candidate was recommended by a stockholder or
not. </FONT></P>
<P align=justify><B><I><FONT face="Times New Roman" size=2>Director
Qualifications</FONT></I></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Nominating and
Corporate Governance Committee believes that nominees for election to the Board
must possess certain minimum qualifications and attributes. The nominee: 1) must
meet the objective independence requirements set forth by the SEC and NASDAQ, 2)
must exhibit strong personal integrity, character and ethics, and a commitment
to ethical business and accounting practices, 3) must not be involved in
on-going litigation with the Company or be employed by an entity which is
engaged in such litigation and 4) must not be the subject of any on-going
criminal investigations, including investigations for fraud or financial
misconduct. In addition, the Nominating and Corporate Governance Committee may
consider the following criteria, among others: </FONT></P>
<TABLE style="TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 border=0>

  <TR>
    <TD vAlign=top noWrap><FONT size=2 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(i)</FONT></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>experience in
      corporate management, such as serving as an officer or former officer of a
      publicly held company, and a general understanding of marketing, finance
      and other elements relevant to the success of a publicly traded company in
      today&#146;s business environment;</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD colSpan=2></TD></TR>
  <TR>
    <TD vAlign=top noWrap></TD>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(ii)</FONT></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>experience in our
      industry and with relevant social policy concerns;</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD colSpan=2></TD></TR>
  <TR>
    <TD vAlign=top noWrap></TD>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(iii)</FONT></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>experience as a board
      member of other publicly held companies;</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD colSpan=2></TD></TR>
  <TR>
    <TD vAlign=top noWrap></TD>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>expertise in an area
      of our operations; and</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD colSpan=2></TD></TR>
  <TR>
    <TD vAlign=top noWrap></TD>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(v)</FONT></TD>
    <TD width="100%"><FONT face="Times New Roman" size=2>practical and mature
      business judgment, including the ability to make independent analytical
      inquiries.</FONT></TD></TR>
</TABLE>
<P align=center><FONT face="Times New Roman" size=2>55</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=left><FONT face="Times New Roman" size=2><A HREF="#toc"><B>Table of Contents</B></A></FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>The Nominating and
Corporate Governance Committee does not specifically consider diversity in
identifying nominees for election as a director. However, specific experience or
expertise that could assist Geron in developing our clinical product opportunity
provides added value and insight to the Board. In general, the Nominating and
Corporate Governance Committee aspires the Board to be comprised of individuals
that represent a diversity of professional experience and perspective and who
portray characteristics of diligence, commitment, mutual respect and
professionalism with an emphasis on consensus building. The Board does not
follow any ratio or formula to determine the appropriate mix. Rather, it uses
its judgment to identify nominees whose backgrounds, attributes and experiences,
taken as a whole, will contribute to the high standards of board service at
Geron. </FONT></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Directors are expected to
rigorously prepare for, attend and participate in Board meetings and meetings of
the Committees of the Board on which they serve, to ask direct questions and
require straight answers, and to spend the time needed and meet as frequently as
necessary to properly discharge their responsibilities and duties as directors.
Each Board member is expected to ensure that other existing and planned future
commitments do not materially interfere with the member&#146;s service as an
outstanding director.</FONT></P>
<P align=justify><B><FONT face="Times New Roman" size=2>General </FONT></B></P>
<P ALIGN="JUSTIFY" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Your proxy is solicited on
behalf of our Board of Directors. Unless otherwise directed, proxies will be
voted at the Annual Meeting (or an adjournment or postponement thereof), &#147;FOR&#148;
all of the nominees listed in Proposal 1 and &#147;FOR&#148; Proposals 2 and 3. If any
matter other than those described in this Proxy Statement were to be properly
submitted for a vote at the Annual Meeting, or with respect to any adjournment
or postponement thereof, the proxy holders appointed by the Board will have the
discretion to vote on those matters for you as they see fit.</FONT></P>
<div align="right">
<div style="width: 50%;">
<P align=justify><FONT face="Times New Roman" size=2>By Order of the Board of
Directors, </FONT></P>
<P align=left><IMG src="geron_def14a5x11x1.jpg" border=0> </P>
<P align=justify><FONT face="Times New Roman" size=2>Stephen N.
Rosenfield<BR></FONT><I><FONT face="Times New Roman" size=2>Executive Vice
President, General Counsel<BR>and Corporate Secretary</FONT></I></P>
</div></div><BR>
<P align=justify><FONT face="Times New Roman" size=2>April 3, 2015</FONT></P>
<P align=center><FONT face="Times New Roman" size=2>56</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=left><FONT face="Times New Roman" size=2><A HREF="#toc"><B>Table of Contents</B></A></FONT></P>
<BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR>
<div align="center"><IMG src="geron_def14a5x12x1.jpg" border=0></div><BR>
<BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR>
<HR align=center width="100%" noShade SIZE=2>
<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=left><FONT face="Times New Roman" size=2><A HREF="#toc"><B>Table of Contents</B></A></FONT></P>
<DIV style="PADDING-RIGHT: 0.25in; PADDING-LEFT: 0.25in; PADDING-BOTTOM: 5%">
<TABLE style="FONT-SIZE: 10pt; FLOAT: left; FONT-FAMILY: Times New Roman; TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 width="20%" border=0>

  <TR>
    <TD width="100%"><IMG src="geron_def14ax2x1.jpg" border=0></TD></TR>
  <TR>
    <TD noWrap width="100%">
      <P align=justify><B><I><FONT face="Times New Roman" size=2>GERON
      CORPORATION<BR>C/O COMPUTERSHARE<BR>350 INDIANA ST., SUITE 750<BR>GOLDEN,
      CO 80401</FONT></I></B></P></TD></TR></TABLE>
<TABLE style="FONT-SIZE: 8pt; FLOAT: right; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse; TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 width="55%" border=0>

  <TR vAlign=bottom>
    <TD width="100%">
      <P align=justify><B><FONT face="Times New Roman" size=1>VOTE BY INTERNET -
      <U>www.proxyvote.com</U></FONT></B></P></TD></TR>
  <TR vAlign=bottom>
    <TD width="100%">
      <P align=justify><FONT face="Times New Roman" size=1>Use the Internet to
      transmit your voting instructions and for electronic delivery of
      information up until 11:59 P.M. Eastern Time the day before the cut-off
      date or meeting date. Have your proxy card in hand when you access the web
      site and follow the instructions to obtain your records and to create an
      electronic voting instruction form.</FONT></P></TD></TR>
  <TR>
    <TD width="100%">&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD width="100%">
      <P align=justify><B><FONT face="Times New Roman" size=1>VOTE BY PHONE -
      1-800-690-6903</FONT></B></P></TD></TR>
  <TR vAlign=bottom>
    <TD width="100%">
      <P align=justify><FONT face="Times New Roman" size=1>Use any touch-tone
      telephone to transmit your voting instructions up until 11:59 P.M. Eastern
      Time the day before the cut-off date or meeting date. Have your proxy card
      in hand when you call and then follow the instructions.</FONT></P></TD></TR>
  <TR>
    <TD width="100%">&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD width="100%">
      <P align=justify><B><FONT face="Times New Roman" size=1>VOTE BY
      MAIL</FONT></B></P></TD></TR>
  <TR vAlign=bottom>
    <TD width="100%">
      <P align=justify><FONT face="Times New Roman" size=1>Mark, sign and date
      your proxy card and return it in the postage-paid envelope we have
      provided or return it to Vote Processing, c/o Broadridge, 51 Mercedes Way,
      Edgewood, NY 11717.</FONT></P></TD></TR>
  <TR>
    <TD width="100%">&nbsp;</TD></TR>
  <TR>
    <TD width="100%">&nbsp;</TD></TR>
  <TR>
    <TD width="100%">&nbsp;</TD></TR>
  <TR>
    <TD width="100%">&nbsp;</TD></TR>
  <TR>
    <TD width="100%">&nbsp;</TD></TR></TABLE></DIV><BR><BR clear=all>&nbsp;<BR><BR><BR><BR><BR><BR>
<DIV>
<TABLE style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt dashed" noWrap align=left width="71%"><FONT size=1 face="Times New Roman">TO VOTE, MARK
      BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS:&nbsp;<font size=2>&#9746;</font><BR>&nbsp;</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt dashed" noWrap align=left width="1%"><FONT size=1 face="Times New Roman">M85938-P60787</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt dashed" noWrap align=left width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1pt dashed" noWrap align=right width="26%"><FONT size=1 face="Times New Roman">KEEP THIS
      PORTION FOR YOUR RECORDS</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="73%" colSpan=3>&nbsp;</TD>
    <TD noWrap align=right width="26%"><FONT size=1 face="Times New Roman">DETACH AND RETURN THIS PORTION
  ONLY</FONT></TD></TR>
  <TR>
    <TD style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; TEXT-ALIGN: center" noWrap width="99%" colSpan=4><FONT style="DISPLAY: inline; FONT-WEIGHT: bold" size=1>THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND
  DATED</FONT></TD></TR></TABLE></DIV>
<DIV style="BORDER-RIGHT: #000000 2.25pt solid; PADDING-RIGHT: 4pt; BORDER-TOP: #000000 2.25pt solid; PADDING-LEFT: 4pt; FONT-SIZE: 8pt; PADDING-BOTTOM: 4pt; BORDER-LEFT: #000000 2.25pt solid; PADDING-TOP: 4pt; BORDER-BOTTOM: #000000 2.25pt solid; FONT-FAMILY: Times New Roman; TEXT-ALIGN: justify">
<TABLE style="FONT-SIZE: 8pt; FLOAT: left; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse; TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 width="53%" border=0>

  <TR>
    <TD vAlign=top width="88%" colSpan=4><STRONG><FONT size=1 face="Times New Roman">GERON CORPORATION</FONT></STRONG></TD>
    <TD vAlign=top noWrap width="1%"></TD>
    <TD vAlign=top noWrap width="3%"></TD>
    <TD vAlign=top noWrap width="4%"></TD>
    <TD vAlign=top noWrap width="4%"></TD></TR>
  <TR>
    <TD vAlign=top width="88%" colSpan=4>&nbsp; </TD>
    <TD vAlign=top noWrap width="1%"></TD>
    <TD vAlign=top noWrap width="3%"></TD>
    <TD vAlign=top noWrap width="4%"></TD>
    <TD vAlign=top noWrap width="4%"></TD></TR>
  <TR>
    <TD vAlign=top width="1%"></TD>
    <TD vAlign=top width="87%" colSpan=3><STRONG><FONT size=1 face="Times New Roman">The Board of Directors recommends
      you vote FOR the following:</FONT></STRONG></TD>
    <TD vAlign=top noWrap width="1%"></TD>
    <TD vAlign=top noWrap align=center width="3%"><STRONG><FONT size=1 face="Times New Roman">For<BR>All</FONT></STRONG></TD>
    <TD vAlign=top noWrap align=center width="4%"><STRONG><FONT size=1 face="Times New Roman">Withhold<BR>All</FONT></STRONG></TD>
    <TD vAlign=top noWrap align=center width="4%"><STRONG><FONT size=1 face="Times New Roman">For
  All<BR>Except</FONT></STRONG></TD></TR>
  <TR>
    <TD style="TEXT-ALIGN: center" vAlign=top width="1%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: center" vAlign=top width="87%" colSpan=3>&nbsp;</TD>
    <TD style="TEXT-ALIGN: center" vAlign=top noWrap width="1%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: center" vAlign=top noWrap width="3%"><FONT style="DISPLAY: inline; FONT-WEIGHT: bold"></FONT></TD>
    <TD style="TEXT-ALIGN: center" vAlign=top noWrap width="4%"><FONT style="DISPLAY: inline; FONT-WEIGHT: bold"></FONT></TD>
    <TD style="TEXT-ALIGN: center" vAlign=top noWrap width="4%"><FONT style="DISPLAY: inline; FONT-WEIGHT: bold"></FONT></TD></TR>
  <TR>
    <TD vAlign=top width="1%">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD vAlign=top width="1%"><FONT size=1 face="Times New Roman">1.&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD vAlign=top width="86%" colSpan=2><FONT size=1 face="Times New Roman">To elect the two nominees for director named
      below to hold office as Class I members of the Board of Directors until
      the 2018 annual meeting of stockholders.</FONT></TD>
    <TD vAlign=top width="1%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: center" vAlign=top width="3%">&#9744;</TD>
    <TD style="TEXT-ALIGN: center" vAlign=top width="4%">&#9744;</TD>
    <TD style="TEXT-ALIGN: center" vAlign=top width="4%">&#9744;</TD></TR>
  <TR>
    <TD vAlign=top width="1%"></TD>
    <TD vAlign=top width="1%"></TD>
    <TD vAlign=top width="86%" colSpan=2>&nbsp;</TD>
    <TD vAlign=top width="1%">&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD vAlign=top width="3%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </TD>
    <TD vAlign=top width="4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </TD>
    <TD vAlign=top width="4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </TD></TR>
  <TR vAlign=bottom>
    <TD vAlign=top noWrap width="1%">&nbsp;</TD>
    <TD noWrap width="1%">&nbsp;</TD>
    <TD noWrap width="98%" colSpan=6><FONT style="DISPLAY: inline; FONT-WEIGHT: bold" size=1>Nominees:</FONT></TD></TR>
  <TR>
    <TD vAlign=top noWrap width="1%"></TD>
    <TD noWrap width="1%"></TD>
    <TD noWrap width="98%" colSpan=6>&nbsp;</TD></TR>
  <TR>
    <TD vAlign=top noWrap align=right width="1%">&nbsp;</TD>
    <TD noWrap align=right width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"><FONT size=1 face="Times New Roman">01)&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD noWrap width="97%" colSpan=5><FONT size=1 face="Times New Roman">John A. Scarlett, M.D.</FONT></TD></TR>
  <TR>
    <TD vAlign=top noWrap align=right width="1%">&nbsp;</TD>
    <TD noWrap align=right width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%"><FONT size=1 face="Times New Roman">02)</FONT></TD>
    <TD noWrap width="97%" colSpan=5><FONT size=1 face="Times New Roman">Robert J. Spiegel, M.D., FACP</FONT></TD></TR>
  <TR>
    <TD vAlign=top noWrap align=right width="1%"></TD>
    <TD noWrap align=right width="1%">&nbsp;</TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap width="97%" colSpan=5>&nbsp;</TD></TR></TABLE>
<TABLE style="FONT-SIZE: 8pt; FLOAT: right; WIDTH: 45%; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse; TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR>
    <TD vAlign=top width="64%">&nbsp; </TD>
    <TD vAlign=top noWrap width="20%"></TD>
    <TD vAlign=top noWrap width="15%"></TD></TR>
  <TR>
    <TD vAlign=top width="64%">&nbsp; </TD>
    <TD vAlign=top noWrap width="20%"></TD>
    <TD vAlign=top noWrap width="15%"></TD>
    <TD vAlign=top noWrap width="1%"></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" vAlign=top width="64%" rowSpan=2><FONT size=1 face="Times New Roman">To
      withhold authority to vote for any individual nominee(s), mark &#147;For All
      Except&#148; and write the number(s) of the nominee(s) on the line
    below.</FONT></TD>
    <TD vAlign=top noWrap width="20%">&nbsp;</TD>
    <TD vAlign=top noWrap width="15%">&nbsp;</TD>
    <TD vAlign=top noWrap width="1%" rowSpan=2>&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR>
    <TD vAlign=top noWrap align=right width="20%">&nbsp;</TD>
    <TD vAlign=top noWrap align=right width="15%">
      <DIV style="BORDER-RIGHT: #000000 2.25pt solid; BORDER-TOP: #000000 2.25pt solid; WIDTH: 0.4in; HEIGHT: 0.4in">&nbsp;&nbsp;</DIV></TD></TR></TABLE>
<TABLE style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse; TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR>
    <TD width="1%">&nbsp;</TD>
    <TD width="99%" colSpan=6>&nbsp;</TD></TR>
  <TR>
    <TD noWrap width="1%">&nbsp;</TD>
    <TD vAlign=top width="93%" colSpan=2><STRONG><FONT size=1 face="Times New Roman">The Board of Directors recommends
      you vote FOR proposals 2 and 3.</FONT></STRONG></TD>
    <TD noWrap width="3%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="PADDING-RIGHT: 4pt; PADDING-LEFT: 4pt; TEXT-ALIGN: center" noWrap width="1%"><FONT style="DISPLAY: inline; FONT-WEIGHT: bold" size=1>For</FONT></TD>
    <TD style="PADDING-RIGHT: 4pt; PADDING-LEFT: 4pt; TEXT-ALIGN: center" noWrap width="1%"><FONT style="DISPLAY: inline; FONT-WEIGHT: bold" size=1>Against</FONT></TD>
    <TD style="PADDING-RIGHT: 4pt; PADDING-LEFT: 4pt; TEXT-ALIGN: center" noWrap width="1%"><FONT style="DISPLAY: inline; FONT-WEIGHT: bold" size=1>Abstain</FONT></TD></TR>
  <TR>
    <TD noWrap width="1%">&nbsp;</TD>
    <TD vAlign=top noWrap width="1%">&nbsp;</TD>
    <TD vAlign=top width="92%">&nbsp;</TD>
    <TD vAlign=top noWrap width="3%">&nbsp;</TD>
    <TD vAlign=top noWrap width="1%">&nbsp;</TD>
    <TD vAlign=top noWrap width="1%">&nbsp;</TD>
    <TD vAlign=top noWrap width="1%">&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap width="1%">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD vAlign=top noWrap width="1%"><FONT size=1 face="Times New Roman">2.&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD vAlign=top width="92%"><FONT size=1 face="Times New Roman">To approve, on an advisory basis, the
      compensation of the Company's named executive officers, as disclosed in
      the accompanying Proxy Statement.</FONT></TD>
    <TD vAlign=top noWrap width="3%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: center" vAlign=top noWrap width="1%">&#9744;</TD>
    <TD style="TEXT-ALIGN: center" vAlign=top noWrap width="1%">&#9744;</TD>
    <TD style="TEXT-ALIGN: center" vAlign=top noWrap width="1%">&#9744;</TD></TR>
  <TR>
    <TD noWrap width="1%">&nbsp;</TD>
    <TD vAlign=top noWrap width="1%">&nbsp;</TD>
    <TD vAlign=top width="92%">&nbsp;</TD>
    <TD vAlign=top noWrap width="3%">&nbsp;</TD>
    <TD vAlign=top noWrap width="1%">&nbsp;</TD>
    <TD vAlign=top noWrap width="1%">&nbsp;</TD>
    <TD vAlign=top noWrap width="1%">&nbsp;</TD></TR>
  <TR>
    <TD noWrap width="1%">&nbsp;</TD>
    <TD vAlign=top noWrap width="1%"><FONT size=1 face="Times New Roman">3.</FONT></TD>
    <TD vAlign=top width="92%"><FONT size=1 face="Times New Roman">To ratify the selection of Ernst &amp; Young
      LLP as the Company's independent registered public accounting firm for the
      fiscal year ending December 31, 2015.</FONT></TD>
    <TD style="TEXT-ALIGN: center" vAlign=top noWrap width="3%">&nbsp;</TD>
    <TD style="TEXT-ALIGN: center" vAlign=top noWrap width="1%">&#9744;</TD>
    <TD style="TEXT-ALIGN: center" vAlign=top noWrap width="1%">&#9744;</TD>
    <TD style="TEXT-ALIGN: center" vAlign=top noWrap width="1%">&#9744;</TD></TR>
  <TR>
    <TD noWrap width="1%"></TD>
    <TD vAlign=top noWrap width="1%">&nbsp;</TD>
    <TD vAlign=top width="92%">&nbsp; </TD>
    <TD vAlign=top noWrap width="3%"></TD>
    <TD vAlign=top noWrap width="1%"></TD>
    <TD vAlign=top noWrap width="1%"></TD>
    <TD vAlign=top noWrap width="1%"></TD></TR>
  <TR>
    <TD noWrap width="1%">&nbsp;</TD>
    <TD vAlign=top width="93%" colSpan=2 style="padding-left: 27pt; text-indent: -27pt"><FONT size=1 face="Times New Roman"><STRONG>NOTE: </STRONG><FONT face="Times New Roman">In their
      discretion, the proxies are authorized to vote on such other matters as
      may come before the meeting and any adjournment(s) or postponement(s)
      thereof.</FONT></FONT></TD>
    <TD vAlign=top noWrap width="3%">&nbsp;</TD>
    <TD vAlign=top noWrap width="1%">&nbsp;</TD>
    <TD vAlign=top noWrap width="1%">&nbsp;</TD>
    <TD vAlign=top noWrap width="1%">&nbsp;</TD></TR>
  <TR>
    <TD noWrap width="1%">&nbsp;</TD>
    <TD vAlign=top width="93%" colSpan=2>&nbsp;</TD>
    <TD vAlign=top noWrap width="3%">&nbsp;</TD>
    <TD vAlign=top noWrap width="1%"></TD>
    <TD vAlign=top noWrap width="1%"></TD>
    <TD vAlign=top noWrap width="1%"></TD></TR>
  <TR>
    <TD noWrap width="1%"></TD>
    <TD vAlign=top width="93%" colSpan=2 style="padding-left: 27pt; text-indent: -27pt"><FONT size=1 face="Times New Roman"><STRONG>NOTE: </STRONG><FONT face="Times New Roman">This proxy
      should be marked, dated and signed by the stockholder(s) exactly as his or
      her name appear(s) hereon, and returned in the enclosed
      envelope.</FONT></FONT></TD>
    <TD vAlign=top noWrap width="3%"></TD>
    <TD vAlign=top noWrap width="1%"></TD>
    <TD vAlign=top noWrap width="1%"></TD>
    <TD vAlign=top noWrap width="1%"></TD></TR></TABLE><BR><BR><BR><BR><BR><BR><BR><BR>
<TABLE style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse; TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 width="48%" border=0>

  <TR>
    <TD noWrap align=left width="2%">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="PADDING-RIGHT: 8pt" vAlign=top align=justify width="97%"><FONT size=1 face="Times New Roman">Please sign
      exactly as your name(s) appear(s) hereon. When signing as attorney,
      executor, administrator, or other fiduciary, please give full title as
      such. Joint owners should each sign personally. All holders must sign. If
      a corporation or partnership, please sign in full corporate or partnership
      name by an authorized officer.</FONT></TD></TR></TABLE>
<TABLE style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse; TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR>
    <TD width="1%">&nbsp;</TD>
    <TD width="48%" colSpan=3>&nbsp;</TD>
    <TD noWrap width="1%">&nbsp;</TD>
    <TD width="49%" colSpan=3>&nbsp;</TD></TR>
  <TR>
    <TD width="1%">&nbsp;</TD>
    <TD width="48%" colSpan=3>&nbsp;&nbsp;</TD>
    <TD noWrap width="1%">&nbsp;</TD>
    <TD width="49%" colSpan=3>&nbsp;</TD></TR>
  <TR style="HEIGHT: 20pt">
    <TD width="1%">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; BORDER-TOP: #000000 1pt solid; PADDING-LEFT: 2.5in; BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1.25pt solid" width="1%"><BR></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; BORDER-TOP: #000000 1pt solid; PADDING-LEFT: 0.5in; BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1.25pt solid" width="1%">&nbsp;</TD>
    <TD width="46%">&nbsp;</TD>
    <TD style="PADDING-LEFT: 2%" noWrap width="1%">&nbsp;</TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; BORDER-TOP: #000000 1pt solid; PADDING-LEFT: 2.5in; BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1.25pt solid" width="1%">&nbsp;</TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; BORDER-TOP: #000000 1pt solid; PADDING-LEFT: 0.5in; BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1.25pt solid" width="1%">&nbsp;</TD>
    <TD width="47%">&nbsp;</TD></TR>
  <TR>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%"><FONT size=1 face="Times New Roman">Signature [PLEASE SIGN WITHIN BOX]</FONT></TD>
    <TD width="1%"><FONT size=1 face="Times New Roman">Date</FONT></TD>
    <TD width="46%">&nbsp;</TD>
    <TD noWrap width="1%">&nbsp;</TD>
    <TD width="1%"><FONT size=1 face="Times New Roman">Signature (Joint Owners)</FONT></TD>
    <TD width="1%"><FONT size=1 face="Times New Roman">Date</FONT></TD>
    <TD width="47%">&nbsp;</TD></TR></TABLE></DIV><BR>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=left><FONT face="Times New Roman" size=2><A HREF="#toc"><B>Table of Contents</B></A></FONT></P>
<BR><BR><BR><BR><BR><BR><BR><BR><BR><BR>
<P align=center><B><FONT face="Times New Roman" size=2>Important Notice
Regarding the Availability of Proxy Materials for the Annual Meeting:
<BR></FONT></B><FONT face="Times New Roman" size=2>Letter to Stockholders,
Notice and 2015 Proxy Statement, and 2014 Annual Report<BR>are available at
<U>www.proxyvote.com</U>.</FONT></P><BR><BR><BR><BR><BR><BR><BR><BR><BR><BR>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD style="BORDER-TOP: #000000 1pt dashed" noWrap align=right width="100%"><FONT face="Times New Roman" size=1>M85939-P60787-</FONT></TD></TR></TABLE>
<DIV style="BORDER-RIGHT: black 2pt solid; PADDING-RIGHT: 15pt; BORDER-TOP: black 2pt solid; PADDING-LEFT: 15pt; BORDER-LEFT: black 2pt solid; BORDER-BOTTOM: black 2pt solid"><BR><BR>
<P align=center><B><FONT face="Times New Roman" size=2>THIS PROXY IS SOLICITED
ON BEHALF OF THE BOARD OF DIRECTORS</FONT></B></P>
<P align=center><B><FONT face="Times New Roman" size=2>GERON CORPORATION<BR>2015
ANNUAL MEETING OF STOCKHOLDERS<BR>TO BE HELD ON MAY 18, 2015</FONT></B></P>
<P align=justify><FONT face="Times New Roman" size=2>The undersigned stockholder
of Geron Corporation, a Delaware corporation (the "Company"), hereby
acknowledges receipt of the Notice of Annual Meeting of Stockholders and Proxy
Statement, each dated April 3, 2015, and hereby appoints John A. Scarlett, M.D.,
and Stephen N. Rosenfield, or either of them, as proxies and attorneys-in-fact
with full power to each of substitution, on behalf and in the name of the
undersigned to represent the undersigned at the 2015 Annual Meeting of
Stockholders of Geron Corporation to be held on May 18, 2015, at 3:00 p.m.
Pacific Daylight Time at the Westin San Francisco Airport, One Old Bayshore
Highway, Millbrae, California 94030 and at any adjournment(s) or postponement(s)
thereof, and to vote all shares of Common Stock that the undersigned would be
entitled to vote if then and there personally present, on the matters set forth
on the reverse side, and in their discretion, upon such other matter or matters
that may properly come before the meeting and any adjournment(s) or
postponement(s) thereof.</FONT></P>
<P align=justify><FONT face="Times New Roman" size=2><STRONG>This proxy
will be voted as directed or, if no contrary direction is indicated, will be
voted as follows:</STRONG></FONT></P>
<TABLE style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse; TEXT-ALIGN: justify" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR>
    <TD style="PADDING-RIGHT: 10pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%"><STRONG>"FOR" the election of the two nominees
      for director named in the accompanying Proxy Statement to hold office as Class I members of
      the Board of Directors until the 2018 annual meeting of
      stockholders;</STRONG></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 10pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%"><STRONG>"FOR" proposal 2, to approve, on an
      advisory basis, the compensation of the Company's named executive
      officers, &nbsp;as disclosed in the accompanying Proxy
    Statement;</STRONG></TD></TR>
  <TR>
    <TD style="PADDING-RIGHT: 10pt" vAlign=top width="1%"><FONT style="FONT-SIZE: 9.5pt">&#9679;</FONT></TD>
    <TD vAlign=top width="99%"><STRONG>"FOR" proposal 3, to ratify the
      selection by the Audit Committee of the Board of Directors of Ernst &amp;
      Young LLP as the Company's independent registered public accounting firm
      for the fiscal year ending December 31, 2015;</STRONG></TD></TR></TABLE>
<P align=justify><FONT face="Times New Roman" size=2><STRONG>and as said proxies
deem advisable on such other matters as may come before the meeting and any
adjournment(s) or postponement(s) thereof.<BR></STRONG>&nbsp;</FONT></P>
<P align=center><B><FONT face="Times New Roman" size=2><B><FONT face="Times New Roman" size=2>(CONTINUED AND TO BE SIGNED ON REVERSE
SIDE)</FONT></B><BR></FONT>&nbsp;</B></P></DIV><BR>
<HR align=center width="100%" noShade SIZE=2>


</BODY>

</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>geron_def14a1x1x1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 geron_def14a1x1x1.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_
MVP!#`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_P``1"``S`&(#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#]%_\`@X"_
M;3_X**>(?VT_V./^"/W_``3/\7R?";XT?M.^"6^,OC+XJZ)K<WA7Q=IW@^'6
MOB/H\%E#XW'FR^"?!'AS1_A?X_\`'OCS4O#=A>>.M6@\/Z/I'AB0,UYX>\6?
MFO\`MLZ1_P`%J?\`@W'USX!?MB7O_!1OXM?\%+?V;O%_BI/AW\9_`/[1?B#X
MB7/AC2_&6K:)JE_I_A(:+XY^+GQ5\0Z;8^(=*TSQ!J_@OXE^"M2T.?0_$OAF
M'3_&'AR[TN]M-(\5_I-^UI_RN+?\$P?^T<WC_P#]-'_!0VNF_P"#R3_E$?X<
M_P"SO_@U_P"H3\7Z`/ZC?AYXUTGXE>`?`_Q%T#S?["\?>#_#/C71?/&)O[)\
M5:+9:[IPE7`VR_8[^#S!@88L,"OX'OV<_B-_P6&_X./_`-K+]IOQC\'/^"@/
MQ!_X)U?L3?L^>+IO!/AB7X!ZSXXT+4G6^O-;?P+I46@>`O'?PT\2_$GQ=K&C
M:,GB3XA^)_&7Q$TG1]"DU6TM/"FC1Z?<6GAS3_[@?V-_^30OV5NO_)M_P.^O
M_),?"_K_`%K^2S_@RJ_Y-[_;_P#^SF?!_P"O@B__`%]NM`$7_!)C]NO_`(*6
M?L1_\%<M7_X(L_\`!2WXF:_^TK8_$VT\2:U\!/CKXV\07OB;Q4EAX9\#^,O'
M?A3Q9I7BJ_N-2U_7?`_Q5\+^#=5L-1\/^-+_`%'Q%X-\=:?!I\>I6I@\0P:E
M_1C_`,%?_P#@H99_\$O_`-@OXN?M7P:'H?BWQUH,_AGP9\)?!/B.;4H-%\7_
M`!,\;:U;:5HVGZI+I3P7S:5HFE#7?&>M6UO?:7<W^B>%]2T^RU.RU"[M)E_G
M$_;!_P"5S7_@GQ_V;K:_^J=_:SK[`_X/&_\`E$3I?_9VGP7_`/47^*5`'YN_
ML9_`G_@Z>_X*7>$-"_:U\:_M])^R+\*?']]HWC7X9^"=<%MX"N_&WPZ\0+:>
M(]*UGPOX!^$WP_OY='\`WVB:A'9^&-0^(FM1>,-=L8[?59;74]+O+/Q)J7Z'
M_P#!QU_P4>_;D^#7Q6_8[_X)K_\`!._4+3P9^T#^V_<-!-\2[*[@T[QSH-IJ
M'C?2/!7@[P_X)\0ZG(FA^"H_$.J_\)#+XL\:W4%QJNB:)I:/HEUHMP\^I5_1
M3^Q.B1_L9_LD(B*B)^S'\!%1$4*J*OPJ\**JHJ@`*J@*H``````'%?RD_P#!
M:C_E99_X(6?]T]_]7OXQH`^/_P!M_P#9W_X+Y?\`!#'X;_"O_@H%IG_!4?XO
M_MT?#OP9XC\'2?M3?#+XJ^,/BAXG^&7@G4?$>OZ/HFG:')X:^)OQ)\5R^-OA
M)XN\1ZVGP_G\8^%[3X6>/-$U+5_#FH:;X>T1KY=2\+_VW_L2?M+6/[8_[(7[
M-G[4]AH0\+)\>_@UX"^)MYX66]?4X_"^L^)]`L[[Q!X:AU22UL7U2#P_KKZC
MH\&IM96;:A#9QWAM+8S^2GY4_P#!T1_R@J_;G_ZY?LV_^M>_`&OI#_@A#_RA
MX_X)X?\`9M7@K^=[0!_-7XU^.?\`P5._X+J?\%;?VN/V.OV4OVWO&G[`?['/
M[#7BKQAX*\2^/O@AJ'BS0/%FKW7@_P`9ZM\/;?6K^X\%>+/`?C/X@^+OB/XQ
MT#7;C2-&N_'GA#X>^%_`7AZXO(;6Y\203#QPS]D/]MS_`(*5_P#!'[_@LW\/
M?^"67_!0G]HSX@_MG_L^?M/:OX#\'_`_XS_%#5]3USQ9<K\5?$%_X5^$GQ2\
M.:CK^L^-_&MB-4^)5O=_"OXB_#WQ9XTUBVT2[@O-=T;5KW3=&T;4O$WI/_!L
M=_REB_X+^?\`9PNK_P#K2?[2%>-?\%_?^5G'_@A]_P!C!^P3_P"O`_&]`'][
ME%%%`'\CG[6G_*XM_P`$P?\`M'-X_P#_`$T?\%#:Z;_@\D_Y1'^'/^SO_@U_
MZA/Q?KRW]OCQYX,^$?\`P=T?\$M/B!\4/%&A^`/`VH?L'^)_!-KXP\6ZE:Z%
MX9;Q7XA/[=WAW0]"EUO49(-/M[_5=?\`%?AC1;**>XC\_4_$&D6:GSK^V23U
M'_@\C8-_P2.\-,I#*W[7WP:*L"""#X(^+Y!!!P01R",Y'/2@#^B[]C?_`)-#
M_96_[-O^!W_JL?"]?Q5?\&K=]^T!I?\`P3?_`."ONI?LI:-IOB/]IFQ\>7UW
M\!-`UF7P]!I&L_%N#X2:_)X"TS4IO%NK:%X8BL;SQ&NGP7+^(-:TK2$B=CJ&
MH6ML))D_M5_8W_Y-#_96_P"S;_@=_P"JQ\+U_)'_`,&5M[9Q?!/_`(*&>'I;
MJWCU[3/VC_`][J.C22HFJ6-G=^$M?L;6ZN[%B+F""XO-*U.UAFEC5)+BPNX5
M8R6\JH`>3_L9_L#?\%]/C)_P7%_9#_X*,_\`!2C]F#PIX0T'X5:/XF\%>-/'
MG@WXG?LOC2-#\(V_PC^,6@^%<^"/AU\:_%WB;4[NX\4>/H;&>?2-&OY@M[%<
M7<4%C9W%S#^B7_!XW_RB)TO_`+.T^"__`*B_Q2K]"/'G_!:/X:^$/^"P7PG_
M`."0VC_"75?&WCGXC^%6U_6OB_H'C[1)M$^'NIP_#GQ_\3+GPSXD\&0Z+=ZJ
MNK6OAWP39W=RDFLV3PV?BC3-0DMTMTQ/^>__``>-_P#*(G2_^SM/@O\`^HO\
M4J`/Z&/V*?\`DS;]DK_LV7X#?^JL\*5_*/\`\%J/^5EG_@A9_P!T]_\`5[^,
M:_JX_8I_Y,V_9*_[-E^`W_JK/"E?R>_\%O;ZRT'_`(.1/^"%FN:W=VVD:+]J
M^'=D=5U*>*RTY;N3X_>([9+=KRX:.!9GN-3TZ%4:0$RWML@&Z=`0#]8_^#HC
M_E!5^W/_`-<OV;?_`%KWX`U](?\`!"'_`)0\?\$\/^S:O!7\[VOE7_@Z;\1^
M']$_X(<?MC:9K&M:5I>H^+=1_9ST'PM87]_:VEYXCUNV_:B^#'B6XTC0[6:5
M)M4U&W\.>'M>UZ>SLDFN(='T75-2DC6SL+J:+ZO_`."$\$UO_P`$>_\`@G?'
M/%)"[?LR^`YU25&1C#<PW-S;2A7528Y[>6*>%P-LD4B2(61E8@'\]G_!L=_R
MEB_X+^?]G"ZO_P"M)_M(5XU_P7]_Y6<?^"'W_8P?L$_^O`_&]>R_\&QW_*6+
M_@OY_P!G"ZO_`.M)_M(5XU_P7]_Y6<?^"'W_`&,'[!/_`*\#\;T`?WN4444`
M?C+_`,%AO^")W[.7_!83X>>#M-^)/B;Q)\)?C3\*(->@^$7QM\)V<>O3>'+/
MQ/-I<^O^'_%W@>\U+2-,\=^%-0GT?3[U-.DU?0-<TG4+=KCP_P")M(@U+7[3
M6?X<O^"U'_!![]IG_@FA^Q1X?^,_Q,_X*/>,_P!J'X:VWQ>\`?"S1/@WJ_AK
MX@>'M`T>;5O#GC&ZT37K"U\0?&+QWH-D/#^G^&I],L]/M-#C>"WU)HK2]MX(
MGBG_`-%+_@HK\:/VB_V=_P!BKX_?&C]DKX3?\+R_:+\`^%--U7X6?"?_`(0/
MQS\3?^$TURY\5>']*O--_P"$$^&FJZ)XY\1_9]#U#5=1^Q^'=5L[N+[%]LED
M:SMKF-_XBO$GP3_X.`_^#D+XC_#'X,_MT?!#4/\`@GQ^QW\)=?@\8>.Y[SX"
M_%/X&Z!JOB.V@OK*UU_0_`/QR\6Z_P#$KXJ?$F30M<U7P_X8EL]5M_AIX4M;
MC4;W5#IFJW4RZX`?W=?L;_\`)H?[*W_9M_P._P#58^%Z_E\_:2_X-D?CS\//
MVQO%O[9G_!(7]NS6?V+O%GQ-N/%>K^/?!7BB?Q1-I5IK?C?7;[6O%-AX8\0^
M$K6\-_\`#G5)[NVOK+X=^-_"WB2'P_KNF6^IZ=K\L<>B6?AK^O/PGX7T3P1X
M6\->"_#5FNG>'/"'A_1O"_A_3T=Y%L=$T#3K;2M*LU>0L[K:V%I;P*[LSL$R
MQ)))Z"@#^;#_`((Q?\&]GAS_`()L_%OXA_M>?M#_`!NN/VK?VTOB,_B6,?$J
M73M<TO0/!%GXYFCU#X@7MBWB'6]8USQKX_\`'&KM?2>(?B-XA&FZ@^D7D^CZ
M?HNGMJ/B'4->^Y/^"T7_``3,U?\`X*Q_L=VG[+&B?&#3?@C>6WQ?\$?%`^--
M4\%77CRU>'PCI7BO39-%&AVGB;PI*LM\?$L<R7QU0I;BT9#:S&8-%^M=%`'E
MWP/^'4OP@^"OP@^$L^K1Z]/\+OA=X`^'4VN0V;:?%K,O@GPGI'AJ358K![B\
M>QCU%],-XEF]W=-;+,(6N)RAE;\FO^"T_P#P1,^"_P#P6%^%GA&S\0^,M9^$
M?[0/P<M/$2_!'XMZ;`^M:%I:>*[WP[=>)?#7C_P9]IL!XK\,:PGANS^QRV6I
MZ/KWAC5=NKZ5J,]E+K?A[Q!^VU%`'\/NF?\`!K-^W)^TQ\0O@)I__!3[_@IY
MJ/[1?[.?[.\*:%X/^'GAO_A/M7\87G@E7ADO/#6G>)O&DFFVW@_4/$,>FZ+I
MVN>,I[;QSXH?0]-L]*BOBFDZ)<:=_:;\-OAWX*^$/P\\"?"?X;>'[+PG\//A
MCX.\,_#_`,">%M-\[^S_``YX/\'Z-9>'O#6A61N)9[AK72M&TZSL8'N)IIWC
M@5III92[GM:*`/PL_P""6W_!'37O^"='[77_``4+_:>U7X]Z1\5[/]N+XC7G
MCS3O!VG_``\O?"%U\.(KKXF_$SX@C3+W6[GQAXBB\3R)%\0(M+-U!IFB*TFE
MR78@"W:V]OQ7_!0O_@B/XB_;C_X*D_L)_P#!1;3OVB=%^'&E?L;ZC^S]?7_P
MHO?AI?>)]0\?#X(_M$:[\<[F*S\80>-=#MO#I\16^LKX;@:?P[K']F3V[:HZ
KWL<@L4_H(HH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@#_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>geron_def14a1x1x2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 geron_def14a1x1x2.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_
MVP!#`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_P``1"`!"`,T#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#^_BBBB@`K
MPS]I']I3X(_LB?!KQ?\`M`_M%>/M*^&7PB\"#1O^$H\8:O#?W5KIS^(-=TSP
MUH\*6.E6E_JE]<W^M:OI]E!:Z?975PS3F7RA#%+(GN=?QY?\''NJ?$+_`(*$
M_M4?L,_\$-?@#/<)XB^*OBFP_:<_:1\16S1):>!/A+X:3Q-HFA:CJ5S-.EC(
MFDZ59_$/QE=:#>H+O4M8T[X<VNGYN-:LXKH`_KWT'7M$\4Z'HOB?PUJVGZ]X
M=\1Z3IVO:!KFDW<-_I6LZ)K%G#J&E:MIE];/);WNGZC8W$%Y97<$CPW%M-'-
M$[1N&.M7)^`O!/A[X:^!?!?PY\)6C6'A7P!X3\.>"?#-BTGFM9>'O"NCV>A:
M+:-)M7S&MM-L+:$R;5WE"VT9Q7EW[3G[47P#_8U^"_BW]H7]ICXD:3\*?@_X
M'&F#Q'XOU6QUS6/(N-:U.TT;2;#3=`\+Z7KOBCQ#JVHZE>V]M9Z/X=T75=4N
M-TDL=FT%O<2Q`'OM%<3\-?B/X'^,/P\\#?%CX9>)-/\`&/PZ^)?A+P]X[\"^
M*]*,QTWQ'X2\5Z5:ZWX?UJR%S%;W4=OJ.EWMK=1Q75O;W4(E\JYMX)TDB3MJ
M`"BBB@`HK\F_^"N'_!6GX-_\$H_@GX?\7^+_``]K?Q/^-WQ?OM:\*_LZ?`WP
MQ!<2:Q\2?&6EP:<+F34[VWAN9=#\'Z)>:[X>@U_5K:SU/57GUO2],T+1M5U.
M_B@3\%-%\,_\'47_``57L$;QQXM\"?\`!)K]G/QC(#/;^'+35_`/QSMO#\9C
M=9M-LK#5O%'QXTW6[H7,D$MGK?B_X-+<_8/-"V5I.J7H!_:?17\;>B?\&@/P
M^^(.G3ZE^U[_`,%)_P!LCXZ>/KU1<S:[H5_HVB6<&I211I<7$C_$^7XS:WJC
MRM&#+<C5-(DNE"?:(=T:M7S1H'[,OQ?_`."`?_!6C_@F/^SU^S1^V9\9_P!H
M/X-_MW^.=1^''Q5_9Y^+DJ/HGASP.GB7PGX?O_'5MI>CZI!X5@U;28_$NH^*
M/#GB#3_#6A:_!=>"M7T:6\U?0];URP8`_N[HH_S_`)_S]**`"BBOY+O^"IO_
M``<@^./V:_VD=?\`V??^"?'P'\._MA#]F?P[J/Q+_;@\=P1^*==\(_"_PIX6
MU1+?Q?X(L->\'W5OIGA_7=`L5EC\5^/-:FUS0/"/B.XL_"C^'M8U^TUZPTD`
M_K1HKR?X#?&+PI^T-\$/A!\>?`LS3^#/C/\`#/P/\4O"TDA_>C0O'?AO3?$V
MF13C"E;F"TU**&Y1E5HYXY$9592!^;G[4?\`P7F_X).?LA:AKOA[XK?MC_#C
M6/&WAV5K34_`7PC36OC1XIM-4CE>&;1-2C^&6F>)='\.ZQ;/%*+RQ\5:SH,E
MDT9CO#!*\,<@!^O=%?QE_$'_`(.IOC-^T'XBOO!__!)C_@F!^T3^U6L4\=A;
M_$?QQX,\9W&BK?(%>[FE\"_".R\5W$6E0Q[Y4NO$'Q%\)W,=JB7=]962NT,7
MC6N_L_\`_!V3_P`%1H=+\.?'+XA^!?\`@G#\"]?U6WNM>M/`WBNR^&7B8>'%
MDC2[B32OA-XJ\??&W6+B>SN9T'@OQSXZ\'Z+JEU9F'5Y].M9H+EP#^LC]KO_
M`(*(?L6?L)>%KCQ5^U/^T1\.?A6L:C[#X6U#6HM6^(>O3/;2745OX;^'&@C4
MO&VNR2PQ%P^G:'/;1!HFN+B!)8V;\:O^",?_``7L^+'_``5M_:M_:"^'.G_L
MA7WPV_9G^'/@ZZU[P-\9[;4M8U>:#6['Q5;:98>&?B+JEW;V7AE?$7C;PSK%
MEK^C>&?#<)U+PZV@Z]]NN->TVZ@U'3/*/V8/^#13_@G]\,M9M_'W[5'Q$^-?
M[9WQ(NY1J/B0>-?$DO@3X<ZQK3RFXEOKCPWX6GE\;:FIE;$]MXC^)6M:=J97
MS=0TV0,L$7]0GPX^&/PW^#W@_2?A]\)O`/@SX9>!-!A\C1/!O@'PSHWA#POI
M41QN6PT+0+*PTRUWE0TK0VRO*XWRL[DL0#N:***`"BBB@`K^5W]@S1_^%T_\
M'.G_``6(^.MY;B[T_P#9X^`W[/?[/'A.>?R)/['F\7>#_AE>:U'9R(5D,MSK
MOPN\;SRG;(UO!JQL[AXV$0E_HM^-O[4'[-W[-6BGQ#^T)\>OA!\%-',-U/!>
M?%#XB>%/!/VY+.)9KE-+M_$&JV%UJUS'&R-]DTR"[NG,D:QPLTB*W^=AI7_!
M>70_V.OB)_P6-^,'[$-KI'Q<_:8_:J_X*`ZMXN^'?B77OASXJ\8_"JV_9#^&
M\?C5;?XGF[LM<\*7@O\`4WU2*32]+U%#::9I-U?ZWJMO'';VT+@'^EEK.M:/
MX<TG4M?\0ZMINA:%HUE<ZEJ^M:S?6NEZ3I6G64+W%YJ&I:E>RP6=C8VD$;S7
M-W=31001(TDLB(I(_P`\S_@XV_X*%:?_`,%=OC]^RY_P2>_X)M^*&^/DJ_%N
M]U3QQ=^%6TF#X>^//C#_`&,^D>!K;P]X^N[E+;5/"GPS\-:I\1-8\;^(TEM?
M!-JM\FI_VEJO_"-S7>E?SL?M$_M)_P#!7_\`X*B>$/$7[17[0OB3]I[XK?LS
M^"_$$]AXW\<^%?AYXM@_9K^$MI,$OM:FO=!^&^@6'@*PM?#FDPB]U"2]@FU*
M*WAMTO\`4#>7\4ES_1__`,$^OV0O@#^R;_P6'_X(/Z!\&?%_@/XE^#V_X)V_
MM`?M.^/_`-H/P[H-_P""=&^*ES\2?"7[6Z:;\1-9L?&%PWB'3$T+P]=>%_#$
M5IKTEG<:!:^'K9KC3-$FBN[6(`_N0_8H^`M[^RU^Q_\`LO\`[-NIZI!KFJ_`
MKX!_"?X4ZQK-KN^R:IK'@;P3HOAW5M0L]\<3_8KO4;"ZFLQ)&D@M7B$BAPPK
MZ=K\'?\`@G-_P7?^`7[<WPW_`."A?Q?\4Z/IOP8^&O[!'Q*\1Q:YXO/B>7Q?
MI/BOX`+8>)[_`,"_%LF#1=+OK/6/%<7@/QBTGA#3;'6%C-MHUMH^K:U>:F]O
M;_H_^QG^W7^SM^W;^S)X=_:X^!7B;41\&_$$OBBVDU/Q[I9\%:IX=O/!FKWN
MC>([7Q-::G</::;_`&?<V,D[7L>H76F3V$MO?6]]+!*&`!]AT'_/X_U]O\:H
MZ9J>FZUI]EJ^C:A8ZMI6IVEO?Z;J>F7=O?Z?J%C=PI<6E[97MK)+;7=I=6\D
M<]O<02R0SPR)+$[(RL?YCO\`@KG_`,%D?VH?"'[2NB?\$M_^"2'PRTSXW?MX
M^*M!.K?$/QK/!I6K^'_V<M+N;&UUBV:ZL/$Z6_@`^)(O#UU;:_K&O?$#4V\#
M^";'4M"@UG1O$&KZ]!I5B`<-_P`'%WA8?!3]JC_@CK_P4P\6>%;_`,5?`#]C
MW]I^]T']HJ6QT.X\2-X)\,?$/7OASJGA'X@2Z=#;/':67AZ_\(^))#J5W<P1
MCQ2_@FPM`^HWUL#_`%0>'O$.@^+-"TCQ-X7UG2_$7AS7].M-7T/7M$OK;4](
MUC2[^%+FRU'3=1LY9K2]LKN"1)K>YMYI(I8W5T=E(-?P@_\`!,#Q)\1OA=_P
M4\^+G_!-[_@II_P4!\'?MYVG_!03]E#Q1H?Q(^#NA>/_`!;\<?!W@C]H]M?N
MM:UCX0ZIK$<7_"-?#/7=!^&-I\3IYY_"O_"/Z=+<WOANRCLM+U'0O"T]?3&N
M?LY_\%7O^#=5O%FN_L%V*?\`!0/_`()86MQJ?Q)\6?`/XIZMI>G_`!J^`\MY
M+(GB5?".O:5]CUBXTD6UOINJR:YX7\.^(]#FE.KW_B#X7:9J1U#Q?JH!_9]7
MYF_%7_@G!^S)\9/^"E'P"_X*`>-_&GC#4/V@_P!G+X5ZKX7^'_PM'C'24\$P
M:7>3^+;+3O'L_@Y;)?$8O])E\?>++9;R+4UT+4+^]TN2^LY+K1[<2_S,?ML?
M\'9FG_'KX4?"#X`?\$I/A]XQ_P"&POVG;K1OAU?ZI\5-#L=%C^`OBKQS<V7A
M?3-%\*7.H:C'X6\9>/+G7M52/P_XLOKD>`="M$M=?UF&[N'FT2PV/^"87_!O
M'_P4L_8W_P""@_[&G[>GQE_:?\*?$_Q!+%\7'_:\TO4O&'BWQ3XH\-Z-XH^'
M'B?1/#GA"P\4^(Y+^3XO/KVL:Y9G7+Z0:%9>#]=T^VU?2#XDAM+;4P`?W`T5
M_`S_`,%_O^#H/Q_\./B9KW['?_!,;XB:7H=]X%O->\+_`!\_:1L_#VE>(-0_
MX2ZTN+O1=3^'WP<N?$%OJ>A6UIX>:.YC\0_$6#2;W4+C76AMO`^HZ1'H,VN:
M[G?\$:_^#C']J'0O`7QM^.W_``5B^.?A&Y_9-^'7PI\+^"?@O+/X/\*Z1\=/
MB[\<O#EQ:V$^D_"[1/#UCIWBSXO:GJ^A)=W7Q;\6:U+<>$O!WB&7PS<:CK/A
M1-9U%+D`_M2_;>_:)TG]DG]C[]I?]I;5[R&RB^"OP4^(7CW36G@-TM[XFT;P
MW?R^$-&CMBI2XNM>\5MHVB6<$QCMY+O4(4N9H+<RS1_R(?L>_LNZ9^Q?_P`&
ML/[=7[1_QDTZ&#XV?MV_LU?%SXL>-O%.N%KC7=5T7XU:+=^!?V=]*GNWC$GE
M:K!XRTGQM8VX4$^(/B'?S2R.70Q?CO\`&S_@K-^UK^W)_P`$R?\`@JS\0?VK
M?VAOA9X>\#_M"?$_]G&S_9/_`&7[KQIX2B\=Z9I_AKX[:;K?Q*T3X4>"+:[3
MQY<_#_POX'LM)L?$WB7Q+926GB75=+N;ZWN/[2BUA:^_M=^,/[4W_!QE?_LY
M_L`?LI?"GXA?`7_@C_\``RV^$.D_'W]HG6O"]OHMUXG/P9\*V=I?VUOKVJW%
MSX>CDTP06]G\.?ACI<NO:DNMKH_Q`\?Q06.EQ:=X:`/Z@/\`@DYX[^'7PP_X
M(U?\$WM-^/\`\3?!/PPMOB3^S/\`"+P'X;O?'?C_`,/^#6\2ZMXY\)R7/A+P
MKX8U/7M2TX:AXLU3PY+%)H^@Z8]QK`^SR1V]K(UG)M_#C]DG_@@G^QO_`,$F
MOA5^W9^TA_P5&^"'P?\`VJ/AA\`KI?BA\"/B[-?>)_&FI>(OA(OAVZM+SP!K
MWP$\3:KIGP\M/'VG>(;+1K/19]7L=8@U;Q!XUGM;#Q/#H^F6TMO^'G_!5_\`
M:5^%7[7_`/P5^_9T_8NMOCC\,?A3_P`$Y_\`@GEJ/PN^#'A+QJ?'=O%X`TCP
M'\-M%\*:Q\:O&EIJ]C/=P^(/B#-;^'/^%6^%[#PW!?:AJ=_X2\.Z=I-I)?7V
MH3S??G_!>W_@O[X4_P""@W[+7QJ_8_\`^">'P<^)WQE^`8TCP=XH_:5_:LN?
M!7COP_X;\&:-X5^)7A[7]'TK2-!N=!M[K3=!U77="T:SU/Q;\09O#D%TUZ=(
MT?P_>EAJZ@'`?\&\'[9G[4'[>?\`P76\1_$Q-5NO!/P"\&?L_P#QN6P^`?@5
M(-`^"'P?^!]UJ?AW3/AY\,_"7@S0X;7PGI36GC;4_!FLZAJ=AIUKJWBGQ#HV
MJ^)-2NKZZO+]S_=#\'_^"@G['?Q]_:3^,W[(OP=^.GA+X@?'[X`:-8Z[\4O!
M/AXZC>QZ#875];:7>BS\2+9#POXAN_#>K7VF:/XPL?#VL:I=^$=:U.QT?Q#%
MI^J2/:1_Y[<'B?3?^"#'_!/?X:_'7]A+]O/]F#XW?'/_`(*`_`'2?"G[2_P8
MO?[`\7^/_`FJ^-/"?B35O"'Q/^!6J^!=6TWQQX*/P17Q)<^&=1TKXHM_PC^J
M>.K:;Q%J6C7M[/9>"?#_`.N?_!EK\!O@'IG[/W[2'[3%MXW\)>+_`-J7QSXZ
M3X;^*O#,&H6]QXU^%/P>\/1:?JV@P:GI\VS4[2#XH>*Y;_7[W4XHY])UFV\*
M>%[=+^35-&U*SLP#^WNBBB@`HHHH`_GH_P""KW_!P5\(/^"=OQ8TK]D_X0_!
M;QS^V)^V=XDT6VO[3X-?#*XW67@V]URUAO?"NF^.;K1M/\2^*&\0Z[I<Z^([
M#P;X<\+:CK,_ATV.I7]QHEEKFBWMW^8'AKPY_P`':?\`P4FL[+6?$OQ!^%'_
M``2X^#OB65K]]%L_#\'@?XD6FF++%%%:V^D&P^)?Q\T;4DA\^46FO^,_AV;R
M4N]U]EC%E&GW9I.A_"[_`()=_P#!<?\`:*_:`_:2:UT?X6_\%:-+^#_A+]GC
M]HC6-+,VA?#7X\>`=,C\.>+/V=/&_B:-)(?!8^*,46@^*O!6N:G]@T/6H='M
M=!N;T76@:A<0_P!-7^>G^?\`//2@#^2/X$?\&EO[.&K>*+SXO?\`!2+]I[]H
M;]OKXU:^]C?>)M0\0^./%/@WPOJ>HQR7#WPU75W\0^(OBKXEBFB-A:037/C_
M`$98X;2X8V!6[ABL/Q8\;_L[>(_AW_P08_X+*:/^RC\*?#6GWWA;_@LM\=OA
M-\3;GP7X3>?QUIW[)WPI\7_#6WT[P-IFM8U?QK>>#_!WB-?#=Y)H^K:WJ=MI
M?A34/&%]?2S"\U>[N_\`2#K^?'_@B9XHA\+?M-_\%R?V9;Y+:#Q!X'_X*H_%
MW]HL1&0KJ$OAK]JS1-$\3Z')-;9:-;(+X.GGL[J-]T_VZ6.:.)H$#`'\TOPH
M\>_M]_\`!9?X$_![_@E]_P`$ROV</$G[#7_!+'X8>$?"7@'X[?%_X@6=M:ZG
M\4/#J7VDWOBO6/$_C!-$BM-6\2^(/$EEXB\5ZK\.OA?J&J:KXTU_5KZ;XA^(
MO^$:OKJ.U_7/_@KY_P`&]WQ[^-.A?L1P_P#!,3XC^&_A3J/[.W[-WB3]A/QI
M%\2?&FK>'[W6OV:?%N@:GH%S?:AXCT+PQJQUBXO-,\3_`!$TKXD6-KHEOJ/B
MJW\=/<Z;;`VD]J?Z]?\`/^'_`-<T4`?PC_&G_@T?_:.\"?#SPK\//^"?_P"W
M+<?"GPM\7/@W\/?`/[=_@GQWXT^)VA^"?CCX\\'7%S?W?C33-$\$Z9J=OK/@
M^XO]6U2XT;X<^-%DA\.N)FL-<DCU_4;:S^;/!W_!-7_@YQUK]F/2_P#@CGIW
MA?X!_`3]C#PW9>)O"GB?XO:3JWP_L_#?Q$\)>)/%^I>.]=DUSQEHDOB?XIZ[
M9^(-9\17;3V6@>`/"NNZS;J^F>+H5@&JK)_HET?Y-`'\RO\`P2&_X(:?MD_\
M$VOC3X9\3?$C_@J=\8OCO^SGX$\&Z[H?A/\`92TQOB#X>^$!UK7]&ETB&\U+
MPGXH^)'C+PM8:1X5:\N]4T*Q\,>']%OKG7;;1=4N-2L[;3[G1]1_/O\`::_X
M-S_^"FGQ5_X*(_MJ_%WX#_MP^!OV?/V8_P!M+QC<>(?B'XUTO4O%TW[0,_@?
MQ(\>L:]\(&M]!\,:+JUQX&T_6Q-IZ^#(/B_H/@?Q+H6G>$KCQ%I^HWFAVUCI
MW]MU?GO_`,%2?V^?"/\`P32_8C^,G[6/B73K/Q%K'@_3;'0?AGX)O;J2RA\=
M_%;Q;>)HO@;PS<7$)%S!I/\`:,[ZYXINK3=>:?X.T3Q#J=I%-<64<,@!_+S^
MV?\`\$*O^"1O_!)K]FKX8?M$>(_VV_VH/V4?VE/AAX@N]9\(_M(?#OQ[%>?'
M;XS^-Y/#5M8:GX/^'WPRM7TRTM(&F^V7MK/X:NM&;P[IOB75K7XB^,=9\.7-
MJUEY9^SG\`_^"OG_``<%>`?`F@_'OXT?%_\`9F_X).Z%-:>'=2A^(%UHZ_M)
M_M7Z3H&IV?BJW\8^(;RP^'7A;3_B)?:K=S:;8V7B75-'T3X.>'QHMA<>'_"W
MCWQ1H&NZGKOW)_P30_X(R?%#]MGXJZ9_P5K_`."U+W'Q0^//Q%O]"^(GP%_9
M7U.YU#_A5OP4\%*;;6/!D?C'P-J37ELLL4*V5WHGPGGNKS0-$L]FH>/X?$'C
M?4M1L_#O]?:JB*J(JHB@*B*`JJJC"JJ@``*H```P`,`8%`'\I/\`P4"_X-3_
M`-BGXQ_LA^$/A7^PQX0\*?LS?M$_""];6_`WQ;UR\\0:U=?%.XNX+2#7M#^.
MGBW9K/BK6(M5DLH=7T#7+"VG7P'KB2IX8T"T\/:GJFBS_B=^UO\`L7_\'8G[
M*O[,4UIXF_;"^+'Q[^!'A&UB3Q=I_P"RK\9?$OCGX]Z)X26:WT^XD?7[[X>>
M"OCYXKL+:RG=[Z/1=?\`$]KINE6]S?ZY#8Z+9W=S#_HTT4`?YH'_``0$_P""
M'O\`P3%_X*$ZS\3_`!O\:OVI_%WQP\2^`;E([W]DF/1K[X#_`!$\.V][<G_B
MK?B3?#Q#XBUWQ;I;RYTR23X8:W;:1I.N`PZ[XHFFO+729?VK_8[_`.#.G]CK
MX0_$SQ!XW_:V^+_CC]KGPGH_B"_'P>^$LD%]\,_!6A^#9+_5+RQL/B3<Z)KU
M_P")?&>L0O?073IX7UGP!X9?4EU*YU#0]7AU,6UG^@O_``5A_P""'OA?]J[6
M;3]L;]B3Q$O[)7_!2+X4F?Q7X`^+7PY>'P-I'QBUNQNDU6/PU\99-`M[6;4=
M0UAX9=*L_'D[7&H0P7PTSQ9#XE\+Q1:79?5O_!&'_@H9XG_X*3?L6V7QA^)O
M@RT^'WQW^&'Q/\=_L[?M#^$=+CN(]$TOXQ?#!=&N-;GT1+EYI(+#6=`\2^&=
M>ET\7-Y%HNIZIJ&A17]]'IBW<P!\3_"O_@U,_P"",OPS\6ZEXKU#X%>/_BJE
MW/=S:;X7^*7QB\:ZGX3\.K=&8+;Z7I?A:[\(7%_#:Q2B&T;Q1?\`B*XB$%O<
MO/)?1_:S^8OB7_@V5_X*7^"-.\5?LF_LN?\`!6WQ'\.?^";7C'7]:EF^$/B'
M4?B3%XST'P=XNU&XN_%/A&7P[X5^Q>%_%EI>P3/%J]M!XP\#>'_&L]WJ-QKO
MAZSDO]0-]_;I10!_.1\+_P#@U4_X(T^!_`GPT\,>,?V>_$GQ;\3^!K:YD\1?
M$+Q9\8/BUHFN_$S6M0MK..^U#Q?IO@3QIX5\/QZ?!<V<<^AZ!H>F:5IND1F2
M,I>S7FIW6H?L!X;_`&"_V-?!G[-WC#]D'P;^S?\`"KPA^S9\0=`UOPUXX^$W
MA7PU;^'/#_BS3?$=LUIK4VOW.C-9:UJ>N7\+*9/$]UJDGB6.>&VNX-6BNK6V
MFB^MZ*`/YP/V>?\`@U3_`."0G[/_`,4M6^*-S\+_`(B_'<W-W?W7AWX>_M!>
M.;#QQ\+_``6E]+(T=II7A+1O"_A/_A)[;3K65M/L!\3M0\?3+`$O+J:[UE!J
MM?&/_!-O_@W7_:/_`."7_P#P6$M_VF?@=\:_!^L?L(ZOX9^-.@ZUX6O-=\1:
M;\6%\$^,M$O9/`?PI\4Z&FCRZ'XR'ACQW:^`/$(\5-K<%OJ:>"#K=WIVEZX]
MII]Q_8;10`4444`%%%%`'C/[0'[/7P8_:F^$WB_X'?'_`.'OA[XG?"_QSIDV
MF:_X8\16IEB82(PM]3TF^@>#4_#_`(ATF8K?:#XET*\T[7M!U.&WU+1]1LKZ
MWAN$_""\T3_@J'_P1WU?5=6\$6GQ!_X*G?\`!,S11)#HOPEM[X^(O^"A?[-V
MA7(MY+9?#FL:O;0-^TKX*\/7QN-,M='N]9G\;P:+?::MO;:%HWAG4-1O?Z1:
M3G_/ISZ?ACICOGI0!^-?[)/_``7O_P""9'[7_B.3X?>'/CL?@M\8;/R;?5?@
MQ^TYH5U\"OB!I>KNC_:O#O\`Q5LR>$=9U_39HI+:_P!+\->+-<GCN%VQ"92K
MU\1^$;B/]FS_`(.;-;\0Z5J&DWGP;_X*L_L-6>I^&-;\.:I87^@>(OCI^S';
MZ5#>QRR6MR\#:AIGPL\(7&HPW=KYEKJ*>-X7MWNKY]7>S_:K]JO_`()\_L5_
MMN>&=1\+_M1_LV?"OXMP:C:SVR^(-<\,VEEX\TKS[8VIN/#WQ$T0:7XZ\.WD
M<6SRKK1/$-C,C0P-N/DQ[?QC^#G_``;!_LI?LM_ME?LY?M=?LJ?'_P#:%^%]
MO\`?B-=^.(O@EXPUG3?BK\/=1TO5M%O?#_B+PMX6U'4H_#WBWP?'XBTF^DL-
M6UC5]9\=W=S9Y@>W;%NUL`?TQT4<_K^GZ?U_P*`"BBB@`K\<?^"Y?["?Q<_;
MX_8FL/!7[/:>$K_]H'X%_'?X3_M/_!;PS\0(M)G\">./&_PKN=9L7\&>+(/$
M`D\-W.E:[X7\6>)(H['Q-;W'AO4]2BL-,U[['I=Y=:E9?L=10!_*]\#/^#I_
M]D?PK/:_!3_@HW\(_CS^PA^TMX&CTWPM\4-#\7?"[7_%?PW7Q5I\<6FZ[JGA
M>^\'1ZUXUM?#+ZA#+J%HNK^"X[6UT>\L6T_7O$EKC5)OV5^&W_!6K_@F)\6M
M$M_$'@C]OC]E"YT^ZB@EBB\0?&[P)X&UA5N$9XDN/#OCG6?#?B"TF"JWFV]U
MID-Q;L`D\4;D*?K+XM?`3X'_`!\T1O#7QQ^#WPP^+^@-;7EFND_$OP+X9\;V
M4%O?QK'>1VD/B/3-16S-PJKYDMIY$NZ.-PX>-&7\H/B+_P`&XO\`P14^)VLS
MZ_X@_80\!:/JD\:QD_#OQY\9OA1I49CV;)8O#/PS^)'A/PNL^8T,DIT5FG^<
M7'G"20.`?>&I_P#!17_@G[HUC<:EJG[<G[(-G96L#W,T\G[27P=(6%"P9T2/
MQB\LIW(R*D2.[NI1%9QMK\_OCK_P<A?\$;?@&UW9ZQ^V+X:^(VNVT:R+H'P1
M\)^.?BW-=;H99@D/B'PCX=O?`T4B^6(IDOO%EH;>:6-+GR1O9.`\/_\`!KA_
MP1`T&5)I?V/=3\0R(\[@>(?VB/VE[NW?SBI$<MC:?%ZPL)TBVGREFM7SO8S&
M5@A3[^^$O_!)C_@F9\#+NQU+X6_L*?LP^&]6TVUAM++6IOA)X3\1:]!'`L"I
M,-=\4:?K6KR7Y^SQ/+J<MZ^HW$@>6>ZDEEE=P#^>3XB_\%XOVZ_^"J/V[]G?
M_@A9^Q[\8/#6K:J96\7?MF_M$Z;X.\(^"OA]X0VW6FWUWX>L;R]\2>"]/UN\
MFO+'4=&U75?%>M>+XX-.U*RT'X4ZUJK&_P!#_>S_`()&_P#!.72_^"8/['>A
M_L^2^-Y_BA\3/%'C7Q/\:/CW\3I5U"*#QY\:?'UOH]KXFUC3K;5+N]OH=*T[
M1_#WASPQI]S=RQWVMV^@+XDU2TL]6UJ_M(?TMT[3=/T>QM=,TFQLM+TRQ@CM
MK+3M.M8+*QL[:)=L5O:6EM'%;V\$:@+'%%&D:*`%4"KM`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
3%%%%`!1110`4444`%%%%`'__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>geron_def14a1x2x1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 geron_def14a1x2x1.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_
MVP!#`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_P``1"``S`-@#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#^_BBBB@`H
MHHH`****`"BBB@`HKP#X%_M0_`_]I34?C+I_P2\;6WCZ/X#?%*?X,_$76=(L
M=2;PS:?$.R\(^%/&VHZ'H?B:6TCT/Q3_`&5HWC/0X]4N_#M]J-K8:C+-87$J
M31KYGO\`0`445^<?_!2/]KKQU^SI\+-$^&?[->BV?Q!_;E_:3U*X^&W[)_PO
M:U_M5'\32"W/BKXP>-M.A6:6P^$'P.\.7-QX[^(7B"[MVTN**STOP_+(+SQ#
M9J0#]'**_FF_:>_9$\;Z9XT_X)37O[3_`,>_&_[2_P#P4.\8_MT_LT:C8>-?
M#MUJO@+X1>!O"'[/S:O\=_VCH_A'\#_"$WA_P9X>\&:U\,?`>K>'/'OB[Q7I
M&L^+/&%WKUC=7UYH^ER>'O!&@?TLT`%%%%`!6=K&L:3X>TG5->U_5-.T/0M$
MT^]U?6=:UB]MM,TG2-*TZVDO-0U/5-1O98+.PT^PM(9KJ]O;N:*VM;:*2>>6
M.)&85?$OB7P[X,\.>(/&'B_7=(\+^$_"FB:KXE\4>)O$&HVFCZ#X=\.Z%83Z
MIK6NZWJ^H36]AI>D:1IMK<ZAJ6HWL\%I8V5O/<W,T<,3NOY`?&/Q]J_Q'^'N
MH?MB_M"^#=<M_@OX-U[11^Q#^Q/K<XT3Q5^T-\=M1\0WW@_X$^*_C'I4.I2:
M7XA\0_&+QYJ?@VZ_9]^#7B&WO=)^%%M>:#\7/B1;VGQ,LX]*^#H!^F/P+_:/
M^`?[3OA;7/&_[.WQC^'/QM\'^&O&GB#X=:_XG^&7BW1O&.AZ3XW\+&S?6_#=
MYJ6B7=Y:Q:E:VFI:3JT$9E,>HZ!K6A^(M-DO-"UO2=0O/::^-/V%/V8]:_9=
M^"5YHOQ!U?PUXJ^/?Q?^(?C7]H/]IWQUX.M-0L/"OC?]H/XK7MOJ7CK5O"]E
MJH34;3PAHMO9:)X'\#VU]#;7L'@GPEX=AO;:"\2=!]ET`%13SPVL$US<RQP6
M]O%)///,ZQQ0PPH9)999'(6..-%9W=B%55+$@`FI:_%;]KGX\ZS\:?@MX^^+
M_A?P?+\4/V9O"E_8^!O@5\$T\S3IO^"C'[2/B?Q#X3\/_"?0]3A\2^'+&!_V
M4+/Q]J`TZ.?2]:NM,^.B6NO^,M6>/X)>$=.?XM`'ZU?#'XI_#KXT>#;'XB?"
MCQEH7Q`\":IJGBG1])\7>%[V/4_#VKWO@SQ5K7@GQ)_9&JP@VFJ65CXG\.ZQ
MIL.J:?+<:7J0LC?:7>7VG3VMW-W]?/W[*7P.@_9J_9N^"GP)COK;5[WX9_#O
MPYX<\1>(+6$V\7BKQI'8QW?COQB;<QQ>3/XQ\9W6N^*+J,11!;K5YL11#]VO
MS)_P4;_X*2_"S_@GK\/?"LNH^&]9^-/[1OQH\06?@#]E[]E;P'<[/B7\?OB5
MJVJ:7HFFZ!HTB:?JR^'?#MIJ6M::WB7QCJ.G75GI%I,L-C8ZWKUUI>@ZB`?H
MY7Q?^W?^UW#^QM\"V\=Z'X)G^+?QE\?>+O#OP?\`V;O@9IVJPZ+K/QM^//CR
M6XMO!'@"QU.>&Z72-/<6FH>(?%GB%[6Y@\,^#=!\0^(;F"2+33$_H?[)OAWX
MZ^&_@!\/8?VF_%\'C+X^:W87_C'XIW>G0V5OX>\.>*_&NKWWBF]^'?A".QMK
M2.3P;\,H]7A^'_A:]N8WU#5=%\.6>K:G--J%]<M7Q;\-['4?VL/^"E_Q>^+F
MOVOAW6/@7_P3RTA?V=O@0I6&_NY_VK?BKX4\+^.?VE?B$LD:M'!<^`OAGJ_P
MR^#WA^2>9[S2]1U[XN6L=O:?;FGN0#]3=&FU.XTC2KC6[*VT[6I]-L9M7T^R
MNS?V=AJ<MK$]_96E\T-NUY;6MV98(+MK>`W,4:3&&(OL4K2HH`P?%/BGPUX(
M\-Z[XQ\9:_HWA7PGX8TJ^USQ'XE\0ZE::/H6A:-IMN]UJ&JZMJE_-!9:?865
MM%)/<W=U-%##$C/(ZJ":_/S3_C1^TY^V%)H^H?LL6%K\`/V7];TK4+M?VI?B
MUX4EN_B_\2!%J,^FVDG[/?[/?B2&U;PQX6U!+:ZO-/\`B]^T/9:9)=1QV&J^
M$O@/\0?!.O:+XVN/D7]JOP5_P4H^-?[65E_PDW[&?PE^,_[#OP8UJ7Q'\)/A
MC8?MCP_#&;XU?$:PATK4/#'Q%_:5\+:U\*?%&C>,O"_@W6M.:Z^'?PFV6V@^
M&O$UX_CKQ7+\0M8T'P7'X;^L-%_:>_X**0PW,_C7_@EXD'E36Z6]I\-/VVO@
MCXUO[J"2Y2.XF5?'7AOX/6$36ULSW1BEU$&9HVMXW+LC,`97_!.[_@F'X#_8
M2O/BG\4];^*/Q/\`VB/VI?C_`'J7WQM^/WQ8\8^*O$>KZWI]GJ=[J?AWP-X8
MTK7]>UJ'P]X*\(&^FMM(B>:[UF\)>:^U%;)=,T?2/U`KX?\`V8/V\_AC^TW\
M4/C)\`D\"_%KX*_M$?L_:7X&UKXN_!/XS^&M(T;Q1X>T7XBVM_<^$_$.C:[X
M2\1^,?`OC+PUJYTN_CM-:\+>*M2B'E0O=PV?VNV623]N3]N_X)_L.?#*;Q!X
M^\4:+>_%WQI9:CH7[.?P$L[MK[XH_M$?%R[-MH_@?X8_#7P7I:W?B3Q#J?BC
MQGK'AOPU->Z?I\FGZ(^MV][J]Y86@:=0#SO]F?\`:G^-_P`??VZ?V]_A<GAC
MP4G[(W[*]U\&?A+\//B/IEMJP\5^-?VAM5\'/XU^/'AN^U"XU273+NQ^&46N
M>$O#U];6.AV":=JMW'"-6UB\DU6TT3](*_/C_@F#\#_&_P"SW^R)X.^'WQ(\
M$77@SQY<^(O&/CSQM>Z]XFTCQ-X[^(OCSXF:W-X]^(WQ5^)`\/6[^'_#/C'Q
M]\1/$'BO69/`^B^(?&]GX-\/OX?T"3QIKM[8W<D/+?#+_@K[_P`$_P#XO6GQ
M^\3>!_CI97_PI_9J\1>'_!/Q)^/%]X?\0:1\#KKXA>)+TZ=IWP[^'WQ&U33K
M72/B?XVDNI+".+1/`(\02:C_`&UHG]BRZI_:MF)`#]'-;US1/#.D:CX@\2:Q
MI7A_0=(M9;[5M;UO4+32=(TRR@&Z:\U'4K^:WL[*UA7YI;BYFBBC'+N!7Y(_
MM8?M(>#OBA\#_C/\4=5\<:SI'[#GPUBL_#-U>_#\7^D_$']M+XP_\)4_ANR^
M"'PN\4+,ET/@_P"*O&LGA3X7#5O"&G2:I\=/%'B/5_#WASQ7H?PWT'4M1^(_
MQ1)!XY_X.#/&FE:G9:IXH^&__!%/X<>,[?4["6S7Q%X1\:_\%-O&7@O7XK76
M-`\2Z/<:II&L>&?V4O"OB31=0MA;ZSH5GKWCCQ%8+<Q6UE?Z;97W@_\`172/
M!^@_M8_M.^#;7PN/"W_#%O\`P3XU^?P_X:\&:+H.F'PMX[_;1\%0:CX+AM-,
M%NT=C9^#OV,O#;W6@6&DV.GSZ4?CKXFEBA?2/$O[/\4<@![K^P)\`O$?[//[
M-7A+P[\0=$\)>&_B_P".M0UGXN_&GP]X!AM(/`7A/XF?$6X36-4^''P_BL(X
MK-/AO\&]&&@_!CX9B&,8^'GP\\+B9YK@2SR_9]%%`'Y5_P#!3?\`X*6VW[#N
MD?#;X2_![X9:O^TC^W1^TU?WWA?]E;]FOPV(RWB?6[2>RM=0\:_$O5CJ.F1^
M!_A/X9>^BDUKQ+>WEJMW-'+:6T]GI]CXB\0>'.1_X)[?\$]O$7[-7B/XD?MU
M?MM_%P_'+]O[XZ>"K1?C7\3M1N8;3X7?`?P)9;/$EU\"?@'I4^VW\)?"CP==
MPQ0ZGK.^TG\92Z!9^(=1L],RUH/T!T']ESX&^'?VBO'/[65IX'MK_P#:$\?^
M"?#WPTU3XFZ_J&J>(]?T3X;^&97O;+X>^!'UR]O[?X>^"K[6I9?$OB#PSX+A
MT/2/$OBF0^(]>M=0UA8[M/@3]O']H3PK\7OB9:_\$XOAM;_$KXI?$/6M!TOX
MG?M/_#OX&&TM/%6E_`FVO+&]T3X4^,O'GB*72/AW\-=(_:4U,0^%/%ESXQ\6
M:-=7WP-A^)6GZ+;S>)?%7@A-1`/3?V--3U[]K+XE>*?V_O%$&EK\*M<T;6OA
MA^P7IL-IJ5OJ7_#->I:KHNI>+/COK\.KQ6]S:^(?VG?%?A/0/$OAJT6SL7TC
MX*>%/A@EQ;6NNZ_XMAF_2^OR/_91_:)_;%\7_MS?$+]F[XN^$_V8/`WPI^$G
M[+/A#QYX@^%GP"O_`!9XXUOX">/_`(@^-[72_@U\-_'/Q6UNU\&>'_$NI:Y\
M,?"?Q!\1IH?A+X3>"=/T/2++PY=J=0T_5])O+O\`0+]H7]H#X>_LS_#+4_BC
M\1Y]9?3(-1TGPWX>T'PSH.L>*/%OCGQWXHO$TCP1\/?!WA[0K*_U'6/%WCCQ
M%<6/AOPUI\<"QW6KZA:13W%O$[S(`>W45P_PR\0^+O%WPY\!^*O'W@.X^%OC
MCQ'X0\.ZYXO^&MWX@TOQ9=>`/$NJZ3:7NM^#;GQ/HB1Z-XAG\-ZC/<:1-K.E
M(FGZE):-=VBK!*@'R3_P41_;.TG]B7X`6GC2VL8O$?Q=^+WQ(\"_LX_LU>!9
M"RKX[_:%^,>I2>'_`(>:1>NA5H/#NC2)J'C/QE=(RSP>$/#&N?V>L^JOI]G<
M@'%?%[QUX:_:)^*_CCX:>(=<\(:9^QY^R6^E^.?VM?%_B*ZEL])\5?%OPD-$
M^)?@SX*WFHWR1^%Y/AK\/=&AL?BG\?I[J\D2>_B^'OPVO(KW1-5^*.E6=;X&
M>!/$/[7OQ0\%_MI_&WPQJWA7X<?#RYUJ[_8;^!'B?2[*QU'PSH7B#1%T*X_:
ME^)NG17-U+%\6?B=X>NM1M?AIX.U-+>Z^"OPIU=8-1L-/^)GC;QO8>'OD_5K
M#X1^'-$\,?L1>/\`XL>#_$/[,'[)3Z+\9/\`@IK^TK\8?%_ACPOHOQ"^.GB?
MQ';?&3PQ\'_B(FL16_A2]U7X\?$[Q+/\?/C7H5UJ4]CI?@)/"?PUU?2]0L/C
M'8R6WW_#^V59?%/PD=4_8[^%GC7]I*;5+1H_"/C--.N_A1^S[+-/9PSZ3K=_
M\8_B%8:1;^)/`;FXB-WKGP/\-?&35$ACGCL/#][<((J`/MMW2-'DD98XXU9W
MD=@J(B@LS,S$!55069F(``R3@&O@C]JG_@H]^SO^RK>7_A#49/%WQF^,ECX;
M\0>+[GX'?`K1['QMX]T'PKX:TJXU?5O%_P`2]0O-6T+X?_!'P-:VMNX_X3CX
MV>-/A]X7NI5EM],U+4+NWGMD_`3XX?%/_@HI_P`%HOC/^T+^P;\!O'6J_`/]
MCCX7^(/!OP,_:$_:Q^#GA#Q!X9\*?$OQ7H_B&74/VG_#_@;XE:[XS@\2W^F>
M&].L)/@;H_PU\.:?KUC\2;O7-9\5?$W5?"/@DCPQ=_H]^V'_`,$Q=3B_9<\+
M_L%_\$_?AGX+^!OP=_:I^*&E^%/V]/CWI^KVI^-%I\`H],N=5^(7B>X\0^)+
MZ;Q=\8?BG\5$TR'X;7.O^*=4\5WEC8>*;Y[_`$R31)[N[TD`[?X(_M<>)?\`
M@KA\,_!5M\$_#WCCX%_LV>+/AQI.H_M7>.M=-[H/Q-MM6\?>$=%\01?LN?!S
M59_#O]E7VJ77A3Q&Q^-/QN\+ZE;W'PUL;ZP\(?#N^MOBQ?:SKGPG\53]MOX"
M_$WX0^+?^"K&@Z.GQ$_8:_8W\/>(/!7[`?PP\&>%+_P[XF^,/QT62?X.>*/'
MWA?P;J]O8&VO[_6;V']FK]F_1HM`L-7T?2M7^+OB!]%N[;QEX4CT[Z)_:RTW
MQQ^S/^R3X0_X)Y_\$Q_AK:M\=?&W@)/A5\+()8]3E\(?L]?##79+W0_'?[37
MQ>\9M-;VUCJ.C)=>)O$WAJ?Q)J\GBOXR?%Y+P:3I?C*^M?%\-O\`(;?\$[/V
MQ;G]G'PGX&^%_P`-O@9\"?\`A@OP3?>$?^":_P``?$GQ'O/%G@W7?CU:6Q\%
MZ9^W5^TUXF\+>%;C0+KQUX;T"_\`$_CWX-?#73/"GB$>'?'_`(M\3>)?'GB7
M5-?U;2_^$3`/TE_:!_;[TSX#?"SP);ZYX7T6#]JKXB?!N3XGK\#-4\8Z9IWA
MKX2Z?I/A%==^(/Q$^.OQ(U)M)TOX?_`;X3:DMWI_BKQ_?P1:UXIN[2'PG\,O
M"OC#XB:YH?A"]_$;_@G[X?\`CA^W!\9]<_X*9:!X<\)>.(]7\6_$70_@W^UE
M^U)\.X/`_P`*_AC\//#>GQ>"K[XN?`KX"V/C"\^+GQ"UKQ&?#^HZ1\.M"\5>
M/O@I\,O@O\&_$6O75C\4/B7\<O'_`.T7JGC;]A?@%_P2A_9_\#_LL>,?V?OV
MDY-<_;&\8_'[3_`=W^U[\:?CAK.M:WX[_:-\5^`[C2-3\-MXGUF/4H=7LO!'
M@S4-&L;3P)X,MM2-CI6C6A769M?US6O%6MZ_^B]_\//!]]\/+_X5)HL.D>`K
M_P`'7G@'_A'_``W+<^&(-.\)WNC2^'WTK0[C0)M.O-`2WTF5K73KC1KBQN],
MVPRZ?/;3PQ2(`?A_^S[_`,%#/C+^UO\`LR?"/P#\)?'?@CQ3^T!\0O"_B/X@
M_M$?M+^&=$CT_P"$/[*G[-VH^/O%X\/>.==CTS5-:TO3_P!IWQ-\%[?0=4^%
M/P5GO-1>+Q6]SX\^(,.E_#G22=>^[O\`@ESX"\(^#/V)_A#KW@WP=JO@32OC
M1;:Q^T!'X;\0W.HWOBG3]/\`C'JMQXR\)67C"^U:\U'4K_QAI7@"_P#".A^)
MM0U#4]5O]1UG2KR^O]9UJ^N+G5[WBOVD?@_^SY^PE_P2H_:G^&OP-\$>%?@?
M\(OAU^R?\<-.T'2O"VGQZ796>JZK\-->T:TU_6K^%1?:IK^JZU>65WXA\7:U
M=76K7]W)/J^LZE+();@?>7PK^(/PK^(OAA[WX.>)_"?BOP5X7U6_\!P:AX%N
M;*_\)6.I>$O)TS4O#^BZAI0;1;F+PY,@T6[CT:>XL=+U&RO-$D>'4-+O;.U`
M/2:***`"O%_C_P#M`?"S]F7X8:Y\6OB]XFL_#GAC29+/3-.MWEB?7/&/B[6I
MQ8>$_A]X'T=I$O/%7C_QMK4EMH'@_P`)Z2EQJVO:S>6]E96[L[,GM%?D-\(_
MV+_C)\:/V\/BS^VQ^W/!I>J:+\&O'7BCX<_\$ZOV?EU71?%'@+X2_#73&M-+
MNOVG]8TRS%[I[_'WXQR65]J>C:G?W4^O_#CP+K">&VBTG5I'T_0P#I?V2?V'
M-:ND_:L_:._:\M8KC]IC_@H/H-EX;^,OAOP?XD\1:5I/P;^`.D^$]0\'_"K]
MG'P?KNCZEI]Y:Z[\/_"&N:I-X\^)'A>;2-1\3_%36_$GB/1;V#3;/PTUIX?^
MR]^Q!^QKX=_:QL?"/[*WP@^$_@[X/_\`!/J>WT3X@:M:>"(/$?Q)^(/[7WBC
MP!92>$+#QC\:_%/]L>-?&9^`7P1\;1Z]=VVM:[JT]GXQ^+'@BXL[VRU'P!]D
ML_W$%?)G[&7[,FM_LI?";6_`'BCXS^*/CUXK\6_%;XG_`!@\5_$+Q5X;\,>$
MY[OQ-\5?%-WXLUS3])T/PS;`VNAV>HWD[V)\0ZUXL\1O)<7)O?$EU:"PL=.`
M/Q4_X*0_LR_\%K/VQ_VI/%/[-/AS4?@1;?\`!*[XC^'K*3Q1:Z5XZO\`X6>*
M?$&C6FBHUQ\/?BWX]TCP]XB^-<L7B#QUIAO/%/ACX-Z5X?TKQ+\.]0M?",_Q
M*\/RZOKM_I/MFN_\$3V_X94\$_`+PA\9M&\.^/;J/X??#?Q]\4=*\"0Z#X>^
M$G[.>GV>IV/Q7^&O[%7PMAO-8TWX"^)/B5X?O)/`^H_%:\\0>)/C/XBTG6-2
M\1_$[XJ_$/7K#3;=_P!\J*`/S#_:N^,GPD_X)[_LY_`S]G'X/ZCI_P`";SQY
M/X<_9Q_9UC\->"+KQY%\*?#VC:3;66I>.].\`VMEK.H^-Y_`/A]+.#P]X<73
M/$&I^/OBGXB\`>$;FPU6\\92,\?P7\"_M+>(OAE\+/A]\"-#_P"&!OV<O`=K
M)X>A@^)G@[PW\3/VMOB)X;TF*2QT[Q&-&DUO5/AE\(-7\8SA?&&M>)?B;!\8
M_B=XDO-2U"3QUX!\!^+I]0E;[''[,?P+;]H.Y_:IO/A]IVK_`!]D\#:?\-M.
M^(FOZAK?B&^\*^"M/O+^_?1/`.E:YJ=_X>^':ZW=ZA)-XNOO`VD>'M2\:&UT
MI/%MYK4>BZ0ME[S0!^<&H?\`!*/]C3Q?>ZKKGQD\,?$[]H?Q9KTE[+K7BSX\
M_'CXS?$+4+I[^)89X].T6[\;VG@KPG80Q)''INC>"?"OAK1-&CBACT;3;"."
M%$\Z_9(_8\^-7['G[6_QE\!?!K5[?1_^"<7B?PGX+^,7A[PEXY\7>-OB9X\T
M7]H7Q3%XM\"^/?AG\+]6\9>+/$&I>$/A1HNC^!?`_P`4]<MM1;[.?%7CRVT?
MP;%)8R>*UT?]9**`"O/?#WPP\!>`M4^(?BOX?^`/!GAWQE\3=8/BSQUK>EZ/
M8Z%J/C[Q;;:/9:)I^K>,M<T_3YM2U6ZATS2],TI+^\34)[+3[6..V@98Q"WH
M5%`'PQ^PO^RGKW[.7A3XH>._BWJ/AKQ/^U1^U)\3M3^.7[4/C/P=>Z]J/@R]
M\>7MC:>'?#'@CX=W'B>RTWQ!%\+_`(2?#S1O#'PX\!0:IIVF7EYINA3^(]0T
MO3]8\0ZI;C[GHHH`*_)?XO?L3_&3]H;_`(*P_LZ?M-?%C5?"5]^QQ^Q?\#?$
M/B3X#?#MBE[K.M_MC_%35=<\*>*/'GB71I8GM)K'X<?#'3-!O/!.JZB);C0_
M%FK6FI>$Q:ZC#K]W'^M%%`'QCX,_X)W_`+$'@/XJ^//CKHO[,'P>O_C5\2_B
M!XC^)_BWXM>+_!VF>//B-<>,O%4_G:U?Z1XQ\;1:_KWA:PG5+>UM]!\+7NC:
M%8V-I96-GIL-K9VT47V:````,`<``8``X``],=/Z4M%`%6SLK+3H/LNGV=K8
MVPEN)Q;V=O%;0">\N);N[F$4*)'YMU=SSW5S)MWS7$TL\I:21V;Y6_;;_:V^
M'O[$W[/'BOXZ_$/4[*R@L]2\,^"_!UA=K/.WB/XB^/\`7;+PKX*T&WL+(_VI
MJ8FUC48]0U2ST>*XU8:!INL75A:W$]JL3?6=>3_%7X$_!SXY/\-V^,/PW\)?
M$E?A#\3="^,WPT@\8Z1;:W9^#OBKX7TG7]$\->/=)L;U9+-?$?A[3_%&N#1+
M^>"=]*O+Q=3L1!J=I8WEL`<=^SOX#U_1M'\0_%+XC:==:9\9/CA>Z;XS^(.C
MW6NS^(8O`=C;:>+/P1\(M#O72&S@T+X9^'I!IUY'HMI8Z-KOC[4/'OCV&RAO
M_&NI-)]$T44`%%%%`'/>+O"/A/Q_X6\1^!O'GACP]XV\$^,-$U3PSXN\'>+M
M%TWQ)X6\4^&];LIM.UKP_P"(_#VLVU[I.MZ)J^GW%Q8:II.IVEU8:A93S6MW
M;S02O&TWAOPSX<\':%IGA?PAX?T3PKX:T2U6QT;P[X;TJPT/0M(LD+,EIIFD
M:9!:Z?86J,S,EO:V\42EF*H"QSMT4`%%%%`!1110`4444`%%%%`!1110`444
H4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`?_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>geron_def14a5x11x1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 geron_def14a5x11x1.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_
MVP!#`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_P``1"``Z`/4#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#^_BBBB@`H
MHHH`****`"BBB@`HHKY(TK]N?]F#7_VO]1_83\.?$NU\2_M,Z#\,=8^+?BGP
M+X<TK6=<L_!OA'1=6\,Z-=)XR\4Z987/AGPQXADN/%_A^>W\,ZQJMIK;V.IV
M%V]G%'J6E?;@#ZWHHHH`**J:AJ%AI-A>ZKJM[::9IFF6ESJ&I:EJ%S#9V&GV
M%G"]S>7M[>7+QV]I:6EO')/<W,\D<,$,;RRNB(S#\`?!GQ2_;&_X*M?M+>._
M%W[*O[54OP,_X(^>$?#]W\(/^%J?"CPGI&G_`!Z_:I^,OAOQ#9W7Q'\1?L^?
M$WQ5X=U#5O`OPP\/WL-S\+'^,^A(EIJXTSQG#\,=+U77]0T;XL_#D`_?;3];
MT75KC5[32M7TO4[OP_J(T?7K;3[^TO;C1-6:PLM4&EZO#;2R2:;J)TS4].U$
M65XL-R;#4+*\$7V>[@DDTZ_G[_X(W_LS_"CX+_M@_P#!8KQU^S/X=?PA^RWK
MW[0GP#_9^^'^BQ:AK^I:7J?Q=_9=^$%_I7[4'B^QU#Q-K&K:QK5_?_&3XE:M
MX/\`%OB2XDF_MOQKX#\123:IJ.HVVH1V/]`E`!1110`5SGC#QAX3^'WA7Q%X
MY\=^)=!\&>"_".C:AXB\5>+/%&K6.A>'/#F@Z3;27NJ:SK>LZG/;:?I>F:?:
M0RW-Y>WEQ#;V\,;R2R*JDU;\1>(O#_A#P_KOBSQ9KNC^%_"OA?1]3\1>)O$W
MB+4[+1/#_AWP_HEE/J6LZ[KNLZE/;:=I&CZ1IUM<ZAJ>IZA<V]E865O/=74\
M4$4DB_C?\8O%`\?>#]4_;<_;GT*]\-?LF?"[4_!OBS]D3]B^[MY)_%WQA^)F
MH:MI]K\$?B+\>/"4EJEQXB^-_P`0/'FL^%])_9V_9GU%+[1?A1XFU/P]XP^(
MFFWGQML-*3X/`'Z#?LT_MH?LT?M@-\3D_9U^)0^(,OP;\5Z=X*^)%O)X0\>^
M#KGPYXAUC0K/Q1HT/V7Q[X6\+W&KZ;K7AW4++6M%\0Z#%JGA[5].N8KK3=5N
MHFW5]15^>/\`P3C_`&6/'G[/'PP^)'Q$^/DVBWW[6O[7?Q<\2_M,?M0W/AN]
MDU+PKX;\=^+K;3])\+?!_P`#7TS2377@+X%_#?1/"7PL\.WLD]PVO3^'=6\6
MO*9_$DR)^AU`!117Q?\`M(?M%^+]&\5VG[,?[,NG^'_&/[7/CCP=)XNTR'Q1
M;ZM=?#'X!_#N[U*Y\/1?';X\7>BJMQ!X;75[35;+X:?#2TU#2O&/QY\6^']:
M\,>%;S0O"_ACXF_$CX;@':ZU^V9^R_H'[3G@O]C._P#C+X4D_:A\?:!X@\5:
M!\&=)_M37_%MMX=\,Z`/%&IZQXL70=.U+3?`%C-H.=0T*7QYJ'AL>*8U>+PP
M-8N(WA7Z;K\0/^"?O[+=C=_MA?';]J.^EU;Q;X7^"&C^)_V0/A%\4/&D&BCQ
MU\>_C@GC*WU'_@H%^UIXPBT32=-T2#Q'X_\`B[X&\!_L[Z'_`&%:Z/I?ACPS
M^S;K'A#PAX?\.?#M_#FC1_M_0`45^"-[_P`%&+__`(*.?MDZ=^Q1_P`$YO&G
MB)_A)^S?\2O"OCS]OG]M?P4UD?`VC^'O!>MS:IHO[+?P7UNZL[J#QIXO^.?B
MK0)?#7C#QUHMU;:)X>^&NA^.)_"UQXQ>^EGTG]N_B-\0O!GPE\`>-?BC\1?$
M&G>$_`/P[\*Z]XU\9^)M7N([33-!\,>&=,N=8UO5KZXE98XK>QTZSN+B0ELD
M)M4%F4$`^$_C'^V;\2(OV]?V?OV%/V;_`(>:!\0-?GT.3X[?MG_$'Q//?Q^%
M/V>/V:9K7Q3H/@JWM)=+U&PDNOC3\8_B+I4.F_#[094UA++P[H'B'7]=\.G0
M+R/Q-H'Z/U^5O_!)ZV\2?%/X/_$?]O;XA^%8/"_C_P#X*(?$<_M$:!IMP+>3
MQ!X>_9AMM`TSP;^QYX*UVXM+BYL_MVG?`?1O#OC?5K.QE%K!XR^(WC&[:*"^
MU"^B3]4J`"BBB@`KYY_:'_:B^$7[,>B>'-0^).J:U>^)/'FL2^&?A;\+?`7A
MO6?'_P`7_B[XLAM3>R^&?AE\-O"]K?\`B7Q5?V5D#J.NW]O9Q>'O".BK/XC\
M9:UX>\.6E[J]OPW[<?[0'QO_`&;/@#K?Q$_9T_95^('[8WQ?EU6Q\.^$/@[X
M`UGP_P"'&>]U*SU*Z/BCQ?X@U^[B&D^"]$&G"/4YM(L-;UNZU"_TC3+/38H;
MZZU?2_QY_98^.OC_`."FNZI^T1^T'_P3R_X*T?M(_MG?%/19M'^(OQHU#X`_
M`S3O#_PZ\'+K]YJ5G\#?V?\`X91_M<:_I'P:^">@WJ17\6B^&KS7/%OQ'ODL
M/&7Q5\7^-/%$=BVB`'IW[;W[.'_!6#_@HIX3;X=>%OB:/^"='P&\9^+]$\+:
MQX:\%?$71=3_`&D&^%$TS7OQ`\>_&'QMX#TSQ;X>.LZCHEK+X'\%_LV?`[XC
MZ=H%]J?B5_&/Q0_:4UWPOHUQ\+-9_7W]EW]F[X9_L@?L^?";]F;X.6^NV_PS
M^#7A"Q\&^$QXGUR[\2>(KBQM))KFXO\`6M:O`CWNIZGJ%U>:C>?9K>QTRWFN
MGM-(TS2]*@LM.M?S[\6_\%J/V:/@]!!J_P"U)\#OVZ?V0?!,@@2\^*/[0?['
MOQ8TWX3Z+=W9N([#3]=^)/PXT_XD^$-)OK^Z@2RM8+S58P]U=V:N\<<XE'ZF
M_#SXA>!_BUX#\'?%#X9^*M#\<_#SX@^&]&\8>"?&/AJ_@U30/$WACQ!80:GH
MVMZ1J%NS0W5CJ%A<PW,$JG)1PKJKAE`!V-?FW_P3!_;K\3_\%#_@W\7OC[>_
M"RV^&OPSL/VG_C)\*OV>=4M=<;Q$OQ<^"7PON]&\*Z9\7IM1BB33$N/$WCNS
M^(&E-8:-+=:;8P>'K>.WO=15AJ=]PW_!87]M[1/V-OV6$T'2_$<^C?'?]K+Q
M?IO[*_[.D6DZ9K'B3Q'I_P`0?BK#-H=[\1M,\(^&+74?%?B5/A1X?NK[QC:Z
M+X?TR[OO$_B^V\&_#^S>VU?QMI$A^T_V1?A?X0^"O[+_`,`OA/X"^%FM_!'P
M?X!^%'@KPWH7PG\3WGAG4O%?@2UT_1+1'T'Q=JO@S5==\+:OXOM[@S2>*]8T
M+6M7T_5_$,NI:E#J5\+HW,@!]%45\[_"_P#:W_9C^-GC+XU_#_X1?';X8_$C
MQ9^SC-X>MOCIIO@WQ9I>OP_"ZZ\46_B*YT:T\6ZMI\\VC:=>31^$?$Z7EH=0
M>YTBYT'5;+6(K"\LYH%_#?X\_M;?&[_@LGX^^)/[#_\`P2H^-%A\,?V9?AU>
MZ;X6_;<_X*.>'Y+J^E2/7Q.-1_9__9#>U6`>*?'VIZ%'=77B?XIV6I:?X?\`
M#VF2VZZ#X@C?4M(U#7`#]5_C/\<?B5\7/%OC3]F[]D77;+PUXF\$WNG:5^T9
M^U-J^F:=K'P__9DL=0TRT\07OA'PE9:N)=&^)G[4.H>$]0L-9T/P-<6UYX%^
M$>A:UI/Q(^.-Y##J'PY^%WQC^1O^"1/[-/A/2[OXR?MO:%H5]HG@S]H>Q\*?
M#S]DO2=>"77B>T_8X^'-YKFN>&?BWXIUF6&/5=>^(/[:/Q6\7?$/]KGX@^)_
M$$MYXG\41?$?P3>>*;LZ]97MK:9?Q?\`A)X:UCPQX&_X(@_LBW'BKPG\/H_A
M7I7B#]MKXR6VKZIJ_BKX6_LO>,?$6JIK_A:^\?W"7']J?M6?MRZ[:^/=*CU+
M67EU?3?`MQ\:/C3?VL.J6G@.U\0_MAH&@Z+X5T+1?#'AO2[+1/#OAS2=-T'0
M=%TVWCM-.TC1='LX=/TO2]/M8@L5M96%C;P6EK;QJL<,$4<:`*H%`&M6'XG\
M3^'/!7AS7_&/C#7M'\*^$_"NC:GXB\3>)O$.I6>C:#X>T#1K.;4=7UK6M7U"
M:WL-,TK2["WGO=0O[V>&UM+6&6>>6.*-F&Y7P]^WU^PKX&_X*'_!S0OV>OBW
M\1_BKX+^#$WQ%\.>,?BSX/\`A5X@LO"EQ\;O"?AJUU::W^$WC/Q$VF7VMZ=X
M$U7Q)<:#X@UY?#%UI&M7W_".6UC;ZI8FX%[:@'X/?%#X@?%'_@Y$^)$/P4_9
M8\??$#X/?\$9/A3XJDT3]J_X_P!I97_@'QQ^V_XUTUTU&?X)_!&WOH'\0CX5
M:-8G1H_%GB#Q/9>&;&:]\17E_J?ASQ'-X=\)Z/JO[0_M-_%CP_\`L'?L_P#P
M>_9J_8]^&/@YOCO\3T3]GK]A3]GC3;.6P\&Q>)-%\-7%_<^+_&%OIA-]HGP,
M^!OA2RNOB1\:/%Y,EU%H.G+I5M<:CXZ\9>&=-UGZ[\%>"O@9^R/\"-,\'>"]
M&\%?`[]GWX#>`+MK2PMFM?#O@GX>^`/!^F76K:QJNI7]Y,L5M8Z?86VH:[XD
M\0ZQ>37E[<'4]>UW4;J^N;V]E_#_`.#/[8%G^T#\<?B1^W?\#_V=OB/^TAXQ
M_P"%6/\`#KX5^)?&?C;P?\%_V6/V/OV<-.73O'7B?1_B/\:_$#Z[96?Q^^->
MOQ:?\3/COX7^$'@/XW?$7X3>$]&^$/P<^,>D_#KQ/\,O%%A>@'[5_LN_`+P[
M^R]\`/A=\"?#-S)JEOX"\.>1KOB6YB\K4O'7CW7K^]\4_$WXE:ZH=U;Q-\3O
MB-KGBGX@^*)E;9/XA\2ZG.BHDBHOO=?)W["7[1/BG]KC]CC]FO\`:>\:?#=O
MA'XC^//PA\'?%*\^'O\`:T^N1>'[?QAID6KZ4;/5KK3=(N;[3M6TBXL-<TR6
MXTZVG&GZG:QRB1T::3MOC-^TI\*O@3XH^!?@;QQJUT_CG]H_XJ67PB^$7@K0
MK>'5/%/BCQ"^DZEXD\1:Q!HWVJWND\'>`?"FCZEXJ\?^)PKV'AG1;>%KDR7^
MI:18:@`>]T45\"_M^?M>W_[,_@_X7_#CX76>E>)OVL?VN/B/;?L__LI>"M6E
M1M)/Q"UG3;O4-=^*_CJTB9M2;X0?`?PM;7WQ*^)T^FV\MU>Z=IFF>#[&6TUS
MQCHLX`.$^,6AG]M?XY77PMUS4]/L?V)_V3_%=AK_`.T@+C5[1=+_`&C/CWH6
MDZ1XV\+_``&\2VK@V-S\`_@II>JZ'\2OCI!JT[:-\0OB+<^!OA7?)<Z#X!^-
M?AG4>.^$_@[Q'_P4"_:!^'W[9WQ+TV[TS]COX(21^*?V"?A+KZ/#>?%?XB:K
MINIZ/J'[<?Q1\*S1SV$-I#X?OY],_8VT>\NKO5-$\&>(]>^-VK66@^+O&OA'
M2_!?CB?LVR^/],\._P#!)_X9^*/%8_9U^!FA>"/&7_!1WX^7MW':>.OVF/%?
MQ9N]?^)7BC]G[^UM+U&'5=(\>_M+ZY=W'QL_:M\3Z>;*/0_A#\2=#\`^$"C?
M%V.^\$??/Q<_;F_9R^"GB0?!W0]4U/XQ_'BT%KI>E?LQ_LXZ`WQ5^,=I,UG;
M3Z5;>)_"OA9VT;X->')M/EBN+?QK\:M;^&?PZM-/BFN+GQ3;6UM(R`'VA7A_
M[0?[2OP#_91^'&H?%O\`:.^+7@CX.?#O3IXK%O$GC?6K?2XM1U:XBFELO#WA
MW3\RZMXI\4ZFEO.-'\*^&K#5O$>L21/#I>EW<RF.OYS/V[_^"S/[5/BG]J:X
M_P""27[#OPT\#^"?VZ_'GPB:]UCQWJ7CN\^(L/P)\;^-UT:^\.>&K2+0/AEK
M/@Z3QK\/?AKK$_QA^+NO^*)Y?AQX&\':??KX6UKXD>,K70_"OB7W_7OV)_BA
M_P`$]_V5I_VN/%7_``T?_P`%D_\`@IC\)?AYX4^'_P`$M2^*.K7_`(ZT[P7\
M1/'6J^'?`%KJWPB^%[30Z=X$\':)KFLVWBCXG_%&>'Q'\;M5\$:7XDU#Q-\1
M[71'O_[(`/JCPA_P6<_9L^,\?BWP3^SQX,^,_P`0OVD[7XEZU\&?AS^S5X[^
M''B'X$_$SQ_X]T3P#H'Q'U?7M2T;XJV>@ZW\-?@UX*\*>*_#?B#XF?%+Q_H6
MBP^$M*U?2;#3]`\2>-O%?@#P9XQ\YU_QKXV^`VG:A^R!X`^+G@;XI?\`!8S]
MM^WA^)?Q.\4^&]+630/@EX7OK?3_``9XC_:`U;0;B1M2\%?LX?LQ^`M-E\'_
M`+.7AGQ43J?Q:^)6E^$_#][;7WB[XE?$CQ3:9G_!+K_@GSI7_!)S]GSX^_M-
M_ML_';0/B;^TW\4;GQ[^T+^U[^TAK?FVWA+P-IUX)/'?CWP]X1OKVVM[U?"M
MIJ=G=>(O%WB5-(T;5_B'J6G>'DU#1;?1?!7P]\.>&OA#]E;Q=^UC\:?VK/C9
M_P`%)/AQ^P]\7=-_:&_X*"_"/2/A-^QKXN^+VFZ;X9_9T_9._8D^'^IVMMH/
MQ)_:/\3W.J6WC6[^('QK\9Z-8_':#X'>!O"&OZOXC\*P?#_3]#U[3=%UC6/&
MMD`?N'^Q9\9OV<;'5?C1^PQ^S_I?Q%BT#_@G%I/P;^#OCKQ_XSLXI/"&M^*/
M$W@2\\57&C6/Q!OM5?6O'WQ(\-Z+9:=XF^-_B+6-%TR-_$?CW2]2_M?7M3U7
M6VTS\5?^"MW_``5NL/'/PE\)?!W]E+Q#IMSX(_:4\:ZG\&?`?Q"OM#^*FM7G
M[77BJSU.TT#7_AY^S_X(^$.E:G\9/&7[/>C:K<W&G?'?XU>"O#]Q<_%6SLIO
MV;OV5HO'/Q'^)=_\1_@]Z;\!_P#@G)_P4.\8^-/B=^S+\;?C--\'O^"=/A_Q
M+!-\5[OP]:>#I/VH/^"H_P`4O&MQ/\1?VDOC-\0?B+X.US4=2^!?P@^//C?Q
M9J?@;5O`=IJ;^,+3X+>&--^$^CZ5X.7/C2+]2O`G_!+C]DKP%^VSXH_;WMO"
MVJ^(?C;??#KX>_";X7Z3XGF\/7WPR_9H^'OP[\&VW@>Q\,?LU^"K#PUID?PO
MT_7-*@GGUU(=1U5DNM6UV#P\V@:1K>IZ7<@'Y<?!M_VAO^"9/@/]A#X"?LR?
MLI>!/!/P8_:`_;`^%GPM^.7Q(_:=\2V-M^UK\>_%GQ.M-;\9?&CXS:;\'?@A
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MFFC@?BSH'A'1_P!O[_@F'^SSX-\->'_"7@'X4?"G]M7]HSPMX/\`#-A;:!X8
M\+7OPJ\$?!K]F3PA9Z+X8T:*QTG3XH/"W[7OC^STIHX/L>FV,>J6<%CYM_%=
M60!^DOA3POH7@CPMX:\%^%[!-*\,^$-`T;POX=TR.2::/3="T#3K;2=(L(Y;
MB2:XE2ST^TM[=9)Y99G6,-+([EF._110`4444`%%%?#7_!1/]NGP)_P3Q_9A
M\3_M!>+_``YK/Q"\23ZWX?\`AO\`!;X.>%VF'C#XX_'/QY<3:=\.?A/X3%MI
M^K72ZIXDOX+FZO;JUTG5KK2_#NE:YK%KI&KW&GQZ9=@'G?\`P4Y_:.U+X7?!
M$_L^?"7P'I/QM_:T_;*T_P`8?`K]F_X%:I+'_8_B74-<\-W5GX^^)/Q*RDW]
MD_`SX,^$-2N?&7Q5UZ[BCL9+%-*\'QW=MK7C#1F;S?P!_P`$X/CO\(?V#_V,
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M_P""@GB/Q/\`&+XZ:KH,.N_LQ_LV?&+]I3XD:C\7O'WC?P_X2UV>R^,_[16C
M+J>EZ3X+^&=I\0/&%A+\)_ACI/P8\*>!_"W_``J'X>W?B>"/68/C'J4P_'_]
MH+_@J-_P49_X*S>//B__`,$X?A!^P%^U_P#L;>&+.22R^+'B#PQK%I9_M#>+
MO!M[+9#3?ASXO\:^.-#^'?PG_9(T7Q[X8\4:%XA^)&N:UKOQ>\0Z=X3BN?#?
MA/PS\1W\6V^G7?\`8W\!OA[9_"3X&_!KX5Z?HD7AJQ^&OPJ^'O@&T\.P:Y+X
MGBT*W\(>$M(\/Q:1'XFGT[1Y_$:Z<FGBT&OSZ3I<^L^3_:,VGV4ERUM'ZQ0!
M_'K\0?\`@AU\=/`/[(/P._8V^`OPU^%/@_3?CI\0]'T#XT^%?`-U>^)/@%\`
M_#Z:#XAU3QU^TW^TGXS^(4^E?$O]O_XZ:#:1V/A;X#^%?&'AWX?_```\'^--
M7T[Q%H?P%T2_\$^%?$FG_O)\-OA+^S/_`,$;OV$O#GPK^!/@"ZF\)_#_`/X1
MWP?X$\&6=[I$/Q,_:0_:'^)^O:1X,\(:;JGB&^2PT_5?BG\;?B5K&@Z'-KNI
M+8^&_"]I>6P6'PS\.?"%M9Z)^DU?FW^UM_P3_N?VU_V@/@QXC^-'QA\36?[*
MOP-T+6/$&G?LW_#][_P=?_%/XW^+]&\>_#[7?%WQ3^)NDZE;>)D\#^'/A/XM
MNO"WA'PAX)E\.:I=:CXQ\=WNN^)GTR6QTBX`/!?@9\:K_P"%.G?$CP?^SE\%
MKK]M[]LSXF_$C7_B;^U[\0_A?KMC\.?V6_"WQTU-++P[J?@KQ7^T]\0;>[LF
M\.?!CP_X>\/?!7P+\//AUX?^-/QO\)^`/`WA.;QY\.=.OK[6-<G^H?$_P4_;
M\^*6FV$NL?ML^#_V:KJ6&&ZN]"_9B_9T\%>+]1T>XG,,USHEQ\2OVG[KXM:3
MXY@TUA+86WBBR^!WPKEU>`_VA-X1T::1;*V^T/`?@+P/\+?!GACX<_#3P?X9
M^'_P_P#!6BV'ASP?X)\&Z'IOAKPKX7T#2X%MM.T70-!T>VM-,TG3+*W18K:R
ML;:&WA0`)&.:ZV@#\%/CCXE_X**_\$X/&_[/GC*']H3XJ?\`!3OX5?''XH:A
M^S==?L_^//A=^SA\*_BKH/Q7^(/@?QSXB^!GCS1/BY\(/AK\-],T_P"&MKX\
M\)V'A?XXZKXL\,^*9?`?PYU[4OB1X>T#7W\)3>%[O]Z4+E$,BJDA53(J.9$5
MR!O5)&2)G56R%=HXRP`8HA.T.HH`^0/VUOV+?AC^WG\*M`^!7QL\2?$JP^#<
M?Q'\->.?B9X!^'?C*]\#V'QR\-^&+#75A^#_`,3]6T>./Q#=?"W6-?U+1/%'
MB'2/#>K>'=9U'5/"&@1Q:]9VJ7<5S\B?\%#?@E\0?BE\)?A#_P`$O?V4_ASJ
M7P1^#/[36G>+/!OQX^-7PM\#VOA?X7_LQ?LE>!+?1KOXC^"/"T.B6VD^$=-^
M)G[0,>O67P9^&W@NWMI81X<\0_$OQM=:2^E>";MG_7JB@#$\->&]"\&^'/#_
M`(0\+:59Z'X9\*Z)I7AOPYHFGQ^38:/H6AV$&F:1I5C#D^59Z?I]K;VEM'D[
M(847)Q7"S?`WX/7/QHMOVB[GX:^#;KX[6/P]3X3Z?\6;G0K&X\=:;\-DUW4?
M$S>"M,\03127VF^'Y]?U;4-4O+&QEMX[ZZN-UYYZPP+%ZK10`5_/=\&?@G\9
MOVS_`/@MY\<?VR?CSX*U[P%\`O\`@F7HU[^RO^Q)X:UG1[NUM?B5\4/BEX/A
MUGX\?'Z*?68A]I@@\.>)-.\(:1J&@6T>CZMI5_X56WU`:SX+\0G5OZ$:*`/Q
MN^$__!'C1_#&J_%'5OC-^W)^W5\<+3XS_%CX@?&+XD_#[2/C7/\`LW?"_P`4
M>+/B!-+%=_VM9_LUZ=\-/BEJ^D:;X?31_!UCX8U_XO:SX,B\%^%_"O@NV\,6
MG@SPYHWAVR_3GX,_`?X*_LZ^#+?X=_`?X4_#[X/^"+:XDO?^$9^'7A/1?"6E
M76ISI&EYK6J0:-9VAUC7]2\I)=6\0:JUYK6KW.Z[U._N[J229O6**`/F'X'_
M`+%_[+?[-WQ`^-/Q8^"OP5\'^"/BG^T3X]\4?$KXT_$J&+4-;\?^/_%7C#6Y
M/$>N?VKXQ\2W^L^(K;PTVMRRZCI/@32M1T_P+X;FD<>'/#FDQL4/TQ<W-O9V
M\]W=SPVMI:PRW-S<W,J06]M;P(TLT\\TK+'###&K22RR,J1HK.[!02)J^</V
MO_@-K?[4?[,'QS_9RT#XH:S\%[[XW?#GQ#\,[CXF^'='@UW7O"NA^+K4Z/XF
MN-(TVXU+1XWU&_\`#=UJVD6MVNI6DVF3:@NIVTAN+.)'`/E#P/X_\$_\%.-6
MLKW3=.N=0_8[^$_BNWUG6]%\1:?H&IZ%^T[X_MI]1UKX5KJEK'J>M6=Y\#]&
M\&7/PU_:8T#2K^QAU'QQJ/C[X+3Z\?#;^!O'_P`/]:_3ZOF']C3]DOX6?L-?
MLT?"G]ESX-IK$G@?X5Z#)IL.M>);U=3\5^+M>U/4+S7?%GC;Q9J:Q01WWB7Q
M?XFU/5=?U9[>WM=/MKB^-AI-CI^D6=A86WT]0`4444`%?!7[57_!.?X#?MB_
M&+X+?&3XN^(?C5IVH?!CP-\8?AHGA#X6_%KQ+\)?"?Q1\`_&^;P#<>-?!GQ=
MO/`+:'X]\5^$)IOASHF?"%AXXT'PKKMK>:UI?C;1?%>DWZ6%O]ZT4`9'A_P_
MH/A/0=$\*^%=$TGPUX8\,Z1IOA_PYX<T#3K/1]"T#0=&LH=.T?1-%TC3X;>P
MTO2=*T^VM['3=.L;>"SL;."&VMH8H8D1=>BB@`HHHH`*YCQ)X(\%^,KCPM=^
M+_"'A?Q5=>!O%%KXW\$W/B30-*URX\'^-+'3-6T6R\7^%IM3M+J3P_XHL]&U
M[7=)M=?TEK35;?3-:U:PBNTM=1O(INGHH`****`"BBB@`HHHH`****`"BBB@
K`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>geron_def14a5x12x1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 geron_def14a5x12x1.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_
MVP!#`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_P``1"`"H`4H#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#^_BBBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`^>_V
MKOVG/A1^QG^SI\7?VH/C?K1T+X9?!KP=J'BWQ%/"(GU'4I(6BL]$\,:#;S2P
M17OB;Q?X@O-*\+>&-/>>!+_7]8TZT>>!)FE3_+#_`."G/_!S-_P4!_;V\97>
MF_"/QWXQ_8P_9]L$O=/T+X7_``1\?:_H7B_Q)93W#M_:GQ3^*&A/H'B#Q/JE
MS;>5:R:)HR>'?!=G:(MNN@7U\;W6M1_:;_@]N_:F\2)XM_8W_8OT76]0L/#"
M^$?%O[2'Q"T*VNKB*Q\1WVKZ_/\`#KX7W&IVZ2+!=#PW_P`(G\3GLDF20)/K
MCS`+)#"P_GN_X(/?\$<->_X*^?M,>(O"_B+Q+J?@+]FSX':=H'B?]H#QMX?D
MLU\7R6WBF;6K;P7X"\"KJ%AJ>G0^*O&MWX>UQQK&JV-SI7A[0-"UW5IK;4=2
MBTC1-7`/Q7U7QIXQUWQ')XPUOQ9XFUCQ;+=?;I?%.JZ]JFH>(Y+T.7%Y)K=W
M=3:F]T')?[0UT9=Y+;\DFOV*_P""??\`P7[_`."D7[`7Q!\*ZOI'QZ^(/QY^
M#NCRFV\0?L\_'3QUXF\<_#[6]!DM9+1].\/WNO7>KZ[\.+ZSWQW^D:GX+NM.
MMX-3M+9M7TK7=):_T>__`-/OPA_P1#_X)'^"OAY9_#+3/^">G[*^I^'[32[?
M27U7Q;\)/"WC+QY?16\*0B]U'XE>*+#5?']YJTNSSI=5D\2?;S<,\L<\;-Q_
M`U_P<C_\$"=$_P"";6M:7^UG^RI;:I-^Q_\`%#QE/X=\0^"]2U&+4;S]G_XA
M:ZU_JGA_PMI=Y>W4FOZY\-_$5E9ZE#X8U+4AJ6I>'+W2_P"P?$6LWDVIZ#=Z
M@`?Z"'_!++_@IS\#?^"K7[+ND_M'?!JSU+PIJ-AK-UX+^*OPK\17EE>^)_A?
M\0=-MK6\O-"OKRPV6NLZ+J>GWMEKGA/Q-;6]I%KNA7UN]WI^C:Y:ZUH&D?I'
M7^3Y_P`&GW[:WB']FC_@J3X&^"6I^+]4TSX/_M?Z)K?PE\4^&7N[I_#EW\2;
M+2;_`,1_![Q%-I4>^!O$<7B33KCP+I&J>4);2Q\?ZO!+*EI<S,G^L'0`5^:W
M_!57_@IU\%/^"47[+&K_`+2'Q=TW4O&.K:AK=GX(^%'PKT"^LM.\0_$[XAZI
M:W=[9Z+;ZA?"6WT30=*TVPO]>\6^)9K6^&BZ%I]P;+3-:UV[T;0=5_2FO\HC
M_@[3_:Z\;?'G_@JQX]^!,OB?6+KX4?LE>%/`WP\\&>$S?7(\.6GC'Q9X+\/?
M$+XD>*;?22XM4\0ZGJ?B:P\*:IJOE?:KO3/!6B6IE-M90*`#X:_;\_X+U_\`
M!2/]OOX@^*]<\3?M!?$/X*_";6I_)T']GOX'>./%'@+X9^']"2TCLX]+U9=!
MU#3=7^(%W<A)+[5=5\<7FL-<ZG>7;:;9Z-I(L-'T_P#(72_%_BS1->7Q5HOB
MCQ%I'BA)WND\2:7K>I:?KR7+G+W"ZQ:7,6H+.YY>87`D8\EB:_JH_P"#;C_@
M@/HG_!2+6-2_:V_:MM=2B_9`^&7C&+P[X;\$:=J4>G7G[0/Q!T%[+4?$/AG5
M;RQNXM?T/X;>'+2\TZ#Q+J.F_P!FZCXDO]2.@^']8LY-+U^YLO[YO$O_``1(
M_P""1OBOP._P\U7_`()V?LGVWAZ2S:R^U^'/A%X:\'>,HXF38TMO\1_"-KH?
MQ#M;YARVI6WBF+42X$ANC(`U`'^<1_P3"_X.9?V_?V!O%]GI'Q;\;^+_`-LW
M]GJ]AL-,UGX7?&OQ[KVM>+O"]A:W"%-3^%/Q.UM]=UWPQJ5K:>9:1Z%K4?B+
MP7>63&V.@Z??+8ZUIW^IY^RE^TW\*?VR_P!G3X0_M/\`P1UHZ[\,OC-X.T_Q
M=X<N)A$FH:<\S2V6M^&M=MX99XK+Q+X1\06>J^%O$^GQSSII^OZ/J5FL\RP"
M5_\`)>_X+V_\$>-8_P""1G[4NE>'_"NL7?BS]F7X\6_B7Q=^SOXFU6<3^)=.
MT_P[=:1%XP^&WC%UA@2Y\1^`+GQ'H<4>M6R&U\2>'-9\/ZP_V35[C6=(TO\`
M<_\`X,K_`-MSQ+HOQG_:(_8`\2W^H7_@GQWX&E_:'^&$-S?7,UCX6\:^"-2T
M3POX_P!)TRQ>1H+9?'/ASQ-HFM7LD,<2+/\`#\,P>;4'8@'^BK1110!\:_MT
M_M[_`+,7_!.;X$ZM^T'^U/\`$"#P5X-MKF31?#6DVEI/J_C#XB>,WTO4=6TO
MP)X#\/6@-QK/B76+?2[LPF:2QT72[>*;5?$6L:+HEI>ZG;?P,?MC?\'H?[8'
MQ,BUCPU^QG\!_AU^S+H4\S0:?\0/'MVOQK^*:VD?F(E]9:??Z7H/PTT"[NP4
MEFT_4?"WCN.R*^1!JMR1]J;\4_\`@NI_P4Q^(?\`P4J_;S^+7C*[\1ZP/@)\
M*_%WB3X9?LZ>`!K6I7/A;0_`OA;4Y=!;QS:Z-.\=A9^*_BI-I:>,?%%]'9B_
M"WNE>&I;Z]TSPSI!BJ_\$@?^"*W[3/\`P5W^*&IZ7\.9;;X9?`/P!J-A:_&#
M]H3Q/IEW?^'O#$MVD=VGA3PCH\$MG)XZ^(]YIT@O[;PS;:CIEAIEC);:CXHU
MW0;34-);4P";7?\`@X5_X+/^(M0EU/4/^"@7QGM[F9BSQZ%:>`O"VGJ2<GRM
M)\,^#M(TJ!?18+*-5'``%?W?_P#!IU^V9^U'^VO^QI^T=X^_:L^-GC3XX^,?
M"G[3<WA#P[X@\;W5I=W^D>&E^%?P]UE=&M'L[.R1+,:IJFH7NQHV;S[J5MV&
M`'E_@'_@S!_X)A:#X;L[#Q]\6_VNOB#XG50VI>(K3QY\.?!NG7$VT!AIWAZQ
M^%FJMI]IN!9(;O6=7N5W$/?2`#'[J_\`!-/_`()<?LT_\$J/A3X\^#O[,5]\
M3K_PE\1?B$_Q+\02?%+Q3I/BO5T\1/X<T/PL4T^\TCPSX7@MM-_LSP_8,+:6
MSN)?M1N)?M)218HP#]!/$7B+0/"'A_7?%GBO6M*\->%_"^CZGXB\2>(M=U"U
MTG0]`T#1;*?4M8UK6=4OI8++3=*TO3[:XOM0O[R:&UL[2":XN)8XHW<?YG'_
M``6,_P"#K3]I;]HCQGXT^`__``3Y\1ZQ^S;^SYX9\5:YH4?QT\':S>6?QN^-
MVFZ1>S6-EXET;Q%':Z???"/P9K/DC5=&TGPV8_'%U9/97&N>*;!+N^\*6G[\
M_P#!XE^V;XW_`&>O^"?_`,-OV=OA]K4_A_4OVQ_B/K/A/QS?6C217U]\'?AK
MH^G^(/&OARUNHV1[6+Q'XDU_P!INLE7QJ'AN36]#N$ELM6NT/^>K_P`$W/V$
M_B)_P4D_;)^#G[(OPXU.#PY??$?5[RY\5>-KRR_M*Q\`?#WPUI]QKWCCQI<Z
M=]KT\:I-HV@V-U_9&C'4-/\`[>\07&D:$NH6+ZDMU"`?*?C_`.*7Q-^+&O3>
M*?BG\1O'?Q*\3W$LLUQXC\?^+_$'C+7IYII#+-+-J_B+4-2U"6664F261[AF
MDD)=B6.:^R_V4_\`@JO_`,%#OV*]=T?5_P!GC]K;XT>$-*TB]M+MOA]J7C36
M/%WPIU9+5X\V>M?#'Q7=:QX*OH)X(S9R3?V-%J,%K(ZV%]9RB.9/]6#]F7_@
M@1_P2=_9H^$_AKX9V_[%OP'^,FJZ7H&G:7XF^)_Q\^&GA+XN?$'QSJ]O9Q0:
MKXDU75/&^EZW;Z'<:W=K+?S:-X2MM!\.Z>\PMM+TNUMH8D7^9'_@X[_X-N/@
MY\,O@MXN_;V_X)Z?#^/X<V?PJTE=9_:"_9Q\)6TTO@V7P!8MJ5YXC^,W@""\
MU*>X\,WG@VV>SF\9^#-+@/AF?P?9W?B?1[;P_>>'=6M_%`!_0]_P0T_X+A_#
M;_@L#\)_%<&L>&=!^#G[4?PE>V'Q.^#EAXE;6K/6O#%S'806/Q9^'IU""TUF
M7P1J6L74NBZGI=XNI:AX)UL6>E:OK&IV^L^'M9UK]XJ_Q$?^"5G[9GCC]@G]
MOC]FW]H[P9KD^D6'A[XC^'/#GQ+LU+O8^)_@]XPU>QT'XF^&=4M0RQW<%[X7
MNKV\TXS+)_9GB'3]%UVV47^E6DD?^W=0`5X-^U!^TA\*_P!D']GSXM_M,_&S
M7!X>^&'P:\&ZEXR\57Z*DEY<16GEVVF:%H]M))$M]XB\4:W=:9X:\-:;YL;:
MGX@U;3=/1T>Y5A[S7^=5_P`'I'[=?B;7/C-\!O\`@GKX4U'4=.\#^`O!EG^T
M!\6HK2_N8++Q;XW\:WNKZ%\/M#U6PCD2"[@\"^&]!U/Q!:-<)-%+>^/HY%2.
MXTB&2@#\JO\`@J!_P<Y_M\?MX>,+C1?@=XU\9_L5_L]::-0L-%\`?!GQYK>A
M_$#Q=9W-QE=6^*7Q0T"31-;U:_GM42`>'/#1T#PE86TDMI/8:Y=^=K5W_.OK
MGC7QEXG\0R^+O$OBWQ-XA\5W%R+R?Q/KFO:KJWB&:\#^8+J76K^[N-2DN0_S
MB=[EI0_S!\\U^Q7_``0S_P""/OBK_@KW^U#JO@"_\27W@#]GKX.Z7I'B[]H7
MX@Z+)9'Q5I^BZ_-JEGX2\'^!;;4;#4].D\:>-]2T;4X;&^U>RFT;0=$T;Q%K
M]W!JMWING^'=<_T]/`O_``0]_P""1_P_^'5C\,=+_P""?'[+FM:%9:3:Z3+K
M7C?X3>%?'?C_`%-+:!(/[0U3XD>+-/U;QS=:O.5-Q-J0UZ.X%R[R0-`"JJ`?
MY='[!7_!=W_@I'^P)\0/"FO^#/VA_B)\7/A=H=P(M<_9]^-WC;Q3\0/A5XBT
M-[:2TFTFQL-<U2]U'P-<1(\=WINK^![W0[NUU"TM'O$U/3?MNE7W^I?_`,$F
M_P#@J3\%_P#@K-^RY9?M"?"O2;_P/XFT'7)O!'Q?^$FN:E9ZKKOPU\>6=I;W
MS6/]I6D=M'KOAC7=.NK?6?"/B9+'3AJ^FRRV]YIVE:YIFM:/IW\!W_!R?_P0
M.\._\$WM<T?]K7]E&RU,?LA_%/QC-X;\2^"-1U.+49_@%\1]<^WZKH'AG1;F
M]N7\0:Q\-_$UA8ZJGAN]U$ZI?^&;_27T+7=9N3JGAZ2Z^=?^#6G]MS6OV3_^
M"JGPB^&NJ^+M8TGX/_M=//\``+QOX;COKMO#^J>._$-O<GX'ZS=Z(LRV-QKU
MK\2O[(\(Z5K$L+7NDZ3XX\1PV\J6NHWT4X!_K;T444`%%%%`!1110`4444`%
M%%%`!1110!_F"?\`!ZM_RE-^`8[?\,`?"S_UHK]JG_`5^I7_``8[QQCX._\`
M!0J4(@E?XE_L_1O*%42/'%X6^*#1HSXW,D;32LBDE4:60J`7;/Y:_P#!ZM_R
ME-^`?_9@'PL_]:*_:JK]3?\`@QX_Y(S_`,%!_P#LIWP"_P#45^)E`']UU?S>
M_P#!V'%%)_P1,_:(>2-'>#XB?L\2PLZ*S0RGXU^#(#)$2"8W,,TT1=2&,<LB
M$[78'^D*OYP?^#L#_E"5^T;_`-E`_9W_`/5X>"*`/\VW_@C<2/\`@K!_P3D(
M)!_X;._9X&02#@_$WPZ",CL02".X)!X-?[:%?XEW_!&__E+!_P`$Y/\`L\_]
MG?\`]6=X<K_;1H`*_P`9C_@X.)/_``6=_P""@>23_P`7M0<\\#P5X2`'T```
M]`,5_LSU_C,?\'!W_*9S_@H)_P!EM7_U"O"=`'^A-_P:>QQI_P`$3/V=V2-$
M:;XA_M#R3,B*K2R#XV>,X1)(0`7<1111!V)81QQH#M10/Z0:_G!_X-/_`/E"
M5^SE_P!E`_:(_P#5X>-Z_H^H`_A._P"#XB*,_!W_`()ZS&-#-'\2_P!H&))2
MJF1(YO"_PO>6-7(W*DK0PM(H(5VBC+`E%Q^&W_!H:2/^"R7@H`D`_L__`!V!
MP>H_L/2S@^HR`<'N`>HK]S/^#X?_`)(S_P`$^/\`LIWQ]_\`45^&=?AE_P`&
MAW_*9/P3_P!D`^.W_IBTR@#_`%>ZR]<=X]%U>2-F1TTO4'1T8JZ.MI,RLK*0
M592`58$$$`@YK4K)U_\`Y`6M?]@G4?\`TCFH`_P(9F9YI7=F9WED9F8EF9F8
MEF9CDEB22222223S7^TK_P`$.OV9O`7[*G_!*G]B?P#X$T^WMG\9?`GX??'#
MQUJ<<*1W?B/XD?&[PMI'Q(\7ZMJ$XS)>/:WFOQ>'=*EG=Y+;PWH.AZ:A2WL(
M(H_\6F3_`%DG^^W_`*$:_P!RC_@G'_RCS_8._P"S,OV7O_5(>!J`/LVBBB@#
M^`7_`(/F))`G_!,B$.PB9OVQ9&CR=AD0?LO*KE>A95=U!Z@,P'4U^7?_``9N
MQQO_`,%<?$#.B.T7[(?QEDB9E5FBD/C/X21%XR02CF*22,LI#&.1T)VNP/Z@
M_P#!\QU_X)C?3]L?^?[+E?F#_P`&;?\`REP\1_\`9H'QE_\`4V^$%`'^IW7R
M5^WW%%/^PG^VK!/&DT,W[)7[1T4T4JJ\<L4GP=\9))'(C`JZ.C%75@592000
M:^M:^3OV]O\`DQC]M#_LT[]HO_U3_C&@#_#`M"5NK9E)#"XA(()!!$BD$$<@
M@\@CD&O]^BTYM;8GK]GA_P#1:U_@+6O_`!\V_P#UWA_]&+7^_3:?\>EK_P!>
M\/\`Z+6@"Q7^3E_P=R$_\/G/B=ST^"7P$`]A_P`(6#@?B2?J37^L;7^3E_P=
MQ_\`*9SXG?\`9$O@)_ZA2T`?N!_P8X11CP%_P4?F$:"9_%_[+T3RA%$C1QZ-
M\=GCC:3&YDC:65D0DJK22%0"[$_WFU_!K_P8X?\`)/O^"CO_`&.7[,/_`*9/
MCG7]Y5`'\V'_``=FQ1R?\$5/CJ[QH[0_%']GR6%G16:*0_%GP["9(B03&YAE
MEB+J0QCED0G:[`_YJO\`P2=_Y2F_\$T_^S__`-C?_P!:*^'-?Z5O_!V7_P`H
M4OCS_P!E._9[_P#5N^&:_P`U+_@D[_RE-_X)I_\`9_\`^QO_`.M%?#F@#_;Y
MHHHH`****`"BBB@`HHHH`****`"BBB@#_,$_X/5O^4IOP#_[,`^%G_K17[55
M?J;_`,&/'_)&?^"@_P#V4[X!?^HK\3*_++_@]6_Y2F_`/_LP#X6?^M%?M55^
MIO\`P8\?\D9_X*#_`/93O@%_ZBOQ,H`_NNK^<'_@[`_Y0E?M&_\`90/V=_\`
MU>'@BOZ/J_G!_P"#L#_E"5^T;_V4#]G?_P!7AX(H`_S;/^"-_P#RE@_X)R?]
MGG_L[_\`JSO#E?[:-?XEW_!&_P#Y2P?\$Y/^SS_V=_\`U9WARO\`;1H`*_QF
M/^#@[_E,Y_P4$_[+:O\`ZA7A.O\`9GK_`!F/^#@[_E,Y_P`%!/\`LMJ_^H5X
M3H`_T*?^#3__`)0E?LY?]E`_:(_]7AXWK^CZOYP?^#3_`/Y0E?LY?]E`_:(_
M]7AXWK]@/VB/V_\`]B3]DCQ/HG@K]IW]JCX&_`;Q=XDT%?%.@>'/BE\0O#_@
M_6-8\.-J%[I*ZWI]CJ]Y;3W.FG4]-O[`7<2-$;JSN(=V^)@`#^0__@^'_P"2
M,_\`!/C_`+*=\??_`%%?AG7X9?\`!H=_RF3\$_\`9`/CM_Z8M,K](?\`@[Z_
M;G_8Y_:^^%/[$.E?LN?M,?!CX^ZGX(^(7QJU#Q?8_"KQYH7C&Z\-V.M>&_A_
M;:1=ZS%H]W<M80:C<:??0V<DX19Y+6=8RQC;'YO?\&AW_*9/P3_V0#X[?^F+
M3*`/]7NLG7_^0%K7_8)U'_TCFK6K)U__`)`6M?\`8)U'_P!(YJ`/\""3_62?
M[[?^A&O]RC_@G'_RCS_8._[,R_9>_P#5(>!J_P`->3_62?[[?^A&O]RC_@G'
M_P`H\_V#O^S,OV7O_5(>!J`/LVBBB@#^`+_@^8Z_\$QOI^V/_/\`9<K\P?\`
M@S;_`.4N'B/_`+-`^,O_`*FWP@K]/O\`@^8Z_P#!,;Z?MC_S_9<K\P?^#-O_
M`)2X>(_^S0/C+_ZFWP@H`_U.Z^3OV]O^3&/VT/\`LT[]HO\`]4_XQKZQKY._
M;V_Y,8_;0_[-._:+_P#5/^,:`/\`"_M?^/FW_P"N\/\`Z,6O]^FT_P"/2U_Z
M]X?_`$6M?X"UK_Q\V_\`UWA_]&+7^_3:?\>EK_U[P_\`HM:`+%?Y.7_!W'_R
MF<^)W_9$O@)_ZA2U_K&U_DY?\'<?_*9SXG?]D2^`G_J%+0!^X?\`P8X?\D^_
MX*._]CE^S#_Z9/CG7]Y5?P:_\&.'_)/O^"CO_8Y?LP_^F3XYU_>50!_-G_P=
ME_\`*%+X\_\`93OV>_\`U;OAFO\`-2_X)._\I3?^":?_`&?_`/L;_P#K17PY
MK_2M_P"#LO\`Y0I?'G_LIW[/?_JW?#-?YJ7_``2=_P"4IO\`P33_`.S_`/\`
M8W_]:*^'-`'^WS1110`4444`%%%%`!1110`4444`%%%%`'^8)_P>K?\`*4WX
M!_\`9@'PL_\`6BOVJJ_4W_@QX_Y(S_P4'_[*=\`O_45^)E?EE_P>K?\`*4WX
M!_\`9@'PL_\`6BOVJJ_4W_@QX_Y(S_P4'_[*=\`O_45^)E`']UU?S@_\'8'_
M`"A*_:-_[*!^SO\`^KP\$5_1]7\X/_!V!_RA*_:-_P"R@?L[_P#J\/!%`'^;
M9_P1O_Y2P?\`!.3_`+//_9W_`/5G>'*_VT:_Q+O^"-__`"E@_P""<G_9Y_[.
M_P#ZL[PY7^VC0`5_C,?\'!W_`"F<_P""@G_9;5_]0KPG7^S/7^,Q_P`'!W_*
M9S_@H)_V6U?_`%"O"=`'^A3_`,&G_P#RA*_9R_[*!^T1_P"KP\;U_-U_P>?_
M``Q^)7CC]N[]EG4/!7P]\<>,+"S_`&2;>SN[[PMX3U_Q!:6MW_PN/XG3_9;B
MYTG3[N&"Y\F6*;R)767RI(Y-NQU)_I%_X-/_`/E"5^SE_P!E`_:(_P#5X>-Z
M_H^H`_P9O^&>_CY_T0_XO_\`AM/&?_REK^E__@TQ^$OQ5\'?\%@/!>M>+OAG
M\0?"NCI\!OCC;/JWB/P9XCT/3%N+C0]-$$#7^IZ;:VJS3%6$41E#R%2$5B#7
M^IU10`5DZ_\`\@+6O^P3J/\`Z1S5K5DZ_P#\@+6O^P3J/_I'-0!_@02?ZR3_
M`'V_]"-?[E'_``3C_P"4>?[!W_9F7[+W_JD/`U?X:\G^LD_WV_\`0C7^Y1_P
M3C_Y1Y_L'?\`9F7[+W_JD/`U`'V;1110!_`%_P`'S'7_`()C?3]L?^?[+E?F
M#_P9M_\`*7#Q'_V:!\9?_4V^$%?I]_P?,=?^"8WT_;'_`)_LN5^8/_!FW_RE
MP\1_]F@?&7_U-OA!0!_J=U\G?M[?\F,?MH?]FG?M%_\`JG_&-?6-?)W[>W_)
MC'[:'_9IW[1?_JG_`!C0!_A?VO\`Q\V__7>'_P!&+7^_3:?\>EK_`->\/_HM
M:_P%K7_CYM_^N\/_`*,6O]^FT_X]+7_KWA_]%K0!8K_)R_X.X_\`E,Y\3O\`
MLB7P$_\`4*6O]8VO\G+_`(.X_P#E,Y\3O^R)?`3_`-0I:`/W#_X,</\`DGW_
M``4=_P"QR_9A_P#3)\<Z_O*K^#7_`(,</^2??\%'?^QR_9A_],GQSK^\J@#^
M;/\`X.R_^4*7QY_[*=^SW_ZMWPS7^:E_P2=_Y2F_\$T_^S__`-C?_P!:*^'-
M?Z5O_!V7_P`H4OCS_P!E._9[_P#5N^&:_P`U+_@D[_RE-_X)I_\`9_\`^QO_
M`.M%?#F@#_;YHHHH`****`"BBB@`HHHH`****`"BBB@#_,$_X/5O^4IOP#_[
M,`^%G_K17[55?J;_`,&/'_)&?^"@_P#V4[X!?^HK\3*_.'_@]C\%:W8?\%$/
MV7OB-/:S)X<\5?L7Z)X*TJ]:&1;>XUOP!\</C1KOB"UBG(\J2:SL/B5X:FGA
M1C)`E];/(%6XB+?0'_!E%^U=\*/`?Q#_`&P/V3O&_BK0/"_Q#^-*?"CXB?!^
MPUO5[+2[CQ[<^`+7Q]I7CCPMX?BOIH#J_B/3M,\0:%XAL]$TW[1J=UHEIXEU
M-+5K+1+V:$`_T3*_G!_X.P/^4)7[1O\`V4#]G?\`]7AX(K^CZOYP?^#L#_E"
M5^T;_P!E`_9W_P#5X>"*`/\`-L_X(W_\I8/^"<G_`&>?^SO_`.K.\.5_MHU_
MB7?\$;_^4L'_``3D_P"SS_V=_P#U9WARO]M&@`K_`!F/^#@[_E,Y_P`%!/\`
MLMJ_^H5X3K_9GK_&F_X.'M,OM)_X+2?M_P!KJ%O):SR_%_2=3CCE5E9K'6?A
MQX(UC3+@!@"8[O3;ZTNHF`VO%,C*2I!(!_H-_P#!I_\`\H2OV<O^R@?M$?\`
MJ\/&]?T?5_,9_P`&C?Q"\(^+?^"-_P`-?".@ZWI]_P"(_A9\8?CAX9\<Z/!=
M02:AH&J:_P"/=3\>Z-'J%FKFXM8]2\->*M*OK*6:-8[I6G$#N;>81_TYT`>/
M_%S]H7X!?`"UT2^^/'QQ^#_P3LO$UQ>VGAR\^+GQ+\%_#>U\076FQV\VHVVB
M7'C+6]&BU6XL(;NUEO8;![B2UCN;=YUC6:,MR'PS_;&_9$^-7BF'P-\'/VJ/
MV</BUXVN+*\U*W\'?#/XX?#+QYXIGT[3D674+^'P_P"%O$^JZM+96,3+)>72
M6C06J,KSR(I!/\6'_!\1X[\+_P#"+_\`!/7X91ZK:2^-!KW[0/CNZT.*>-[[
M3_"[:?\`"_P_8:K?6RL9K:TU?55U*STJ>1%CO9M$UF.%F;3YPGXY_P#!H!I5
M_J/_``6)T&[L[=YK?0OV;_CEJNJ2(K%;2PF@\,:''<2D`A4;4]9TZU#,54R7
M,:YW,JD`_P!6JLG7_P#D!:U_V"=1_P#2.:M:LG7_`/D!:U_V"=1_](YJ`/\`
M`@D_UDG^^W_H1K_<H_X)Q_\`*//]@[_LS+]E[_U2'@:O\->3_62?[[?^A&O]
MRC_@G'_RCS_8._[,R_9>_P#5(>!J`/LVBBB@#^`+_@^8Z_\`!,;Z?MC_`,_V
M7*_,'_@S;_Y2X>(_^S0/C+_ZFWP@K]5?^#Y31;Z;0_\`@FGXB2&1M,L-6_:T
MT6ZN`A,45]J]G^SE?6$,DF=JR7%OHFHO$A&9%M9F!Q&U?CY_P:`^.O"_@_\`
MX+":/H_B+5K33+_XD_LW?&GP+X/ANIHX3K'BB*;P;XZ.DVID91)=OX;\$>([
MZ*%,R2K8.J*S8%`'^K37R=^WM_R8Q^VA_P!FG?M%_P#JG_&-?6-?!7_!4GXK
M>`O@M_P3C_;?\?\`Q)\2Z5X5\-67[+WQLT2._P!6O(;.._\`$?B[X?:_X4\'
M^&K!IF7[5KGBOQ5K.C^&]!T^(-/J&L:I9VD*,\HH`_Q`[7_CYM_^N\/_`*,6
MO]^FT_X]+7_KWA_]%K7^!-H&EWVMZ]HFBZ9;R76I:OJ^FZ7I]K$K/+<WU_>0
MVEI;QH@9GDFGECC154LS,``20*_WV[=&C@@C;[R0QHV.FY453^HH`FK_`"<O
M^#N/_E,Y\3O^R)?`3_U"EK_6-K_)R_X.X_\`E,Y\3O\`LB7P$_\`4*6@#]P_
M^#'#_DGW_!1W_L<OV8?_`$R?'.O[RJ_@U_X,</\`DGW_``4=_P"QR_9A_P#3
M)\<Z_O*H`_FS_P"#LO\`Y0I?'G_LIW[/?_JW?#-?YJ7_``2=_P"4IO\`P33_
M`.S_`/\`8W_]:*^'-?Z5O_!V7_RA2^//_93OV>__`%;OAFO\U+_@D[_RE-_X
M)I_]G_\`[&__`*T5\.:`/]OFBBB@`HHHH`****`"BBB@`HHHH`****`/YWO^
M#D+_`()*:O\`\%0_V-;'6/A0)9/VF?V5CXV^)7P9T*#3XKV;XG:=K&AV0\=_
M!RWE>ZM3IVJ^-H_#7AR^\+7Q,\+>+/#FBZ1>16VGZS>ZG8?Y+FG:C\0_@Y\0
M;74]*O?&/PN^*GPR\6)<V=]93ZSX+\>^`/'/A+5<I+!/$VF^(/"_BGPUK=CP
MRM8ZKI&J69!^SW4!"_[XE?BI_P`%)_\`@@7_`,$\O^"FWVSQ5\4?AO-\)OCI
M<2_:#^T)\#8="\&_$?6)@`IC\>Q3Z-J7AKXDP2*D,)N_&.B:EXBLK6".TT3Q
M#I$)=7`/X6?@1_P>#?\`!5_X._#O1?`7BW3?V;OVA+[0K:&RM_B)\9/A[XS'
MQ!U&SMT,4":_J/PV^)/P\T/6KM(A&DFK77AX:Q?-']IU2_O[Z:XNI?"?^"AO
M_!S/^V[_`,%)_P!ECQO^R1\:_A!^RYX2^'OCS6/!>M:KKOPQ\*_%32O&-K=>
M!O%FD^+]*CT^]\4?%[Q;HT<%SJ&D6]O?K<:'<R264DR6\EM.R3Q_OGK?_!C?
MX+GU*YE\.?\`!2'Q1IFD/*[6=EK?[+6DZYJ5O"6/EQW.J6'QZ\/6MY*JX#S1
M:/8H[`LMO&#M'YB_\%9O^#6S3?\`@F'^Q#\2/VQ+?]MN]^-,O@#Q!\.M"7X?
M3?L\P?#^/5?^$]\<Z'X-:Z;Q0GQJ\9M9?V6NLG41"/#]U]L:W%J9;42FXC`/
MP\_X(W_\I8/^"<G_`&>?^SO_`.K.\.5_MHU_B7?\$;_^4L'_``3D_P"SS_V=
M_P#U9WARO]M&@`K_`#C?^#Q__@FGXH\%?'#PI_P4Y\#12:K\//C+:^#_`(0?
M&^RM=,D,W@KXF>#_``X-%\!>*M1U".>1)=#\=^"M$LO#$3RV=K'H^N>#+:WG
MO;N;Q7I=K;?Z.5<!\4OA5\-?C?\`#_Q3\*OC!X$\*?$SX;>-M+GT7Q9X'\;:
M'I_B+PUK^F3X+6VHZ3J<%Q:S^7(D=Q;3>6+BSNX8+RTE@NH(9D`/\8[_`()1
M?\%9/VC/^"2GQ]N?B]\%1I_BWP/XTMM+T3XV?!3Q'<O9^%/BQX8TB34)=)M[
MC5(+2]O_``QXI\-7&JZC?>$/%^F6UQ<Z-=WM[:WVGZWX>U76]`U3^P/Q/_P?
M`_!A/`+77@S]@CXGW'Q1ELV":%XG^,GA2R\`V&H.A".WBO2O"-_XAU>SMY"'
M:(>#-$GNT4Q":R9_.CY3]O/_`(,MK+Q9XZ\9?$/_`()\?M$^%OAWX;U_4+[5
M]%_9Z^.FE>*;K0?!YN`]S_87AGXQZ%<>+/$MWH,5PS6FC67BKP1J>KZ=9+`F
MJ^+M;F62[/XVZ)_P:`_\%B-4\5KX?U'0/V<_#FC&[:W?QUJOQPM+KPRMNKJO
MVY;'0?#NL>,W@=27BB/A-+L[2LMO"2*`/PS_`&[?VX_CY_P40_:4\>?M/?M$
M^)9-;\9>,+N6VT/0;2:\_P"$4^&W@BVOKZZ\-_#;P%IUY<W4FD>#_"\=_<QV
M-LT\UY?WUSJ6OZU=ZCX@UC5M3O/]`G_@T&_X)>>)/V:?V>?&W[?7QD\.P:3\
M1?VMO#?A_1_@GI]["RZ[X=_9SL[PZ^?$%P6V&TB^,_B&'0/$=G9,DAF\*>#?
M!>NQ7`CU][:'+_X)F?\`!GO\!OV<O'>A?&/]O3XF^'?VM/$F@""]T7X&>'_"
M=WI'P$L]<123=^-;GQ'<2^(?BW86LNV6PT/4="\$^')Y$9/$NA>)+&8V$?\`
M9IINFZ=HNG:?H^CZ?9:3I&DV5KINEZ7IMK!8:=ING6,$=K8Z?I]C:QQ6UG96
M=M%%;VMK;11P6\$<<,,:1HJ@`NUDZ_\`\@+6O^P3J/\`Z1S5K54O[7[=8WME
MO\O[9:7-KYFW?Y?VB%XM^S<N[9OW;=R[L8W#.:`/\!63_62?[[?^A&O]RC_@
MG'_RCS_8._[,R_9>_P#5(>!J_CC;_@QKTAF9O^'F&I#<2<?\,BVO<Y_Z.4K^
MX3]G/X1K^S_^SW\"/@,FOMXK3X)_!KX8?"-/%#:8-%;Q(OPW\$:'X-77VT87
M^JC26U@:,-1.F#5-2%@;DVHO[P1?:)`#V6BBB@#\(_\`@X@_X)E:U_P4W_X)
M[^*/!7PUL[F__:#^!6N-\<O@5I%F;..;QKXDT'0=8TGQ!\,'FOY[6VB_X3WP
MSJE]::-)+=V<,?C/3_"<][=1Z;#?+)_D9^`/'_Q8_9P^+WAOXA_#_7O$_P`*
M?C-\'O&D&L^']<L1+I'BKP3XV\*ZDP!:WNX=]MJ&F:A;2VE_INH6LD4FVYT_
M4;26"2XMW_WJ*_F)_P""N'_!L%^R;_P4>\5:K\=/@_XDC_9(_:9UF?4-1\7^
M*O"WA"R\0?#/XMZQJ%U%>7.M_$GP';W^@7,7B^XE6Y$WC?PMK.F7U_+J-WJ'
MBK2/%U\EI);`'Y#_`+-W_![;H.G?#'0]%_:L_8R\6:]\5M$T*QL-6\<?!CX@
M^';?PSX]UJTLXH;G7KCP?XIT;2Y_`AU6Z22XNM-T_7?%UI:R2NUEY5N8K&#\
M`?\`@M/_`,'!?Q__`."N;>&_AK8>##^SQ^RYX/U!-=M?@SIGBYO&.H^.?&%J
M]S'IWC3XC^*ET#PPFJW&DV<[Q>'?#-AI%MHN@375[=RS:YJ3VNIVOT_\4/\`
M@SQ_X*W>"O$DVE^!#^SA\8_#S32"R\4>%_BX_A=#:AAY,FJ:-\1/#GA34+*Z
M9#F:VT\ZU!$RNL=]<#8[_;O[*/\`P9/_`+0_B:_TG6?VS_VJ?AK\*O#OGQ7&
MI^"?@/I.L?$_QO=V093+IK>+?%MAX*\)>&-2D7>JZC::1\0+&V8*WV2]!*J`
M?D[_`,&V?_!+3Q?_`,%"?V\_`?Q'\1Z)J]I^S)^RAXK\+?%[XK^+EM(3I&O^
M+_"^KV7B'X<_!Z"XN747%_XUUK3H[WQ%#:PSO8^!=)\022S:??ZAH4ES_KI5
M\S?LD_L=_LX?L,?!C0?@'^R[\+O#_P`*_AMH<AO9-.T>)Y=4\2:_/:VEGJ'B
MWQCK]VTVK^*_%FK0V%G'J.O:U=W5[)!:VEC"\&G6-C9VWTS0`5_DY?\`!W'_
M`,IG/B=_V1+X"?\`J%+7^L;7\HO_``5K_P"#8#3_`/@J9^V7XG_:YN?VU+SX
M(R^(_!7@+P<?`,'[/L'Q#CLU\$:*-'&H#Q-)\9_!37!U+'V@VO\`8,(M,^4+
MBYQYA`/SO_X,</\`DGW_``4=_P"QR_9A_P#3)\<Z_O*K\(O^"('_``1+M/\`
M@C-X?_:,T*U_:1N/VB!^T!K'PQU9[JX^$T7PL/A0_#BR\<V:P+#'\1_B$-:&
ML#QH9#(9-*^P?V<%"7GVO=;?N[0!_-G_`,'9?_*%+X\_]E._9[_]6[X9K_-2
M_P""3O\`RE-_X)I_]G__`+&__K17PYK_`%V/^"K_`/P3W@_X*@_L6>//V/KC
MXL2_!2+QOXF^'WB-OB!#X)3X@R::?`GB[3/%2V8\,/XK\%K=C5#IPL3.=?MO
ML8F-P(;HIY#_`,V?[*/_``9N:5^S!^U)^S9^TM'_`,%"M0\:R?L\?'WX._'-
M/!K_`++EMX?3Q:_PE^(GASQ\OAE]?7]H'6FT1=>;P^-*;5QH^K'31=F]&F7Y
M@^RR@']MM%%%`!1110`4444`%%%%`!1110`4444`%%%?!7[>?_!2_P#8\_X)
MI>$O`/CC]L+XCZK\./#?Q-\1:GX4\'7NE>`?'?CU]2US2-,35[^UFM/`OA[Q
M!=:>D5@ZS+<7\-O;RDF.*1Y`5`!]ZU_-?_P=G:QIFF?\$5/CI97][!:W7B'X
MI?L^:/HL$SA)-2U.#XL>'=?ELK53S+/'H^AZMJ+(O(MK"XDZ1FKVM_\`!V'_
M`,$3=*TJ^U&Q_:'^(GB6[M+=YK?0M%_9X^-4&JZI(OW;2QF\1^#=`T..XD_@
M;4]9TZU&/WERG%?P=?\`!<[_`(+F_%3_`(*[?%32M`T#2M9^%7[(WPIUG5;C
MX3?">?59WU/Q7J;S7ME:_%CXL6MG>W&AW/C^YT*X;3])TFP:^TOP#I5_JNC:
M-JFJW&K:_KVN`'Q__P`$8[*[U#_@K-_P3FM[&VENIU_;'^`=XT4*%W6UT[XA
MZ'J%].0.D5I96MQ=3MT2&&1SPIK_`&QZ_P`OS_@T!_X)^^-OCE^W;<?MP:_X
M7@?X%_LE:1XJTS2_$6J"WDMM9^/OCCPJ^@>'/#NCV4P9[V[\*>#?$VM^--4U
M&%<>&[[_`(0QG*76N:?(G^H'0`4444`%%%%`!1110`4444`%%%%`!1110`44
M44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!111
M0`5_'E_P>%?LR?M)?M-?LW?L=:%^S=^SY\</V@];\,?&_P`=ZMXET?X(?"?Q
MY\5]5\/:5>>`X+.TU/7-/\!Z!K]WI.GW5V#:V][?PV]M/<@P12-*"M?V&T4`
M?XA,?_!)K_@J?+(D:_\`!-3]OP-(ZHID_8[_`&AH8P6(`+RR_#M(HT!/S22.
MB(,LS!02/V__`."='_!I3^WU^TQXN\&>*?VQ=&D_8Z_9ZOD.K>(3K>J:!J?[
M0&KZ6())+72O#?PTM9=73P?J^H72Q6EY<_%!]`O?#EM)+J;>%-?F@AT>\_U-
MZ*`/EG]C/]C3]G[]@?\`9\\$_LS?LT>#5\&_#+P3'=3QI<W;ZIXB\3^(M4E%
MSK_C+QEKTZI<Z_XJ\078$^HZA*D-O;P1V>D:/9:7H&EZ5I-C]3444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444
M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110
M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
%%%`'_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>geron_def14ax2x1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 geron_def14ax2x1.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_
MVP!#`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_P``1"`!!`)8#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#^_BOYJOVR
MO^#G7]C;]FCXF:[\)_A-X"\:_M0Z]X1U2ZT;Q7XJ\'Z]H?A'X86NJV,SVU_I
MOA[QAJ,&NWWBVXT^[BFM[K4-)\-#PQ.RK)H_B+5HF=X_TY_X*[?%'Q?\&O\`
M@FE^V5\0O`6I3:-XLTSX,ZUHVDZQ;2/#>Z0WC.^TWP3>ZIIUQ&5EM=5T_3O$
M5W=Z5>1,LMGJ,-K=1,LD*D?B9_P;%?L0?LS:U^QAKG[3?C?X1^!?B+\8?'WQ
M5\;^$U\4^/?#&D>+9_"G@WPA;:9I5EX<\)V^OVVHV>@1ZC=7VM:CX@U'2;:R
MU+Q`M_::;K%Q>:?HFDP6P!^H/_!-W_@MU^R)_P`%(M:G^''@O_A)OA'\=[33
M+K5Q\(/B7_927_B;3=.@%SJ^H?#OQ)I-[=:1XQM](MRUSJ.FR)HGBNWL;:_U
M=O#']AZ?>:I%^QU?P4_\%;?V>?AA_P`$_O\`@M#^P?\`$_\`9/\`#>G?!Q/B
M9XH^$'Q#UGP;X+M4T'PAI_BJU^,TG@WQ,-!T33#;:?H?AOQMX7-OI?B#PII=
MK::+.LVN%;80:Y<VT?\`>M0!^2G_``4D_P""RW[)O_!-$Z3X5^)<OB/XD?&G
MQ'I2ZWH7P9^'$>FW'B&VT2:2>"T\1>,]7U6]LM(\':!?7-M/;V$ET]_KVIO%
M-/H_AW4K*TOKJT_-_P#9D_X.IOV._C#\1-(\!?&[X3?$/]FJP\1:C;Z7I7Q%
MU;Q!H?Q`^'^E7-TWEP3>.-0TRQ\.ZYX6TR2=HK=M7M?#^OZ9IYE^V:Y=:1I$
M%YJ=M^7W[!_P/^''_!0;_@XC_;ON?VKM`M?BWH?P>\2_M+>/?#_@WQ7%#K'A
M+6)_A'\<_`_P+^&GAWQ7HM_'/:Z_X4\)>#-=M#:>'KQ&TR^N_#NC0:K;7VDB
M^TV\_5?_`(./OV#/V6[K_@GG\0OVE_#?P@\"_#[XQ?`'5_A=+X9\7_#_`,*Z
M%X1U#7/#GC'XF^#?AEJO@OQ8=#L+*+7_``[;67B_^V]$AU".>ZT#5])@_L2Z
MT^RU37[350#^FVTN[2_M;:_L+FWO;&]MX;NSO+2:.YM;NTN8UFM[FVN(6>&>
MWGA=)89HG>.6-U=&96!/$?%+XJ_#7X(^`O$?Q1^+WCGPQ\-_AWX1L?[1\2>,
M?&&L6>AZ#I-L98[>$7%]>RQ1M<WEU-!8Z=8P^;?:GJ%Q;:?I]O<WMS!;R?E_
M_P`$#_'/BKXB?\$C?V,_$'C'6+G7-8L?"GQ%\$VU]=MNFB\,?#/XU_$OX;^"
M-*#=X-!\%^%-`T.TSEA:Z="&)8$G^>S_`(.O/C)\5?%G[1/[*'[&_AZ\NO\`
MA!;WX?6'Q:A\-V5U+!%XL^)GCSQ]XN^&>@2:Q`9%MKE_#>G>$Y[;PY)*H-D_
MC#Q$2Q%TI0`_5SXB?\'2'_!,'P1XAN]#\/#]HKXM6-K(\:^*OAW\*=(L_#UV
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MX<U&&(K'<:/!XHT'PWKZV;J8UU/P[I%PN#:J"`><?%;_`(.TOV4O"WCV\\/_
M``J_9Q^,/Q7\#Z??26;?$'4O$'AWX='5XH)VB?5/#OA._LO$.JSZ7<Q*+G3O
M^$CN?"NK2QNB:AI&ES;XD_<S]@+_`(*1_LQ?\%(?AMJ?Q`_9[\1:HFJ>%;BR
ML?B%\,_&=E:Z+\1?A]?ZDEQ)I@U_2+/4-5T^ZTK6([2[?1/$6@ZKJ^A:DUG?
M627\>K:9JVFV'Q]_P21_X)T?L:^!O^"<7[-]Q=_L_?"OQ_KG[0WP"^&/Q9^,
M'B;XE>`O"GCG7O&VM?%/P7HWC6^T75;[Q%I-^Q\)^'6UL:+X9\-0+#I&GV%D
MM\UK-KNHZSJVI?@C^P=\.-#_`&%_^#G3XA?LJ_`:?4M!^#/BFW^)OA:7PO<7
M]U>PV?@SQ!^SK'^TEI'A19[N:XN[^P\'>+M+T73-!O=4N+W5SI.DP-J&H7E[
M<7MS<@']T]?SY_M_?\'&'['G[$GQ.\0_`WPQX7\8_M)?%SP7?R:1X\T[P#J6
MBZ!X#\$Z]:2F+4_">M^/=5-^UWXNTAQY.KZ5X:\-Z_9Z+J"7>A:YJVE^(=-U
M+2+3]@/VPOB/XB^#O[)'[4GQ<\(2QP>+/A9^SG\;OB/X7GE1)(H?$7@?X9^)
M_$VBRR1R)(CQQZEI=L[H\;HR@JR,"5/\AW_!K;^Q;\`/CCHO[1G[5GQO\`>&
M_C!\2/"GQ'T/P#X&/Q(TBS\8:9X3EGT./QCXD\7V6FZ\E_IUUXQUZ^U;3($\
M27MG/K.BP:3<#1[ZT.NZQ]J`/V+_`.">O_!PQ^Q]^W=\2-'^"&J^'_%_[.WQ
MG\4S_8_!/ASXA7VC:QX0\=ZHZEH/#OA;QYI+VL9\4W*I(++1/$>@^'#K$YM]
M.\/W6LZO=1:<?WRK^%'_`(.B?V4O@G^S/X]_9)_::_9X\$:#\%/B1X]\0?$2
MQ\8S_#32K/P=INK>(/A_/X'\4^#/'<&F:!%I^G:;XUT[4-<UK^T_$5I:+J>N
MEM'FU"Z:XT6"2;^VGX/^)M2\:_"3X6^,M9,3:QXM^'7@CQ-JK01K%`=2U[PS
MIFJWQAB7"Q1&ZNY3'&ORHF%'`H`]%HHHH`****`/R?\`^"Y?_*)W]M;_`+)G
MI'_JP?!M?(G_``;!_P#*+#PQ_P!EO^,7_ISTFOKO_@N7_P`HG?VUO^R9Z1_Z
ML'P;7R)_P;!_\HL/#'_9;_C%_P"G/2:`/RV_X.._^4IG_!,G_KS^'/\`ZT4E
M?VR5_$W_`,''?_*4S_@F3_UY_#G_`-:*2O[9*`/XC_\`@AU_RL(?\%2/^P/^
MVW_ZVW\):_<#_@XG_P"4/'[7/_73X!_^M,_!JOP__P""'7_*PA_P5(_[`_[;
M?_K;?PEK&_X+'?M<?\%??V@]7_:\_8/T3]A3QCXJ_98U#XGP^'/"OQ*\`?LJ
M?M&ZUXM\1^$?AS\1?#_C?PEK.E^.[+6=9\#:N-2U+PKI@OM4TWPN^GZAITEV
MEA%:2317,(!^[O\`P;M?\H<_V/O^[@?_`%J3XVU_/G_P<G?\I>/V%?\`LC_P
M(_\`6G/BM7]'O_!!GX>>/_A3_P`$H/V5/`/Q1\#>,?AMX[T'_A>7]N^"O'WA
MG6O!WBW1?[4_:1^,.M:9_:WASQ%9:=K&G?VCH^HZ?JUA]LLX?MFF7]G?V_F6
MMU!*_P#.%_P<G?\`*7C]A7_LC_P(_P#6G/BM0..Z]5^9_=Q7\JO_``=L?\F.
M?L[_`/9UVD?^JA^*]?U55_*K_P`';'_)CG[._P#V==I'_JH?BO0(_<[_`()G
M_P#*.3]@7_LR_P#9?_\`5)^":_ET\+?\K@6L?]?_`(B_]=U3U_47_P`$S_\`
ME')^P+_V9?\`LO\`_JD_!-?RZ>%O^5P+6/\`K_\`$7_KNJ>@#^IW_@HQ_P`H
M]_V[O^S-?VG_`/U27CBOY_/^#1[_`)-)_:C_`.SB],_]5IX8K^@/_@HQ_P`H
M]_V[O^S-?VG_`/U27CBOY_/^#1[_`)-)_:C_`.SB],_]5IX8H`\N_P"#OC_D
MF?[#G_8]?'+_`-1_X:U_5O\`LX?\F\?`;_LC'PN_]0?0J_E(_P"#OC_DF?[#
MG_8]?'+_`-1_X:U_5O\`LX?\F\?`;_LC'PN_]0?0J`/9Z***`"BBB@#\G_\`
M@N7_`,HG?VUO^R9Z1_ZL'P;7R)_P;!_\HL/#'_9;_C%_Z<])K]B_VP?V==&_
M:V_9>^.O[-NO7YTBR^,7PW\1^#K;6Q&\PT#7;RT,_ACQ"UNC(UW'H'B2VTG6
M9+,.@O([%K5F59B1_"]^Q+_P5!_:N_X('ZQ\3_V(?VK/V7]4\;^$(/&FK>,?
M#ND3^)[GP+K&BZKJ*6FE:GXI^'OBZZ\,>)O#_P`0OACXOBT.SOM.CLK:QMX=
M4>_U.VUN.[GU71Y`#[-_X.._^4IG_!,G_KS^'/\`ZT4E?VR5_FE_MR?\%0?#
MW_!4C]OO]A?XF^'?A!K/P>M_AKXR^%W@2XTC6O%]CXPFU::[^-&G>(!J4-W8
MZ#H"6D2)>BU-L\$[L\9E$P#!!_I:4`?Q'_\`!#K_`)6$/^"I'_8'_;;_`/6V
M_A+7]EOQ5^+7PR^!G@/7?BC\8_'GA;X9?#GPR=,'B'QMXUUFR\/^&M%.M:QI
M_A_21J6KZA+#9VG]HZYJNFZ59^;*OGW]]:VT>9)D4_PH_&'Q_P#%C_@@U_P7
M`^,W[37C3X7ZUX^_9[_:HUGXLZW#JFF1Q6LGBWX6?&KQSHWQ/\6:9X'UR^QH
M\7Q"^$OQ"T_18+_PYK%Q9SZOIFCVL%Y=:%HWCG1_%4/4?\%<O^"\O@+_`(*.
M?`+3/V(/V+/@M\9M3N_CAXP\"6WC2]\=>%]%B\6ZY-H?BO1O$OA#X=_#CP7X
M(\2>.;_6M>USQQI?AR6[U-KVUE1=+;0]*TC6?[=;4M-`/[A_A5\6?AE\<O`6
M@_%+X.^//"WQ,^''BC^U/^$<\;^"M9LO$'AG6_[$UG4?#NK_`-F:OI\LUG=_
MV;KND:II%YY,K?9]0L+NUDVRPNH_B)_X.3O^4O'["O\`V1_X$?\`K3GQ6K^K
M'_@E1^RWXM_8O_X)\_LR?LX>/YXY/'?@7P;K.K>-;:&6UN(M%\7?$GQOXI^*
M?B3PO%>6,]S8ZA'X2UGQM>^&$U.RN)K34UT@:A;2/#<HQ_E._P"#D[_E+Q^P
MK_V1_P"!'_K3GQ6H''=>J_,_NXK^57_@[8_Y,<_9W_[.NTC_`-5#\5Z_JJK\
M(?\`@XA_8K^*G[9_[`<EE\%-)O/%/Q$^!'Q+T?XXVG@72K.74->\>>'-&\*^
M,?"OBOP]X8LH2)KWQ-:Z9XL_X2C2M-MDNK_7!X<N?#NCV%]KFLZ9`P(_0+_@
MF?\`\HY/V!?^S+_V7_\`U2?@FOY=/"W_`"N!:Q_U_P#B+_UW5/2_\$[O^#FG
MX$?L\?L;_#7X`_M-?!OXQ7WQ.^`'@31OA9X/U+X4Z5X.U/PSXY\(^!]+M_#_
M`(&76_\`A*/&/A34?!WB+3M$LM-T+Q$%L?$=G>G2I_$UK<I=ZI_PB]CA?\$1
M/"'QV_X*,?\`!6WXS?\`!6SX@^"9?`OPV\,W'CI]&NK>.XD\/W?C7Q9X`'PA
M\(?"_P`/ZO<VNGCQ5/X#^$M[/<>+O$%I:QF+4;/P_<ZIIVFS^++*",`_JY_X
M*,?\H]_V[O\`LS7]I_\`]4EXXK^?S_@T>_Y-)_:C_P"SB],_]5IX8K^@/_@H
MQ_RCW_;N_P"S-?VG_P#U27CBOY_/^#1[_DTG]J/_`+.+TS_U6GAB@#R[_@[X
M_P"29_L.?]CU\<O_`%'_`(:U_5O^SA_R;Q\!O^R,?"[_`-0?0J_E(_X.^/\`
MDF?[#G_8]?'+_P!1_P"&M?U;_LX?\F\?`;_LC'PN_P#4'T*@#V>BBB@`HHHH
M`*Y'QC\/O`7Q#L(-+^('@CPAXYTRVF-S;:=XQ\-:-XFL+>X*[3/!::U97MO%
M,5^4RQQJ^WC=CBNNK^>#_@L-\%?^"T'Q-^.'PUU/_@FK\0O$/A#X36?PFCTS
MQY9:-\5/`'@&.Y^(1\7>*+B6[:Q\67MKJ-S/_P`(U<:#$-0LQ]G"Q)"CB>"3
M`!^.?_!>WPE\)_#7_!6G_@G1\.O@[X0\">&M<MQ\&)_$OA3X=>&M"T&4:GXE
M_:%EB\.+J^G^';&SC?5M2M;-FLH+I&OS8O9S!%M+RS>;^ZNOY.?^"6?_``0*
M^-GPZ_:8TS]N[_@I)\3[+XI_'#0-=7QOX+\!Q^*=4^)FICXB10Q1Z1\0?BQ\
M1=?B*:SX@\'S1_;O"V@^')M9L;/6;+P[X@;Q?C1AX=E_K&H`\V^*_P`&_A+\
M=_!U[\/?C5\,_`?Q9\#:A+%<W?A+XB>%-$\8>'Y+RW61;6_72]>LKZTAU&S\
MV1K'48(X[ZQD<RVEQ#)AZ\,^`?[`?[%7[+FO3>*_V?OV8?@U\+?%T\-W;'QC
MX;\%:4OC*&ROQMOM.L_%M]#>^(K#2[Q0JW.E6.IV^G3JD:R6S+&@7Z\HH`*\
M]\4_"/X4>.=;T[Q+XV^&/P\\8>(](@MK;2?$'BGP7X;\0:WI=M9W<U_:6^G:
MKJVFW=_906M_<7%[;16T\4<%W/-<Q*LTKNWH5%`!1110!\1?%7_@FO\`L!_&
M_P`>2?$_XK_L@_`+QM\0+J^;4]5\5ZM\.M`75?$>H-C=>>+I;.UM8_&-PX"H
M\OBF/6&:-4C8E$51]=^$O"'A/P#X;T;P;X%\+^'?!?A#P[8Q:9X?\*^$]%TW
MPYX;T+38,^3I^C:'H]M9Z9IEE%N;RK6RM8((]QVQC)KHJ*`*.J:7IFN:9J.B
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MJ(JJH`GHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
-**`"BBB@`HHHH`__V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
